<SEC-DOCUMENT>0000719135-20-000076.txt : 20201109
<SEC-HEADER>0000719135-20-000076.hdr.sgml : 20201109
<ACCEPTANCE-DATETIME>20201109150205
ACCESSION NUMBER:		0000719135-20-000076
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201109
DATE AS OF CHANGE:		20201109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apyx Medical Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		201297268

	BUSINESS ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760
		BUSINESS PHONE:		7273842323

	MAIL ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL Corp
		DATE OF NAME CHANGE:	20150319

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>apyx-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:2ea9de42-aac7-46ca-94f8-c6912c5c1c9a,g:a9cfc7c0-2655-4cf5-9110-bf28a20f93b1,d:85d2870f2c594539a4d7339b7b1f7fd1--><html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:apyx="http://apyxmedical.com/20200930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>apyx-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV8xLTEtMS0xLTA_af652279-2e82-4488-95ea-d27b9f826458">0000719135</ix:nonNumeric><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV8yLTEtMS0xLTA_ee616794-d3da-4efb-a955-20282e77974a">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV8zLTEtMS0xLTA_9dc4e553-10ac-487a-81a4-a471212bcfdd">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV80LTEtMS0xLTA_9eec1596-c4ff-494b-8d4e-c99ab8d53c6a">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV81LTEtMS0xLTA_03feaed7-3a0d-4577-87af-da50bd8761e8">2020</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="apyx-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib05f5eea79d74e0aaa4c9a5d10733dfd_I20201105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3aeb98b19ed344b38761f3312c3cef29_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73c621036a99473780d3074110069a13_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a8c6709ab6545788f01bb876f8ad5fb_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae41f525baaa42f39576509f7721cc15_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0cce47726d34e2ebdd2418732677619_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec6913c76db848e48f75b33fdd549043_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f64a85dde3d4406b0968a6843b6650a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1017cca871c456794046e8f6db58bad_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55f9c780b1545c394b8709a246c5d8d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icccdbde53c634286a08502b7067c3bd4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8247c825010848fe816f263c06eb0578_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78ecaae1891940d8b30cde984cfab290_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib934edd7927e448fa857c4334c0b224d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic57895c375be486494052fff7c84896e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e15604132e64bd7be8c75ff25d7ad0f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925ea0d8fa8047c0944ddd95c69a0069_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbfeeeeb5d894c0aa6a94f455268d87a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67fcb851c8f84550946c58cdf9f7aa5c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf1b493fcef4659bc8ded12611e9884_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f5e2ba84d164ba7a5ffa6e3aeaae063_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1b33044ef2c41908861223ecfd71ee6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e52d7a0147408f9c71d68e6fbcaa1d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc2aaaf8f7f4a9b85cf16e63389f75a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i913d962436cd4db8a7740c64ad7493b5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f36fa133df4eaf9642016fef6664fe_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a5510f10b3844959983d33e64e5204e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92085eaad57f43949f28a8490b3618a3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274049f33bc542f2b5c4a1edc98332f2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0abc8cd3d9e4b8aacdbb3de72f2dd69_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef3ec014e56475892c3f14c254b885d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a68681edbde45efadb3509ae7c13af1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ae8661537740f6926d686bfe24cd51_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fbc93ccd4814ef99c90d7c8890ea00d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf8a9b477f84987a0b6c058bcd7e649_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48fc99dafca2425db5c4a6fcb37ec8ea_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b83789be6c1428f8e0e804d7baf2a2f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf6a9cfc3ce4884aee9545865031864_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa6da815695f48cf8033a128044cf36f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba6dfcb91e634687989de6d0e02edef7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a48387011840968abaf55fba3a032e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b5bfcc70b54a58914b26f39e6b0701_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7aebc2db6474548be882738252f5712_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifde6c535194047a4ab3e479617f5d580_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca82284cce84aec9905621979eac687_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0448759fc2be4fa382f8f4658e300986_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14b6c67e6dd455abc6901028ba4538a_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i852d57be8ad6467b9ab3b88460783b01_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956b294a00a54308901dd7f15329f5a2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i35b49cbb47b64d98abab16201295d5a6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c0390a429a4234aa1f855c20366a70_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dd1a24600384e0c988695d6cf2c976e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bc6a13d050543ca9de29ba517195a6e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied11d7234a5948deb5fe2210e04162f5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i055002fdfdea449397dfa999e230e0cb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4e8528a777540ed922e20d4c68e0ad9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a828c250044883817cff327ba04649_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0ef098d3204c5c98b0e22874cdea4f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231f501bd1f2450b9fa914b657791e11_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a1bdc5e0da4360939ec99da52debd2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd5dddf56d00470b8aa7a88a79e92300_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f0487382914de3b1695fcaf943831e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f84ddfcfe34ee2b4fe9e0f5995eafe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc35ac6e31d4dd7a206d50f3668f460_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabf0bad69e934fb18dc921efbd473e9f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:BulgariaManufacturingPlantPurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aad088e173447ad8a7e163f390e1c17_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:BulgariaManufacturingPlantPurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i356212dfd54e49b3aaec12d12ef5c598_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759891cb08514e4a9829b1b1f2315bfc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i573e9d9d81ad4ecb9dbd2be6bddc6fb8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>apyx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i055a981a44044179a950382ce6694d05_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba6db9cd9234659951d70f1a84a0210_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c4a8fb0f73460292e4e20ebc69a371_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied82ea81f7c940e7ab5b2c914bbb80be_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c037d9010f4687af65b47252416f9d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3b458e10584d0ca1129fd062442050_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392395d0a19242688757fc5acfd48f41_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153bf9c378f14f8cae2822d51169a108_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b43886dc0fa410d95320ffb2f4fede0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_1"></div><div style="min-height:31.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU3_07f80dc2-88c3-4dad-896c-fca7f37202dc">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZDQ4ZDhlNTA4NjA1NDdmZjhmMDMxZjNhNmEyZWU2OTkvdGFibGVyYW5nZTpkNDhkOGU1MDg2MDU0N2ZmOGYwMzFmM2E2YTJlZTY5OV8wLTItMS0xLTA_8b91956c-bb9d-4649-930f-4db442200b5e">&#9746;</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the quarterly period ended</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZDQ4ZDhlNTA4NjA1NDdmZjhmMDMxZjNhNmEyZWU2OTkvdGFibGVyYW5nZTpkNDhkOGU1MDg2MDU0N2ZmOGYwMzFmM2E2YTJlZTY5OV8xLTQtMS0xLTA_12dae4d2-cbcc-481b-82aa-1109ec9b5f93">September 30, 2020</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">or</span></td></tr><tr style="height:3pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZDQ4ZDhlNTA4NjA1NDdmZjhmMDMxZjNhNmEyZWU2OTkvdGFibGVyYW5nZTpkNDhkOGU1MDg2MDU0N2ZmOGYwMzFmM2E2YTJlZTY5OV81LTItMS0xLTA_ac1f2b28-433e-4a49-a0db-ae654c65adbf">&#9744;</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from _____ to _____</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZDQ4ZDhlNTA4NjA1NDdmZjhmMDMxZjNhNmEyZWU2OTkvdGFibGVyYW5nZTpkNDhkOGU1MDg2MDU0N2ZmOGYwMzFmM2E2YTJlZTY5OV83LTQtMS0xLTA_fb3b9014-8440-4113-bc86-3d03edbe92d8">0-12183</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:114pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="apyx-20200930_g1.jpg" alt="apyx-20200930_g1.jpg" style="height:145px;width:223px;"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZGI0MDE5NjcyNTZiNDYyZjgyZDRkMDg5YWRlZWQ2NTIvdGFibGVyYW5nZTpkYjQwMTk2NzI1NmI0NjJmODJkNGQwODlhZGVlZDY1Ml8xLTAtMS0xLTA_c50abff8-d228-425f-9b36-e42aa0cdb053">APYX MEDICAL CORPORATION</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MTgyMTRhNmJkZTAxNDE5OTg2MzQ4M2I3NGE0ZjExMzEvdGFibGVyYW5nZToxODIxNGE2YmRlMDE0MTk5ODYzNDgzYjc0YTRmMTEzMV8wLTAtMS0xLTA_789b2201-b5f0-4c3b-9ddd-53ba07107b2e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MTgyMTRhNmJkZTAxNDE5OTg2MzQ4M2I3NGE0ZjExMzEvdGFibGVyYW5nZToxODIxNGE2YmRlMDE0MTk5ODYzNDgzYjc0YTRmMTEzMV8wLTItMS0xLTA_ae3ce53e-78da-48b3-ab87-ee577edd1876">11-2644611</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU4_6bd0b139-23aa-40c2-942f-a4a58554921a">5115 Ulmerton Road,</ix:nonNumeric> <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU5_ae3a1daf-9b1b-4445-93e9-3d3a3e673698">Clearwater</ix:nonNumeric>, <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTYw_6098fa18-8488-4432-96c7-84d03d10f673">FL</ix:nonNumeric> <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTUx_2fac5774-9d8f-4c08-9637-debeec180f44">33760</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTUy_4f0c428e-160f-4d11-a7ee-b07ae5208a64">727</ix:nonNumeric>) <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTUz_6b9e5951-03e5-4ed8-9acf-64b09064fe9b">384-2323</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities Registered Pursuant to Section 12 (b) of the Act:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MjVhZmQ1NDcyMDgzNGE4ZDk3ZWUzZmU5NjlhZDM3YTEvdGFibGVyYW5nZToyNWFmZDU0NzIwODM0YThkOTdlZTNmZTk2OWFkMzdhMV8xLTAtMS0xLTA_a96232fd-eedc-44e7-b6fb-46b263e691c4">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MjVhZmQ1NDcyMDgzNGE4ZDk3ZWUzZmU5NjlhZDM3YTEvdGFibGVyYW5nZToyNWFmZDU0NzIwODM0YThkOTdlZTNmZTk2OWFkMzdhMV8xLTEtMS0xLTA_60237d9b-dcbe-4fa4-a276-f4bb6d162856">APYX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MjVhZmQ1NDcyMDgzNGE4ZDk3ZWUzZmU5NjlhZDM3YTEvdGFibGVyYW5nZToyNWFmZDU0NzIwODM0YThkOTdlZTNmZTk2OWFkMzdhMV8xLTItMS0xLTA_8f2d85d3-20b2-4b7e-8ae8-b51a6b8b0191">Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU0_44341943-f37f-4c52-856d-508f44235816">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU1_f51b1397-064c-40bd-9568-52f16f63198c">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6YmQ0MzQ3N2U0Mzg0NDQzOTkzYTlmMWJiMzE5MTcxNGYvdGFibGVyYW5nZTpiZDQzNDc3ZTQzODQ0NDM5OTNhOWYxYmIzMTkxNzE0Zl8wLTMtMS0xLTA_a501f3b3-851f-4980-80eb-a2f31a2b03b1">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6YmQ0MzQ3N2U0Mzg0NDQzOTkzYTlmMWJiMzE5MTcxNGYvdGFibGVyYW5nZTpiZDQzNDc3ZTQzODQ0NDM5OTNhOWYxYmIzMTkxNzE0Zl8xLTQtMS0xLTA_51a31a13-ab03-4f34-b7df-4131790edd31">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6YmQ0MzQ3N2U0Mzg0NDQzOTkzYTlmMWJiMzE5MTcxNGYvdGFibGVyYW5nZTpiZDQzNDc3ZTQzODQ0NDM5OTNhOWYxYmIzMTkxNzE0Zl8yLTQtMS0xLTA_a975a459-997a-4df8-98ce-2447e9cf55b9">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU2_01314eaa-845f-405f-9ff0-4a8e8dbb2484">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">s of November 5, 2020, <ix:nonFraction unitRef="shares" contextRef="ib05f5eea79d74e0aaa4c9a5d10733dfd_I20201105" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8yMTk5MDIzMjU3MjE5_0c25b83e-332a-4048-9ada-70da2fbbe26e">34,274,771</ix:nonFraction> shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">of the registrant&#8217;s $0.001 par value common stock were outstanding.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO QUARTERLY REPORT ON FORM 10-Q</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended September 30, 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_10">Financial Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_10">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_13">Fi</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_13">nancial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_16">Consol</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_16">idated Balance Sheet</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_16">s at </a>September 30, 2020 and December 31, 2019</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_22">C</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_22">on</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_22">solidated Statements of Operations for the three </a>and nine months ended September 30, 2020 and 2019</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_22">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_25">C</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_25">onsolidated Statements of Changes in</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_25"> Equity for the </a>three and nine months ended September 30, 2020 and 2019</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_25">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_28">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_31">Notes to </a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_31">Condensed </a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_31">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_31">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_70">Mana</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_70">gement&#8217;s Di</a><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_70">scussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_70">17</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_79">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_79">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_82">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_82">26</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_85">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_85">28</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_88">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_88">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_91">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_91">29</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_97">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_100">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_103">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_106">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_106">30</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_109">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_109">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_112">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i85d2870f2c594539a4d7339b7b1f7fd1_112">32</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_10"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. &#160;&#160;&#160;&#160;Financial Information</span></div><div><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_13"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share data, Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMy0xLTEtMS0w_96a0d977-ce76-4a6d-89d4-0db3c9fadc2a">43,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMy0zLTEtMS0w_408dc61b-c386-4a40-b930-426913ef3200">58,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts receivable, net of allowance of $<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNS0wLTEtMS0wL3RleHRyZWdpb246MTQ5YzMxNTE2ODAxNDBiNGJmM2Y1NjI5ZTU0NDJlNjBfNTQ5NzU1ODEzODk0OA_b9ae97de-bd04-4c55-97f4-daec57be37ec">760</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNS0wLTEtMS0wL3RleHRyZWdpb246MTQ5YzMxNTE2ODAxNDBiNGJmM2Y1NjI5ZTU0NDJlNjBfNTQ5NzU1ODEzODk1Nw_274bdb23-8674-4be2-a434-f1a3fb174038">273</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNS0xLTEtMS0w_671294a5-868d-4716-966e-c466d7643c6e">6,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNS0zLTEtMS0w_58e49a51-0d77-479b-ba5a-0190fa6e302a">7,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNi0xLTEtMS0w_bb4ca73f-2887-45f9-820b-557134471c2f">7,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNi0zLTEtMS0w_2ddfecd4-41c0-4a6f-bc5b-f3054d34e219">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNy0xLTEtMS0w_5bf01d9f-d91f-4e10-824e-e53e96339479">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNy0zLTEtMS0w_2749cab9-d1ff-4231-947d-31dfc487f096">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net of provision for obsolescence of $<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOC0wLTEtMS0wL3RleHRyZWdpb246ZDcyYzcyYThlNWY0NDRiMDk2NTM2YjYyNjUzM2UyYmVfNTQ5NzU1ODEzODk1MQ_9a0e7801-df0b-4f6e-a077-13fc1001967f">537</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOC0wLTEtMS0wL3RleHRyZWdpb246ZDcyYzcyYThlNWY0NDRiMDk2NTM2YjYyNjUzM2UyYmVfNTQ5NzU1ODEzODk1OQ_13216140-4954-42e2-91e2-5631394175f1">392</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOC0xLTEtMS0w_8edf29a6-c991-4f65-9e17-b39a64e0fd4b">5,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOC0zLTEtMS0w_868fe0b8-cfd2-4a4f-bf5d-2cfb5b697df9">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOS0xLTEtMS0w_a72a1813-fbb8-406e-b19c-65d18ae0dd3f">4,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOS0zLTEtMS0w_a4d438e5-f1dc-41ba-8af5-311f19b4a901">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTAtMS0xLTEtMA_d488215a-d4ad-4e51-bf25-230db68475c8">67,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTAtMy0xLTEtMA_e780cf80-acee-417b-b775-e23261762343">76,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjJiNmNhZWVlMGRmNTRkZjRhOTQ5MTA1N2YwMjVmN2Y5XzU0OTc1NTgxMzg5ODM_2982d2ea-3bf8-4c58-bbbb-55cd44e45575">4,677</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjJiNmNhZWVlMGRmNTRkZjRhOTQ5MTA1N2YwMjVmN2Y5XzU0OTc1NTgxMzg5OTM_873742bf-5028-42f5-a80a-6b08bd2da24b">4,403</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTEtMS0xLTEtMA_8ae000f6-f361-472b-8eeb-ca60a3da6630">6,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTEtMy0xLTEtMA_e5792dcb-887b-4d9e-b18c-5b7f3ada8314">6,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTItMS0xLTEtMA_a9164c69-99a9-454c-a74d-8b14af9e9ef3">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTItMy0xLTEtMA_163d010f-b7dc-47da-bf03-6cb726d3b598">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTMtMS0xLTEtMA_e5a932dd-850f-4336-859b-eb9afa155a5c">629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTMtMy0xLTEtMA_feb82611-dbb8-4ba9-ba87-6da9ac302a59">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTUtMS0xLTEtMA_a343f81d-319f-4733-9dce-7a122934b206">508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTUtMy0xLTEtMA_38124c8d-ce42-4721-af63-675088ae5995">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTYtMS0xLTEtMA_de80e3f0-a44d-47d1-9ae8-41805833bc56">75,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTYtMy0xLTEtMA_23b3660b-4249-4592-9e4b-8dbada68db77">84,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjItMS0xLTEtMA_b1eef9fe-0806-4a1b-b163-4a569f298371">2,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjItMy0xLTEtMA_8b6e0d71-8c6a-4220-8a58-dc2095862eee">2,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjMtMS0xLTEtMA_db2f397f-878c-469e-80d9-5f100b3f7a79">6,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjMtMy0xLTEtMA_da83ff65-293b-4c77-997f-453f908d9a18">9,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjQtMS0xLTEtMA_87585322-7807-4b91-8a2f-91e4b70faefc">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjQtMy0xLTEtMA_ba7135ac-5d21-4d40-83c3-065cc785391d">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjUtMS0xLTEtMA_c49929fc-8d4e-441b-afb7-403fbccf1fa5">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjUtMy0xLTEtMA_7f733c34-7159-4e70-9135-5ef568666d0d">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjYtMS0xLTEtMA_78faecd7-6490-4f09-9441-71a912c1c559">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjYtMy0xLTEtMA_991486c4-93d8-44e1-8c04-b0614ef05936">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjctMS0xLTEtMA_029d8500-29cc-415c-8076-9249ee8edfe1">9,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjctMy0xLTEtMA_d7714246-49f2-4a58-b2e9-e53161abdbe0">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjgtMS0xLTEtMA_0fc8d352-3be4-403b-81db-7e9bb70bf6ad">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjgtMy0xLTEtMA_9cf80f19-4d7e-47d5-80a6-56da9e9ad16c">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjktMS0xLTEtMA_1ba4c154-f526-453f-92e8-017bb50fbdfe">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjktMy0xLTEtMA_de449070-6b0e-4c5a-8ea5-1ce91f3330ec">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzAtMS0xLTEtMA_6212cca3-0c0a-4e41-8be3-7bc5a4eed31e">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzAtMy0xLTEtMA_025ddebb-0df2-4801-a03f-b17ce2260128">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzItMS0xLTEtMA_b818760f-7995-4570-8466-fd12db09695b">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzItMy0xLTEtMA_a34f5458-91aa-4753-8b29-6d3341f45bda">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzMtMS0xLTEtMA_cc086f6c-9e80-4916-8839-a6f4d41ec794">11,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzMtMy0xLTEtMA_f250d12d-2a43-4f31-aa8f-7c627fc52d4f">13,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkwODQ_14fd3191-fbbb-49b2-a54d-e33234ab8caa"><ix:nonFraction unitRef="usdPerShare" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkwODQ_acd45b57-7add-4e2f-ae21-f531ed6b456b">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkwOTg_17e2e957-b123-40c8-a2fe-4b3ff035bdda"><ix:nonFraction unitRef="shares" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkwOTg_673121d8-38c2-460d-985f-9a67a1a8b58e">75,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkxMTE_7cfd729b-74d2-4994-8f5b-5f3d1909ddb7"><ix:nonFraction unitRef="shares" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkxMTE_89f122c1-a090-4371-83d6-3f2f2dbff0b2">34,222,505</ix:nonFraction></ix:nonFraction> issued and outstanding as of September 30, 2020, and <ix:nonFraction unitRef="shares" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkxMjQ_6caa97e9-4d32-438e-94b3-3ac9c714da30">34,312,527</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkxMzc_0fdcf7b1-39c0-4174-8c45-b082662cb02c">34,169,952</ix:nonFraction> outstanding as of December 31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMS0xLTEtMA_19da23fd-146e-46c5-af4a-eb2c3657759e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMy0xLTEtMA_a7a1116f-66ec-465f-befc-d829edd95c63">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzYtMS0xLTEtMA_59a759a3-5b52-4cf4-bd92-b39fb6fef8ce">60,014</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzYtMy0xLTEtMA_274363e6-ef3e-498e-b701-e4fca36800e3">56,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzctMS0xLTEtMA_4cb30e6f-27a6-4cbb-a7ec-0c474169f7e3">4,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzctMy0xLTEtMA_1d67d88c-183e-43af-ab71-d07fada80621">14,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzgtMS0xLTEtMTQzNw_a3671aa7-e642-411f-91a5-ff6dff1e39e1">64,196</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzgtMy0xLTEtMTQzNw_a293f5ad-b024-421e-9564-8f9b428695c4">71,259</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzktMS0xLTEtNDkz_3ea45035-dda9-460c-95a3-0e333e9a391f">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzktMy0xLTEtNDk2_c6f94b7e-553e-457e-9612-a8e2a3598ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNDAtMS0xLTEtMA_2982e694-877a-4f37-b7e4-afb4e29ea221">64,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNDAtMy0xLTEtMA_cce51627-f07e-4720-950d-4fed9e5a06b0">71,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNDEtMS0xLTEtMA_67de530d-db2f-4338-8d16-d11e312f8d30">75,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNDEtMy0xLTEtMA_cda531d9-5098-4fc4-aacf-bf0499a54a4a">84,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data, Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:49.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.774%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMi0xLTEtMS0w_1d7132a7-79d1-4c35-a3da-fc37666b1d3b">6,954</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMi0zLTEtMS0w_569d1879-66ff-4fca-9f51-a99717693fc7">7,575</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMi01LTEtMS0w_8685870b-9f1f-4e17-8996-315085bba581">16,247</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMi03LTEtMS0w_99a063de-902c-4111-a2aa-07ffe9ed1f54">19,853</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMy0xLTEtMS0w_481e46a4-030a-4426-b207-9e8700e826c2">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMy0zLTEtMS0w_7f4a6da8-130a-4b3d-a664-e5151bce1d5e">2,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMy01LTEtMS0w_9a27a49d-c5af-4675-8fd5-d264b178afc4">6,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMy03LTEtMS0w_6148dc10-d06a-4805-bb4b-0f7d50d44074">6,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNC0xLTEtMS0w_53caf8d4-6f09-4020-8d11-2c18fcbc2ddd">4,725</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNC0zLTEtMS0w_e73bc6bd-947d-412c-8a54-1aaee076f211">5,294</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNC01LTEtMS0w_c3865745-0dd4-4736-a9e0-a7e30f195757">9,803</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNC03LTEtMS0w_4ffc588f-704b-43c6-a120-6e9ab6bd60f1">13,531</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNi0xLTEtMS0w_f85d2e71-fb2a-4c3b-b02f-7e5af47fd1d6">1,047</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNi0zLTEtMS0w_28ce74cc-c524-4e33-b6f9-4adf0f4a4922">1,016</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNi01LTEtMS0w_374242a6-2d90-4158-a3e3-9053b183990e">3,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNi03LTEtMS0w_540d33fc-f0f2-4d33-a613-debfb5d7e9a5">2,634</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNy0xLTEtMS0w_ad970967-5f42-4de3-b5bd-6456779e97d5">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNy0zLTEtMS0w_02546a50-5f6f-427c-bec0-15eb99eb1b76">2,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNy01LTEtMS0w_f122b3fa-8b58-40c1-9c03-7ba4642946e8">5,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNy03LTEtMS0w_d24dd312-fc51-49e4-a1bb-7c4c5d894ec0">5,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOC0xLTEtMS0w_15bbcfe1-6b50-4f7a-95ab-a3ae321a82d5">3,508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOC0zLTEtMS0w_ee2be44c-516a-43e5-9199-cc7b58e99188">3,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOC01LTEtMS0w_cde976ed-3d31-46ce-9635-3d9aad688cbc">10,258</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOC03LTEtMS0w_d2959f8b-0d0d-478f-a100-afc0e792cad5">10,157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOS0xLTEtMS0w_1caea3f8-b289-4827-b6ff-3c024ed1dbff">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOS0zLTEtMS0w_65e02f9a-4033-431a-9d0a-6b6181751dd8">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOS01LTEtMS0w_af7a5522-554c-4d7d-8efc-74c7417baf96">8,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOS03LTEtMS0w_fa58f4ec-c0f7-408d-b1ae-528da2195d2e">9,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTItMS0xLTEtMA_235c0f32-a8f5-476e-928d-5ce37aa56b36">9,096</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTItMy0xLTEtMA_0c8b67cb-705a-4e69-8583-83774708aa12">10,050</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTItNS0xLTEtMA_2ccf7be9-4795-4d1f-87ea-3780b4aa68fd">27,833</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTItNy0xLTEtMA_ccc189e5-9afa-4126-9d9b-81eb74f36d15">28,439</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTMtMS0xLTEtMA_5f807800-2f17-472e-95dd-33208bf619ae">4,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTMtMy0xLTEtMA_458d1df2-78eb-4d90-b820-be03b8de1152">4,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTMtNS0xLTEtMA_0b6c050c-c562-4c4d-9e59-5f74c290e67a">18,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTMtNy0xLTEtMA_7cbe3912-7980-4080-bc8a-a27afd5676af">14,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTQtMS0xLTEtMA_5b83d3a7-1f23-4111-92f3-d69eba21bfde">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTQtMy0xLTEtMA_81b6ffc0-6e17-47d9-b05d-1d1ef1b990ad">327</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTQtNS0xLTEtMA_186065c9-1492-4be4-901d-1f59cab85717">233</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTQtNy0xLTEtMA_f86fbfee-eb72-4ab7-a8e0-beb4bf383a1d">1,153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTctMS0xLTEtMA_a5acbf41-ad74-4693-86be-3284fa221e62">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTctMy0xLTEtMA_899c10b3-0287-42d2-8256-b6e0fa94de86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTctNS0xLTEtMA_efff4e42-2fa8-446f-a508-f47152101da9">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTctNy0xLTEtMA_790b6431-f48a-41ad-86c1-9f17da936825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTgtMS0xLTEtMA_97b0acbe-52df-42e6-818e-68ecece5744e">63</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTgtMy0xLTEtMA_89b4180a-b9f2-4c64-b17d-02cbc8d0b41e">230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTgtNS0xLTEtMA_3b374796-dcab-43ae-ab95-115fd6a5ac6d">349</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTgtNy0xLTEtMA_3fb8d264-5c23-453a-a8a7-946503abc176">265</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other (loss) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjEtMS0xLTEtMA_1b6abb39-3683-4ec3-83f6-b52116aba682">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjEtMy0xLTEtMA_b9af75bd-d7fc-48f0-b961-5e32eafdec2d">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjEtNS0xLTEtMA_35e977c0-916a-4e72-8540-109b13fa177a">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjEtNy0xLTEtMA_c90114f9-809c-4cde-af22-95eb027a9000">888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjItMS0xLTEtMA_6bd2c926-26f0-4a5b-be60-1791b1b8d78a">4,449</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjItMy0xLTEtMA_41af75b5-d75a-415f-9ce1-a0c92609283a">4,199</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjItNS0xLTEtMA_16d3cd2d-92f1-45c3-97e5-f275f93d28c9">17,487</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjItNy0xLTEtMA_2647c2e9-8c8d-4b34-8912-4d3898d8d013">14,020</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjMtMS0xLTEtMA_51f1211c-e470-445a-aa0d-1ee1271c2040">715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjMtMy0xLTEtMA_65384acf-bfd5-43fc-a799-a6512792429e">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjMtNS0xLTEtMA_5e38b147-4c9e-42c0-aeea-1af758ce3386">7,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjMtNy0xLTEtMA_3cfb4585-8b23-4214-8e8b-a263cbf1df6d">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtMS0xLTEtMA_01215ac8-c5ff-4ac3-a44c-40d2d83510ee">3,734</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtMy0xLTEtMA_361f459f-b83f-4389-9c92-511b6b9b9529">4,370</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtNS0xLTEtMA_7f21f655-2bff-41a2-8634-58c47414f93d">10,375</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtNy0xLTEtMA_624a91ae-8064-4455-a7f8-006dd315caea">14,273</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net loss attributable to non-controlling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjctMS0xLTEtNTA5_26da5411-bcbf-4aff-bf65-734d345bbf3f">6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjctMy0xLTEtMTQ1Nw_9e3e6c5a-baea-4246-83a9-53e6faedd68d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjctNS0xLTEtNTE5_9eff1044-5c77-42be-ba5c-9261d9fea0d5">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjctNy0xLTEtMTQ1Nw_e71ba39d-dabb-4471-b603-242cb04186cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Apyx</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtMS0xLTEtMTQ1Nw_e6db3069-dbbd-4a1e-a296-4fa96c4b790a">3,728</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtMy0xLTEtMTQ1Nw_1f1b4c01-8665-42de-a6f7-79fcb23e8fa3">4,370</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtNS0xLTEtNTIw_5129959b-be5e-4c90-8d1a-561b9babe1b3">10,369</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtNy0xLTEtMTQ1Nw_eab218ca-0e01-4446-8279-a694e0aeab20">14,273</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (loss) per Share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMzItMS0xLTEtMA_fa8c7be1-2f88-46fc-ae9b-994c9bca9204">0.11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMzItMy0xLTEtMA_cf8be5e0-3a85-494a-bb7e-3f8bfd7a5607">0.13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMzItNS0xLTEtMA_7359c49f-1698-4a9a-b543-45dc76399701">0.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMzItNy0xLTEtMA_a7d05f28-6e9f-44b4-80bf-100aceacf6ea">0.42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.402%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended September 30, 2019 and 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance<br/>June 30, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a8c6709ab6545788f01bb876f8ad5fb_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy01LTEtMS0w_eeb7e0e9-19b9-4f40-8ba5-2a45f1dfeffd">33,921</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8c6709ab6545788f01bb876f8ad5fb_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy03LTEtMS0w_1ce9dc70-48fb-4465-b89e-8242fdfb2409">34</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae41f525baaa42f39576509f7721cc15_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy05LTEtMS0w_c433c52e-1479-4b2e-a120-593c7125673f">55,086</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0cce47726d34e2ebdd2418732677619_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy0xMS0xLTEtMA_529a0a3e-8a9e-47ef-a60c-4547f3d0e7fe">24,320</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec6913c76db848e48f75b33fdd549043_I20190630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy0xMy0xLTEtMTQ2Ng_d41fba2c-183c-4e4e-8783-c7d70bdc6a82">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f64a85dde3d4406b0968a6843b6650a_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy0xNS0xLTEtMA_bcc5bc9f-04d9-4bac-9d2e-f47a2f0aa1bd">79,440</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options exercised for cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1017cca871c456794046e8f6db58bad_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNC01LTEtMS0w_248adac3-192b-46aa-b9ad-5a53bb6a7237">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55f9c780b1545c394b8709a246c5d8d_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNC05LTEtMS0w_1e23685b-62de-426d-9235-b616edd4043a">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNC0xNS0xLTEtMA_39437f67-8682-4253-a3dc-84f65fd362c3">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55f9c780b1545c394b8709a246c5d8d_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNS05LTEtMS0w_5dad065f-bf3c-48a9-8ca1-e7e6e2827209">543</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNS0xNS0xLTEtMA_e97e8cac-e43c-4067-b212-972aaa0ce1bf">543</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1017cca871c456794046e8f6db58bad_D20190701-20190930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNi01LTEtMS0w_5a36d28e-cb3f-4457-ac4f-2fa838deb34f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="apyx:StockSwapToAcquireOptionsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNi0xNS0xLTEtMA_58aef9fd-7042-458c-80b5-d64ef0f53e97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icccdbde53c634286a08502b7067c3bd4_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNy0xMS0xLTEtMA_a6439ef8-b9ab-43f5-a7e1-1c669639cdbb">4,370</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNy0xNS0xLTEtMA_24a44a10-c2ca-4eeb-94a4-a42b777fe3eb">4,370</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance <br/>September 30, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8247c825010848fe816f263c06eb0578_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC01LTEtMS0w_974538f6-28dc-4adf-93ab-3a455b1a3ac3">33,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8247c825010848fe816f263c06eb0578_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC03LTEtMS0w_a24dd748-4d07-47de-859b-f9a388e27202">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ecaae1891940d8b30cde984cfab290_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC05LTEtMS0w_8f485885-8cd6-4d61-9004-3709a540fa50">55,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib934edd7927e448fa857c4334c0b224d_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC0xMS0xLTEtMA_b8e2a388-1af6-458d-bfcd-57f701234866">19,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic57895c375be486494052fff7c84896e_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC0xMy0xLTEtMTQ3Mg_ac1deba1-5520-4921-af28-b733c6cbe300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e15604132e64bd7be8c75ff25d7ad0f_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC0xNS0xLTEtMA_4cb33de8-44ee-483a-b073-d0ef322cf21d">75,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance<br/>June 30, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i925ea0d8fa8047c0944ddd95c69a0069_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtNS0xLTEtMA_395d3459-4339-42db-8466-a6714f804adf">34,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925ea0d8fa8047c0944ddd95c69a0069_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtNy0xLTEtMA_ee05791f-f577-4614-88b5-f56e4ffcad76">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbfeeeeb5d894c0aa6a94f455268d87a_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtOS0xLTEtMA_6fe0b3d1-d3d6-459a-b164-1dcfa520da7a">58,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67fcb851c8f84550946c58cdf9f7aa5c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtMTEtMS0xLTA_db673d33-152e-4b21-903e-7d2cf7cb9417">7,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bf1b493fcef4659bc8ded12611e9884_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtMTMtMS0xLTA_184a6430-1a66-4ef2-82d7-753ba0947bb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f5e2ba84d164ba7a5ffa6e3aeaae063_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtMTUtMS0xLTA_ff5d1c31-d895-48c9-938c-fcb5abfb58be">66,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b33044ef2c41908861223ecfd71ee6_D20200701-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtMTMtMS0xLTUzMw_bb423cef-5e6e-41e0-91aa-4ac1c8cd6b33">148</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtMTUtMS0xLTU1MA_551f69b1-7416-40da-8f61-ec69ad94fc43">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options exercised for cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64e52d7a0147408f9c71d68e6fbcaa1d_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtNS0xLTEtMA_e61211ea-5cf3-4724-a2ba-fce665135d34">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc2aaaf8f7f4a9b85cf16e63389f75a_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtOS0xLTEtMA_dea6a744-bcc0-4eaf-ad0a-303b4d6ce29f">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtMTUtMS0xLTA_e0c3dd8b-4e47-4bcb-aee0-fd15db40bf32">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc2aaaf8f7f4a9b85cf16e63389f75a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTItOS0xLTEtMA_f4d6b906-6542-4c41-a3c6-09bbc7b0d5e4">1,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTItMTUtMS0xLTA_6a436622-d3b1-4986-8875-86029f0aced0">1,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64e52d7a0147408f9c71d68e6fbcaa1d_D20200701-20200930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTMtNS0xLTEtMA_8a449585-a1ea-4609-8d9f-aeed897af1aa">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="apyx:StockSwapToAcquireOptionsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTMtMTUtMS0xLTA_b6910021-5770-452f-8ed5-28086c532683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i913d962436cd4db8a7740c64ad7493b5_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTQtMTEtMS0xLTA_66b55dfb-12e3-4717-acb5-967cd97ccd68">3,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1b33044ef2c41908861223ecfd71ee6_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTQtMTMtMS0xLTA_c357d017-ec33-439d-b62a-18e19824a585">6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTQtMTUtMS0xLTA_ac2819eb-b0fa-49d9-8ed8-513675327517">3,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance <br/>September 30, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28f36fa133df4eaf9642016fef6664fe_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtNS0xLTEtMA_e350e604-8d37-4e76-95c7-dc8ccae8db6d">34,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f36fa133df4eaf9642016fef6664fe_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtNy0xLTEtMA_256f9f63-fe3c-4884-82e1-7e4443eef9f9">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a5510f10b3844959983d33e64e5204e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtOS0xLTEtMA_49a1c308-5ecf-49a5-98f6-269b8bb114e2">60,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92085eaad57f43949f28a8490b3618a3_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtMTEtMS0xLTA_efb91159-01ee-4542-b2d2-38672e68b532">4,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274049f33bc542f2b5c4a1edc98332f2_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtMTMtMS0xLTA_c03485fd-1fc2-4ecd-8233-e9cbaa4be807">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtMTUtMS0xLTA_571c3d64-78d1-4066-90dc-c9801163b968">64,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine months ended September 30, 2019 and 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance<br/>December 31, 2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0abc8cd3d9e4b8aacdbb3de72f2dd69_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtNS0xLTEtMA_073f9eb9-9265-414e-a11e-5be884728e0e">33,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0abc8cd3d9e4b8aacdbb3de72f2dd69_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtNy0xLTEtMA_1d7a3985-a3e2-49d8-85ee-abba56609e0d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef3ec014e56475892c3f14c254b885d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtOS0xLTEtMA_2a2ec329-6e98-47a7-9f8f-2766a7db18e3">52,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a68681edbde45efadb3509ae7c13af1_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtMTEtMS0xLTA_70d06fba-b585-4281-9f82-7816c2c9ffcf">34,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ae8661537740f6926d686bfe24cd51_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjEtMTMtMS0xLTE0NzY_af5853dc-d42f-402e-8ab0-a678f74165d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbc93ccd4814ef99c90d7c8890ea00d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtMTUtMS0xLTA_681d2745-7ab8-4ebb-8cc1-f48d8d9b93e9">87,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options exercised for cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bf8a9b477f84987a0b6c058bcd7e649_D20190101-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjEtNS0xLTEtMA_b54be022-c7b0-4a9d-bbe1-e91ba96763c9">51</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48fc99dafca2425db5c4a6fcb37ec8ea_D20190101-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjEtOS0xLTEtMA_f8708d0d-4b0c-42c3-a8ec-d15d2f00b8df">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjEtMTUtMS0xLTA_556c1480-3a5f-4a27-b175-b4dba9c79643">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48fc99dafca2425db5c4a6fcb37ec8ea_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjYtOS0xLTEtMA_e654d63c-22a3-497d-9ff7-e9ab115c3eb9">2,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjYtMTUtMS0xLTA_e2bfbbde-1e57-4480-b23a-acb912286d93">2,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bf8a9b477f84987a0b6c058bcd7e649_D20190101-20190930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjgtNS0xLTEtMA_69286109-2d79-4b5c-9aa7-32a09d9f18c4">221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="apyx:StockSwapToAcquireOptionsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjgtMTUtMS0xLTA_f66a6636-4412-4df7-a4cf-4694d52ac4d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b83789be6c1428f8e0e804d7baf2a2f_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjktMTEtMS0xLTA_b41f5c06-b310-49f3-a506-ff02a7922a3c">14,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjktMTUtMS0xLTA_bb7026e2-47db-4709-aa78-188313e90ab2">14,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance<br/>September 30, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8247c825010848fe816f263c06eb0578_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtNS0xLTEtMA_45daa9fe-e963-4609-85e4-18253ac70e43">33,977</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8247c825010848fe816f263c06eb0578_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtNy0xLTEtMA_3a47f623-0c11-4482-90ab-6477fd12ca08">34</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ecaae1891940d8b30cde984cfab290_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtOS0xLTEtMA_f1a13bd7-3b0b-4ffd-bc4d-8fb9911317b4">55,668</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib934edd7927e448fa857c4334c0b224d_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtMTEtMS0xLTA_7d1f1900-bfab-4bf2-90d3-9ab9e026019c">19,950</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic57895c375be486494052fff7c84896e_I20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzEtMTMtMS0xLTE0Nzk_13900279-6c78-436b-984f-da0468677c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e15604132e64bd7be8c75ff25d7ad0f_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtMTUtMS0xLTA_de0e67e6-a548-4c42-b787-5880d29023a3">75,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance<br/>December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedf6a9cfc3ce4884aee9545865031864_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtNS0xLTEtMA_067e7f0d-a014-4ece-baef-5f8db25bc09f">34,170</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf6a9cfc3ce4884aee9545865031864_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtNy0xLTEtMA_6b9f712f-493c-4dcf-a239-1f6278fcc52a">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa6da815695f48cf8033a128044cf36f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtOS0xLTEtMA_d6da7268-a88f-4c17-a02b-4ca9199a8cf8">56,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6dfcb91e634687989de6d0e02edef7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtMTEtMS0xLTA_4413e221-6de4-4181-9cac-23e6cf9d1118">14,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a48387011840968abaf55fba3a032e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzQtMTMtMS0xLTE0ODE_6ae8f061-87be-4ce8-b572-59d1d1104645">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtMTUtMS0xLTA_2b48e2aa-856a-4123-9da8-1a38d4e88e06">71,259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contributions from non-controlling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54b5bfcc70b54a58914b26f39e6b0701_D20200101-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzUtMTMtMS0xLTU1NA_3983aceb-f8da-4eb3-b787-5987d3fe95f4">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzUtMTUtMS0xLTU1NA_063f54b0-9446-4e11-9741-fba418379bf2">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options exercised for cash</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7aebc2db6474548be882738252f5712_D20200101-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzQtNS0xLTEtMA_a57cefaa-e9b5-42bc-9dc7-c867e5321788">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde6c535194047a4ab3e479617f5d580_D20200101-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzQtOS0xLTEtMA_38c95318-1edf-4efe-84cd-01afc58ca0cb">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzQtMTUtMS0xLTA_9085cbf9-3396-4891-a576-24eacc9b2b39">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifde6c535194047a4ab3e479617f5d580_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzktOS0xLTEtMA_a9b09057-a0c9-4e07-a55c-cd36eaf4d35b">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzktMTUtMS0xLTA_0972cb04-2079-4fc9-9740-c5d226218835">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7aebc2db6474548be882738252f5712_D20200101-20200930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDAtNS0xLTEtMA_f7975d0f-e673-4e18-9fae-e6f438f45c7c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="apyx:StockSwapToAcquireOptionsAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDAtMTUtMS0xLTA_2610e748-568c-4b3a-a09b-5069f21f861c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ca82284cce84aec9905621979eac687_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDItMTEtMS0xLTA_02a21a28-1e67-4b5a-87a8-1e26347b8065">10,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54b5bfcc70b54a58914b26f39e6b0701_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDItMTMtMS0xLTA_58a0f039-bcbb-4783-9d50-c91ceb936320">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDItMTUtMS0xLTA_607e386e-da2e-4b5e-bdd2-4480d076c419">10,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance <br/>September 30, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28f36fa133df4eaf9642016fef6664fe_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtNS0xLTEtMA_c97b60e4-16dc-47db-bdc3-1ecbda7b17df">34,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f36fa133df4eaf9642016fef6664fe_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtNy0xLTEtMA_c71c5ce7-73cd-4e62-8748-28eb5d3f5bf7">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a5510f10b3844959983d33e64e5204e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtOS0xLTEtMA_6759407e-0e05-43a6-a6a1-5fef21b1bb8d">60,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92085eaad57f43949f28a8490b3618a3_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtMTEtMS0xLTA_d0e6238d-697d-451e-8ba3-530aa9ad1bc1">4,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274049f33bc542f2b5c4a1edc98332f2_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtMTMtMS0xLTA_534657b9-ebd3-4add-9a1a-1c9d037ad3e0">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtMTUtMS0xLTA_de0a1f0f-b561-44ac-b39d-ede22530c0ac">64,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMy0xLTEtMS0w_b9dbd6fa-ab2b-43cf-87b2-e4fa3cabfce2">10,375</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMy0zLTEtMS0w_0e11c0e6-d9ea-4f7c-807d-67543206b920">14,273</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNy0xLTEtMS0w_86e9913f-9b91-4071-ba9a-c81592d82813">662</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNy0zLTEtMS0w_7af58124-d41b-4acd-a717-e6a918fb6811">510</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for inventory obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfOC0xLTEtMS0w_e6b24278-b0c9-4d6e-81ac-6b1439016756">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfOC0zLTEtMS0w_6461d10f-0fc0-49b9-9257-d1ac68833f4e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTAtMS0xLTEtMA_3b5e0519-d2c4-45e9-877e-433471d0e261">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTAtMy0xLTEtMTUwMg_85c77a7e-fe29-45fb-aa8c-cbed2e57efca">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTEtMS0xLTEtMA_c3e7bd4c-b1b5-4d33-88a7-b9a438320da9">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTEtMy0xLTEtMA_85f88fd6-74e2-49dd-a77b-4fd08c5527f1">2,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net, non cash lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTMtMS0xLTEtMA_ec4f5421-dbcd-4081-beeb-c16d9a6a4958">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTMtMy0xLTEtMA_899dd88c-5db1-4109-acfb-9ea1effb9db5">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on short term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTQtMS0xLTEtMA_65f8eaac-b38e-4d73-9b7c-b10bea1f4b67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTQtMy0xLTEtMA_2c2162d7-6a0d-4bc3-bf69-efc06e265e24">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for allowance for doubtful accounts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTUtMS0xLTEtMA_10e8441d-a90d-4ecf-8bd2-60aba00cf3f3">486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTUtMy0xLTEtMA_11245e67-ebcd-44cb-897a-9a074b933d92">238</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTgtMS0xLTEtMA_b890597b-aa1f-41e6-ae2c-5930cad42d50">1,389</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTgtMy0xLTEtMA_91f94ba6-d234-42ce-bea6-da2636098096">2,397</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables, prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="apyx:IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTktMS0xLTEtMA_e7aad6bf-c732-444e-aa8b-4c629b46772f">7,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="apyx:IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTktMy0xLTEtMA_885bd428-c34e-4d4e-9674-39a383cca5f8">1,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjAtMS0xLTEtMA_93c590ba-23b8-4e4c-817f-a5270773beea">717</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjAtMy0xLTEtMA_f470bcae-3c0e-4f62-b60e-c9ca56fb474b">1,772</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjItMS0xLTEtMA_2db857ab-72a8-470a-bdc0-1092d7d1d50f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjItMy0xLTEtMA_48544e0f-3d9f-442a-8c5a-accc16ee0dcd">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjUtMS0xLTEtMA_af14903b-1b70-41f9-85fa-1ff08f41945b">2,352</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjUtMy0xLTEtMA_61a79522-8824-4590-b693-8d289e7387b7">1,611</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjctMS0xLTEtMA_bbb28e81-9488-4778-85e0-0e60f17f2263">15,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjctMy0xLTEtMA_099efc67-f24a-42c3-a82a-bbf63a99afb9">15,224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjktMS0xLTEtMA_7d52f463-47d6-4a3c-8572-0837cb52496b">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjktMy0xLTEtMA_90d317d3-697b-4573-b6f0-20c7a2c3491f">1,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzAtMS0xLTEtMA_0b3989f1-3b43-420c-a17a-1e78227177fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzAtMy0xLTEtMA_bc0a5b77-dfea-48f5-aa40-4fb45ee8c51b">18,884</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzEtMS0xLTEtMA_93f56c52-8b24-428a-9aa9-66afadd64b60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzEtMy0xLTEtMA_52c9e7d0-7dc2-4a01-afac-6bcac3569fba">80,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by  investing activities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzUtMS0xLTEtMA_3b3907a2-2849-47f0-976b-eb77b84dfdd8">193</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzUtMy0xLTEtMA_f226818a-f83b-4ce5-95c0-7e4f75c1d28d">60,766</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzctMS0xLTEtMA_daad03ad-aad0-447c-a93e-a500ff87c445">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzctMy0xLTEtMA_19526f9c-484b-440d-a103-9160024924f2">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="apyx:RepaymentofFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzktMS0xLTEtMA_c83f1188-bd5e-4695-9142-bda310648f6a">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="apyx:RepaymentofFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzktMy0xLTEtMA_efc405e0-a560-490b-8c60-df17400404be">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDAtMS0xLTEtMA_7604de05-3891-4c7a-b93b-fe4642818dbf">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDAtMy0xLTEtMTUwMA_04574bb7-cc52-435f-b843-0dd9b143cac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDQtMS0xLTEtMA_5962a179-ea8d-48be-8842-f25f65200644">61</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDQtMy0xLTEtMA_a15bfdc4-d0f6-4fd8-8280-c3cba4e167ce">152</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDUtMS0xLTEtMA_7a568cd7-246e-4846-b755-fc42f158fed0">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDUtMy0xLTEtMA_1bc28229-d3c7-49f7-9081-cca0eb57aec4">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDYtMS0xLTEtMA_4ecc01a2-c43b-4ac4-9dd1-11982398a502">15,273</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDYtMy0xLTEtMA_f8e551bb-774b-475a-8e29-c8a508e22550">45,676</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDctMS0xLTEtMA_cbe133c9-2764-455b-9d08-70794e50e9f2">58,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbc93ccd4814ef99c90d7c8890ea00d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDctMy0xLTEtMA_dbba8824-97e2-45db-b0ff-306080240224">16,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDgtMS0xLTEtMA_05d497dc-b214-4d5f-84eb-65adc7551a6b">43,539</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e15604132e64bd7be8c75ff25d7ad0f_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDgtMy0xLTEtMA_5d8e0874-c376-49ce-bb18-2648dedfc412">62,272</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTEtMS0xLTEtMA_09cdc57d-2226-492e-8fe1-ded43e5253dc">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTEtMy0xLTEtMA_9c8849ec-aaa6-4a53-bc2a-f5066f8854d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTItMS0xLTEtMA_ea408cf8-14ec-41ee-8bf8-ba30968df8c5">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTItMy0xLTEtMA_60f69a26-d423-47f4-a7e2-51adbc13519b">248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non cash activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="apyx:LeaseAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTYtMS0xLTEtMA_dca68aa6-972b-4b35-8ace-49c10bfb0c2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="apyx:LeaseAdoption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTYtMy0xLTEtMA_a91e767f-05fb-4717-b0e2-f5b8ed73280f">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="apyx:CapitalizationOfLeaseNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTctMS0xLTEtMA_cd747b43-435f-41c3-bdbd-86911282fd6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="apyx:CapitalizationOfLeaseNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTctMy0xLTEtMA_a8fe0365-1999-42de-a01c-83e4bc4f4156">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="apyx:CapitalizationOfLeaseExecution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTgtMS0xLTEtMA_ae182425-1c5f-45f2-915e-85d27aac8929">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="apyx:CapitalizationOfLeaseExecution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTgtMy0xLTEtMA_81e0c51a-2833-4e4b-973b-5e905fa5457e">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Transfer of other assets to property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="apyx:NonCashTransferOfOtherAssetsToFixedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTktMS0xLTEtMA_3b84e84a-7a6e-49a6-8238-33643b86ea0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="apyx:NonCashTransferOfOtherAssetsToFixedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTktMy0xLTEtMA_7ce16032-d9f6-4228-9614-a2fdef0609ee">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Transfer of inventory from property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="apyx:NonCashTransfersOfInventoryToFromFixedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNjAtMS0xLTEtMA_3129ecca-380e-45e7-8df1-517ad4b9739a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="apyx:NonCashTransfersOfInventoryToFromFixedAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNjAtMy0xLTEtMA_2f881a36-6103-4712-b8ab-59c893e4ba7b">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_34"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8zNC9mcmFnOjQzOGZkNzY4ZTA3ZTQyNTJiN2JmYzgyZjRhMmI3YmUwL3RleHRyZWdpb246NDM4ZmQ3NjhlMDdlNDI1MmI3YmZjODJmNGEyYjdiZTBfNDM4NA_043e0974-fd70-4d01-aee7-6f760a24489a" continuedAt="i5fc195b841284229bf090def71ddc441" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5fc195b841284229bf090def71ddc441"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise indicates, the terms  &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Apyx,&#8221; and similar terms refer to Apyx Medical Corporation and its consolidated subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization recognized the novel strain of coronavirus ("COVID-19"), as a pandemic. This pandemic has severely restricted the level of economic activity around the world. In response, the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. The long-term impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict as the environment created by the pandemic is rapidly changing. In late February, we began to experience the effects of the pandemic which have been material and adverse on our business. However, starting late in the second quarter and continuing through the third quarter, we started to see positive indications in our business. We believe the severity of the impact of the COVID-19 pandemic on our business will continue to depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers and suppliers, all of which are uncertain and cannot be predicted. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the procedures performed using our Helium Plasma Technology are elective, and as a result many of our customers have been affected by the actions taken by various governmental authorities requiring non-essential businesses to shut down temporarily.   As these shut-downs have begun to be reversed, we have started to see an increase in demand for elective cosmetic and plastic surgery procedures, resulting in higher than expected revenues in our Advanced Energy segment.  In international markets, a greater portion of these procedures are performed in a hospital, and it is less certain when elective procedures will fully return to normal.. While we experienced a significant decline in sales towards the end of our first fiscal quarter, we began to see an increase in sales towards the end of our second fiscal quarter, which continued through the third quarter, as local jurisdictions started to re-open. As cases have started to increase again, it is unknown whether these trends will continue. The full extent to which the COVID-19 pandemic may materially and adversely impact the Company's future financial position, liquidity, or results of operations remains uncertain. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019. These condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:AccountingChangesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8zNy9mcmFnOmFmMjJmMTFiM2UzNzRlYzY5M2E2ZjQyZjIzNWFhOWYzL3RleHRyZWdpb246YWYyMmYxMWIzZTM3NGVjNjkzYTZmNDJmMjM1YWE5ZjNfMTAyNQ_00641d00-31c6-48e6-88ce-4f811018ca44" continuedAt="ie94e488825f94536a4bf91bf03c34ec2" escape="true">CHANGE IN ACCOUNTING POLICY</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="ie94e488825f94536a4bf91bf03c34ec2"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8zNy9mcmFnOmFmMjJmMTFiM2UzNzRlYzY5M2E2ZjQyZjIzNWFhOWYzL3RleHRyZWdpb246YWYyMmYxMWIzZTM3NGVjNjkzYTZmNDJmMjM1YWE5ZjNfMTAyNw_6a88681b-bede-431e-862d-e29ec9ab0392" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span></ix:nonNumeric></ix:continuation></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_40"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80MC9mcmFnOmQ2ZjU1Y2YwZGRiMjQ0ZTBhZjZhZGViNDA2ZGU3YmJjL3RleHRyZWdpb246ZDZmNTVjZjBkZGIyNDRlMGFmNmFkZWI0MDZkZTdiYmNfMjU4OQ_3943c0be-4168-4174-9d83-c315e2af417f" continuedAt="i60d52af0aa0b44a9849d5609d302bfdc" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i60d52af0aa0b44a9849d5609d302bfdc"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80MC9mcmFnOmQ2ZjU1Y2YwZGRiMjQ0ZTBhZjZhZGViNDA2ZGU3YmJjL3RleHRyZWdpb246ZDZmNTVjZjBkZGIyNDRlMGFmNmFkZWI0MDZkZTdiYmNfMjU4NQ_6d474095-923e-4704-8a36-14df4723a31d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements, we do not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU 2017-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#8217;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_1112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTAx_b610bbdb-bca9-42bc-8552-56ed7be075c7" continuedAt="i49c59e1eb99146548045a3e0b636b97f" escape="true">DISPOSAL OF BUSINESS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i49c59e1eb99146548045a3e0b636b97f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, we closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly-owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie&#174; brand and trademarks, to Symmetry for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0448759fc2be4fa382f8f4658e300986_D20180830-20180830" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTAz_7004f703-d5fc-4f4f-99bf-46f85e2993cf">97</ix:nonFraction>&#160;million in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, we entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a <ix:nonNumeric contextRef="ib14b6c67e6dd455abc6901028ba4538a_D20180830-20180830" format="ixt-sec:durwordsen" name="apyx:AssetPurchaseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMzU0_76742043-6a49-4398-b70e-60cc22753618">four-year</ix:nonNumeric> term, whereby we will manufacture certain Core products and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in our Condensed Consolidated Statements of Operations as other income or (loss). Core activity for the three months ended September 30, 2020 amounted to&#160;$<ix:nonFraction unitRef="usd" contextRef="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTE2_622f1aba-4f2d-4e2a-9eda-194f50e66c77">1.8</ix:nonFraction>&#160;million&#160;with cost of sales equivalents of&#160;$<ix:nonFraction unitRef="usd" contextRef="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTMw_60202f12-1f0c-4ca5-b94c-505ee523c99b">1.6</ix:nonFraction>&#160;million&#160;and related other expenses of&#160;$<ix:nonFraction unitRef="usd" contextRef="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTQ0_66eeefa8-2272-4237-91b3-171eb651ec85">0.3</ix:nonFraction>&#160;million for net other (loss) of $<ix:nonFraction unitRef="usd" contextRef="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjAw_a6aaee67-6b3d-4177-af11-a00ff3988484">0.1</ix:nonFraction>&#160;million. Core activity for the three months ended September 30, 2019 amounted to&#160;$<ix:nonFraction unitRef="usd" contextRef="i852d57be8ad6467b9ab3b88460783b01_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTU4_54d3b701-e25d-4db7-b70f-32e2aa5ff7ea">2.5</ix:nonFraction>&#160;million&#160;with cost of sales equivalents of&#160;$<ix:nonFraction unitRef="usd" contextRef="i852d57be8ad6467b9ab3b88460783b01_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMzI4_3b2824a8-90bd-4c16-a54e-e973d0fb7672">2.2</ix:nonFraction>&#160;million&#160;and related other expenses of&#160;$<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMzkz_d9b98bd5-338e-48cf-953b-2a2967532ba4">0.1</ix:nonFraction>&#160;million for net other income of $<ix:nonFraction unitRef="usd" contextRef="i852d57be8ad6467b9ab3b88460783b01_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTcy_5a3ae48b-8345-4b55-af89-00a2a833785a">0.2</ix:nonFraction>&#160;million. Core activity for the nine months ended September 30, 2020 amounted to&#160;$<ix:nonFraction unitRef="usd" contextRef="i956b294a00a54308901dd7f15329f5a2_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjI4_6fae21ff-12ae-436a-8669-991e101bfa33">6.9</ix:nonFraction>&#160;million&#160;with cost of sales equivalents of&#160;$<ix:nonFraction unitRef="usd" contextRef="i956b294a00a54308901dd7f15329f5a2_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTg2_48d8b465-6f53-4097-9bed-938a2bd6e63d">6.1</ix:nonFraction>&#160;million&#160;and related other expenses of&#160;$<ix:nonFraction unitRef="usd" contextRef="i956b294a00a54308901dd7f15329f5a2_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMzEy_9eba25fd-9b3d-4d3e-a09c-0372ab108335">0.5</ix:nonFraction>&#160;million for net other income of $<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxNDA3_311bba90-62c8-4433-be37-c1c5521ffacb">0.3</ix:nonFraction>&#160;million. Core activity for the nine months ended September 30, 2019 amounted to&#160;$<ix:nonFraction unitRef="usd" contextRef="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjk4_270631e3-f6e9-448e-a8be-5a925a7e5dd5">6.9</ix:nonFraction>&#160;million&#160;with cost of sales equivalents of&#160;$<ix:nonFraction unitRef="usd" contextRef="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjU2_a8dd5db3-ad85-41cb-86d6-4b8474fcf907">6.6</ix:nonFraction>&#160;million&#160;and related other expenses of&#160;$<ix:nonFraction unitRef="usd" contextRef="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjcw_829b6d61-71ae-43f9-ba95-b9406e8286ab">0.2</ix:nonFraction>&#160;million for net other income of $<ix:nonFraction unitRef="usd" contextRef="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjg0_30c2881f-97a5-4c82-89cc-1a19c1a803d6">0.1</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_43"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. &#160;&#160;&#160;&#160;INVENTORIES</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RleHRyZWdpb246YzZiYTUxNGEzY2NkNDY3NThhYmEyMjRjMWU5ZjhjMTFfMTAwNg_4e3d108a-11f4-4658-a829-aa2007c52698" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RleHRyZWdpb246YzZiYTUxNGEzY2NkNDY3NThhYmEyMjRjMWU5ZjhjMTFfMTAwMg_032b7afc-bf8c-474f-9b83-af93f0877077" escape="true">Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RleHRyZWdpb246YzZiYTUxNGEzY2NkNDY3NThhYmEyMjRjMWU5ZjhjMTFfMTAwOQ_81fdf870-a4e9-45dc-a28c-fcf013b80da0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMS0xLTEtMS0w_9053d8a6-5134-49ec-8c6a-a3945a669dfc">2,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMS0zLTEtMS0w_c40c097b-e8c5-47ee-9280-7aee5241f977">2,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMi0xLTEtMS0w_210d7977-2a3c-4a89-90bd-bb99a5fd1b20">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMi0zLTEtMS0w_e2f20e62-d71f-4ecd-bdc3-ea3f1b273ac9">1,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMy0xLTEtMS0w_85f4bb09-b995-46df-ad26-2234e2c6537b">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMy0zLTEtMS0w_99bb7b09-150c-4d1d-b8d7-98cda7a8bc64">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNC0xLTEtMS0w_54b24571-3664-405c-b305-f057e0e05a3e">5,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNC0zLTEtMS0w_5d8bee3f-6e04-45ff-9262-ce64d8e04d43">5,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNS0xLTEtMS0w_0a0dc6f4-84bf-4845-8bf0-cf1ab2648cc1">537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNS0zLTEtMS0w_7001e2b3-b0e5-4284-831c-44e0f2be0957">392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNi0xLTEtMS0w_3eed6657-1d1e-416e-a71a-a7b98cd64468">5,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNi0zLTEtMS0w_29d79677-e620-49f6-b541-522db7fa5b86">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs, and earlier than expected completion of product registrations in some of our foreign markets.&#160; As a result, certain products were reduced to a lower carrying value, and some components were also written down as we determined to cease further production on these older models. The total impairment was approximately $<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RleHRyZWdpb246YzZiYTUxNGEzY2NkNDY3NThhYmEyMjRjMWU5ZjhjMTFfODYw_0afdb9f6-d285-4547-bd86-e1692d911eb1">400,000</ix:nonFraction> and is included in cost of sales in the accompanying consolidated statement of operations for the nine months ended September 30, 2020.</span></div></ix:nonNumeric><div id="i85d2870f2c594539a4d7339b7b1f7fd1_49"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RleHRyZWdpb246ZTU5ZGI5NzAwMGZjNDhmODhjOWY2OTQ0NmQ1NTk5YWJfMTQ3_affead6e-bbdc-4e61-ad56-9fb2789a3cbf" continuedAt="i2a973bb423194f809a46c567b17cec84" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i2a973bb423194f809a46c567b17cec84"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RleHRyZWdpb246ZTU5ZGI5NzAwMGZjNDhmODhjOWY2OTQ0NmQ1NTk5YWJfMTQ5_d274714d-82dd-46d7-ace9-c3384338ecce" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:62.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, <br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMS0xLTEtMS0w_28f1995d-3828-4929-95f9-c8443a3e790c">497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMS0zLTEtMS0w_8c7dae9e-7f9a-4aed-b96c-dab8ea3eafe3">694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMi0xLTEtMS0w_102678c9-1b5e-47b4-b62e-fc2c7247cdeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMi0zLTEtMS0w_60fda279-f8bf-401b-9b3c-2d662f552d5f">1,306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMy0xLTEtMS0w_5e1e541d-89ba-4265-8434-e5a6dc61ff02">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMy0zLTEtMS0w_66e7a68d-cfd7-4abe-b38a-0795612ebb31">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNC0xLTEtMS0w_02dbef7b-8ad2-4eb3-80e8-ee47658b8288">471</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNC0zLTEtMS0w_81b2fee2-7da7-456a-89f9-e1bb0f3de63c">452</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNS0xLTEtMS0w_06f9bac1-da5a-4880-b340-bbd16ed65adb">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedInsuranceCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNS0zLTEtMS0w_6b36cf5c-166c-4a38-ba16-078678a7ccee">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNi0xLTEtMS0w_1a64c1de-a549-459a-8d66-15b0a1e52572">744</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNi0zLTEtMS0w_34dce3bf-8f65-4e3a-952e-ca5d6deabb02">1,383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNy0xLTEtMS0w_6614f9de-fadd-4cb3-8ab4-a27803fba97c">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNy0zLTEtMS0w_7c76c515-d0dd-4382-8c27-a0739622072c">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="apyx:UncertainTaxPositionsLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfOC0xLTEtMS0w_266386ee-50ad-40ae-b812-02861766388b">1,616</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="apyx:UncertainTaxPositionsLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfOC0zLTEtMS0w_c3f5d1fd-1f43-4756-9063-32bfdd4a386b">1,491</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfOS0xLTEtMS0w_dc55aa39-46ad-4d80-bdc4-461c39e5a1ad">963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfOS0zLTEtMS0w_458a93f8-1394-48bb-a26f-69b8d32d0685">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMTAtMS0xLTEtMA_db2f397f-878c-469e-80d9-5f100b3f7a79">6,588</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMTAtMy0xLTEtMA_54e68571-abfc-4067-bb70-95cb49def25c">9,396</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_1058"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3NzMz_8d396a0a-3b7b-4903-801f-9cf3cbd7b1a5" continuedAt="i914b6159bfe04ecbab3cf27aa898a37a" escape="true">NON-CONTROLLING INTEREST</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i914b6159bfe04ecbab3cf27aa898a37a" continuedAt="if8c0a8c2455c42a79f497dae67c73c27"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2019, we executed a joint venture agreement with our Chinese supplier ("China JV"). The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="apyx:NoncontrollingInterestRequiredCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3NzEz_1bb28c0a-cfa4-4f7a-a0c7-8d1db6907aed">360,000</ix:nonFraction>, of which approximately $<ix:nonFraction unitRef="usd" contextRef="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3NzIz_88387c44-3df6-4916-be3e-ae877d23b5a0">154,000</ix:nonFraction> was contributed during the three months ended September 30, 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="apyx:NoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3NzMy_81483306-b679-4a06-a59e-5e2d9ea40507" continuedAt="i7b530251cb3642e29d22c32285f0f634" escape="true">Changes in our ownership interest in our <ix:nonFraction unitRef="number" contextRef="i35b49cbb47b64d98abab16201295d5a6_I20200930" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3Njk5_b4f329d2-787a-48d0-bb24-8554ba22058e">51</ix:nonFraction>% owned China JV were as follows:</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="if8c0a8c2455c42a79f497dae67c73c27"><ix:continuation id="i7b530251cb3642e29d22c32285f0f634"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.072%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c0390a429a4234aa1f855c20366a70_I20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF8yLTEtMS0xLTE2NDU_a5a409e5-1fd3-48a9-be05-897892d3699c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dd1a24600384e0c988695d6cf2c976e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF8yLTUtMS0xLTE2NDg_f5130467-2c77-4977-a86f-b4921c69dbdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc6a13d050543ca9de29ba517195a6e_D20200701-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF8zLTEtMS0xLTE2NDU_35a0063b-90cf-4447-89e4-dca05c166fca">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF8zLTUtMS0xLTE2NDg_1016869b-299e-4ceb-a31a-c8610fb5fdf2">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc6a13d050543ca9de29ba517195a6e_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF80LTEtMS0xLTE2NDU_94e45d00-c219-4eb3-9d37-a3edfbadca12">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF80LTUtMS0xLTE2NDg_473d8861-728a-4988-b5de-5f2c3f253600">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied11d7234a5948deb5fe2210e04162f5_I20200930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF81LTEtMS0xLTE2NDU_d23b2d71-d90a-4cd9-b3d2-dc2e734c603c">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied11d7234a5948deb5fe2210e04162f5_I20200930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF81LTUtMS0xLTE2NDg_503ddd45-e0f1-4f12-9641-61a203b68ddb">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_52"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RleHRyZWdpb246OGMwY2YxNDJmNTIxNGM4ODlhYjI0ODNlNWYzODg2NGRfNTc0_ab24df65-1b8d-4315-a566-658af8463244" continuedAt="ia3bb3272247c492d8f5762a490b13b15" escape="true">EARNINGS (LOSS) PER SHARE </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia3bb3272247c492d8f5762a490b13b15"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings per share (&#8220;basic EPS&#8221;) by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period adjusted for other units required to be included in basic EPS. Diluted earnings per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As we are in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RleHRyZWdpb246OGMwY2YxNDJmNTIxNGM4ODlhYjI0ODNlNWYzODg2NGRfNTgx_82b6a82d-d1b9-4dc1-987b-c5c34f129e61" continuedAt="i1e5a8a626fe644d7b1ebdf3612a85f77" escape="true">The following table provides the computation of basic and diluted earnings per share.</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i1e5a8a626fe644d7b1ebdf3612a85f77"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.193%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMy0yLTEtMS0w_e39c8c1c-e682-4234-b4c3-b95245c38a08">3,728</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMy00LTEtMS0w_739023bf-9e5c-4b1e-9677-9f61b3d7ec69">4,370</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMy02LTEtMS0w_aec9a028-c3ae-4275-b866-917087251c66">10,369</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMy04LTEtMS0w_3ac992ef-7d71-4c96-a2af-6f346f1f9f82">14,273</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfNi0yLTEtMS0w_cd6f184b-5f52-45c8-bfdd-d10f9708b561">34,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfNi00LTEtMS0w_8c62d7e3-fb3f-4106-86c6-c33b3639b7da">34,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfNi02LTEtMS0w_57ba4d33-a3c7-432f-bb81-770957fcece2">34,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfNi04LTEtMS0w_0e282e37-c916-4d99-9b50-2389b6b6cab3">34,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfOS0yLTEtMS0w_e2509928-95e1-44f8-8d90-65d81366c98c">0.11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfOS00LTEtMS0w_49b7d2a0-30d3-43fc-9f06-6d82c16ed3af">0.13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfOS02LTEtMS0w_a268c015-6391-4375-af64-4610f543ad80">0.30</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfOS04LTEtMS0w_b5f8f978-6f25-49f6-bf67-09ed71f17501">0.42</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i055002fdfdea449397dfa999e230e0cb_D20200701-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItMi0xLTEtMTY2Mw_81d73e37-b3db-404f-8695-ae7e2f29740c">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4e8528a777540ed922e20d4c68e0ad9_D20190701-20190930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItNC0xLTEtMTY2Mw_a5fef082-50b6-4800-90ee-9c42aef0583a">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98a828c250044883817cff327ba04649_D20200101-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItNi0xLTEtMTY2Mw_d6b53ac8-83c1-4f67-807d-97a805888d54">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d0ef098d3204c5c98b0e22874cdea4f_D20190101-20190930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItOC0xLTEtMTY2Mw_f597854d-4682-4a4a-aa09-9bd437b7d991">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i231f501bd1f2450b9fa914b657791e11_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItMi0xLTEtMA_db2ea22b-d442-4de8-8126-ceb663f30f49">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34a1bdc5e0da4360939ec99da52debd2_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItNC0xLTEtMA_ab953c9f-a82b-4bfd-a822-181c0f26ebcd">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd5dddf56d00470b8aa7a88a79e92300_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItNi0xLTEtMA_030665ca-169f-4944-acfa-cf6dfd2f5599">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99f0487382914de3b1695fcaf943831e_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItOC0xLTEtMA_c0bd6a66-e958-43bf-bc03-4b3743d3d1f1">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMTc3MQ_28e5e43a-3833-402b-850a-0bfef3ae1379" continuedAt="ibecaa700e0554305a6c0a74faa170ec7" escape="true">STOCK-BASED COMPENSATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ibecaa700e0554305a6c0a74faa170ec7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our stock option plans, our board of directors may grant restricted stock and options to purchase common shares to our employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing a trinomial lattice model through 2018 and the Black Scholes model for grants in 2019 and 2020, both of which include a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfNjQ5_e1b9def6-6c53-404c-a197-452707948a4d">1,063,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfNjU2_97deb726-8153-4771-9e82-bc35edb27cef">3,209,000</ix:nonFraction>, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2020, as compared with $<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfNzUy_f917ee42-7833-46a7-aca0-bd0951c213a5">543,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfNzU5_f2380eb9-6d89-42d7-a69f-5a793076c205">2,594,000</ix:nonFraction>, respectively, for the three and nine months ended September 30, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMTc3OQ_6ad3aa2f-12f5-43bb-9d3d-b93a190e0ed6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNS0xLTEtMS0w_be475cf6-e1e5-4941-9ece-a94ef43cec84">3,966,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i73c621036a99473780d3074110069a13_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNS0zLTEtMS0w_874d4b8d-0255-473c-9f71-d2904e6ef9ea">4.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNi0xLTEtMS0w_8bc844f3-3655-43d6-ac71-ebc5d47ecd84">1,376,900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNi0zLTEtMS0w_d368f0f8-5c57-4f3b-9155-1098da86ef11">7.94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNy0xLTEtMS0w_3a7970b1-caa3-47af-a728-63f5d72897fc">81,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNy0zLTEtMS0w_09d3f170-6c7c-4a73-b862-61d3cd7f32eb">3.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfOC0xLTEtMS0w_9d3f88e9-496f-4a35-a887-6ba8ba20f535">234,600</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfOC0zLTEtMS0w_42763469-4745-480f-9bac-400b3050676b">7.57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfOS0xLTEtMS0w_a7340e71-b7e6-4d8a-bc7f-8656f2d6c4df">5,028,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfOS0zLTEtMS0w_6dd5aee9-64c5-4ed9-9c38-bc17d5b8cd7d">5.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allow stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2020 and 2019, respectively, we received <ix:nonFraction unitRef="shares" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzYyNw_5bcf114f-5413-4662-a82a-c4479e37af57">16,140</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzYzNQ_056c9885-5667-4f00-994d-13f6750207fd">26,572</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzY2MA_75b06028-c93b-4f1a-be94-c84772df1d5d">10,610</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzY2OA_4d262493-157f-4ddc-84d1-90a0b417edf3">34,928</ix:nonFraction> options. For the nine months ended September 30, 2020 and 2019, respectively, we received  <ix:nonFraction unitRef="shares" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzY0Mw_0f543cdd-27ff-49d1-bf0e-367bea08b390">29,149</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzY1MQ_9a7432fc-6979-47aa-aeeb-7a1bec4e09b0">118,170</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzYxMA_3675169f-1cdb-4c2a-8d07-cfcd18834ae2">32,637</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzYxOA_c4761703-7b05-44eb-98e0-c6ef3a3a5adc">220,879</ix:nonFraction> options. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from our authorized and unissued shares. <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMTc4MA_9db98e97-597b-49ca-af78-c1df8b22a3eb" continuedAt="i0836507d228d4b559b7de5ee99639247" escape="true">We calculated the grant date fair value of options granted in 2020 ("2020 Grants") utilizing a Black Scholes model with an expected life calculated via the simplified method.</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="i0836507d228d4b559b7de5ee99639247"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:68.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.373%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if7f84ddfcfe34ee2b4fe9e0f5995eafe_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMS0xLTEtMS0w_9843f360-c0a9-47f9-8423-9c334eca0612">4.98</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibbc35ac6e31d4dd7a206d50f3668f460_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMS0zLTEtMS0xNjcx_5e090d07-bd98-4b9c-892f-0ff3750139c8">8.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7f84ddfcfe34ee2b4fe9e0f5995eafe_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMi0xLTEtMS0w_994e527e-f086-4874-a949-e32e1ca87a53">0.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibbc35ac6e31d4dd7a206d50f3668f460_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMi0zLTEtMS0xNjcz_4e3a428a-7983-4205-b8ea-36b037f15e18">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMy0xLTEtMS0w_4472740b-b302-48dc-967f-7613ce3931ec">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7f84ddfcfe34ee2b4fe9e0f5995eafe_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfNC0xLTEtMS0w_ef6745bf-ea0c-43df-9640-e1d7bab2365f">65.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibbc35ac6e31d4dd7a206d50f3668f460_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfNC0zLTEtMS0xNjc1_5ca38fd4-fabb-4630-8bb2-6c799394aa09">70.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfNS0xLTEtMS0w_b2969c12-501a-4158-9928-32d583f95f4c">6</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_58"></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjczNg_7a545046-55d4-41a2-8399-f98d884e5572" continuedAt="ib0f73f2abb5744d195b4f06c0551cff5" escape="true">INCOME TAXES </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib0f73f2abb5744d195b4f06c0551cff5" continuedAt="idf0f224f43844b75a178597a14e8cca3">On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#8217;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, we generated a significant amount of taxable income in 2018. Subsequent to this, we generated net losses in 2019 and through the first three quarters of 2020. For the net losses generated in 2019, we previously recorded a full valuation allowance on the deferred tax assets associated with our NOL carryforwards due to realization of the NOL not being probable under then existing tax law. The CARES Act makes these assets realizable, and as of the date of the CARES Act, we have recognized an income tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfODc3_ff06d704-0751-42c2-966e-bfc15dae4c53">3.7</ix:nonFraction> million associated with the release of the valuation allowance on our Federal NOL carryforward related to 2019. We also recognized income tax benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQxMQ_f1d6b1d9-7fe2-44a1-a8a9-aa488e115e95">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQyNQ_5c7d6e18-f32f-4b5a-bd72-8bfae2c1200d">3.3</ix:nonFraction>&#160;million, related to our loss before income taxes for the three and </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="idf0f224f43844b75a178597a14e8cca3" continuedAt="i00c9132bf3ff4bd09cf50ea74036ef5c"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2020, respectively. There are approximately $<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="apyx:CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQzOQ_a8cd8c0c-b391-4cf5-a149-db8de1605688">2.4</ix:nonFraction>&#160;million of 2018 Federal income tax payments available to offset against any other 2020 losses that may be incurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax (benefit) expense was approximately  $(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMzI5ODUzNDg4ODk0Mw_baaf2027-0bb5-4db0-a539-b91bb42839d6">715,000</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMzI5ODUzNDg4ODk1Nw_396354f5-5d20-4495-8963-d2a7c4fc1882">171,000</ix:nonFraction> with an effective tax rate of <ix:nonFraction unitRef="number" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ2OA_9e9bf7e0-9b68-4359-91f5-19f8c8a1e162">16.1</ix:nonFraction>% and (<ix:nonFraction unitRef="number" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ3NQ_cb165b18-27f7-447e-9bdb-759bf2f3e232">4.1</ix:nonFraction>)% for the three months ended September 30, 2020 and 2019, respectively. Our income tax (benefit) expense was approximately $(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMzI5ODUzNDg4ODk4OA_e3daf71e-0860-4e0a-b4bf-c2f344bf28ff">7,112,000</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODUwNg_52b02d98-81f0-4b67-a5a0-3da439832c54">253,000</ix:nonFraction> with an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ1Mw_67455f25-3cd1-4d04-8f14-cde4fc1e5157">40.7</ix:nonFraction>% and (<ix:nonFraction unitRef="number" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="INF" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ2MA_479a03ef-50d6-4b74-a959-049c2d4bb12b">1.8</ix:nonFraction>)% for the nine months ended September 30, 2020 and 2019, respectively. For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our NOL carryforward from 2019. For the three months ended September 30, 2020, and the three and nine months ended September 30, 2019, the effective rate differs from the statutory rate primarily due to interest and penalties on our uncertain tax positions. </span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00c9132bf3ff4bd09cf50ea74036ef5c">We have gross unrecognized tax benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2OTQ0OQ_6ab8bdbc-19ad-4e9b-b77f-66e95f837c06">1,313,000</ix:nonFraction> at September 30, 2020. We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in our condensed consolidated financial statements. As of September 30, 2020, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ4Mw_70502b1b-a6d8-4949-8957-42297d322ccc">300,000</ix:nonFraction> in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax benefit for the three and nine months ended September 30, 2020, respectively are approximately $<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjM2Ng_0565a096-1fef-46df-8d60-49d57839e708">43,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ5Mw_cf9004ac-f0e4-4daa-9327-e9fe404c9d5a">125,000</ix:nonFraction> of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjU4OQ_2160b17a-7a5f-470c-ba97-65ed35a73ba9">1,616,000</ix:nonFraction> of income tax benefits in the consolidated statement of operations. It is expected that all of the uncertain tax positions should be resolved by October 2022.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_61"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82MS9mcmFnOjNmZGNlNTZmNWNiZDQzZTdiZjUwYTk5YTY1ZTUyODdiL3RleHRyZWdpb246M2ZkY2U1NmY1Y2JkNDNlN2JmNTBhOTlhNjVlNTI4N2JfNDQ4Nw_e15994f4-353f-42b3-ad58-cb0b31e94c7d" continuedAt="i58f3235d6b404c09acea4d7da24463bc" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i58f3235d6b404c09acea4d7da24463bc" continuedAt="i4e07028cdc6c43e6860a6c2179ce26e7"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. We believe that such claims are adequately covered by insurance; however, in the case of one of our carriers, we are in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policies or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated results of operations, financial position or cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2019, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.&#160; On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#8217;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#8220;Amended Complaint&#8221;) with the Court.&#160; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#8217;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#8217;s J-Plasma&#174; technology for use in dermal resurfacing procedures. &#160;On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.&#160; On July 10, 2020, the parties executed a settlement agreement, which was subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020.&#160;The settlement agreement provides for the dismissal of the action with prejudice.&#160;On November 6, 2020, the Court issued its final order approving the settlement and dismissing the action and all claims contained in the Amended Complaint with prejudice. At September 30, 2020,&#160;we have settled and fully paid all obligations related to this matter.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4e07028cdc6c43e6860a6c2179ce26e7"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, we had purchase commitments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82MS9mcmFnOjNmZGNlNTZmNWNiZDQzZTdiZjUwYTk5YTY1ZTUyODdiL3RleHRyZWdpb246M2ZkY2U1NmY1Y2JkNDNlN2JmNTBhOTlhNjVlNTI4N2JfMjE5OTAyMzI3MDQyNQ_e0b4ae14-75f0-4b5b-8a62-04f2088d1939">1,800,000</ix:nonFraction>, substantially all of which is expected to be purchased within the next six months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">China Joint Venture</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreement in the China joint venture requires the Company to make a capital contribution into the newly formed entity of $<ix:nonFraction unitRef="usd" contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930" decimals="-3" format="ixt:numdotdecimal" name="apyx:NoncontrollingInterestRequiredCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82MS9mcmFnOjNmZGNlNTZmNWNiZDQzZTdiZjUwYTk5YTY1ZTUyODdiL3RleHRyZWdpb246M2ZkY2U1NmY1Y2JkNDNlN2JmNTBhOTlhNjVlNTI4N2JfMjE5OTAyMzI3MDUyMQ_48838517-cd01-45a1-b142-ee5c37528e56">357,000</ix:nonFraction>. As of the date of these consolidated financial statements, approximately $<ix:nonFraction unitRef="usd" contextRef="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="apyx:PaymentsToAcquireInterestInJointVentureRemaining" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82MS9mcmFnOjNmZGNlNTZmNWNiZDQzZTdiZjUwYTk5YTY1ZTUyODdiL3RleHRyZWdpb246M2ZkY2U1NmY1Y2JkNDNlN2JmNTBhOTlhNjVlNTI4N2JfMjE5OTAyMzI3MDUzMQ_ef7801c2-f3b0-485b-a25b-485d63499b57">203,000</ix:nonFraction> of our capital commitment remains to be funded.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfODg2_34217bbe-e248-4526-8a6b-ee4f0193d40d" continuedAt="i08acafd3084e486ab90481a7e58b83f0" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i08acafd3084e486ab90481a7e58b83f0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is the Manager of Production and Human Resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is an engineer in the quality assurance department.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of the purchase of the Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for $<ix:nonFraction unitRef="usd" contextRef="iabf0bad69e934fb18dc921efbd473e9f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfNTcx_4c8335eb-6157-4f28-aaa2-417b2d53df01">140,000</ix:nonFraction> to be paid <ix:nonNumeric contextRef="i6aad088e173447ad8a7e163f390e1c17_D20200101-20200930" format="ixt-sec:duryear" name="apyx:TermOfPaymentDueNotesPayableRelatedParties" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfNTg1_8b650386-8021-4d71-89c9-dbf576432a0f">5</ix:nonNumeric> years after the original purchase date, which came due in October 2020. The note was paid in full on October 20, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in our China joint venture is also a supplier of the Company. During the three and nine months ended September 30, 2020, we made purchases from this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="i356212dfd54e49b3aaec12d12ef5c598_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfMjE5OTAyMzI1NjY0MQ_a64fe967-9d10-4e17-af36-73338d636c2e">410,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i759891cb08514e4a9829b1b1f2315bfc_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfMjE5OTAyMzI1NjU3NA_bbcd4a9f-2637-450a-b487-36ebe1f2903c">1,250,000</ix:nonFraction>, respectively. At September 30, 2020, we owed this supplier approximately $<ix:nonFraction unitRef="usd" contextRef="i573e9d9d81ad4ecb9dbd2be6bddc6fb8_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfMjE5OTAyMzI1NjU4Ng_cb985e04-a80f-47d9-a838-a53aa4cbcb65">123,000</ix:nonFraction>.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTcyOA_755921b1-19ef-40a9-ac11-f77e2d6b9340" continuedAt="i81c218f2ad8f4f5b862138d9aabd3352" escape="true">GEOGRAPHIC AND SEGMENT INFORMATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i81c218f2ad8f4f5b862138d9aabd3352" continuedAt="i11b5bda935454a7db70b7211d1917266"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, we have not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are principally organized and managed as&#160;<ix:nonFraction unitRef="segment" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfODM0_294f2127-fdf5-40df-bce1-19e3bb5dd738">two</ix:nonFraction>&#160;operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i11b5bda935454a7db70b7211d1917266" continuedAt="i056c42d1ce4447a2b4a01a9481b7c667"><ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTcyOQ_04c384b3-a9bf-4fa7-93ce-af5ed86a0de8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMi0zLTEtMS0w_88b4af7c-8f63-40ef-aaf6-70e69cd0a90a">5,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMi01LTEtMS0w_25c40129-4940-4a72-9ee4-5ced87df96f9">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMi03LTEtMS0w_70eb2b05-e976-4235-95a0-3b74034a0dff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMi05LTEtMS0w_33a4ad91-4a35-4f93-a65d-75bd9c470309">6,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTQtMy0xLTEtMA_af9401d1-e9e4-455a-ae7e-d53faf513d61">1,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTQtNS0xLTEtMA_0c4e6465-bdc5-4126-8af0-e985f138eb7b">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTQtNy0xLTEtMA_992a9553-9fbb-4a7e-8aa3-82fa8fa8c743">3,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTQtOS0xLTEtMA_3f475eba-ef69-4187-afab-42d9afa82c06">4,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTYtMy0xLTEtMA_90189d3e-6447-4cb3-ba35-a2e8f9ef14a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTYtNS0xLTEtMA_2ffbfe8e-50f4-4fef-ae00-b92ab8ef6c7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTYtNy0xLTEtMA_c06a0cd0-74db-4d89-9489-f297d734797e">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTYtOS0xLTEtMA_5a84e989-41a9-4868-ae4a-bd3237f8185d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTctMy0xLTEtMA_941b1436-1b52-4159-b715-efa32a98ebae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTctNS0xLTEtMA_f6c17853-ebc9-472e-a175-60d1ae721c4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTctNy0xLTEtMA_134a06f7-640b-4cce-abdc-0aa792062006">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTctOS0xLTEtMA_f8ae160c-1807-4345-be84-76b9a8cec825">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTgtMy0xLTEtMA_a1682239-f69d-48fe-ab85-7b8387be090b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTgtNS0xLTEtMA_4629dec1-c989-466c-858b-f8899607e115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTgtNy0xLTEtMA_a9903ffb-2071-4bc3-985b-a0e3a660a64c">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTgtOS0xLTEtMA_f6bcd764-bda9-4a47-b528-51659d18be49">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMjItMy0xLTEtMA_080801c3-99cb-447b-9ebd-22cd323180e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMjItNS0xLTEtMA_84b10e5e-3400-4ee8-bbfe-c4a71fb200fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMjItNy0xLTEtMA_5ef53591-4114-4342-9c6d-57462ba61548">715</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMjItOS0xLTEtMA_eb0f93ab-f94a-4ffa-a8b9-632ad0225eab">715</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMi0zLTEtMS0w_5518842a-ab43-4029-96e5-1bcfd435913e">6,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMi01LTEtMS0w_fbe6f11c-41b4-438c-8a23-0c7859543148">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMi03LTEtMS0w_5fcb2647-a393-4c26-8b83-816071430e87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMi05LTEtMS0w_7d3f2b23-4ef8-4c19-8a5a-5e9978bd4c8d">7,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTQtMy0xLTEtMA_aafc8eb9-f3f5-41af-8534-53ac76c43a79">1,357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTQtNS0xLTEtMA_c69f3d4e-8d06-4e07-a902-6ef0e9a780d7">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTQtNy0xLTEtMA_e8954f8e-e492-4d40-b11b-954a3089d1db">3,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTQtOS0xLTEtMA_2b25bd71-917e-43e7-b868-dec7824241be">4,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTYtMy0xLTEtMA_fd6f24c7-2530-430f-bb2e-6493061ce142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTYtNS0xLTEtMA_7ccc6aac-8780-493a-a45b-044adb161bf9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTYtNy0xLTEtMA_b7d5f0a3-b649-46ac-8080-d0ac142259bd">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTYtOS0xLTEtMA_697fa0c5-ce33-4396-b0e1-7c7da604279a">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTgtMy0xLTEtMA_562eeb4b-9ba3-411e-899a-eb41a57b964e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTgtNS0xLTEtMA_17301445-2d07-4c65-9cd7-d0dd8f1718e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTgtNy0xLTEtMA_c83bfc6d-b875-4e6c-8efc-df8a763a7794">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTgtOS0xLTEtMA_3dd9b3e9-8189-4418-af8a-539f29fbb582">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMjItMy0xLTEtMA_0e6b80fa-af45-439b-bb5f-a22650f76941">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMjItNS0xLTEtMA_d9cfadaf-c121-4f7d-9eb7-acc07d4ca7a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMjItNy0xLTEtMA_d52df477-61aa-4e41-ad8d-3e0162c1cae5">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMjItOS0xLTEtMA_cbb3525e-b033-4e84-9b85-9bd2dd792e29">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMi0zLTEtMS0w_ab76031b-26e2-4111-828a-a2aebbf547f6">12,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMi01LTEtMS0w_c86c6a4f-716d-4827-af47-28b4087ca8a2">3,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMi03LTEtMS0w_d42659bd-6221-4700-ac99-d1408b932411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMi05LTEtMS0w_8685870b-9f1f-4e17-8996-315085bba581">16,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTQtMy0xLTEtMA_738aa4d8-3c45-4317-a520-1b5e16f0bda3">8,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTQtNS0xLTEtMA_d9653ccd-220e-442f-b78d-445b8c4b2449">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTQtNy0xLTEtMA_5cd5dfa4-cdca-4a6b-992d-d7e71c32e59c">11,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTQtOS0xLTEtMA_0b6c050c-c562-4c4d-9e59-5f74c290e67a">18,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTYtMy0xLTEtMA_b8408eca-ff70-4e90-a71b-5d4c0f9cd531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTYtNS0xLTEtMA_2a2bdedf-f549-4390-8306-89852a78ae36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTYtNy0xLTEtMA_186065c9-1492-4be4-901d-1f59cab85717">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTYtOS0xLTEtMA_6f9d1eb7-1b7b-4812-a12e-1230e2480b46">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTctMy0xLTEtMA_6f097119-f090-40fb-a131-0c2fbfd8bcc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTctNS0xLTEtMA_b3eae4c7-c7ca-408a-b4a2-7b0b497bb93f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTctNy0xLTEtMA_efff4e42-2fa8-446f-a508-f47152101da9">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTctOS0xLTEtMA_e19b6d4d-6ed7-492c-a112-73b37f4d2eb6">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTgtMy0xLTEtMA_118f9897-a374-4c91-8985-b04d9fc4c252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTgtNS0xLTEtMA_12ca2ef3-8724-4001-904d-38797025651a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTgtNy0xLTEtMA_86cf3d9b-b22c-41a4-80c6-f9b47dc0ce95">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTgtOS0xLTEtMA_f490ecae-b0c8-426a-88a8-5d392859a4cf">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMjItMy0xLTEtMA_4570c61f-6c39-4b96-b1eb-ac952ec02466">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMjItNS0xLTEtMA_f4133c3b-c2ff-4729-a0dd-5bdb35813fbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMjItNy0xLTEtMA_5e38b147-4c9e-42c0-aeea-1af758ce3386">7,112</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMjItOS0xLTEtMA_0157032d-91b8-41b6-aeac-60dd9f6f29c2">7,112</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfMi0zLTEtMS0w_3068db34-d643-432d-b457-732101b536f1">15,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfMi01LTEtMS0w_b36d4968-5549-4966-bb73-ce20c58e7265">4,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfMi03LTEtMS0w_7a2e1cfd-2f8c-4035-b8fb-0a126c9dddfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfMi05LTEtMS0w_a38ced24-f5a7-412f-ac1f-74ff92ff686a">19,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNC0zLTEtMS0w_5b727d20-b389-4b8e-93e6-0efcc59fc9f0">5,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNC01LTEtMS0w_7fbe75a5-57fa-40b9-bb42-6b0c4cc00b78">995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNC03LTEtMS0w_c7f18409-0045-44a4-a750-ed5c5d1a3edd">10,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNC05LTEtMS0w_f62b2ac0-ed4b-479b-b7c5-dcf7b8c039c6">14,908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNi0zLTEtMS0w_a2fbc1bb-8e00-4be5-8892-35ac63904d52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNi01LTEtMS0w_89c16e63-2e21-4e17-bbd7-7cd5f299ebb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNi03LTEtMS0w_bf6625df-6940-4c2e-97c3-2859094ed531">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNi05LTEtMS0w_4b19e11d-0e9e-4bf2-a01e-06f3f73ae1c9">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNy0zLTEtMS0w_1ff99a0a-e1b7-4633-b19a-13f2195d0c56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNy01LTEtMS0w_4fef79ae-c58e-4438-98f2-04a4d97a8705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNy03LTEtMS0w_7d561bd4-981e-453a-8876-479d70760310">265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNy05LTEtMS0w_66349e5b-373f-45e9-b223-d6b908948e5c">265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfOC0zLTEtMS0w_eb35feb3-2659-4be9-ad44-0c1e37b923f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfOC01LTEtMS0w_3bb7edc6-78f8-4965-979c-48b0e90674d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfOC03LTEtMS0w_01486099-b97d-4612-9d25-89f9335e2fca">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfOC05LTEtMS0w_f5f2078d-81f9-492e-8d23-5d6d6aef8df3">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i056c42d1ce4447a2b4a01a9481b7c667"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately <ix:nonFraction unitRef="number" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTM4NA_c0beed91-13f3-4d9e-b502-766089bfa1fa">25.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTM5MQ_4b3cfe50-2124-4e64-aed9-844398eb7739">24.8</ix:nonFraction>% of total revenues for the three and nine months ended September 30, 2020, respectively, as compared with <ix:nonFraction unitRef="number" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTQ5Mw_a2550040-e9d9-4961-8192-b16d307b6584">26.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTUwMA_212ddd8b-8ccb-45df-9218-d948ceec61df">29.5</ix:nonFraction>% of total revenues for the same prior year period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our sales are denominated in U.S. dollars. <ix:nonNumeric contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTczNw_6e9dede3-6ed6-486d-ac30-557c603b5670" continuedAt="ib95a0fe39be24fd1989c9a0adaccf84e" escape="true">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="ib95a0fe39be24fd1989c9a0adaccf84e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ba6db9cd9234659951d70f1a84a0210_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfMy0xLTEtMS0w_b9278000-1df6-4632-aa80-cfab5b91340f">5,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c4a8fb0f73460292e4e20ebc69a371_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfMy0zLTEtMS0w_665d18f2-7132-4c6a-a07d-320e8b4b5541">5,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied82ea81f7c940e7ab5b2c914bbb80be_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfMy01LTEtMS0w_60d083d2-d2ff-4873-9b73-5b7cd8f9e63b">12,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c037d9010f4687af65b47252416f9d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfMy03LTEtMS0w_a2ceca53-6fe7-42fb-b10e-d228f854d919">14,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d3b458e10584d0ca1129fd062442050_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNC0xLTEtMS0w_c2f3b107-ef85-4f4b-8a97-6bb03f59e9b3">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392395d0a19242688757fc5acfd48f41_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNC0zLTEtMS0w_6b9f6a43-4259-4e89-b1f9-062bd055eb39">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153bf9c378f14f8cae2822d51169a108_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNC01LTEtMS0w_cc70cf07-af94-440b-90f4-bc0246068091">4,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b43886dc0fa410d95320ffb2f4fede0_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNC03LTEtMS0w_d9c8d7ff-cbde-417d-94a6-00c5c0112df8">5,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNS0xLTEtMS0w_1d7132a7-79d1-4c35-a3da-fc37666b1d3b">6,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNS0zLTEtMS0w_832fe136-60fa-4452-952d-eeb54b6081dd">7,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNS01LTEtMS0w_8685870b-9f1f-4e17-8996-315085bba581">16,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNS03LTEtMS0w_81430b14-a2e4-4b76-86c6-04dfb0d15102">19,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Level Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in our Annual Report on Form 10-K for the year ended December 31, 2019 ("2019 Form 10-K"), an outbreak of a novel strain of the coronavirus, COVID-19, was identified in China and has subsequently been recognized as a pandemic by the World Health Organization. The COVID-19 outbreak has severely restricted the level of economic activity around the world. In response to the COVID-19 outbreak the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. Temporary closures of businesses in some jurisdictions have been ordered and numerous other businesses have temporarily closed voluntarily. Many other businesses are operating at reduced capacity. Given the variability in measures taken, the uncertainty of any potential resurgence of COVID-19, the overall economic effects of these restrictions and patients' willingness to undergo elective procedures, the related financial impact cannot be reasonably estimated at this time. As a result, there could continue to be significant adverse impacts to the results of our operations  into the fourth fiscal quarter and possibly beyond. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the spread of COVID-19 into the US and international markets, we experienced positive year-over-year growth trends in the sale of our capital and disposable products, indicating increased utilization of our technology. Beginning in late February we began to see declines in the sale of our Helium Plasma Technology in European markets. These declines continued and also spread to the North and Latin American markets in March. Towards the end of the second quarter, and through the third quarter, we began to see improved demand for our products, primarily in the U.S. market, however the sustainability of this improvement remains uncertain. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source the components used in our products from a variety of suppliers and we have collaborative arrangements with three key foreign suppliers. At this time our suppliers have experienced no significant disruptions as a result of COVID-19. We have experienced minor delays in our procurement from these suppliers as a result of the availability of shipping from third party freight carriers. These delays have not, to date, had a significant impact on our operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to COVID-19, we have taken action in these key areas:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protecting the Health and Safety of our Employees: To reduce the risk to our employees and their families to potential </span></div><div style="padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exposure to COVID-19, we have required that all non-essential employees work remotely until further notice. We have also split the shifts of our manufacturing personnel to allow for adequate social distancing, and require all personnel to utilize personal protective equipment while on site at our facilities. We have also significantly reduced business travel and access to our facilities. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintaining Engagement of or Sales Team and Our Customers:  In addition to the initiatives we have put in place to protect health and safety for all employees, we have focused our direct sales team on remaining in close contact with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their existing surgeon customers to do everything they can to provide them with support during this difficult time. With this goal in mind, we have implemented additional training for our sales reps in order to sharpen their ability to engage with our customers virtually. In addition to engaging with existing customers via virtual methods, our reps also continue to target and reach out to prospective accounts so that they will be well-positioned when the recovery occurs and surgeons return to conducting elective cosmetic procedures. Outside the U.S., we are closely monitoring the activities of our distributor partners and helping them navigate the challenges they face as a result of the slower demand they are seeing in their respective countries.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating Expenses: We continue to take preemptive steps to curtail spending, including implementing hiring restrictions, reducing most discretionary spending, reducing capital expenditures, and delaying certain R&amp;D projects and clinical research studies. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental Policy: On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. We continue to take advantage of certain provisions of the CARES Act which are applicable to us, including utilizing NOL carryback provisions and the deferral of payroll taxes. We expect that utilizing these provisions will significantly help mitigate the working capital impact COVID-19 has had on our sales and operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we continue to drive sales in our Advanced Energy business by increasing the adoption and utilization of our generators and handpieces in the U.S. cosmetic surgery market and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 50 countries. As of September 30, 2020, we had a direct sales force of 31 field-based selling professionals and a network of 4 independent sales agencies, led by 5 sales managers. This selling organization is focused on the use of Renuvion&#174; in the cosmetic surgery market. In addition, we have inv</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ested in training programs and marketing-related activities to support accelerated adoption of Renuvion&#174;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first two months of 2020, our plans to host new Physician Mentor Programs, or &#8220;PMPs,&#8221; and expand our presence and educational programming at industry conferences and trade shows proceeded as expected. Our events planned for March, however, were canceled due to COVID-19. In lieu of this in-person programming, our sales, marketing and field clinical teams have been very active in engaging with our customers - and prospects - around the world. We have hosted educational events virtually where we featured some of our leading clinician customers speaking on a wide range of topics, including side-by-side results comparing Renuvion&#174; to a leading competitor technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our virtual educational events have also included case studies to illustrate how our leading clinician customers have adopted Renuvion&#174;, their strategies for marketing and selling to new patients, and their thoughts on pricing and return on investment. We recently hosted the first installment of a planned series of webinars designed to assist our customers and prospects with opening their practices post-COVID 19.   We also engaged with clinician customers outside the U.S. including hosting multiple continuing education training sessions on J-Plasma&#174; and Renuvion&#174; with our current international distributors and conducting multiple calls with groups of international prospects interested in learning about our Renuvion&#174; technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, we have not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are principally organized and managed as&#160;two&#160;operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly encourage investors to visit our website: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.apyxmedical.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;to view the most current news and to review our filings with the Securities and Exchange Commission.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Reportable Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Energy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OEM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,853&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by (8.2)% and (18.2)%, or approximately $(0.6) million and $(3.6) million, for the three and nine months ended September 30, 2020, respectively, when compared with the three and nine months ended September 30, 2019. Advanced Energy segmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t sales decreased (10.1)% and (22.0)%, or approximately $(0.6) million and $(3.5) million, for the three and nine months ended September 30, 2020, respectively, when compared with the three and nine months ended September 30, 2019. The impact of COVID-19 has resulted in decreased demand for our products, both domestically and internationally in the first three quarters of 2020, although, sales began to recover late in the second quarter, and through the third quarter as many of our customers resumed operations in a limited capacity. However, we continue to see reduced demand for our products, both domestically and internationally, from our pre-COVID-19 levels.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 25.0% and 24.8% of total revenues for the three and nine months ended September 30, 2020, respectively, as compared with 26.7% and 29.5% of total revenues for the same prior year period.  Management estimates our products have been sold in more than 50 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the three months ended September 30, 2020, decreased (10.7)% to $4.7 million, compared to $5.3 million for the same period in the prior year. Gross margin for the three months ended September 30, 2020, was 67.9%, compared to 69.9% for the same period in 2019. Our decrease in profit margins for the three months ended September 30, 2020 as compared to the same period in the prior year is primarily attributable to product mix within our Advanced Energy segment and higher OEM segment sales as a percentage of total sales. These were partially offset by improved product margins within our Advanced Energy segment as a result of our continued manufacturing efficiency initiatives and improved margins attributable to product mix within our OEM segment.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the nine months ended September 30, 2020, decreased (27.6)% to $9.8 million, compared to $13.5 million for the same period in the prior year. Gross margin for the nine months ended September 30, 2020, was 60.3%, compared to 68.2% for the same period in 2019. During the second quarter, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs, and earlier than expected completion of product registrations in some of our foreign markets.&#160;As a result, certain products were reduced to a lower carrying value, and some components were also written off as it was determined to cease further production on these models. This resulted in a decrease in gross profit of approximately $0.4 million during the nine months ended September 30, 2020. The remaining decrease in gross profit margin is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">driven by product mix within our Advanced Energy segment, and higher OEM segment sales as a percentage of total sales. These decreases are partially offset by geographical revenue mix within our Advanced Energy segment and improved product margins in our Advanced Energy segment as a result of our continued manufacturing efficiency initiatives.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our spending in the three and nine months ended September 30, 2020 reflected normal business activities into February and March and then a curtailment of certain costs associated with the impact of COVID-19 through most of the third quarter, including restrictions on travel which are still continuing. While certain spending decreased as a result of a reduction in revenue and activities limited by COVID-19, some of our strategic spending has and will continue. For example, while we have restricted new hirings, we have no plans to reduce our headcount or furlough any employees at this time. Certain costs declined and continue to remain below previously expected levels as the related underlying activities are restricted by COVID-19, including travel, trade shows and related expenses, clinical trials and in-person physician training. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased 3.1% and 14.0% for the three and nine months ended September 30, 2020, respectively, primarily due to spending on our two investigational device exemption (IDE) clinical studies, which had applications submitted to the FDA in late 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,039&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional ser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vices expense decreased (10.0)% for the three months ended September 30, 2020, primarily attributable to a decrease in physician consulting fees ($0.3 million), partially offset by an increase in accounting and auditing fees ($0.1 million) related to our change in our independent accounting firm during the quarter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professio</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nal services expense increased 1.1% for the nine months ended September 30, 2020, primarily attributable to an increase in accounting and auditing fees ($0.8 million) related to recent financial statement restatements and continued efforts to remediate our internal control deficiencies and material weaknesses. This increase was partially offset by decreases in legal expense ($0.2 million) associated with the class action lawsuit and a decrease in option expense related to options granted to our partner physicians ($0.5 million), as additional grants did not occur in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and related costs</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, salaries and related expenses increased approximately 11.0% and 1.0%, respectively, primarily driven by higher stock option expense ($0.5 million and $1.2 million, respectively). These increases were partially offset by lower bonus expense in 2020 ($0.4 million and $0.9 million, respectively).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A Expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, selling, general and administrative expense decreased (29.5)%, primarily driven b</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y decreases in travel and entertainment expense ($0.3 million), advertising including show fees and related costs ($0.3 million), commissions on Advanced Energy sales ($0.2 million), training expenses ($0.1 million), and a decrease in regulatory registration and related quality audit expenses associated with reduced governmental activity due to COVID-19 ($0.1 million). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, selling, general and administrative expense decreased approximately (11.6)%, primarily driven by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreases in travel and entertainment expense ($0.6 million), commissions on Advanced Energy sales ($0.4 million), advertising including show fees and related costs ($0.4 million), and a decrease in customer samples ($0.2 million) associated with restricted travel and decreased sales activity from COVID-19. These decreases were partially offset by higher bad debt expense ($0.6 million) related to increased uncertainty on the collection of our receivables due to the economic environment resulting from COVID-19.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased (96.9)% and (79.8)% for the three and nine months ended September 30, 2020, respectively, as compared with the same periods in the prior year. This decrease is due to a lower yield, as well as a lower average balance, on our investments in U.S. Treasury securities included in cash and cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (loss), net decreased (127.4)% for the three months ended September 30, 2020, as compared with the same period in the prior year</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This decrease is primarily due to a higher volume of orders from Symmetry Surgical in the same period in the prior year under our transition supply agreement with them following the disposition of our Core business in 2018. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (loss), net increased 231.7% for the nine months ended September 30, 2020, as com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pared with the prior year. This increase  is primarily due to the receipt of refunds on tariffs paid in the prior year during the first quarter of 2020 combined with the recognition of a joint and several liability for failure to collect and remit payroll taxes related to stock option exercises in the prior year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:30.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(518.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,911.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax (benefit) expense was approximately $(715,000) and $171,000 with an effective tax rate of 16.1% and (4.1)% for the three months ended September 30, 2020 and 2019, respectively.  Our income tax (benefit) expense was approximately $(7,112,000) and $253,000 with an effective tax rate of 40.7% and (1.8)% for the nine months ended September 30, 2020 and 2019, respectively.  For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our NOL carryforward from 2019. For the three months ended September 30, 2020, and the three and nine months ended September 30, 2019, the effective rate differs from the statutory rate primarily due to interest and penalties on our uncertain tax positions. On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback NOLs generated in the period 2018 through 2020 to prior years. As a result, we released the full valuation allowance of approximately $3.7 million on our Federal NOL carryforward from 2019 during the first quarter of 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our working capital at September 30, 2020 was approximately $58.1 million compared with $64.4 million at December 31, 2019. The decrease in working capital from December 31, 2019 to September 30, 2020 was primarily due to the net loss incurred by the Company during the first three quarters of 2020 partially offset by non cash activity including stock-based compensation expense and our provision for allowance for doubtful accounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, net cash used in operating activities was approximately $15.0 million, which principally funded our operating loss of $18.0 million, compared with net cash used in operating activities of approximately $15.2 million million in the same period for 2019. Utilizing the provisions of the CARES Act, we recognized an income tax benefit of approximately $7.1 million in the first nine months of 2020, of which we expect to receive a tax refund of approximately $3.7 million by the end of 2020. We expect that utilizing the NOL carryback will significantly help mitigate the working capital impact COVID-19  has had on our sales and operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also allows us to defer the payment of payroll taxes incurred between March 27, 2020 and December 31, 2020, with half of the resulting liability due on December 31, 2021, and the remainder due on December 31, 2022. As of September 30, 2020, we deferred approximately $0.3 million in taxes utilizing this program. We expect to defer and additional $0.1 million to $0.2 million under this program by December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impact of COVID-19 on our customers, we have received multiple requests for extension on the payment of receivables. While we are committed to working with our customers to collect the receivables as expeditiously as possible, collectability of these receivables is more uncertain and we have recorded an increased allowance for doubtful accounts as a result. A primary focus for the Company in 2020 continues to be maintaining appropriate balance sheet flexibility, including cash on hand, due to the uncertain nature and unpredictable timing of the impacts of COVID-19.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September 30, 2020 was $0.2 million, related to investments in property and equipment. Net cash provided by investing activities for the nine months ended September 30, 2019 was approximately $60.8 million, primarily related to the maturity of short term investments and reinvestment in cash equivalents. This was partially offset by investments in property and equipment of approximately $1.1 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, we had purchase commitments totaling approximately $1.8 million, substantially all of which is expected to be purchased within the next six months.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019 Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on March 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model in 2019 and 2020 and the trinomial lattice option-pricing model in prior years, both of which includes a number of estimates that affect the amount of expense to be recognized. We have determined that the most critical of these estimates are the expected life and volatility used in the calculations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as the we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. Relevant guidance allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable Allowance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze specific unremitted customer balances for known collectability issues, review historical bad debt experience, customer credit worthiness and economic trends,  and we make estimates in connection with establishing the allowance for doubtful accounts, including the future impacts of current trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory Obsolescence Allowance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income tax expense (benefit) includes federal, foreign, state and local income taxes currently payable or receivable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expense or benefit is based on the changes in the deferred tax asset or liability from period to period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of historical losses exclusive of the sale of the Core business in 2018, and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on the net deferred tax asset and do not anticipate recording an income tax benefit related to these deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results improve and it becomes more likely than not that the deferred tax assets will be realizable. As management expects the Company to continue to generate losses in 2020 and the foreseeable future after 2020, we will continue to record a valuation allowance on the remaining deferred tax asset balance as of September 30, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation has not materially impacted the operations of our Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements at this time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_40">See Note 3 of the Notes to Consolidated Financial Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_79"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:4.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures </span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.59pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2020, due to the material weaknesses in our internal control over financial reporting previously identified and reported in our 2019 Form 10-K which, as described below, continue to exist, our disclosure controls and procedures were not effective.</span></div><div style="margin-top:4.59pt;padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="margin-top:4.59pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding such material weaknesses, which is described below in Management&#8217;s Report on Internal Control over Financial Reporting, our management has concluded that the consolidated financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with GAAP.</span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="margin-top:4.59pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:0.4pt"><span><br/></span></div><div style="margin-top:4.59pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). The Company's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:0.2pt"><span><br/></span></div><div style="margin-top:4.59pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, management carried out an evaluation of the effectiveness of the Company's internal control over financial reporting as of December 31, 2019, based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control- Integrated Framework (2013). Based on that evaluation, management concluded that, as of December 31, 2019, the Company's internal control over financial reporting was not effective as a result of the material weaknesses described below.</span></div><div style="margin-top:4.55pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="margin-top:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December 31, 2019 was audited by BDO USA LLP, an independent registered public accounting firm, as stated in their report included in  Part II, Item 8 of our 2019 Form 10-K, contains an adverse opinion on the effectiveness of our internal control over financial reporting.</span></div><div style="margin-top:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-top:4.59pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that material misstatements of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="padding-left:40.5pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As of December 31, 2019, we had identified the following three material weaknesses:An ineffective control environment requiring additional qualified accounting personnel with an appropriate level of knowledge and experience with generally accepted accounting principles.  This was a deficiency from the prior year that had not been fully remediated. </span></div><div style="padding-left:40.5pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ineffective control activities due to the lack of documentation and timeliness in executing certain business process controls, specifically related to procure to pay and inventory processes and footnote reporting disclosures related to income tax accounts, primarily related to our United States operations.  This was a deficiency from the prior year that had not been fully remediated. </span></div><div style="padding-left:40.5pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ineffective control activities over financial reporting in our Bulgarian subsidiary related to the purchasing of goods </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="padding-left:40.5pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and services, including the processing and payment of vendor invoices.</span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Remediation Efforts to Address Material Weaknesses</span></div><div><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is committed to maintaining a strong internal control environment. In response to the identified material weaknesses, management, with the oversight of the Audit Committee of the Board of Directors, has taken actions toward the remediation of the respective material weaknesses in internal control over financial reporting as outlined below.</span></div><div style="margin-top:0.1pt"><span><br/></span></div><div style="padding-left:40.5pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are in the process of remediating the material weakness associated with the lack of sufficient qualified accounting personnel with an appropriate level of knowledge and experience with generally accepted accounting principles by hiring a new Chief Financial Officer in January 2019 and, in September 2019, a new Corporate Controller with experience in internal controls and financial reporting. Both have been actively engaged in remediation efforts to address the material weaknesses to date and will continue throughout fiscal year 2020. We will continue to recruit qualified professionals with appropriate levels of knowledge and experience to assist in resolving accounting issues related to non-routine and complex transactions. We have also enhanced our policies, procedures, and controls for all key business processes. In addition, management will continue to train personnel to ensure consistent application of accounting principles and adherence to the Company&#8217;s policies, procedures, and controls. </span></div><div style="padding-left:40.5pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are in the process of remediating the material weakness associated with the ineffective control activities due to the lack of documentation and timeliness in executing business process controls by enhancing our processes and  review controls associated with the processes noted above. We have reviewed current financial controls to assess if additional management review controls are necessary and will continue to work with all finance personnel to ensure the appropriate documentation criteria for the existing controls, including evidence of review, timeliness and variance thresholds. We  will continue to work with the third-party specialists we engaged to review, document, and enhance   the design of our controls, with the goal of designing and implementing controls that address the completeness and accuracy of data used in the performance of certain controls as well as the precision of management's review, but also enhance our ability to manage our business.</span></div><div style="padding-left:40.5pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have enhanced, or are in the process of enhancing, certain controls over purchasing and disbursements in our Bulgarian subsidiary, including approving and validating vendor invoices received by verifying the related purchase authorization and the receipt of the goods or services.</span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes the steps outlined above, along with the implementation of a new financial reporting system, will remediate the material weaknesses described above. The Audit Committee of the Board of Directors and management are actively monitoring the design and operating effectiveness of enhancement to internal controls in these areas to confirm the successful implementation of these remediation measures.</span></div><div style="margin-top:4.59pt;padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="margin-top:4.59pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we continue our efforts to remediate these deficiencies.</span></div><div style="margin-top:4.59pt"><span><br/></span></div><div style="margin-top:4.59pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth above, there were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2020 that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_85"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#160;&#160;&#160;&#160;Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61">See Note </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61"> of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61"> Notes to</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61"> Conde</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61">nsed</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61"> Consolidated Financial Statements</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61"> in Part </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61">, Item 1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_61"> of this Form 10-Q.</a></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. Risk factors</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Risk Factors described in Part I, Item1A-Risk Factors in our 2019 Form10-K other than the following:</span></div><div><span><br/></span></div><div style="margin-top:7pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">THE COVID-19 Pandemic has had and continues to have a material and adverse affect on our business</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations expose us to risks associated with public health crises and outbreaks of epidemic, pandemic, or contagious diseases, such as the current outbreak of COVID-19. To date, COVID-19 has had, and may continue to have, a material and adverse impact on our operations. Due to these impacts and measures, we have experienced and may continue to experience significant and unpredictable reductions in the demand for our products as actions taken by governmental bodies have restricted our customers' business activities. There continues to be a significant amount of uncertainty as to when these restrictions will be lifted and when patients will choose to undergo the elective procedures provided by our customers. While many of our customers have begun to experience positive trends in these restrictions being lifted and some patients have started elective procedures again, there is no guarantee that restrictions won't be reinstated or that patients will not choose to forgo elective procedures. In addition, our customers may delay, cancel or redirect planned capital expenditures in order to focus resources on COVID-19 or in response to continued economic disruption related to COVID-19. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 outbreak, many businesses experienced temporary closures of facilities as a result of being considered non-essential businesses. As performers of elective procedures, these temporary closures have impacted many of our customers and materially reduced demand for our products. As a medical device company, while we have currently been exempt from these guidelines and have largely continued operations, if we continue to experience future materially reduced demand for our products, we may have to scale back our operations. In addition, if the guidelines change, we or our suppliers could be impacted, and we could be adversely affected through supply chain interruptions, manufacturing restrictions or labor restrictions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic has adversely affected, and may continue to adversely affect, the world economy and financial markets , which has resulted in a period of significant global economic slowdown  which has curtailed and delayed spending by physicians and affected demand for our products as well as increased risk of customer defaults or delays in payments. COVID-19 and the current financial, economic, and capital markets environment, and future developments in these and other areas present material uncertainty and risk with respect to our performance, financial condition, volume of business, results of operations, and cash flows. Due to the uncertain scope and duration of the pandemic, the and uncertain timing of global recovery and economic normalization, we are unable to estimate the impacts on our operations and financial results, but believe they will be material into the fourth quarter of 2020 and possibly beyond.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_97"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. Defaults Upon Senior Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_106"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_109"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Articles of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">By laws of the Registrant (Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q3exhibit35.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 3, 2017).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx_201805xex31certificate.htm">Certificate of Elimination (Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on May 3, 2018)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000086/0000719135-18-000086-index.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant's Current Report of Form 8-K filed on December 28, 2018)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II Amended and Restated Employment Agreement (Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on September 18, 2020).</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Harris Semb Amended and Restated Employment Agreement (Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on September 18, 2020).</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Todd Hornsby Amended and Restated Employment Agreement  (Incorporated by reference to the Registrant&#8217;s             Current Report on Form 8-K filed on September 18, 2020).</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q310-qexhibit311.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 202</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q310-qexhibit312.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 202</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q310-qexhibit321.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 202</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2020q310-qexhibit322.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 202</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Presentation Document</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration&#160;statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i85d2870f2c594539a4d7339b7b1f7fd1_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i85d2870f2c594539a4d7339b7b1f7fd1_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apyx Medical Corporation</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 9, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 9, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasurer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2020q310-qexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if5813aef59fe433db0865b4d10e35e32_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2020q310-qexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie06a471c95af41aab1ca33dc9501702d_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tara Semb, the Registrant's Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:42.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2020q310-qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i50b7669ac5124de1836e95ac08f1d988_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the period ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a2020q310-qexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i419fd9539b1244448180f83e138edde2_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the period ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>apyx-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2ea9de42-aac7-46ca-94f8-c6912c5c1c9a,g:a9cfc7c0-2655-4cf5-9110-bf28a20f93b1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:apyx="http://apyxmedical.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://apyxmedical.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://apyxmedical.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION">
        <link:definition>2101101 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPolicies" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies">
        <link:definition>2202201 - Disclosure - BASIS OF PRESENTATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHANGEINACCOUNTINGPOLICY" roleURI="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY">
        <link:definition>2103102 - Disclosure - CHANGE IN ACCOUNTING POLICY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2104103 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSALOFBUSINESS" roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESS">
        <link:definition>2105104 - Disclosure - DISPOSAL OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSALOFBUSINESSDetails" roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails">
        <link:definition>2406401 - Disclosure - DISPOSAL OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://apyxmedical.com/role/INVENTORIES">
        <link:definition>2107105 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://apyxmedical.com/role/INVENTORIESTables">
        <link:definition>2308301 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESDetails" roleURI="http://apyxmedical.com/role/INVENTORIESDetails">
        <link:definition>2409402 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESNarrativeDetails" roleURI="http://apyxmedical.com/role/INVENTORIESNarrativeDetails">
        <link:definition>2410403 - Disclosure - INVENTORIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>2111106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>2312302 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>2413404 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NONCONTROLLINGINTEREST" roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTEREST">
        <link:definition>2114107 - Disclosure - NON-CONTROLLING INTEREST</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NONCONTROLLINGINTERESTTables" roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables">
        <link:definition>2315303 - Disclosure - NON-CONTROLLING INTEREST (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NONCONTROLLINGINTERESTNarrativeDetails" roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails">
        <link:definition>2416405 - Disclosure - NON-CONTROLLING INTEREST - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NONCONTROLLINGINTERESTRollforwardofJointVentureDetails" roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails">
        <link:definition>2417406 - Disclosure - NON-CONTROLLING INTEREST - Rollforward of Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2118108 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2319304 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>2420407 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2121109 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2322305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2423408 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails">
        <link:definition>2424409 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails">
        <link:definition>2425410 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://apyxmedical.com/role/INCOMETAXES">
        <link:definition>2126110 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2427411 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2128111 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>2429412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2130112 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2431413 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATION" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION">
        <link:definition>2132113 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONTables" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables">
        <link:definition>2333306 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2434414 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
        <link:definition>2435415 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
        <link:definition>2436416 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="apyx_SymmetrySurgicalInc.Member" abstract="true" name="SymmetrySurgicalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" abstract="false" name="CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwaps" abstract="false" name="StockIssuedDuringPeriodSharesStockSwaps" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_JointAndSeveralPayrollLiability" abstract="false" name="JointAndSeveralPayrollLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" abstract="false" name="ProceedsFromStockOptionsExercisedAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_UncertainTaxPositionsLiability" abstract="false" name="UncertainTaxPositionsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_RepaymentofFinanceLeaseLiabilities" abstract="false" name="RepaymentofFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" abstract="false" name="StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_NonCashTransfersOfInventoryToFromFixedAssets" abstract="false" name="NonCashTransfersOfInventoryToFromFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_CapitalizationOfLeaseNonCash" abstract="false" name="CapitalizationOfLeaseNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" abstract="false" name="IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_LeaseAdoption" abstract="false" name="LeaseAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_PaymentsToAcquireInterestInJointVentureRemaining" abstract="false" name="PaymentsToAcquireInterestInJointVentureRemaining" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" abstract="true" name="ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_OEMMember" abstract="false" name="OEMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" abstract="false" name="CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_StockSwapToAcquireOptionsShares" abstract="false" name="StockSwapToAcquireOptionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_StockSwapToAcquireOptionsAmount" abstract="false" name="StockSwapToAcquireOptionsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_CapitalizationOfLeaseExecution" abstract="false" name="CapitalizationOfLeaseExecution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ChineseSupplierMember" abstract="true" name="ChineseSupplierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_NoncontrollingInterestRequiredCapitalContribution" abstract="false" name="NoncontrollingInterestRequiredCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AdvancedEnergyMember" abstract="true" name="AdvancedEnergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" abstract="false" name="CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_TotalRevenuePercent" abstract="false" name="TotalRevenuePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="apyx_BulgariaManufacturingPlantPurchaseMember" abstract="true" name="BulgariaManufacturingPlantPurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="apyx_NoncontrollingInterestTableTextBlock" abstract="false" name="NoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="apyx_ProvisionForInventoryObsolescence" abstract="false" name="ProvisionForInventoryObsolescence" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_OtherAccruedExpensesAndLiabilitiesCurrent" abstract="false" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ProvisionForObsolescenceInventory" abstract="false" name="ProvisionForObsolescenceInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_NonCashTransferOfOtherAssetsToFixedAssets" abstract="false" name="NonCashTransferOfOtherAssetsToFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_TermOfPaymentDueNotesPayableRelatedParties" abstract="false" name="TermOfPaymentDueNotesPayableRelatedParties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_AssetPurchaseAgreementTerm" abstract="false" name="AssetPurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>apyx-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2ea9de42-aac7-46ca-94f8-c6912c5c1c9a,g:a9cfc7c0-2655-4cf5-9110-bf28a20f93b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20200930.xsd#Cover"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ef33ce18-e401-4838-8935-149f7d338a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ae38c955-73e9-48d1-b0a4-e533366d7790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef33ce18-e401-4838-8935-149f7d338a1e" xlink:to="loc_us-gaap_AssetsCurrent_ae38c955-73e9-48d1-b0a4-e533366d7790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68d5e889-36f0-46a2-be3a-bf8c2b525b5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef33ce18-e401-4838-8935-149f7d338a1e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68d5e889-36f0-46a2-be3a-bf8c2b525b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0cefab9e-e1db-4145-9002-bfab585930ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef33ce18-e401-4838-8935-149f7d338a1e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0cefab9e-e1db-4145-9002-bfab585930ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_a2cce5aa-20dc-46f2-b3d4-89825a0e73f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef33ce18-e401-4838-8935-149f7d338a1e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_a2cce5aa-20dc-46f2-b3d4-89825a0e73f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3a8c3d51-b725-45cd-97e1-1fbf2a2b93de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ef33ce18-e401-4838-8935-149f7d338a1e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3a8c3d51-b725-45cd-97e1-1fbf2a2b93de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ccd8d71b-46c8-42f7-a781-5bfeef56336a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2e6a2e70-249e-4b66-9f3b-0d91de408e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ccd8d71b-46c8-42f7-a781-5bfeef56336a" xlink:to="loc_us-gaap_CommonStockValue_2e6a2e70-249e-4b66-9f3b-0d91de408e58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a4fed4d9-4b29-4729-ac6d-2083d7b8597f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ccd8d71b-46c8-42f7-a781-5bfeef56336a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a4fed4d9-4b29-4729-ac6d-2083d7b8597f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e42c2e4e-0aae-4bae-a3b0-c8f0ffe906f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ccd8d71b-46c8-42f7-a781-5bfeef56336a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e42c2e4e-0aae-4bae-a3b0-c8f0ffe906f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f79f6f1-4cfe-41cb-ae90-a3238fafa8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55123e30-4e22-414a-88ec-c7ff93df3327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f79f6f1-4cfe-41cb-ae90-a3238fafa8be" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55123e30-4e22-414a-88ec-c7ff93df3327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2b9b2bc6-86fd-4934-b23b-7e9505a31f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f79f6f1-4cfe-41cb-ae90-a3238fafa8be" xlink:to="loc_us-gaap_Liabilities_2b9b2bc6-86fd-4934-b23b-7e9505a31f30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d4608ec6-6f99-447f-8414-d2cccaea5824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b5c855e-729c-44bd-a869-74c5aa66ee2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d4608ec6-6f99-447f-8414-d2cccaea5824" xlink:to="loc_us-gaap_LiabilitiesCurrent_7b5c855e-729c-44bd-a869-74c5aa66ee2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c21c8791-9d94-427b-a57c-62df6a19fb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d4608ec6-6f99-447f-8414-d2cccaea5824" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c21c8791-9d94-427b-a57c-62df6a19fb21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2d1992d4-f12d-47c3-88ae-51bdc4feadb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d4608ec6-6f99-447f-8414-d2cccaea5824" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2d1992d4-f12d-47c3-88ae-51bdc4feadb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_92a189f4-e532-4e72-8191-7ef403bc18af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d4608ec6-6f99-447f-8414-d2cccaea5824" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_92a189f4-e532-4e72-8191-7ef403bc18af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f7581435-79c2-4a6c-808c-0011ae485075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d4608ec6-6f99-447f-8414-d2cccaea5824" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f7581435-79c2-4a6c-808c-0011ae485075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f556ce8-79e9-42ba-9e0b-378d1462e27c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_bfac9d96-5be9-4d5e-b6bc-4ada33b3c883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f556ce8-79e9-42ba-9e0b-378d1462e27c" xlink:to="loc_us-gaap_MinorityInterest_bfac9d96-5be9-4d5e-b6bc-4ada33b3c883" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a21b88f2-1432-46cf-a0b5-b18224b64f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6f556ce8-79e9-42ba-9e0b-378d1462e27c" xlink:to="loc_us-gaap_StockholdersEquity_a21b88f2-1432-46cf-a0b5-b18224b64f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_87dfaa1a-8959-43d1-a2e5-a279e8b6682c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29d51e93-9ce3-4dbb-b7e4-3cc3d59e9958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_87dfaa1a-8959-43d1-a2e5-a279e8b6682c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29d51e93-9ce3-4dbb-b7e4-3cc3d59e9958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_04aa2b70-0805-44bf-801d-c82eee26a180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_87dfaa1a-8959-43d1-a2e5-a279e8b6682c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_04aa2b70-0805-44bf-801d-c82eee26a180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_27aadcdc-9b12-4405-acc3-24c6ba022743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_87dfaa1a-8959-43d1-a2e5-a279e8b6682c" xlink:to="loc_us-gaap_IncomeTaxesReceivable_27aadcdc-9b12-4405-acc3-24c6ba022743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_3dfcc0f4-d83b-4c93-a033-09f1cff3fbcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_87dfaa1a-8959-43d1-a2e5-a279e8b6682c" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_3dfcc0f4-d83b-4c93-a033-09f1cff3fbcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d1ccc7bc-a0e7-43e8-b715-150c109ba3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_87dfaa1a-8959-43d1-a2e5-a279e8b6682c" xlink:to="loc_us-gaap_InventoryNet_d1ccc7bc-a0e7-43e8-b715-150c109ba3bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fdf5eb3e-4775-44a6-b021-920592667119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_87dfaa1a-8959-43d1-a2e5-a279e8b6682c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fdf5eb3e-4775-44a6-b021-920592667119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cf275065-779f-4206-9a09-084f4457c332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_40fb5a46-544e-4562-b93c-2dd827b72abd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf275065-779f-4206-9a09-084f4457c332" xlink:to="loc_us-gaap_AccountsPayableCurrent_40fb5a46-544e-4562-b93c-2dd827b72abd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_53c9e998-5040-4e3a-8090-df10e33e7148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf275065-779f-4206-9a09-084f4457c332" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_53c9e998-5040-4e3a-8090-df10e33e7148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eeb44f37-c1a5-4acb-82a5-5f9155a15a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf275065-779f-4206-9a09-084f4457c332" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eeb44f37-c1a5-4acb-82a5-5f9155a15a0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_429c2905-eaa4-451c-92a3-a22ba07de6c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf275065-779f-4206-9a09-084f4457c332" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_429c2905-eaa4-451c-92a3-a22ba07de6c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_cedae8c0-d56e-4779-9e17-f7efdd26f826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf275065-779f-4206-9a09-084f4457c332" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_cedae8c0-d56e-4779-9e17-f7efdd26f826" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f3dc2950-8dcd-4028-bd8c-acf839f64c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9bb65a70-8df1-453a-829a-9e55e4a49d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f3dc2950-8dcd-4028-bd8c-acf839f64c26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9bb65a70-8df1-453a-829a-9e55e4a49d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_d286142b-6646-4a6a-a4c3-1e5ffac550e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f3dc2950-8dcd-4028-bd8c-acf839f64c26" xlink:to="loc_us-gaap_ProfessionalFees_d286142b-6646-4a6a-a4c3-1e5ffac550e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_66d1545d-04d0-4963-95eb-d5149bf9bf2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f3dc2950-8dcd-4028-bd8c-acf839f64c26" xlink:to="loc_us-gaap_SalariesAndWages_66d1545d-04d0-4963-95eb-d5149bf9bf2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7a8875b1-202c-4c59-9a51-23dec9fb3640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f3dc2950-8dcd-4028-bd8c-acf839f64c26" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7a8875b1-202c-4c59-9a51-23dec9fb3640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c5b2a1b8-f9e7-4a07-9bf9-c8a373e170c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c755b49c-bc7e-43c8-a177-0614f847fc10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c5b2a1b8-f9e7-4a07-9bf9-c8a373e170c6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c755b49c-bc7e-43c8-a177-0614f847fc10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f5cb4545-0357-4daa-a536-b62e5660ef65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c5b2a1b8-f9e7-4a07-9bf9-c8a373e170c6" xlink:to="loc_us-gaap_OperatingIncomeLoss_f5cb4545-0357-4daa-a536-b62e5660ef65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8f70380b-b695-4fbb-a3be-4b03703be376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_56ae8985-4635-4596-aa4e-03a541b61781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8f70380b-b695-4fbb-a3be-4b03703be376" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_56ae8985-4635-4596-aa4e-03a541b61781" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a47d9c84-a787-4960-894a-01fddf5e8986" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8f70380b-b695-4fbb-a3be-4b03703be376" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a47d9c84-a787-4960-894a-01fddf5e8986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_00097e48-3c65-44b3-8085-a818dfbf0172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_729f81bd-8d6b-49c2-94f3-e2035a733ba3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_00097e48-3c65-44b3-8085-a818dfbf0172" xlink:to="loc_us-gaap_InterestIncomeOperating_729f81bd-8d6b-49c2-94f3-e2035a733ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_10183282-7a6c-463a-a030-0501e4ed492c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_00097e48-3c65-44b3-8085-a818dfbf0172" xlink:to="loc_us-gaap_InterestExpense_10183282-7a6c-463a-a030-0501e4ed492c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_e4b04476-cbdb-499c-854f-03137b4e99dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_00097e48-3c65-44b3-8085-a818dfbf0172" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_e4b04476-cbdb-499c-854f-03137b4e99dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e64513a-2a2a-4587-8f96-ccd6209e8017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fe981c1a-668f-47b3-94a2-8049a7f7727f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1e64513a-2a2a-4587-8f96-ccd6209e8017" xlink:to="loc_us-gaap_ProfitLoss_fe981c1a-668f-47b3-94a2-8049a7f7727f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5f7be869-ab10-481f-8b30-3316caee0b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1e64513a-2a2a-4587-8f96-ccd6209e8017" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5f7be869-ab10-481f-8b30-3316caee0b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7ac476b9-1101-4ecb-ae16-108671181911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_344c1453-131a-47ea-a175-854c4144119b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_7ac476b9-1101-4ecb-ae16-108671181911" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_344c1453-131a-47ea-a175-854c4144119b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_039e5e40-f94f-4951-89f1-f4c0cd6268ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_7ac476b9-1101-4ecb-ae16-108671181911" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_039e5e40-f94f-4951-89f1-f4c0cd6268ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f9271d5d-c1c6-46f2-9c0d-6433a54a3530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a303277b-a6cd-45f6-b585-23ce25d1c864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f9271d5d-c1c6-46f2-9c0d-6433a54a3530" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a303277b-a6cd-45f6-b585-23ce25d1c864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8651bb3-0abb-41ff-ac57-8a5e13860881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f9271d5d-c1c6-46f2-9c0d-6433a54a3530" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8651bb3-0abb-41ff-ac57-8a5e13860881" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07099a53-6550-4607-a976-1d8c11d180cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f9271d5d-c1c6-46f2-9c0d-6433a54a3530" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_07099a53-6550-4607-a976-1d8c11d180cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1531c298-4d52-49ed-8764-ca5c872bcefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f9271d5d-c1c6-46f2-9c0d-6433a54a3530" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1531c298-4d52-49ed-8764-ca5c872bcefa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fa729a4-13bf-4137-8d4a-147740dd9b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_51dbb70c-e140-4d42-b855-bd94dbb81aac" xlink:href="apyx-20200930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fa729a4-13bf-4137-8d4a-147740dd9b1b" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_51dbb70c-e140-4d42-b855-bd94dbb81aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_a7b2357e-25d5-42b2-bdbc-dfd916943113" xlink:href="apyx-20200930.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fa729a4-13bf-4137-8d4a-147740dd9b1b" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_a7b2357e-25d5-42b2-bdbc-dfd916943113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_3935ed75-4bdb-4adf-8ffc-1768305cb887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fa729a4-13bf-4137-8d4a-147740dd9b1b" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_3935ed75-4bdb-4adf-8ffc-1768305cb887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb4d960-acb6-492e-834e-6360cbd0ee1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9138f863-2fd7-4430-99a6-c59d5fcad90e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb4d960-acb6-492e-834e-6360cbd0ee1a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9138f863-2fd7-4430-99a6-c59d5fcad90e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_16c27dbc-b14a-46c6-bdd7-b69c5e616229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb4d960-acb6-492e-834e-6360cbd0ee1a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_16c27dbc-b14a-46c6-bdd7-b69c5e616229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_39084de5-95a2-4431-a556-a8464860c1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cdb4d960-acb6-492e-834e-6360cbd0ee1a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_39084de5-95a2-4431-a556-a8464860c1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_085b8c67-c8d0-424f-9cb8-1c2d20bcf61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_ProfitLoss_085b8c67-c8d0-424f-9cb8-1c2d20bcf61d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1c6f1bb4-d619-4b73-a500-552db751a162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1c6f1bb4-d619-4b73-a500-552db751a162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_52ceb59a-1fbf-4cf9-88ab-02bf408e5554" xlink:href="apyx-20200930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_52ceb59a-1fbf-4cf9-88ab-02bf408e5554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2eb2358a-02f0-4bd9-9dac-49e30088d2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_ShareBasedCompensation_2eb2358a-02f0-4bd9-9dac-49e30088d2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_72ff576a-1b37-4d47-8fe6-5aee6924a5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_GainLossOnInvestments_72ff576a-1b37-4d47-8fe6-5aee6924a5b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_93cb7352-c0fb-4f2f-b430-0f1e11667a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_93cb7352-c0fb-4f2f-b430-0f1e11667a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0974abc-197d-4618-a18f-d78f01e156b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a0974abc-197d-4618-a18f-d78f01e156b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets_344c982e-dc2a-487c-adc9-8b311c2f9e35" xlink:href="apyx-20200930.xsd#apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets_344c982e-dc2a-487c-adc9-8b311c2f9e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6920e96f-801a-48ec-a61d-edc7cd4721cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6920e96f-801a-48ec-a61d-edc7cd4721cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_796b86c4-ec03-467d-b848-fcb174fcf5b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_796b86c4-ec03-467d-b848-fcb174fcf5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e5302f8e-9e0c-40f1-a714-d24b812d75b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e5302f8e-9e0c-40f1-a714-d24b812d75b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_92fcce95-eb2c-4de7-a042-abc455a74904" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_92fcce95-eb2c-4de7-a042-abc455a74904" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_57081cc4-020d-4663-9daa-06e835ae7371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d0eec28-45af-4a9e-a701-257c9640e870" xlink:to="loc_us-gaap_OperatingLeaseExpense_57081cc4-020d-4663-9daa-06e835ae7371" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#BASISOFPRESENTATION"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="simple" xlink:href="apyx-20200930.xsd#BASISOFPRESENTATIONPolicies"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="simple" xlink:href="apyx-20200930.xsd#CHANGEINACCOUNTINGPOLICY"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20200930.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="simple" xlink:href="apyx-20200930.xsd#DISPOSALOFBUSINESS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#DISPOSALOFBUSINESSDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_72ada079-ce79-4689-8988-8b2ddb3980b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_fec4fb0e-eabb-4cde-9931-5e927e27e2bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_72ada079-ce79-4689-8988-8b2ddb3980b3" xlink:to="loc_us-gaap_InventoryGross_fec4fb0e-eabb-4cde-9931-5e927e27e2bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_f8fc1950-8811-4a44-991c-2b605f43fad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_72ada079-ce79-4689-8988-8b2ddb3980b3" xlink:to="loc_us-gaap_InventoryValuationReserves_f8fc1950-8811-4a44-991c-2b605f43fad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_634634b9-1c99-4ea4-8d18-ce17a00afb7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_a11b48be-1167-4abc-ac1c-24aad4d57bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_634634b9-1c99-4ea4-8d18-ce17a00afb7e" xlink:to="loc_us-gaap_InventoryRawMaterials_a11b48be-1167-4abc-ac1c-24aad4d57bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_da6449dd-2560-4421-838c-6bebc29007aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_634634b9-1c99-4ea4-8d18-ce17a00afb7e" xlink:to="loc_us-gaap_InventoryWorkInProcess_da6449dd-2560-4421-838c-6bebc29007aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_03c48847-8a33-4337-b4eb-1c72afb7cf17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_634634b9-1c99-4ea4-8d18-ce17a00afb7e" xlink:to="loc_us-gaap_InventoryFinishedGoods_03c48847-8a33-4337-b4eb-1c72afb7cf17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_451d7850-7cde-4edb-8b81-0e22595b6a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_us-gaap_AccruedSalariesCurrent_451d7850-7cde-4edb-8b81-0e22595b6a79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_bdc3f125-171c-47eb-a585-3e1b545f9dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_us-gaap_AccruedBonusesCurrent_bdc3f125-171c-47eb-a585-3e1b545f9dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_676622d3-7519-4556-b4fe-4aa50f025b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_676622d3-7519-4556-b4fe-4aa50f025b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_cc41aef2-bfa1-491e-af12-0edf4699790e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_cc41aef2-bfa1-491e-af12-0edf4699790e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_41c611bf-dabe-4c12-9a66-9612eca2d6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_41c611bf-dabe-4c12-9a66-9612eca2d6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f0c8e44a-2faf-447b-8905-542e55b6ced4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f0c8e44a-2faf-447b-8905-542e55b6ced4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_fdffee09-36d1-4d61-925b-945e9789e27e" xlink:href="apyx-20200930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_fdffee09-36d1-4d61-925b-945e9789e27e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_73417341-69f0-4076-8092-b57c18fe3ee7" xlink:href="apyx-20200930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_apyx_UncertainTaxPositionsLiability_73417341-69f0-4076-8092-b57c18fe3ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_a33b542d-6e2e-4f6b-8ba9-3b1053df65e3" xlink:href="apyx-20200930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b1851bff-4325-4b16-9995-61e0d266e148" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_a33b542d-6e2e-4f6b-8ba9-3b1053df65e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTEREST" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTEREST"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTEREST" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20200930.xsd#INCOMETAXES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INCOMETAXESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>apyx-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2ea9de42-aac7-46ca-94f8-c6912c5c1c9a,g:a9cfc7c0-2655-4cf5-9110-bf28a20f93b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20200930.xsd#Cover"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended" id="i0622369c03b54f038f721ec25a14e0d6_Cover"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i780e242d535240baaad019d20d1ad9b4_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i6f1916820cfa430785bd6e93b106fd5f_CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i454cf59e1ffa4cad933dbbe940aa0036_CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended" id="i746d3d89d07549ee9d17031d0f67b437_CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6aa7625-11b8-4bd5-8502-76003a69990f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6aa7625-11b8-4bd5-8502-76003a69990f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_10bb15c2-094f-45cd-9726-f76c3de5099b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_SharesIssued_10bb15c2-094f-45cd-9726-f76c3de5099b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_761b3dc2-03ab-45a1-a0f2-d679e86a5120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_761b3dc2-03ab-45a1-a0f2-d679e86a5120" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_88b17ce6-2b02-4f05-86b7-3fe0a318c939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_ProfitLoss_88b17ce6-2b02-4f05-86b7-3fe0a318c939" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_5d23d28f-7107-4621-ae31-cdb9e1efb96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_5d23d28f-7107-4621-ae31-cdb9e1efb96a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3c36b915-013a-406b-83dd-b61f8145f440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3c36b915-013a-406b-83dd-b61f8145f440" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f8e9c4e0-3dcd-473a-8df2-782630e57550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f8e9c4e0-3dcd-473a-8df2-782630e57550" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee33ea02-d5a3-41a8-a6cb-d0ee747d5ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee33ea02-d5a3-41a8-a6cb-d0ee747d5ec7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_2b1ff50f-7a2d-40cb-adfd-ca3716c8dae6" xlink:href="apyx-20200930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_2b1ff50f-7a2d-40cb-adfd-ca3716c8dae6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsAmount_ad666569-dcab-4e29-9f28-5bb4e330a18f" xlink:href="apyx-20200930.xsd#apyx_StockSwapToAcquireOptionsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_apyx_StockSwapToAcquireOptionsAmount_ad666569-dcab-4e29-9f28-5bb4e330a18f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_67211be3-d7ff-4630-80f2-5c7d52ffe1ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7eae8126-b5f5-43c7-ab26-4a627f4fd3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6f08181b-8c2c-4e78-b0e3-14952bd9948e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c6aa7625-11b8-4bd5-8502-76003a69990f" xlink:to="loc_us-gaap_StatementTable_6f08181b-8c2c-4e78-b0e3-14952bd9948e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3287574d-8000-4d5a-9344-af2800a6cfbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6f08181b-8c2c-4e78-b0e3-14952bd9948e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3287574d-8000-4d5a-9344-af2800a6cfbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3287574d-8000-4d5a-9344-af2800a6cfbe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3287574d-8000-4d5a-9344-af2800a6cfbe" xlink:to="loc_us-gaap_EquityComponentDomain_3287574d-8000-4d5a-9344-af2800a6cfbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3287574d-8000-4d5a-9344-af2800a6cfbe" xlink:to="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ae743144-93d1-455b-bbd6-262c1b76e9f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:to="loc_us-gaap_CommonStockMember_ae743144-93d1-455b-bbd6-262c1b76e9f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_01d5b6f2-bff4-469c-a984-9d141b26519a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_01d5b6f2-bff4-469c-a984-9d141b26519a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_80cea6c8-4e1b-4a83-8458-9ab5b4413c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:to="loc_us-gaap_RetainedEarningsMember_80cea6c8-4e1b-4a83-8458-9ab5b4413c28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_16c46fea-8383-445c-92f4-c568841a623a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:to="loc_us-gaap_NoncontrollingInterestMember_16c46fea-8383-445c-92f4-c568841a623a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ie1082562764847e5868318e90746f17a_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#BASISOFPRESENTATION"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="extended" id="i3cf6e7dd315743f6b010cfd1f7667e0a_BASISOFPRESENTATION"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="simple" xlink:href="apyx-20200930.xsd#BASISOFPRESENTATIONPolicies"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="extended" id="if3fc88a74f0446b19130d0635136515f_BASISOFPRESENTATIONPolicies"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="simple" xlink:href="apyx-20200930.xsd#CHANGEINACCOUNTINGPOLICY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="extended" id="i50e8e021973145daab2279af0ca536f3_CHANGEINACCOUNTINGPOLICY"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20200930.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended" id="iefa2a38d9ac940da99e74ad7e78556d3_RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="simple" xlink:href="apyx-20200930.xsd#DISPOSALOFBUSINESS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="extended" id="i180338ebfe9847fcbcf00b694d5b13be_DISPOSALOFBUSINESS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#DISPOSALOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="extended" id="id3504ce1338d47b99b75ec0bf5d51d11_DISPOSALOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c19fbe23-738c-4282-9678-b64fedf5e922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c19fbe23-738c-4282-9678-b64fedf5e922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_3d5581e1-8ab5-4c12-aac0-654137c5b080" xlink:href="apyx-20200930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_3d5581e1-8ab5-4c12-aac0-654137c5b080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_04fd2931-9947-4dc4-b9a5-279af1cc762c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_04fd2931-9947-4dc4-b9a5-279af1cc762c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_200ebca3-8d8a-4ee9-aa81-80b4acd828d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_200ebca3-8d8a-4ee9-aa81-80b4acd828d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fff3fbcb-a696-46d3-9578-580822d4dfa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fff3fbcb-a696-46d3-9578-580822d4dfa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_70a95895-b5dd-4b31-8aa5-010728d9f4e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_70a95895-b5dd-4b31-8aa5-010728d9f4e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_78b9aafc-5ced-427d-95c9-5c35187dce6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_78b9aafc-5ced-427d-95c9-5c35187dce6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_78b9aafc-5ced-427d-95c9-5c35187dce6a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_78b9aafc-5ced-427d-95c9-5c35187dce6a" xlink:to="loc_us-gaap_RelatedPartyDomain_78b9aafc-5ced-427d-95c9-5c35187dce6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fbef8e43-4dc9-4900-b06d-5be0c59fb501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_78b9aafc-5ced-427d-95c9-5c35187dce6a" xlink:to="loc_us-gaap_RelatedPartyDomain_fbef8e43-4dc9-4900-b06d-5be0c59fb501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_0ca62789-5929-405b-a768-f7ef3e29148e" xlink:href="apyx-20200930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_fbef8e43-4dc9-4900-b06d-5be0c59fb501" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_0ca62789-5929-405b-a768-f7ef3e29148e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0825c64d-354d-4aa1-82ad-26bcf6b6937c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0825c64d-354d-4aa1-82ad-26bcf6b6937c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0825c64d-354d-4aa1-82ad-26bcf6b6937c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0825c64d-354d-4aa1-82ad-26bcf6b6937c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0825c64d-354d-4aa1-82ad-26bcf6b6937c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c70e7fd0-2e28-4584-92bf-0ba921b2e6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0825c64d-354d-4aa1-82ad-26bcf6b6937c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c70e7fd0-2e28-4584-92bf-0ba921b2e6f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_b55d0d9f-a9e8-49d6-af78-a8958308dd5d" xlink:href="apyx-20200930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c70e7fd0-2e28-4584-92bf-0ba921b2e6f3" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_b55d0d9f-a9e8-49d6-af78-a8958308dd5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended" id="i0075099393c84b47b8c56501b07f7c14_INVENTORIES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended" id="i53f24e9dd73b4414b617ef50a4327a4b_INVENTORIESTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended" id="ie5e2da84db8b4bad93063d9005409433_INVENTORIESDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INVENTORIESNarrativeDetails" xlink:type="extended" id="id7e4e4013135487bbbdf8044b5b3f1f1_INVENTORIESNarrativeDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended" id="i6c9c41c499f242af9b81b2d7db31a097_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended" id="i961ca9ace98646469bf4c9994a5d31a8_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended" id="i0756a6a39b1640ada8ba773c43f140c6_ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTEREST" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTEREST"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTEREST" xlink:type="extended" id="ia2a0443c48e14d17a3573ca49fae5dd3_NONCONTROLLINGINTEREST"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables" xlink:type="extended" id="i408582ca877b44cdb7d95ae77654a17a_NONCONTROLLINGINTERESTTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails" xlink:type="extended" id="i1def07e8d90549f4b87be58b348cc0f2_NONCONTROLLINGINTERESTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_6cb68df0-7ac9-4485-baa2-27a3cd0bd368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_2054783e-536f-47c8-a6e5-2b31ba1ffd5f" xlink:href="apyx-20200930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6cb68df0-7ac9-4485-baa2-27a3cd0bd368" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_2054783e-536f-47c8-a6e5-2b31ba1ffd5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_ed8b8d81-3227-4d9c-a6f7-5a8e63d16957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_6cb68df0-7ac9-4485-baa2-27a3cd0bd368" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_ed8b8d81-3227-4d9c-a6f7-5a8e63d16957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_bb769dbe-6a2d-4120-99a4-1ad792bff0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_6cb68df0-7ac9-4485-baa2-27a3cd0bd368" xlink:to="loc_us-gaap_MinorityInterestTable_bb769dbe-6a2d-4120-99a4-1ad792bff0e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_523f2f7d-b92a-4a43-af8f-8efed0c3428f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_bb769dbe-6a2d-4120-99a4-1ad792bff0e8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_523f2f7d-b92a-4a43-af8f-8efed0c3428f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_523f2f7d-b92a-4a43-af8f-8efed0c3428f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_523f2f7d-b92a-4a43-af8f-8efed0c3428f" xlink:to="loc_us-gaap_RelatedPartyDomain_523f2f7d-b92a-4a43-af8f-8efed0c3428f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_21d51b91-1d80-493a-9988-9a095ca5a7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_523f2f7d-b92a-4a43-af8f-8efed0c3428f" xlink:to="loc_us-gaap_RelatedPartyDomain_21d51b91-1d80-493a-9988-9a095ca5a7e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_ee309263-4ede-40f0-9651-e966166ec0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_21d51b91-1d80-493a-9988-9a095ca5a7e4" xlink:to="loc_us-gaap_CorporateJointVentureMember_ee309263-4ede-40f0-9651-e966166ec0fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails" xlink:type="extended" id="ia80e214d2b094202bed919d1cc533faf_NONCONTROLLINGINTERESTRollforwardofJointVentureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_48914031-8ef9-4507-a175-64a37bc11dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_9835fbe2-1609-4633-983b-27921fb9626e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_48914031-8ef9-4507-a175-64a37bc11dff" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_9835fbe2-1609-4633-983b-27921fb9626e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_48914031-8ef9-4507-a175-64a37bc11dff" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d8740720-a3c8-4bdc-9c24-0f7c33350553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:to="loc_us-gaap_MinorityInterest_d8740720-a3c8-4bdc-9c24-0f7c33350553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_962368ad-b7a7-4b0b-b30e-3758113e4e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_962368ad-b7a7-4b0b-b30e-3758113e4e1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b781b263-9e9f-4d36-b70d-d347989a8c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b781b263-9e9f-4d36-b70d-d347989a8c92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_fcf93269-6f33-4afe-9244-e7a6df47549e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_48914031-8ef9-4507-a175-64a37bc11dff" xlink:to="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e29bb9fc-9659-4717-91ae-45ce84f576ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e29bb9fc-9659-4717-91ae-45ce84f576ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e29bb9fc-9659-4717-91ae-45ce84f576ef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e29bb9fc-9659-4717-91ae-45ce84f576ef" xlink:to="loc_us-gaap_RelatedPartyDomain_e29bb9fc-9659-4717-91ae-45ce84f576ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f8252681-67f5-4457-905c-587f591c72a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e29bb9fc-9659-4717-91ae-45ce84f576ef" xlink:to="loc_us-gaap_RelatedPartyDomain_f8252681-67f5-4457-905c-587f591c72a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_1bde4cdc-8f92-404c-b938-4d87eb65872a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f8252681-67f5-4457-905c-587f591c72a5" xlink:to="loc_us-gaap_CorporateJointVentureMember_1bde4cdc-8f92-404c-b938-4d87eb65872a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:to="loc_srt_OwnershipAxis_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38" xlink:to="loc_srt_OwnershipDomain_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_457abebb-3ac6-4746-bbeb-eea02ac4eb72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38" xlink:to="loc_srt_OwnershipDomain_457abebb-3ac6-4746-bbeb-eea02ac4eb72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_d041fa65-90e2-4ea1-bf60-849b465397cf" xlink:href="apyx-20200930.xsd#apyx_ChineseSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_457abebb-3ac6-4746-bbeb-eea02ac4eb72" xlink:to="loc_apyx_ChineseSupplierMember_d041fa65-90e2-4ea1-bf60-849b465397cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended" id="i05e619b86b38429dba550f8d00e06ff2_EARNINGSLOSSPERSHARE"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended" id="ie28d328004464813a5fc8724a7368d9f_EARNINGSLOSSPERSHARETables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="i7f4c23eb02b644418e1f36a543d966c9_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_693ba596-f62f-4883-8245-760538c78894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_693ba596-f62f-4883-8245-760538c78894" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8b770cf-257d-43fa-b82e-70f767ce2daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_693ba596-f62f-4883-8245-760538c78894" xlink:to="loc_us-gaap_NetIncomeLoss_f8b770cf-257d-43fa-b82e-70f767ce2daf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_318e8412-ddd2-42af-916e-2d3910d46e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_318e8412-ddd2-42af-916e-2d3910d46e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_198f49b3-d264-4b92-b606-a12aa8b3dd65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_318e8412-ddd2-42af-916e-2d3910d46e0a" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_198f49b3-d264-4b92-b606-a12aa8b3dd65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_364c9627-7489-46be-b54b-427c9790e27d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_364c9627-7489-46be-b54b-427c9790e27d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6407c371-d50c-4044-896f-3e9dd5929932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_364c9627-7489-46be-b54b-427c9790e27d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6407c371-d50c-4044-896f-3e9dd5929932" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_0dc4257a-9749-45b8-a5cb-a92a425ea591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_0dc4257a-9749-45b8-a5cb-a92a425ea591" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ff5439cb-5617-4fa9-933d-96bbafea683c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_0dc4257a-9749-45b8-a5cb-a92a425ea591" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ff5439cb-5617-4fa9-933d-96bbafea683c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23741cf9-b9c4-463e-a5dd-79682dead46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23741cf9-b9c4-463e-a5dd-79682dead46e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bc0e3b04-4831-4b35-8177-f275663324a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23741cf9-b9c4-463e-a5dd-79682dead46e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bc0e3b04-4831-4b35-8177-f275663324a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc0e3b04-4831-4b35-8177-f275663324a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bc0e3b04-4831-4b35-8177-f275663324a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc0e3b04-4831-4b35-8177-f275663324a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_087ab634-2904-482c-9ed5-cfc2ef2fec44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bc0e3b04-4831-4b35-8177-f275663324a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_087ab634-2904-482c-9ed5-cfc2ef2fec44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3dd52b5e-a5b2-4eeb-a9b9-6235cf9d6a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_087ab634-2904-482c-9ed5-cfc2ef2fec44" xlink:to="loc_us-gaap_RestrictedStockMember_3dd52b5e-a5b2-4eeb-a9b9-6235cf9d6a30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0e21869b-4806-4b43-b638-b8e1e041accf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_087ab634-2904-482c-9ed5-cfc2ef2fec44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0e21869b-4806-4b43-b638-b8e1e041accf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended" id="i3ceab01e360d4320a1de39be95513740_STOCKBASEDCOMPENSATION"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended" id="i60af7ea8958f43119655f973b30cff56_STOCKBASEDCOMPENSATIONTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i4bbc25a1beb347bfb3eed4cbfacc3179_STOCKBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3b3fb9fb-a7f2-4633-94cb-acba21272b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3b3fb9fb-a7f2-4633-94cb-acba21272b77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_274af901-3231-4d9e-ab29-73455dde07d5" xlink:href="apyx-20200930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_274af901-3231-4d9e-ab29-73455dde07d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_14dd792d-f625-43b6-bc3e-492a9bd0a8d1" xlink:href="apyx-20200930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_14dd792d-f625-43b6-bc3e-492a9bd0a8d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b88e5c-0deb-4074-8d09-4c56b5da9fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b88e5c-0deb-4074-8d09-4c56b5da9fc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9ab5fb49-6ce7-4f14-a344-60034dccabbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b88e5c-0deb-4074-8d09-4c56b5da9fc1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9ab5fb49-6ce7-4f14-a344-60034dccabbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ab5fb49-6ce7-4f14-a344-60034dccabbb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9ab5fb49-6ce7-4f14-a344-60034dccabbb" xlink:to="loc_us-gaap_ClassOfStockDomain_9ab5fb49-6ce7-4f14-a344-60034dccabbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_202bc50a-ba05-4a82-b372-bacb46ea2e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9ab5fb49-6ce7-4f14-a344-60034dccabbb" xlink:to="loc_us-gaap_ClassOfStockDomain_202bc50a-ba05-4a82-b372-bacb46ea2e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07f7ef35-0343-427a-b332-948826435874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_202bc50a-ba05-4a82-b372-bacb46ea2e95" xlink:to="loc_us-gaap_CommonStockMember_07f7ef35-0343-427a-b332-948826435874" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="extended" id="ia69f17c366e14bb293903a95f2cf8f1e_STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="extended" id="i834aded9f635455abcc2d199d411343a_STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a28af5d7-50a7-4ba9-bb00-679d0ddc2b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a28af5d7-50a7-4ba9-bb00-679d0ddc2b08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_281ca68f-4b5e-4e2a-bca4-b2b4a0945ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_281ca68f-4b5e-4e2a-bca4-b2b4a0945ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4fd73279-641f-4c3d-841d-6a24f81e7540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4fd73279-641f-4c3d-841d-6a24f81e7540" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b57838c5-7e20-4d54-bc8f-f47bc9e248d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b57838c5-7e20-4d54-bc8f-f47bc9e248d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a6c006fb-8691-4246-8c67-3ff880c516b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a6c006fb-8691-4246-8c67-3ff880c516b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592053df-4461-4ebf-a427-fbaa188c1597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592053df-4461-4ebf-a427-fbaa188c1597" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7d0a0a0-0822-40d0-bc7d-d61394786a3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592053df-4461-4ebf-a427-fbaa188c1597" xlink:to="loc_srt_RangeAxis_c7d0a0a0-0822-40d0-bc7d-d61394786a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7d0a0a0-0822-40d0-bc7d-d61394786a3a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c7d0a0a0-0822-40d0-bc7d-d61394786a3a" xlink:to="loc_srt_RangeMember_c7d0a0a0-0822-40d0-bc7d-d61394786a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f869c5d8-b504-4915-95f0-c4fff7fdfe47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c7d0a0a0-0822-40d0-bc7d-d61394786a3a" xlink:to="loc_srt_RangeMember_f869c5d8-b504-4915-95f0-c4fff7fdfe47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e69a2913-31e2-43c7-8e7b-cb4bb8961e22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f869c5d8-b504-4915-95f0-c4fff7fdfe47" xlink:to="loc_srt_MinimumMember_e69a2913-31e2-43c7-8e7b-cb4bb8961e22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40bf115f-ab07-460c-b46a-845fe70ba3a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f869c5d8-b504-4915-95f0-c4fff7fdfe47" xlink:to="loc_srt_MaximumMember_40bf115f-ab07-460c-b46a-845fe70ba3a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20200930.xsd#INCOMETAXES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended" id="i4e613591c6504dd8a6e3e8b2eb12d571_INCOMETAXES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i9b34c480cd8444a1b24b1369c04256d3_INCOMETAXESNarrativeDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended" id="id8a6055fd28846b58c570839fbd95fc1_COMMITMENTSANDCONTINGENCIES"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="ib7e98d22cb0d45669d82cefb9f469695_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_fb9c6ae0-2161-4b07-84ba-670e081e7d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:to="loc_us-gaap_PurchaseObligation_fb9c6ae0-2161-4b07-84ba-670e081e7d83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_97fca3d4-12dc-4908-85af-52b52ec50f57" xlink:href="apyx-20200930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_97fca3d4-12dc-4908-85af-52b52ec50f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining_93c88da1-a365-46f4-9701-bee652d08fe9" xlink:href="apyx-20200930.xsd#apyx_PaymentsToAcquireInterestInJointVentureRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:to="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining_93c88da1-a365-46f4-9701-bee652d08fe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_91123c61-9244-4abb-ba78-35826779bf30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:to="loc_us-gaap_OtherCommitmentsTable_91123c61-9244-4abb-ba78-35826779bf30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_53757b7f-8d30-4202-966d-6e3e7aee3bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_91123c61-9244-4abb-ba78-35826779bf30" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_53757b7f-8d30-4202-966d-6e3e7aee3bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_53757b7f-8d30-4202-966d-6e3e7aee3bac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_53757b7f-8d30-4202-966d-6e3e7aee3bac" xlink:to="loc_us-gaap_RelatedPartyDomain_53757b7f-8d30-4202-966d-6e3e7aee3bac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_24b043cb-f377-43f9-9c0b-b36a71aab8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_53757b7f-8d30-4202-966d-6e3e7aee3bac" xlink:to="loc_us-gaap_RelatedPartyDomain_24b043cb-f377-43f9-9c0b-b36a71aab8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_4891a815-538b-423d-b189-40c900430d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_24b043cb-f377-43f9-9c0b-b36a71aab8d5" xlink:to="loc_us-gaap_CorporateJointVentureMember_4891a815-538b-423d-b189-40c900430d1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended" id="ic3aca9b279034bc28846c3c3a56b51b7_RELATEDPARTYTRANSACTIONS"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i0e6c85ff4c604dcf8acebeb940a8d0b5_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_8cddfc76-96c6-4326-a547-65996343b472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_8cddfc76-96c6-4326-a547-65996343b472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_af0c610d-7488-403a-8248-aa17b150262a" xlink:href="apyx-20200930.xsd#apyx_TermOfPaymentDueNotesPayableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_af0c610d-7488-403a-8248-aa17b150262a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_b734d3c4-5a2b-4b71-8692-84e1e8168062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_b734d3c4-5a2b-4b71-8692-84e1e8168062" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_98bbdfa0-5f1d-41c3-bc49-f02b11fb0b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_98bbdfa0-5f1d-41c3-bc49-f02b11fb0b3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f8a1b9-14e1-4984-9a20-28b55d399fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f8a1b9-14e1-4984-9a20-28b55d399fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_48f8a1b9-14e1-4984-9a20-28b55d399fc9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f8a1b9-14e1-4984-9a20-28b55d399fc9" xlink:to="loc_us-gaap_RelatedPartyDomain_48f8a1b9-14e1-4984-9a20-28b55d399fc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1965b97a-aeae-4dd9-ac08-798da8137e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f8a1b9-14e1-4984-9a20-28b55d399fc9" xlink:to="loc_us-gaap_RelatedPartyDomain_1965b97a-aeae-4dd9-ac08-798da8137e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_2ed5fe80-8f1d-4fc7-a1f7-37426d7ce4e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1965b97a-aeae-4dd9-ac08-798da8137e0f" xlink:to="loc_srt_DirectorMember_2ed5fe80-8f1d-4fc7-a1f7-37426d7ce4e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_a439aae9-c678-44ad-b940-3ef54c4806da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1965b97a-aeae-4dd9-ac08-798da8137e0f" xlink:to="loc_us-gaap_CoVenturerMember_a439aae9-c678-44ad-b940-3ef54c4806da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_39c8b52a-2faf-4079-bcf2-fb4ebc44de09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_39c8b52a-2faf-4079-bcf2-fb4ebc44de09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_39c8b52a-2faf-4079-bcf2-fb4ebc44de09_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_39c8b52a-2faf-4079-bcf2-fb4ebc44de09" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_39c8b52a-2faf-4079-bcf2-fb4ebc44de09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e92db6d1-6592-41a8-a85e-a7cbe13d99f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_39c8b52a-2faf-4079-bcf2-fb4ebc44de09" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e92db6d1-6592-41a8-a85e-a7cbe13d99f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_BulgariaManufacturingPlantPurchaseMember_09f2621e-edf4-42ae-89ad-70078845e448" xlink:href="apyx-20200930.xsd#apyx_BulgariaManufacturingPlantPurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e92db6d1-6592-41a8-a85e-a7cbe13d99f0" xlink:to="loc_apyx_BulgariaManufacturingPlantPurchaseMember_09f2621e-edf4-42ae-89ad-70078845e448" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended" id="i145ef233061b4306ac41bacc69ac914e_GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended" id="id0ff6b9a4a6440cfb8c71515bb3006b2_GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="i4b176ebb2399421dbaa890d7acbe92df_GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended" id="if7b8f0708a1c4159b9653f1ed557c2cb_GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dd15f12-1b89-4cb7-8d70-f1d9eae4df35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dd15f12-1b89-4cb7-8d70-f1d9eae4df35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_953260d5-925a-4d63-bc97-75086d0d1923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_OperatingIncomeLoss_953260d5-925a-4d63-bc97-75086d0d1923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_92ec31d8-b874-4bae-948f-5c2e304c70cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_InterestIncomeOperating_92ec31d8-b874-4bae-948f-5c2e304c70cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ffdd465c-e058-43d0-ab12-25ffb3951a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_InterestExpense_ffdd465c-e058-43d0-ab12-25ffb3951a11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_eaa0b1d9-2d51-442e-a496-2f12fea1cb60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_eaa0b1d9-2d51-442e-a496-2f12fea1cb60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70fba991-c53a-4ef2-9919-65f17219be95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70fba991-c53a-4ef2-9919-65f17219be95" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e6d0084a-70aa-4161-9e20-e2c5a341452b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:to="loc_srt_ConsolidationItemsAxis_e6d0084a-70aa-4161-9e20-e2c5a341452b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e6d0084a-70aa-4161-9e20-e2c5a341452b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e6d0084a-70aa-4161-9e20-e2c5a341452b" xlink:to="loc_srt_ConsolidationItemsDomain_e6d0084a-70aa-4161-9e20-e2c5a341452b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_de58bd77-c642-4b74-8a54-cf9139cf343a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e6d0084a-70aa-4161-9e20-e2c5a341452b" xlink:to="loc_srt_ConsolidationItemsDomain_de58bd77-c642-4b74-8a54-cf9139cf343a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c9b238b8-d848-4094-9659-973f3263fee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_de58bd77-c642-4b74-8a54-cf9139cf343a" xlink:to="loc_us-gaap_OperatingSegmentsMember_c9b238b8-d848-4094-9659-973f3263fee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b73f86da-e64e-42cc-b1ad-ad13f2dad168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_de58bd77-c642-4b74-8a54-cf9139cf343a" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b73f86da-e64e-42cc-b1ad-ad13f2dad168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3cc6efa2-e453-4047-a256-20425c183669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3cc6efa2-e453-4047-a256-20425c183669" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3cc6efa2-e453-4047-a256-20425c183669_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3cc6efa2-e453-4047-a256-20425c183669" xlink:to="loc_us-gaap_SegmentDomain_3cc6efa2-e453-4047-a256-20425c183669_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3dbf6e20-ced3-4daf-91ed-1ec26720df20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3cc6efa2-e453-4047-a256-20425c183669" xlink:to="loc_us-gaap_SegmentDomain_3dbf6e20-ced3-4daf-91ed-1ec26720df20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_6abe143c-6347-4d33-b616-0d26064a11a8" xlink:href="apyx-20200930.xsd#apyx_AdvancedEnergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3dbf6e20-ced3-4daf-91ed-1ec26720df20" xlink:to="loc_apyx_AdvancedEnergyMember_6abe143c-6347-4d33-b616-0d26064a11a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_c363957c-5712-438d-8d9a-7fd9e0b929f1" xlink:href="apyx-20200930.xsd#apyx_OEMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3dbf6e20-ced3-4daf-91ed-1ec26720df20" xlink:to="loc_apyx_OEMMember_c363957c-5712-438d-8d9a-7fd9e0b929f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended" id="ia73b6ee017454e719e63acb451e54c4b_GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_623df63e-e60d-4e0c-8240-5eba73de9105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_750dcb33-5302-4267-9a86-350d2869d342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_623df63e-e60d-4e0c-8240-5eba73de9105" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_750dcb33-5302-4267-9a86-350d2869d342" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_26d513c3-b684-4957-8d9f-50d084eb58c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_623df63e-e60d-4e0c-8240-5eba73de9105" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_26d513c3-b684-4957-8d9f-50d084eb58c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_06b862f1-332a-436d-b578-e7af15a2f9d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_26d513c3-b684-4957-8d9f-50d084eb58c7" xlink:to="loc_srt_StatementGeographicalAxis_06b862f1-332a-436d-b578-e7af15a2f9d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_06b862f1-332a-436d-b578-e7af15a2f9d6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_06b862f1-332a-436d-b578-e7af15a2f9d6" xlink:to="loc_srt_SegmentGeographicalDomain_06b862f1-332a-436d-b578-e7af15a2f9d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_01819a65-e126-495e-9713-0ddbb7731289" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_06b862f1-332a-436d-b578-e7af15a2f9d6" xlink:to="loc_srt_SegmentGeographicalDomain_01819a65-e126-495e-9713-0ddbb7731289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3c9f15de-da84-46be-b30b-bb5007d27915" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_01819a65-e126-495e-9713-0ddbb7731289" xlink:to="loc_country_US_3c9f15de-da84-46be-b30b-bb5007d27915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_c161a501-e897-48d1-86f7-e89f002d1225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_01819a65-e126-495e-9713-0ddbb7731289" xlink:to="loc_us-gaap_NonUsMember_c161a501-e897-48d1-86f7-e89f002d1225" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>apyx-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2ea9de42-aac7-46ca-94f8-c6912c5c1c9a,g:a9cfc7c0-2655-4cf5-9110-bf28a20f93b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_a4827a9f-b2b8-4c01-b22a-da8299a07a87_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e640450d-50bc-4083-90c7-4385c7a13bca_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (loss) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c16e4cc3-ce91-4df6-abcf-fde832e11b11_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_03165180-0fb5-4d4b-bce1-442c857b4c8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6ef4b57a-0a9a-43c3-a713-bf567d1ff2a4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_ac9ec906-4a83-4143-a44e-69260ae54bc2_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e23a0477-4c87-4956-8b6a-792a49fc66f3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_603e991d-4637-4c1a-a9c5-b3624fe7a82d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_84d64051-0ae2-453c-b451-db932887ab15_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_68232bb9-8de0-4f44-bb4c-d08685c0795a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_ede6a969-cb36-4ba6-8673-fccdb083e6db_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4e0dd3e8-d481-4a07-a7db-806d57382e9f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c364eb8c-caae-4787-b1bc-004b0780c704_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_b2bc77d8-66ab-433c-8731-06e480d89c58_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_11f868e5-0aca-4a45-8549-6dea066b76f7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1b44daaa-d9b1-4b1c-abe0-05ee0b7ee666_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TotalRevenuePercent_22a999a5-743e-42cb-8030-e3318c7687e4_terseLabel_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International sales, percent of total revenue</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_label_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_documentation_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent" xlink:href="apyx-20200930.xsd#apyx_TotalRevenuePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TotalRevenuePercent" xlink:to="lab_apyx_TotalRevenuePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_9b9f6e14-6b87-4e01-9c99-8cdccbee9d5c_negatedTerseLabel_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of valuation allowance</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_label_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_documentation_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:href="apyx-20200930.xsd#apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:to="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ae67c37f-2134-4f22-bbdc-54351bf4c3eb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1789ba36-9cd1-44db-8e11-4ad61d35c268_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_95dca383-262f-4066-9af8-2305d13d7878_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_3449964d-9666-49b0-9ef8-5b1c603fa4b5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bc972614-074e-45e1-8253-c00b2c8807ec_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Apyx</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604c280a-ee61-46b1-b0d2-96fbf075f4f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_94d6bdd5-6e65-4869-ba33-72233afd6bbe_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:href="apyx-20200930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f8b5b83c-b74a-4f63-a382-7ca378380c0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of option fair value assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_ae7a6038-fbba-4786-a7b8-85b2fd1e4b2c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_98974cb0-0e9d-4d6d-b3e7-08e439a4fb4e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e5088b99-be27-4401-9973-4ecc0126d59a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_d2371b52-0fb4-4b90-9ff4-83a28473349d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_df621d18-245a-4870-84a2-74eaecb0ac8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_99a54d4f-8ed6-4f52-9f2a-127cdaf35f8f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5b2e081e-085d-4a79-b792-51d6894926c1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_1e5cbaa0-6035-4d81-8690-27d3cd9c7953_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0e52567d-10b0-46df-8154-6ff570d7e20c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock options and stock awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_e8699f2e-cdd7-48c6-9436-8f14665d319e_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Execution</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseExecution_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseExecution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Execution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseExecution" xlink:href="apyx-20200930.xsd#apyx_CapitalizationOfLeaseExecution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseExecution" xlink:to="lab_apyx_CapitalizationOfLeaseExecution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d638306f-3078-41a1-9169-d2675f216d34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_32475164-8b7c-4a0b-8db5-92edb33308ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a83a09bf-e962-414a-87a1-d36ae4594a08_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5d327644-06d9-4c37-a349-70f064317011_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_ad345400-cab2-4741-98d9-e94255ef1d38_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NON-CONTROLLING INTEREST</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_eb159cf0-bf48-4e15-9edb-c29425f5a10f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_19edcfc5-3327-4d0e-9023-49b3c0cf6050_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b2280c24-4a01-4c3d-b18b-02688331eda1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_f4b1ae9a-2f3e-43fa-8dcf-b5ad949c6de0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OEMMember_673ab2e6-8751-4a97-a39a-53bea0e7aa00_terseLabel_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM</link:label>
    <link:label id="lab_apyx_OEMMember_label_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember" xlink:href="apyx-20200930.xsd#apyx_OEMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OEMMember" xlink:to="lab_apyx_OEMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c82c5a74-2863-4eae-9de8-ac3211edcf28_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e24bb691-3c06-4d20-9947-eec78e16e87a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e7bc509a-c9ca-438e-ba32-884b8dab60ef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_8f1ddd2f-1b5d-46ab-a4c9-5f6579b7286f_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party note payable</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_bc8cfb32-be20-484d-a260-c8aeaaef15cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_e60d1247-129c-47a0-b24d-5c5a63d6063d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_03d9518a-5e73-4902-960e-f73f4a605647_terseLabel_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_label_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_documentation_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:href="apyx-20200930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:to="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_c0afceed-7f8a-4e2c-bbd4-9db71217465b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_4b0de9c7-d256-44ab-bab1-d7898389777d_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_90beafb5-3e4d-472a-ab95-ab24a3f92521_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_22f956fc-2138-45b8-b77a-b6302973fc6d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e0dea194-b546-440f-9d67-17d3fb1c01f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5f58259a-3224-4150-8199-0bf8f12e4ca4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_852c96e9-6939-4d7f-a19b-2399804b5e5f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net of allowance of $760 and $273</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_b036b6f2-1715-4525-ae0c-947af2fc0787_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_f69db5f3-f85d-43aa-8fb2-801d9248ce5a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_d7cffe0d-5119-441d-8e96-a37b3b6cceb8_terseLabel_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_label_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_documentation_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm" xlink:href="apyx-20200930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AssetPurchaseAgreementTerm" xlink:to="lab_apyx_AssetPurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_5be059ed-d64c-4a3a-9aae-d5148d26dbab_terseLabel_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of inventory from property and equipment</link:label>
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_label_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfers Of Inventory To (From) Fixed Assets</link:label>
    <link:label id="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets_documentation_en-US" xlink:label="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfers Of Inventory To (From) Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:href="apyx-20200930.xsd#apyx_NonCashTransfersOfInventoryToFromFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:to="lab_apyx_NonCashTransfersOfInventoryToFromFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_6751d74a-5586-45b0-ab17-db6d824a70e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bb46a9f9-3419-482e-a35a-2ff87d057e86_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_98f2f463-41ae-433c-ac21-8843fdecbb31_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_163ad20d-0ce2-4a44-88fb-7fb420d7379a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases from related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ddc8c5b7-b8af-4ec7-acc5-9401007aefa6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a22dee56-ccd9-474c-98eb-7ff4f67d3539_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_d7061d41-c9d8-4603-9362-301802228447_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_a14c8ae0-3976-40f2-81c4-f49fae97a55c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e5b77ea3-c924-4d41-87b1-9cdee75bde94_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ca891c1e-5ec7-4611-8b85-35ce78ca1c82_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_335a622c-f098-4c58-8fe2-df705bcd5673_negatedTerseLabel_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of finance lease liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_label_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities" xlink:href="apyx-20200930.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RepaymentofFinanceLeaseLiabilities" xlink:to="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_04548b42-34af-4489-afe6-b81ea2c31bf1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_97dea25a-4ef3-40b6-8c2f-36291b361ce7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8fabe5f6-eb18-4f1c-b1f5-0a13a7fa417b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_946860ce-8215-4fe3-b734-4c8bfb229a58_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_031afb75-a0e2-426c-8eed-46e7d5dddd33_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2d0e9416-df69-45cc-b4e1-d7a83a34a891_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c88eb352-e755-4442-aa30-015362c53a92_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net of provision for obsolescence of $537 and $392</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8400a4b3-ba78-47f8-b18d-e2ffed4bf0cb_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b52f9faa-ba7a-4a47-93cb-babad197c5d0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7823897d-a5e9-439a-aacb-e6255acb06dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_c846b0d9-cf54-482b-9b57-a0a3d5c3506c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISPOSAL OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1cf78e42-2ebf-408d-bc56-f0bf7f0656c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_009fd84a-df57-4f4a-ba09-206b625ba7e5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7283e540-445c-43fc-8e78-a937cb4d58d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_392937d2-88be-4399-9b6c-eeeb1449de62_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d83a5fee-bbb0-4588-85ed-62f3d170d79a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_3393474e-c3e7-43d9-99bd-8c892991d817_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, provision for obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_label_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_documentation_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory" xlink:href="apyx-20200930.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForObsolescenceInventory" xlink:to="lab_apyx_ProvisionForObsolescenceInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8d91b577-2c72-4ff3-82ca-6928df939337_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d4994627-bfe2-4a5b-82c2-61a59853f8cb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_0f9623fc-905f-49ee-8158-b9f47c598811_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c3a397bd-24de-404f-8920-354db86b739b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8254125e-7c8b-43e0-ac1b-6b666016e1fe_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_db76c1ce-7aed-4adf-8afd-8bc3e5929592_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_903051c0-493c-4f09-8f98-cc8ed42099af_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_779fbe6e-8896-43d0-bda7-d9221ea1eba0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_61e34453-87e5-4579-b523-1edd78f498ed_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesTextBlock_04596f1e-9e1b-49a1-a55c-3d6cc6564cae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Policy</link:label>
    <link:label id="lab_us-gaap_AccountingChangesTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountingChangesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesTextBlock" xlink:to="lab_us-gaap_AccountingChangesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_e27cbc79-8a8e-4d30-bc97-e661ea6b4b27_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: provision for obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_ae639773-9cac-4d3e-9844-4a819da616d3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_db509e3e-2a6e-4665-b17f-9e98f09dc9e6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ee019c90-c281-4f6a-9023-c56f7bf63cb3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_03b01548-733a-4c97-b8f5-4b8fd2b00af7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,222,505 issued and outstanding as of September 30, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_61279f07-305f-49fd-b2d9-b2d9ad837f93_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6ba4c3c2-9d27-483a-8bb9-1e08fe0cb10d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_430ffece-d559-4453-9c53-5291315802f8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_fee5343b-29ea-4a6c-b6f8-33ab8dba6b31_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (loss) income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_65396f47-2b25-48a8-ade4-fd11df8e8b5f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_033e97b5-d762-4c23-b6d9-c29fa3e5d69b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cf3febe5-543c-46d9-86e3-2e940e6aa9ad_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_eec4c89d-4603-4718-83ab-f36a5868be37_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_21f01daf-1185-4125-b0b4-350205e2b663_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_acf2e157-dbef-407d-ae0f-3bfee7ba155f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4a9ce379-bd6c-4554-bb20-ea670e41246f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e33a2156-c147-414d-a6e3-a896af469ada_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638849f4-e449-4319-8b1c-801eaf2a5be0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_6bd6888c-112b-419d-9567-fd5f61e1f98e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_3e3d6a59-8a6e-465b-ad2e-4d4170819f64_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_c17cc259-9fec-4076-90ae-2776e4526bba_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_710ef811-c13c-4357-a275-bfb1ca02c0f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_14a39d40-3246-4b76-ac76-00879d795609_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8522ab8c-76c5-4545-9d0f-a18720a7783d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_71fa253d-8342-4e86-8d89-34d039cdfc62_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_d6b99911-6c45-4425-83eb-cba292a7cd7d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate &amp; Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4e153168-dfd1-4dc1-9fc9-148935e6949e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2f2c82a1-2d5e-4b3c-a00a-26e9866a8723_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_484221db-fddc-4edd-8fcf-ddfda05fcfd2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_370a2583-e0e7-44f1-811c-fe45767d61a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a0acd75c-0b7e-4ac4-8037-77fb73641442_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_972f4528-3a43-4641-8f9f-24078a9fe977_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_164d4ff4-10d6-4aa8-a76b-bb484c33b567_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_431565a5-8913-4773-9d63-a7a33cd882f7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_31ca5806-beaf-4b7c-a88b-846a5b989878_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8c363675-f025-45d7-8bde-3bbea220546d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f7df8bdd-6f84-4a70-b3c5-df9d1754a6bf_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_BulgariaManufacturingPlantPurchaseMember_6fd2b7e4-a0a0-4119-a9f1-a40c84a7c97c_terseLabel_en-US" xlink:label="lab_apyx_BulgariaManufacturingPlantPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bulgaria Manufacturing Plant Purchase</link:label>
    <link:label id="lab_apyx_BulgariaManufacturingPlantPurchaseMember_label_en-US" xlink:label="lab_apyx_BulgariaManufacturingPlantPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bulgaria Manufacturing Plant Purchase [Member]</link:label>
    <link:label id="lab_apyx_BulgariaManufacturingPlantPurchaseMember_documentation_en-US" xlink:label="lab_apyx_BulgariaManufacturingPlantPurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bulgaria Manufacturing Plant Purchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_BulgariaManufacturingPlantPurchaseMember" xlink:href="apyx-20200930.xsd#apyx_BulgariaManufacturingPlantPurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_BulgariaManufacturingPlantPurchaseMember" xlink:to="lab_apyx_BulgariaManufacturingPlantPurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_87a6664a-0031-47a7-afc6-613d1abdf0f6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5bfa1c15-3090-42c0-9103-2bee3e7c4862_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_2d9c39ed-7033-4648-8581-a77099c262fa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_197f8da0-1e36-47af-88d1-415322ccf445_terseLabel_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_label_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_documentation_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:href="apyx-20200930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:to="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_24cbe94d-e0a9-4846-97d0-716c9122d1e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_837e82a3-843e-4f37-bb8e-34b397f866e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_11f5561d-1fbe-4161-a128-895a67ed9447_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_df4c2a3c-6752-4255-80de-c9ffdf9368ae_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a7930bd5-3057-4374-94cf-db28498fe0f6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c2d95da6-9fe2-4ceb-a657-15415551563e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_838484f2-c552-40d9-a031-09d8d6db1d70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_16d596f6-5cb0-45cd-99a5-5c670a5bc545_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1443563a-c071-49e2-88aa-d040c70e6b2f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_32cf1c8d-e643-4e4f-84fe-8f7c9133c814_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_8f0e57ae-13c0-414e-82bc-bb2825888142_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_efb7b635-f3f7-40a1-9b73-dc4355e50db9_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eed2e03a-2097-487b-af9a-c0a4a047907b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c648bff9-050c-4e2b-b9bc-3adc4b730790_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $4,677 and $4,403</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_b57d9ef6-6246-42d3-9413-07cbe68c380c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a17168d5-469d-4091-b555-75310da22379_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_6dfc7375-e585-4339-8eda-92e9d660fb7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonuses</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_674023e1-8fb8-4f13-9888-17c7169d029f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue by geographic area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6e5e8bf3-fc5e-43a0-8e28-b5fabf59bbe6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_0a854a72-92ff-4cb4-b1ca-8052852e7341_terseLabel_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_label_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_documentation_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability" xlink:href="apyx-20200930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_UncertainTaxPositionsLiability" xlink:to="lab_apyx_UncertainTaxPositionsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8063fe0f-2055-4003-a9c4-923964b3602b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Apyx</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_aa2425c1-ebef-4cdb-bbe1-1bcf46a5afa4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Apyx</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_48471979-5b0a-45b2-b37a-ed35b1fbedbc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_43d51114-a38c-4306-8866-eba4bebfa279_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_d45ecdfc-3d7a-4432-88b8-e0ef5f48329d_terseLabel_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of other assets to property and equipment</link:label>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_label_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfer Of Other Assets To Fixed Assets</link:label>
    <link:label id="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets_documentation_en-US" xlink:label="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash, Transfer Of Other Assets To Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:href="apyx-20200930.xsd#apyx_NonCashTransferOfOtherAssetsToFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:to="lab_apyx_NonCashTransferOfOtherAssetsToFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a6b8b3e0-e0b2-43b1-a31e-a2d97236e91d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_90941e9d-5d05-48f5-a086-e4a911f34fa5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_8b54f420-e087-4d6f-954b-48d22aaef0cc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_dcbb3dbf-8a6e-47d4-80dc-d8ec769f2daa_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEOGRAPHIC AND SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d24da942-3798-454c-acb7-7ca5705a11ae_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0931d0c6-9f48-4b2e-8c86-bfdc3bea1b9d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_52d2dcda-7695-48d5-b2fc-85eadee73943_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on net settlement of stock options (in shares)</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options, Shares</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares" xlink:href="apyx-20200930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsShares" xlink:to="lab_apyx_StockSwapToAcquireOptionsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4b067b16-49a7-482c-9925-802bac585466_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2449e15b-3b37-4f4a-82bf-0c2d36f416ba_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_61948630-8ac0-4940-89ca-ce7f32c0f3eb_terseLabel_en-US" xlink:label="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax payments available to offset current period losses</link:label>
    <link:label id="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_label_en-US" xlink:label="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses</link:label>
    <link:label id="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_documentation_en-US" xlink:label="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" xlink:href="apyx-20200930.xsd#apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" xlink:to="lab_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_09abbcce-8db3-48df-a1d3-53dc258e5616_terseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_label_en-US" xlink:label="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of New Accounting Pronouncements Not yet Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:to="lab_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d4f35352-80fb-4253-b55e-0258652be8b2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per Share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8aa75dfa-a28a-45e0-ab4a-fbab0ce9ee4b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_27809f3b-1424-440f-8b4d-951e57ee67ae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_a9e12316-81b7-4e3b-9646-d54cbd843526_terseLabel_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses and current liabilities</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:href="apyx-20200930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:to="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c9d08368-e814-4fc4-b315-dab6d94a7d2e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_d71f0484-269b-440f-9348-f01ed5f19a12_terseLabel_en-US" xlink:label="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of payment due</link:label>
    <link:label id="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_label_en-US" xlink:label="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Payment Due, Notes Payable, Related Parties</link:label>
    <link:label id="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties_documentation_en-US" xlink:label="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Payment Due, Notes Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:href="apyx-20200930.xsd#apyx_TermOfPaymentDueNotesPayableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:to="lab_apyx_TermOfPaymentDueNotesPayableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_5cc193b6-e61c-4537-9f80-031134d559ba_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_50ef9e65-237f-48d1-a01a-e6a284f4444e_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a67b9814-5ec1-46eb-827a-03c9a3b70492_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_397e2195-9975-44d0-8982-1ef2452902dd_negatedTerseLabel_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefits, related to current period net loss before income taxes</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_label_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_documentation_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" xlink:href="apyx-20200930.xsd#apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" xlink:to="lab_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_644c7456-87ba-49c8-a76c-79b9d32bcdea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c89c913b-ac65-4582-a4c6-b40c965b3a32_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a722237d-dec3-40ed-8688-aef0aa9aa528_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_f07e2821-dbe7-4aac-98b6-58218062843a_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e5c3df67-5152-4c22-9633-55544c12b18f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_03800637-b0cc-430d-b80e-fdfd6a6d8f6f_terseLabel_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_label_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Non Cash</link:label>
    <link:label id="lab_apyx_CapitalizationOfLeaseNonCash_documentation_en-US" xlink:label="lab_apyx_CapitalizationOfLeaseNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization Of Lease, Non Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseNonCash" xlink:href="apyx-20200930.xsd#apyx_CapitalizationOfLeaseNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CapitalizationOfLeaseNonCash" xlink:to="lab_apyx_CapitalizationOfLeaseNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_c1174178-b25d-4728-bc28-e59b70594a0f_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability" xlink:href="apyx-20200930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollLiability" xlink:to="lab_apyx_JointAndSeveralPayrollLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesAndWages_c1dbc1ce-f760-40d2-957a-0081a4addd09_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and related costs</link:label>
    <link:label id="lab_us-gaap_SalariesAndWages_label_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages" xlink:to="lab_us-gaap_SalariesAndWages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e31966d5-9c90-436f-bd0e-8141997b9e59_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_9d3724fa-836c-44ce-8458-05bbc0c57862_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ca742e2b-0a0a-486c-bca0-92a27f3b67ec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1e56f8ba-7d4a-48e8-8aac-edf633de4033_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a66cd3eb-4efd-40e4-b465-df8dabd61541_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_fcc61d2e-2cb3-4fb1-b0f0-442ae35afa4b_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_b02b1157-0089-4a39-8447-89d6a0b2481d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8196fdc0-be2f-4faf-82ff-4f675a7753f1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2a586fc0-a74d-4252-b636-499c9fa4fd18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_2d444c12-dcc2-4d0e-bec0-9bcac941fb46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72ab8c30-ecd7-4d6c-8997-652547fd3a51_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_29be4b5b-08d7-4ee2-9a8f-2602bb280192_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties included in income tax expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0f4597be-59e8-4139-acd0-18904d721b58_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_56aca77a-b669-40fb-9043-ed28675bb897_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net, non cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_839ea8f9-d1e7-484b-a8eb-edfcae63c24f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_c4b63ab0-2aff-4797-8f15-b77d54e8613c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4fdc89c8-02d3-4768-ab8f-27333a8e7d8d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_21a8ac35-6999-4332-93b7-eeb9e715609c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_88148be6-635b-4aab-bfc0-485a6354117c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_7bded276-fdd5-469c-a547-978685c3bd13_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_5d040081-40e4-4e4e-a7f7-afe6e7d0b1bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_ef18ea81-b989-41cd-8921-9cf0afdf7f07_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:href="apyx-20200930.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:to="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets_6573c119-583d-4543-b22a-1e5fa0feba97_negatedTerseLabel_en-US" xlink:label="lab_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables, prepaid expenses and other assets</link:label>
    <link:label id="lab_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets_label_en-US" xlink:label="lab_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Income Tax Receivables, Prepaid Expenses And Other Assets</link:label>
    <link:label id="lab_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets_documentation_en-US" xlink:label="lab_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Income Tax Receivables, Prepaid Expenses And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" xlink:href="apyx-20200930.xsd#apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" xlink:to="lab_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b6453710-ef6f-4567-8092-a0b2d88eddfd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_ef86ba8a-f795-4277-b5a1-eb753014a1e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_c0e6324a-c0bb-4306-aeca-589f03e2eedc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments excluded from diluted loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AdvancedEnergyMember_c370c3fb-f029-4e8c-a456-dad19ed25f1d_terseLabel_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_label_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_documentation_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember" xlink:href="apyx-20200930.xsd#apyx_AdvancedEnergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdvancedEnergyMember" xlink:to="lab_apyx_AdvancedEnergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d0830e9b-a33a-4d3e-ad15-7e4bbac0ee74_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_b3435fb2-4a00-49d1-92ba-fce56c6414f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_0f3c2316-f540-4855-94d3-ba68caac470c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f44ebe17-5068-4d5f-b0c7-de5cd8e54c50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_32417521-51c7-43c5-8539-035124881466_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8a3c040a-dbe3-48b6-b520-3208ce182362_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_ea8de4b7-17f7-4719-ac95-5833dd59cab8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b72ae4b7-72a7-4a5a-a87b-462ecbfd943c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c6c40e3d-f950-4aaa-a1be-d7ec9ae40101_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1de8c4e5-b2a7-427d-aadc-70ef7fe200e7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_96d21b79-3af7-456a-8f4a-f94a2c1d7107_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3686cc04-462d-46d8-a25f-4a06a5574741_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cdad7376-dfe2-4602-8977-6836775404c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_f43a3daf-acd1-485e-baef-e263275d563b_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required capital contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:href="apyx-20200930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:to="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_eac6b774-36e5-45ff-afcd-02785b50805d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_82069cd4-c347-40d2-8c46-4133c64f4d4d_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_627618ed-5e1e-4c78-b43e-b180a116459f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5b1d91e-baea-4e5c-a537-368acb5090e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_556c65b0-1b16-491f-a337-ad57505fff00_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_fc6e6255-9b8a-4e05-95af-f410d60e6e01_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_36f0de17-44df-40cd-b007-c11ce0a0c10c_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7dafc4d2-a8e0-46a3-8b99-4e0f3f7ce4c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_cf8934b7-3863-42e8-963e-0a806ca41ad8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_37fb3caf-e36f-4a0c-8a34-872f6d6ab237_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reporting information by segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e8051540-d54e-42a2-b1fd-bbb97f5dae93_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc91e9fb-6cc7-4d5a-bd0b-9643e243505f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6d8ec5e2-ec41-494d-9b55-2ae9e14ae3b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_43ab8f66-1ecb-46ea-80b3-31a0d6cecb7f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_84c2a819-733f-409f-9968-ff5ad1ce3256_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_facf4999-6571-4179-94ed-2ed3e3c08791_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_3926b1da-1d29-435e-8743-0ad71e1571ab_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_c527bc09-16af-4950-9b69-0b7fc2037dd9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_87756024-8c60-4daf-b673-9cddf8b41e24_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c137d766-8fbb-41a1-859b-858717838b3e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4d3a5a55-54c9-454a-984b-17b15b2e833c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f33a4331-71b1-491f-a673-fa3a415ab0b0_netLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_da79f1eb-7a73-44fc-8071-d943563d92a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposition of Core business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_effb829c-122d-4b04-8009-3cf063f2a5a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_648bcd37-de6d-44e3-9144-9161a855f2a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b2bc6ff-16c0-4e48-b3da-19a482659504_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_40bd8e83-9a68-463f-bbb9-81aaa93cbfdc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_66ce7042-a74b-4fd2-b3fd-411880f0911f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_016192e1-c8b6-451d-bd55-3fd6b76dd795_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_22ffdb1f-68bf-48b0-8ce4-57a6d62f246f_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_bd9edfa2-a31b-4d30-82b2-1945da5594e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued insurance</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_4f10d898-a925-4891-8b48-7961445a2d9a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_76ddf185-0ea3-4f8f-837f-d830c5a7f449_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_73b154e1-331c-40f8-940b-4d0eba93e072_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swaps equity instruments received (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:href="apyx-20200930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e331ba71-b2d3-4c5a-881c-2bdc4c13ffdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_59d38e8c-4051-42ed-8107-cc55c05ec9c2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other income (loss)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb208893-49c9-4ab9-8862-8085f02b9eb8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_e2d5ea52-b781-4b49-a10f-4418688c3c15_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_93c540f7-e458-41fa-b170-a08beda54553_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f5fdcd9f-5fc9-4f2c-9241-eb5222e864a8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_e0fbe957-6e3f-4008-ac09-4cbf088da59c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_43333d61-6b9d-4c5c-9092-208924d8b5d7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d4ad609a-45a2-44ec-9f09-f04f8f073239_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ChineseSupplierMember_5d631581-bb35-4c0f-8e14-b7164342afd9_terseLabel_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_label_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier [Member]</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_documentation_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember" xlink:href="apyx-20200930.xsd#apyx_ChineseSupplierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ChineseSupplierMember" xlink:to="lab_apyx_ChineseSupplierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e2f5d4e1-c8f0-42d3-a4e2-dbb3ef54af92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CoVenturerMember_f4ee1244-49b8-44af-8fa1-87493454bab7_terseLabel_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer</link:label>
    <link:label id="lab_us-gaap_CoVenturerMember_label_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CoVenturerMember" xlink:to="lab_us-gaap_CoVenturerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f404540-bc66-4907-9aef-b44192c44512_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9fa51725-1b8c-474b-b98c-312d04b1ab14_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_b3239d3f-0d78-4a44-a7eb-f43eb8aae6e3_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_187ed685-def1-4544-985c-7b5e1bb3f420_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_ea4b97cc-513e-4d52-8d6b-4011eeaeda65_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_b9badaed-a61a-4c38-9111-179d1947c4f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on short term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5ce71990-e60a-430b-8513-6e1f4858ddd8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_01be2385-8481-4f2d-a2b1-bbf04d5a7960_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4530ccca-bbf5-4de6-92a0-8da5a32c48b4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_75659790-fbb4-40ac-b5ff-40e7494800d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_e824cdfd-d92e-4840-a53f-4ff11ccc62f2_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c582a774-896e-46e0-970d-563046453ec4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_3883f21f-dff1-406e-9081-86e51493bbe3_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_f2bce442-51cc-4c7d-9561-984f879ab8cc_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7440b464-276c-493b-afdb-08dbbc58a52e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_3900ba2f-ad54-492a-8545-b96b3e3e2eff_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_01a26dca-aeed-43e9-a0b9-4354ad0a3b95_terseLabel_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc.</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_label_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_documentation_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member" xlink:href="apyx-20200930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SymmetrySurgicalInc.Member" xlink:to="lab_apyx_SymmetrySurgicalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1bae7967-e0e4-421f-8133-c25226018254_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsAmount_d51f47a4-efe9-4390-9019-dceacd1ac3b1_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on net settlement of stock options</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsAmount_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options, Amount</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsAmount_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsAmount" xlink:href="apyx-20200930.xsd#apyx_StockSwapToAcquireOptionsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsAmount" xlink:to="lab_apyx_StockSwapToAcquireOptionsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6e616bee-ebc1-4569-9272-9f86340d03ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e8bcb2ab-1572-4394-acfb-82656179746a_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_689401d3-6b4f-4f09-bc6b-3fe5d614178f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_LeaseAdoption_5cac8002-d07e-4d95-8c13-932648028643_terseLabel_en-US" xlink:label="lab_apyx_LeaseAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</link:label>
    <link:label id="lab_apyx_LeaseAdoption_label_en-US" xlink:label="lab_apyx_LeaseAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Adoption</link:label>
    <link:label id="lab_apyx_LeaseAdoption_documentation_en-US" xlink:label="lab_apyx_LeaseAdoption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseAdoption" xlink:href="apyx-20200930.xsd#apyx_LeaseAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_LeaseAdoption" xlink:to="lab_apyx_LeaseAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_71de721e-bc27-4c7d-bf97-f94f7539d7d9_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_label_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_documentation_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence" xlink:href="apyx-20200930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForInventoryObsolescence" xlink:to="lab_apyx_ProvisionForInventoryObsolescence" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining_c96dd5c5-7b3b-4378-b013-125d56efbbe7_terseLabel_en-US" xlink:label="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining payments to acquire interest in joint venture</link:label>
    <link:label id="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining_label_en-US" xlink:label="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Interest In Joint Venture, Remaining</link:label>
    <link:label id="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining_documentation_en-US" xlink:label="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Interest In Joint Venture, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:href="apyx-20200930.xsd#apyx_PaymentsToAcquireInterestInJointVentureRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:to="lab_apyx_PaymentsToAcquireInterestInJointVentureRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b501eba2-8de9-4118-bce6-37fbf3bef8ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ed205480-e91f-4d3f-a209-a70b64d16b8d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8f52b53-4569-4db4-b2df-9f93de44c9ea_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_26a4a746-5fe4-4c9b-8d8c-db8d11679a1a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_faf227fd-b351-404a-8c54-383f9ab15689_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_053266f4-0d88-40d6-8234-a5e8490c01c7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bce86950-0d4e-4789-b67a-f327ada96038_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c0fd7d10-00bc-4664-8549-9077e0c80c85_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_a508255d-161f-4960-a6aa-d16c40dc3f58_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>apyx-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:2ea9de42-aac7-46ca-94f8-c6912c5c1c9a,g:a9cfc7c0-2655-4cf5-9110-bf28a20f93b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20200930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aa5404a2-bba8-4752-9637-268d1eb36856" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_DocumentType_aa5404a2-bba8-4752-9637-268d1eb36856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_020b5a30-b9ef-4105-85f2-6d5331074bed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_DocumentQuarterlyReport_020b5a30-b9ef-4105-85f2-6d5331074bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_de67ab73-a51d-4e0d-b6c9-c6d8a58589ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_DocumentPeriodEndDate_de67ab73-a51d-4e0d-b6c9-c6d8a58589ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_886cd8aa-202e-4193-905c-3307dafbae97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_DocumentTransitionReport_886cd8aa-202e-4193-905c-3307dafbae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b0dd735c-8778-4ed1-ac54-c848b64717c5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityFileNumber_b0dd735c-8778-4ed1-ac54-c848b64717c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1f87da0a-def9-44b4-8266-5892306c67d2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityRegistrantName_1f87da0a-def9-44b4-8266-5892306c67d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_375722a4-5ed0-4622-be02-bde5967e6a30" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_375722a4-5ed0-4622-be02-bde5967e6a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4f82a6a7-2530-4ae2-94b0-75495805dd08" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityTaxIdentificationNumber_4f82a6a7-2530-4ae2-94b0-75495805dd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d6225e7a-c251-439a-b718-63047a3eb8da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityAddressAddressLine1_d6225e7a-c251-439a-b718-63047a3eb8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_982cf5e7-ad8b-4adb-921a-5dfd5402f92d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityAddressCityOrTown_982cf5e7-ad8b-4adb-921a-5dfd5402f92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e3e4c45f-6284-400f-988b-40ba5b9af97f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityAddressStateOrProvince_e3e4c45f-6284-400f-988b-40ba5b9af97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2dadadd0-d252-4fa5-87f5-3ebd76e37d42" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityAddressPostalZipCode_2dadadd0-d252-4fa5-87f5-3ebd76e37d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2aef1083-c068-4845-b5a0-3ec71ee96522" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_CityAreaCode_2aef1083-c068-4845-b5a0-3ec71ee96522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cde381f3-2b46-4c67-855e-2bc09c616afe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_LocalPhoneNumber_cde381f3-2b46-4c67-855e-2bc09c616afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4e023a07-7f88-4ae9-af7f-b88f1408095d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_Security12bTitle_4e023a07-7f88-4ae9-af7f-b88f1408095d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_10dd288a-dc92-4db0-a560-9e1e09e9c52b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_TradingSymbol_10dd288a-dc92-4db0-a560-9e1e09e9c52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b7aea55d-ce25-404a-9ff0-def3a9c93aaf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_SecurityExchangeName_b7aea55d-ce25-404a-9ff0-def3a9c93aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d1a4f9ae-2ff7-4f77-aa8d-f82d442c8a66" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityCurrentReportingStatus_d1a4f9ae-2ff7-4f77-aa8d-f82d442c8a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_aa29aba5-b118-4eca-8109-ec4340d6430e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityInteractiveDataCurrent_aa29aba5-b118-4eca-8109-ec4340d6430e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d852156a-1022-4e63-ab4f-ed4bc93c3f4e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityFilerCategory_d852156a-1022-4e63-ab4f-ed4bc93c3f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d79dddcb-e382-4bcd-9114-f8de16acb92a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntitySmallBusiness_d79dddcb-e382-4bcd-9114-f8de16acb92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a860ec06-2419-4814-8da4-91cc2f473166" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityEmergingGrowthCompany_a860ec06-2419-4814-8da4-91cc2f473166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4c8ac3e5-a7df-4eb6-a591-d1a6d35445b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityShellCompany_4c8ac3e5-a7df-4eb6-a591-d1a6d35445b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_70e4a788-0beb-4e2e-bd4d-e3564cf55b12" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_70e4a788-0beb-4e2e-bd4d-e3564cf55b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cef2725e-230c-4de4-a377-6624a79c78d8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_CurrentFiscalYearEndDate_cef2725e-230c-4de4-a377-6624a79c78d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6afad526-d61a-405a-8856-93d460bf353f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_AmendmentFlag_6afad526-d61a-405a-8856-93d460bf353f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2a65d7ff-4dbb-4069-9884-5732b112fda0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_EntityCentralIndexKey_2a65d7ff-4dbb-4069-9884-5732b112fda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_76cac87c-f617-4b15-97ce-403bae83b752" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_76cac87c-f617-4b15-97ce-403bae83b752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6727e71e-f712-4299-bd85-d24f2cfd4cd6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b312c8c0-a14f-4fda-a20a-661e58ad302a" xlink:to="loc_dei_DocumentFiscalYearFocus_6727e71e-f712-4299-bd85-d24f2cfd4cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5c5e0bdc-abce-4c8e-ae26-ce2039e5cf09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1a4754e3-00f9-4efd-a4ab-09f003976e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5c5e0bdc-abce-4c8e-ae26-ce2039e5cf09" xlink:to="loc_us-gaap_AssetsAbstract_1a4754e3-00f9-4efd-a4ab-09f003976e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4754e3-00f9-4efd-a4ab-09f003976e1d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20db9007-a136-49c3-b3d4-970dce48e133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20db9007-a136-49c3-b3d4-970dce48e133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_73a8b7c6-06b0-4db7-b863-159a3982a86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_73a8b7c6-06b0-4db7-b863-159a3982a86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_d01756a2-8256-41b3-9188-cee980e48586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:to="loc_us-gaap_IncomeTaxesReceivable_d01756a2-8256-41b3-9188-cee980e48586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_34a58937-6b1a-45cc-ac4d-928859f37c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_34a58937-6b1a-45cc-ac4d-928859f37c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_02c97980-ad79-4089-b471-5ff62a6d7a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:to="loc_us-gaap_InventoryNet_02c97980-ad79-4089-b471-5ff62a6d7a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a4da4f4-573f-41fc-a12e-17c9c64b545a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a4da4f4-573f-41fc-a12e-17c9c64b545a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cb4654ad-4bd7-47d5-a394-83b60219120b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4cb80f54-ece1-456c-b0d6-f086530cbf34" xlink:to="loc_us-gaap_AssetsCurrent_cb4654ad-4bd7-47d5-a394-83b60219120b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f195e8dd-6b89-44ce-b9f5-67f8b2e6fed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4754e3-00f9-4efd-a4ab-09f003976e1d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f195e8dd-6b89-44ce-b9f5-67f8b2e6fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f6aa712b-a3db-48dc-a95a-06623562ad88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4754e3-00f9-4efd-a4ab-09f003976e1d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f6aa712b-a3db-48dc-a95a-06623562ad88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c11d7abc-5d96-497c-aab5-2fcd0b3aed83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4754e3-00f9-4efd-a4ab-09f003976e1d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c11d7abc-5d96-497c-aab5-2fcd0b3aed83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f54e5db3-2775-457d-89ae-99619095655f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4754e3-00f9-4efd-a4ab-09f003976e1d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f54e5db3-2775-457d-89ae-99619095655f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5a1ab6d1-1c81-4a46-b821-ddcb7b4aee07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a4754e3-00f9-4efd-a4ab-09f003976e1d" xlink:to="loc_us-gaap_Assets_5a1ab6d1-1c81-4a46-b821-ddcb7b4aee07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5c5e0bdc-abce-4c8e-ae26-ce2039e5cf09" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_2a999ccd-12f1-4472-8ea9-d220ed114629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_2a999ccd-12f1-4472-8ea9-d220ed114629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_11b866ef-a96d-46e8-b3d6-4ea389cf44a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a999ccd-12f1-4472-8ea9-d220ed114629" xlink:to="loc_us-gaap_AccountsPayableCurrent_11b866ef-a96d-46e8-b3d6-4ea389cf44a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3cc00727-398b-4245-a03b-0cf8252cad49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a999ccd-12f1-4472-8ea9-d220ed114629" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3cc00727-398b-4245-a03b-0cf8252cad49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_930aabac-0840-41d1-9568-6ab6c8354746" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a999ccd-12f1-4472-8ea9-d220ed114629" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_930aabac-0840-41d1-9568-6ab6c8354746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_14e7a517-3034-45f9-9d58-e8741cacb8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a999ccd-12f1-4472-8ea9-d220ed114629" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_14e7a517-3034-45f9-9d58-e8741cacb8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_e527f326-88a9-4fa1-874f-f882388c2d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a999ccd-12f1-4472-8ea9-d220ed114629" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_e527f326-88a9-4fa1-874f-f882388c2d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a160cb52-50de-48b1-aa48-3a38a588ce96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_2a999ccd-12f1-4472-8ea9-d220ed114629" xlink:to="loc_us-gaap_LiabilitiesCurrent_a160cb52-50de-48b1-aa48-3a38a588ce96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b02375a3-2be4-4a99-ba47-f47e5a0ab76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b02375a3-2be4-4a99-ba47-f47e5a0ab76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a20b082b-a26d-49bd-b776-f6ad30592b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a20b082b-a26d-49bd-b776-f6ad30592b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5dbc87c7-a2ed-487f-ad65-e74fb4b429c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5dbc87c7-a2ed-487f-ad65-e74fb4b429c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d495a14f-a98e-404e-9359-208b9dcf8650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d495a14f-a98e-404e-9359-208b9dcf8650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ecc07214-dbdf-42f7-9b31-496e1cd0012a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:to="loc_us-gaap_Liabilities_ecc07214-dbdf-42f7-9b31-496e1cd0012a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_dbd9924a-289e-4af2-86d4-68d052db9a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:to="loc_us-gaap_StockholdersEquityAbstract_dbd9924a-289e-4af2-86d4-68d052db9a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e714113d-90b1-4072-9b47-66e6039325e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dbd9924a-289e-4af2-86d4-68d052db9a59" xlink:to="loc_us-gaap_CommonStockValue_e714113d-90b1-4072-9b47-66e6039325e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_729e0a1c-29b7-4ca4-90c0-fe52c82803e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dbd9924a-289e-4af2-86d4-68d052db9a59" xlink:to="loc_us-gaap_AdditionalPaidInCapital_729e0a1c-29b7-4ca4-90c0-fe52c82803e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d08f4a4-e3f4-4594-9928-3e48d803911b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dbd9924a-289e-4af2-86d4-68d052db9a59" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4d08f4a4-e3f4-4594-9928-3e48d803911b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_54c1e827-81aa-4404-80c7-7fe107fd9bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dbd9924a-289e-4af2-86d4-68d052db9a59" xlink:to="loc_us-gaap_StockholdersEquity_54c1e827-81aa-4404-80c7-7fe107fd9bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_32cb93be-cca5-4625-aa3b-5355e3d7b3c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dbd9924a-289e-4af2-86d4-68d052db9a59" xlink:to="loc_us-gaap_MinorityInterest_32cb93be-cca5-4625-aa3b-5355e3d7b3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6618c970-30de-4cfe-85ca-3e82a6ce0020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dbd9924a-289e-4af2-86d4-68d052db9a59" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6618c970-30de-4cfe-85ca-3e82a6ce0020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1a10feb5-7e9b-4613-ad13-96e34bec7522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_88b52cde-e6dc-494f-a69f-8cd69161da95" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1a10feb5-7e9b-4613-ad13-96e34bec7522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_01f0edeb-0262-4e5b-a399-1871ade6352f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_de9cfd09-8762-4bb0-92cb-f9a43229f716" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f0edeb-0262-4e5b-a399-1871ade6352f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_de9cfd09-8762-4bb0-92cb-f9a43229f716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory_2f5848bd-ea1a-4988-abfa-31b676e9700e" xlink:href="apyx-20200930.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f0edeb-0262-4e5b-a399-1871ade6352f" xlink:to="loc_apyx_ProvisionForObsolescenceInventory_2f5848bd-ea1a-4988-abfa-31b676e9700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c983b658-edcd-4ac0-abcf-16109820d8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f0edeb-0262-4e5b-a399-1871ade6352f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c983b658-edcd-4ac0-abcf-16109820d8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f78a3c63-60a3-4dba-8d9a-d91166c2ca37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f0edeb-0262-4e5b-a399-1871ade6352f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f78a3c63-60a3-4dba-8d9a-d91166c2ca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fd033896-1666-4172-aea8-f77850146d1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f0edeb-0262-4e5b-a399-1871ade6352f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fd033896-1666-4172-aea8-f77850146d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b7dbf63-5649-4f06-9630-d8281265e498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f0edeb-0262-4e5b-a399-1871ade6352f" xlink:to="loc_us-gaap_CommonStockSharesIssued_4b7dbf63-5649-4f06-9630-d8281265e498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_09f24fb8-8b1f-4860-a0dd-8d89e69862cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01f0edeb-0262-4e5b-a399-1871ade6352f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_09f24fb8-8b1f-4860-a0dd-8d89e69862cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_769cb621-f741-4155-9df2-778863cc596d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_769cb621-f741-4155-9df2-778863cc596d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1dbd0d91-d8a9-4629-b9e3-a241258ae6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1dbd0d91-d8a9-4629-b9e3-a241258ae6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_d880bded-da3c-4feb-8493-032376fed146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_GrossProfit_d880bded-da3c-4feb-8493-032376fed146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_076d81f3-e83d-4efe-85bf-2705d4c2535b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_076d81f3-e83d-4efe-85bf-2705d4c2535b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ad536a1c-f20d-480d-9a96-787b305030c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_076d81f3-e83d-4efe-85bf-2705d4c2535b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ad536a1c-f20d-480d-9a96-787b305030c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_4519cea4-ffcd-4a56-8066-23efaa2e644b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_076d81f3-e83d-4efe-85bf-2705d4c2535b" xlink:to="loc_us-gaap_ProfessionalFees_4519cea4-ffcd-4a56-8066-23efaa2e644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_57f8e253-0728-4983-9a44-41c3cbf8f400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_076d81f3-e83d-4efe-85bf-2705d4c2535b" xlink:to="loc_us-gaap_SalariesAndWages_57f8e253-0728-4983-9a44-41c3cbf8f400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2a13a7ff-dd1f-49e3-a4d0-cd0ba6ea335f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_076d81f3-e83d-4efe-85bf-2705d4c2535b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2a13a7ff-dd1f-49e3-a4d0-cd0ba6ea335f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_065bb432-6e2e-48cf-9343-bec415a8ba04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_076d81f3-e83d-4efe-85bf-2705d4c2535b" xlink:to="loc_us-gaap_OperatingExpenses_065bb432-6e2e-48cf-9343-bec415a8ba04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ae7083d-5d03-44e7-9a41-96e629c09fcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_OperatingIncomeLoss_2ae7083d-5d03-44e7-9a41-96e629c09fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_10bf218c-45dd-4e79-9a91-3ae98fd7e5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_InterestIncomeOperating_10bf218c-45dd-4e79-9a91-3ae98fd7e5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e3bceb6e-f4b8-42a8-a69e-968a73336b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_InterestExpense_e3bceb6e-f4b8-42a8-a69e-968a73336b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_69cff678-0433-41b4-befd-8dcc0dfbbb35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_69cff678-0433-41b4-befd-8dcc0dfbbb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6e8bbad9-cc6c-4428-b2dd-ac684b33783a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6e8bbad9-cc6c-4428-b2dd-ac684b33783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5866522a-737a-40cc-9c59-e8f719aa9d50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5866522a-737a-40cc-9c59-e8f719aa9d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7be069ac-2aa2-4dbb-a4da-411135109315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7be069ac-2aa2-4dbb-a4da-411135109315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a865f447-c8be-4bd2-835b-bbe73958c4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_ProfitLoss_a865f447-c8be-4bd2-835b-bbe73958c4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_60c24076-c395-460d-a77d-5516443ab710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_60c24076-c395-460d-a77d-5516443ab710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a591c3f-3d8d-4d9d-a356-0e7ae872ac5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_NetIncomeLoss_1a591c3f-3d8d-4d9d-a356-0e7ae872ac5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b82dc09e-26c3-437c-9957-db9385c351f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ec8847ba-aac7-46d3-aa02-161e72c589d9" xlink:to="loc_us-gaap_EarningsPerShareAbstract_b82dc09e-26c3-437c-9957-db9385c351f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_ffd00ae7-aa70-48e6-bc12-7d7737743539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b82dc09e-26c3-437c-9957-db9385c351f2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_ffd00ae7-aa70-48e6-bc12-7d7737743539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_28d508b8-5c8b-47d2-865b-de1f406c5b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6f08181b-8c2c-4e78-b0e3-14952bd9948e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_28d508b8-5c8b-47d2-865b-de1f406c5b88" xlink:to="loc_us-gaap_StatementTable_6f08181b-8c2c-4e78-b0e3-14952bd9948e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3287574d-8000-4d5a-9344-af2800a6cfbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6f08181b-8c2c-4e78-b0e3-14952bd9948e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3287574d-8000-4d5a-9344-af2800a6cfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3287574d-8000-4d5a-9344-af2800a6cfbe" xlink:to="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ae743144-93d1-455b-bbd6-262c1b76e9f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:to="loc_us-gaap_CommonStockMember_ae743144-93d1-455b-bbd6-262c1b76e9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_01d5b6f2-bff4-469c-a984-9d141b26519a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_01d5b6f2-bff4-469c-a984-9d141b26519a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_80cea6c8-4e1b-4a83-8458-9ab5b4413c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:to="loc_us-gaap_RetainedEarningsMember_80cea6c8-4e1b-4a83-8458-9ab5b4413c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_16c46fea-8383-445c-92f4-c568841a623a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8506804-87bf-4d96-b7e5-68637e571ae8" xlink:to="loc_us-gaap_NoncontrollingInterestMember_16c46fea-8383-445c-92f4-c568841a623a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6aa7625-11b8-4bd5-8502-76003a69990f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6f08181b-8c2c-4e78-b0e3-14952bd9948e" xlink:to="loc_us-gaap_StatementLineItems_c6aa7625-11b8-4bd5-8502-76003a69990f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6aa7625-11b8-4bd5-8502-76003a69990f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_10bb15c2-094f-45cd-9726-f76c3de5099b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_SharesIssued_10bb15c2-094f-45cd-9726-f76c3de5099b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_761b3dc2-03ab-45a1-a0f2-d679e86a5120" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_761b3dc2-03ab-45a1-a0f2-d679e86a5120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_88b17ce6-2b02-4f05-86b7-3fe0a318c939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_ProfitLoss_88b17ce6-2b02-4f05-86b7-3fe0a318c939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_5d23d28f-7107-4621-ae31-cdb9e1efb96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_5d23d28f-7107-4621-ae31-cdb9e1efb96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3c36b915-013a-406b-83dd-b61f8145f440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3c36b915-013a-406b-83dd-b61f8145f440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f8e9c4e0-3dcd-473a-8df2-782630e57550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f8e9c4e0-3dcd-473a-8df2-782630e57550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee33ea02-d5a3-41a8-a6cb-d0ee747d5ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ee33ea02-d5a3-41a8-a6cb-d0ee747d5ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_2b1ff50f-7a2d-40cb-adfd-ca3716c8dae6" xlink:href="apyx-20200930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_2b1ff50f-7a2d-40cb-adfd-ca3716c8dae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsAmount_ad666569-dcab-4e29-9f28-5bb4e330a18f" xlink:href="apyx-20200930.xsd#apyx_StockSwapToAcquireOptionsAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_apyx_StockSwapToAcquireOptionsAmount_ad666569-dcab-4e29-9f28-5bb4e330a18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_67211be3-d7ff-4630-80f2-5c7d52ffe1ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_SharesIssued_67211be3-d7ff-4630-80f2-5c7d52ffe1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7eae8126-b5f5-43c7-ab26-4a627f4fd3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b832a82b-8efe-4aec-a233-b7d718d3a2a9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7eae8126-b5f5-43c7-ab26-4a627f4fd3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f171a5fc-6749-415a-8463-e44b090e2edf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_ProfitLoss_f171a5fc-6749-415a-8463-e44b090e2edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f32d4550-2898-4524-89c8-5ee51ff58638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f32d4550-2898-4524-89c8-5ee51ff58638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f32d4550-2898-4524-89c8-5ee51ff58638" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2afca405-0393-4891-99e2-e37d395f76eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2afca405-0393-4891-99e2-e37d395f76eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_fea368eb-5b4a-4e8e-938d-96272d869037" xlink:href="apyx-20200930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_fea368eb-5b4a-4e8e-938d-96272d869037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_975e8c20-b762-425d-8a32-5957bbeae11f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_975e8c20-b762-425d-8a32-5957bbeae11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_90b5a515-8dcb-48f5-a162-c8ea9359dcdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:to="loc_us-gaap_ShareBasedCompensation_90b5a515-8dcb-48f5-a162-c8ea9359dcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_04ea9a9f-e885-47dd-93c5-cd573bea36e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:to="loc_us-gaap_OperatingLeaseExpense_04ea9a9f-e885-47dd-93c5-cd573bea36e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_fea1c613-a659-42e3-a1c9-0314b5b3b31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:to="loc_us-gaap_GainLossOnInvestments_fea1c613-a659-42e3-a1c9-0314b5b3b31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_9e7f509f-0487-4ae6-88f1-1c14c6a669bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_9e7f509f-0487-4ae6-88f1-1c14c6a669bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_87a4c58c-02ce-47bd-83f9-b14a8f85e944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ae087cfe-2192-4133-989a-2dc67db2e4d1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_87a4c58c-02ce-47bd-83f9-b14a8f85e944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_de202458-40a6-4088-b418-de2a8eb2b117" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_87a4c58c-02ce-47bd-83f9-b14a8f85e944" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_de202458-40a6-4088-b418-de2a8eb2b117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets_0f217126-964a-417a-b8e6-06cfd29cf8cb" xlink:href="apyx-20200930.xsd#apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_87a4c58c-02ce-47bd-83f9-b14a8f85e944" xlink:to="loc_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets_0f217126-964a-417a-b8e6-06cfd29cf8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_863de29c-3499-44cb-a754-e38eb8b47f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_87a4c58c-02ce-47bd-83f9-b14a8f85e944" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_863de29c-3499-44cb-a754-e38eb8b47f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d122c050-1bef-49e8-b63d-fbb1195841b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_87a4c58c-02ce-47bd-83f9-b14a8f85e944" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d122c050-1bef-49e8-b63d-fbb1195841b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d5f18e31-506a-44bb-8614-5d30acbfdf1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_87a4c58c-02ce-47bd-83f9-b14a8f85e944" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d5f18e31-506a-44bb-8614-5d30acbfdf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7e5c7fb-21b0-4827-9715-8082178c650c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f32d4550-2898-4524-89c8-5ee51ff58638" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7e5c7fb-21b0-4827-9715-8082178c650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5572564-8b1a-48e2-961f-28abcac0e576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5572564-8b1a-48e2-961f-28abcac0e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_072b12e6-f0d4-48d9-a989-457567806f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5572564-8b1a-48e2-961f-28abcac0e576" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_072b12e6-f0d4-48d9-a989-457567806f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_833879d4-d3d1-4e84-9837-3d4741a70b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5572564-8b1a-48e2-961f-28abcac0e576" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_833879d4-d3d1-4e84-9837-3d4741a70b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_182ffa6e-cc39-4efe-8b76-9711cecaff92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5572564-8b1a-48e2-961f-28abcac0e576" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_182ffa6e-cc39-4efe-8b76-9711cecaff92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3f115fc-5167-467f-9e55-d51774076901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f5572564-8b1a-48e2-961f-28abcac0e576" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c3f115fc-5167-467f-9e55-d51774076901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60ea05c8-6db8-4b73-ac70-38be580bec09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60ea05c8-6db8-4b73-ac70-38be580bec09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_272b45c6-d222-4d7e-baa6-941e3ddd0f18" xlink:href="apyx-20200930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60ea05c8-6db8-4b73-ac70-38be580bec09" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_272b45c6-d222-4d7e-baa6-941e3ddd0f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_92ed9883-8602-420e-8b5f-021d3e1ff4c0" xlink:href="apyx-20200930.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60ea05c8-6db8-4b73-ac70-38be580bec09" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_92ed9883-8602-420e-8b5f-021d3e1ff4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_d97e4016-0a08-4c0d-ad26-f8c7bb7a1d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60ea05c8-6db8-4b73-ac70-38be580bec09" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_d97e4016-0a08-4c0d-ad26-f8c7bb7a1d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20fb839f-f675-45bb-ab49-654de63c00c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60ea05c8-6db8-4b73-ac70-38be580bec09" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20fb839f-f675-45bb-ab49-654de63c00c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54de79e2-fd9f-4384-acac-e633f0bb6071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54de79e2-fd9f-4384-acac-e633f0bb6071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_63d5c592-e603-47a9-ae83-28ef9c04f509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_63d5c592-e603-47a9-ae83-28ef9c04f509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76246baf-b522-4927-8286-2e7f44e52d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_76246baf-b522-4927-8286-2e7f44e52d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c3760f4-bfff-4a1e-bdc4-169c34d3b026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c3760f4-bfff-4a1e-bdc4-169c34d3b026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_04dbc1be-8569-4cbf-bbce-9a86add29488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_04dbc1be-8569-4cbf-bbce-9a86add29488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_61c3be88-77af-43c3-a895-d1dd9dd55c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_04dbc1be-8569-4cbf-bbce-9a86add29488" xlink:to="loc_us-gaap_InterestPaidNet_61c3be88-77af-43c3-a895-d1dd9dd55c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_060ef5af-a18c-4498-b5d7-55f358c18d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_04dbc1be-8569-4cbf-bbce-9a86add29488" xlink:to="loc_us-gaap_IncomeTaxesPaid_060ef5af-a18c-4498-b5d7-55f358c18d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_18933fa7-c78e-4636-92f4-df51e26effb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a39b1727-f1ef-4c22-a2fd-31daf4325c83" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_18933fa7-c78e-4636-92f4-df51e26effb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_LeaseAdoption_5701d9cd-dc9c-443a-a30d-662265414b03" xlink:href="apyx-20200930.xsd#apyx_LeaseAdoption"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_18933fa7-c78e-4636-92f4-df51e26effb5" xlink:to="loc_apyx_LeaseAdoption_5701d9cd-dc9c-443a-a30d-662265414b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseNonCash_3a252016-09cf-448c-93d8-003ad29de5e6" xlink:href="apyx-20200930.xsd#apyx_CapitalizationOfLeaseNonCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_18933fa7-c78e-4636-92f4-df51e26effb5" xlink:to="loc_apyx_CapitalizationOfLeaseNonCash_3a252016-09cf-448c-93d8-003ad29de5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CapitalizationOfLeaseExecution_b4cb8cb7-a2cd-4b84-9fad-f95381afb01f" xlink:href="apyx-20200930.xsd#apyx_CapitalizationOfLeaseExecution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_18933fa7-c78e-4636-92f4-df51e26effb5" xlink:to="loc_apyx_CapitalizationOfLeaseExecution_b4cb8cb7-a2cd-4b84-9fad-f95381afb01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_301c1fd0-6e2a-490e-8509-0784b82b02b2" xlink:href="apyx-20200930.xsd#apyx_NonCashTransferOfOtherAssetsToFixedAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_18933fa7-c78e-4636-92f4-df51e26effb5" xlink:to="loc_apyx_NonCashTransferOfOtherAssetsToFixedAssets_301c1fd0-6e2a-490e-8509-0784b82b02b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets_458114a8-83a5-42cd-b4f0-888d5fc3b9cb" xlink:href="apyx-20200930.xsd#apyx_NonCashTransfersOfInventoryToFromFixedAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_18933fa7-c78e-4636-92f4-df51e26effb5" xlink:to="loc_apyx_NonCashTransfersOfInventoryToFromFixedAssets_458114a8-83a5-42cd-b4f0-888d5fc3b9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9fd5b40-28fc-48c2-98dc-26ac2bf54c63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7b0a4511-5650-497b-afdd-f87020b5bb07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9fd5b40-28fc-48c2-98dc-26ac2bf54c63" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7b0a4511-5650-497b-afdd-f87020b5bb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="simple" xlink:href="apyx-20200930.xsd#BASISOFPRESENTATIONPolicies"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9b20509-895a-4d9c-98f2-5afb351b4776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b9f03b58-76c7-4d1c-8cbe-157252ed91ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9b20509-895a-4d9c-98f2-5afb351b4776" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b9f03b58-76c7-4d1c-8cbe-157252ed91ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38ff81e8-2f6e-4b0b-a5ee-b293fe93d5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9b20509-895a-4d9c-98f2-5afb351b4776" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_38ff81e8-2f6e-4b0b-a5ee-b293fe93d5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_aab4c804-a59c-4bfe-ab71-12b9d5427269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f9b20509-895a-4d9c-98f2-5afb351b4776" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_aab4c804-a59c-4bfe-ab71-12b9d5427269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="simple" xlink:href="apyx-20200930.xsd#CHANGEINACCOUNTINGPOLICY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_5777c0b7-55ef-4197-805b-63e97671f34f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesTextBlock_17b27089-4b13-419a-b2cc-ddc173a2a6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_5777c0b7-55ef-4197-805b-63e97671f34f" xlink:to="loc_us-gaap_AccountingChangesTextBlock_17b27089-4b13-419a-b2cc-ddc173a2a6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20200930.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_cd78e6f9-1701-4eee-86fb-eaaffa307ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_3adeed4d-6b08-450d-8093-e35ff9117c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_cd78e6f9-1701-4eee-86fb-eaaffa307ed9" xlink:to="loc_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted_3adeed4d-6b08-450d-8093-e35ff9117c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="simple" xlink:href="apyx-20200930.xsd#DISPOSALOFBUSINESS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_59fe2981-3175-43a1-99c2-1331dfc9e94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1c61053a-b905-4b47-b358-ef06893bb38d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_59fe2981-3175-43a1-99c2-1331dfc9e94a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1c61053a-b905-4b47-b358-ef06893bb38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#DISPOSALOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d155baa8-208b-462b-b528-c836def62f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d155baa8-208b-462b-b528-c836def62f50" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_78b9aafc-5ced-427d-95c9-5c35187dce6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_78b9aafc-5ced-427d-95c9-5c35187dce6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fbef8e43-4dc9-4900-b06d-5be0c59fb501" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_78b9aafc-5ced-427d-95c9-5c35187dce6a" xlink:to="loc_us-gaap_RelatedPartyDomain_fbef8e43-4dc9-4900-b06d-5be0c59fb501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_0ca62789-5929-405b-a768-f7ef3e29148e" xlink:href="apyx-20200930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_fbef8e43-4dc9-4900-b06d-5be0c59fb501" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_0ca62789-5929-405b-a768-f7ef3e29148e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_0825c64d-354d-4aa1-82ad-26bcf6b6937c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_0825c64d-354d-4aa1-82ad-26bcf6b6937c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c70e7fd0-2e28-4584-92bf-0ba921b2e6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_0825c64d-354d-4aa1-82ad-26bcf6b6937c" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c70e7fd0-2e28-4584-92bf-0ba921b2e6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_b55d0d9f-a9e8-49d6-af78-a8958308dd5d" xlink:href="apyx-20200930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c70e7fd0-2e28-4584-92bf-0ba921b2e6f3" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_b55d0d9f-a9e8-49d6-af78-a8958308dd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_45f966ee-6959-427d-b5bb-b6a365fa5ac6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c19fbe23-738c-4282-9678-b64fedf5e922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_c19fbe23-738c-4282-9678-b64fedf5e922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_3d5581e1-8ab5-4c12-aac0-654137c5b080" xlink:href="apyx-20200930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_3d5581e1-8ab5-4c12-aac0-654137c5b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_04fd2931-9947-4dc4-b9a5-279af1cc762c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_04fd2931-9947-4dc4-b9a5-279af1cc762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_200ebca3-8d8a-4ee9-aa81-80b4acd828d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_200ebca3-8d8a-4ee9-aa81-80b4acd828d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fff3fbcb-a696-46d3-9578-580822d4dfa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_fff3fbcb-a696-46d3-9578-580822d4dfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_70a95895-b5dd-4b31-8aa5-010728d9f4e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_aaa374e8-2019-46f9-a2e0-6b611dc01c95" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_70a95895-b5dd-4b31-8aa5-010728d9f4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5f880c0a-aa52-4cbf-b0a8-e822e0b079f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_67164144-6e2d-4476-bb6d-22cd9f2c4f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5f880c0a-aa52-4cbf-b0a8-e822e0b079f5" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_67164144-6e2d-4476-bb6d-22cd9f2c4f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0f4737f3-96ee-4869-8971-715339a98fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d8888ff7-f9af-47c1-bf66-ef38df05af72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0f4737f3-96ee-4869-8971-715339a98fe7" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d8888ff7-f9af-47c1-bf66-ef38df05af72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_09107bcd-13ec-4793-8348-1d18f5c773bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_4f2ae437-8ba0-4d70-8ef0-4f6be9de1b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_09107bcd-13ec-4793-8348-1d18f5c773bd" xlink:to="loc_us-gaap_InventoryRawMaterials_4f2ae437-8ba0-4d70-8ef0-4f6be9de1b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_3fa1f9f0-14d8-43ea-a78f-b63a93103ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_09107bcd-13ec-4793-8348-1d18f5c773bd" xlink:to="loc_us-gaap_InventoryWorkInProcess_3fa1f9f0-14d8-43ea-a78f-b63a93103ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_5977bca8-50ef-4608-992c-7b94cae9d1a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_09107bcd-13ec-4793-8348-1d18f5c773bd" xlink:to="loc_us-gaap_InventoryFinishedGoods_5977bca8-50ef-4608-992c-7b94cae9d1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_af37d2ae-0955-40dd-ab04-a7381fb6401e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_09107bcd-13ec-4793-8348-1d18f5c773bd" xlink:to="loc_us-gaap_InventoryGross_af37d2ae-0955-40dd-ab04-a7381fb6401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_019d6801-74de-417f-bcd6-5a8a99bad47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_09107bcd-13ec-4793-8348-1d18f5c773bd" xlink:to="loc_us-gaap_InventoryValuationReserves_019d6801-74de-417f-bcd6-5a8a99bad47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4bab88d9-f552-4d32-9091-f984b257b302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_09107bcd-13ec-4793-8348-1d18f5c773bd" xlink:to="loc_us-gaap_InventoryNet_4bab88d9-f552-4d32-9091-f984b257b302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INVENTORIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_cb300ba1-1f9e-453f-88bd-ebb98f3ff272" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d0de4e4c-6678-470b-bedb-9e19937f2488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_cb300ba1-1f9e-453f-88bd-ebb98f3ff272" xlink:to="loc_us-gaap_InventoryWriteDown_d0de4e4c-6678-470b-bedb-9e19937f2488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d4f6794a-0afe-4427-ae48-bd01318caeb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_052942ce-6c97-476a-afc2-46e863855670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d4f6794a-0afe-4427-ae48-bd01318caeb0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_052942ce-6c97-476a-afc2-46e863855670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8432ec6b-59cb-4cd9-8bb5-69d3100bd6a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6a09672e-64d9-4fc0-8c60-0ad446d2ca92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8432ec6b-59cb-4cd9-8bb5-69d3100bd6a7" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6a09672e-64d9-4fc0-8c60-0ad446d2ca92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_24bb0052-2de4-475a-9188-55e677172985" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_us-gaap_AccruedSalariesCurrent_24bb0052-2de4-475a-9188-55e677172985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_07e95771-aec7-4ecf-8f76-7ef6d36a41ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_us-gaap_AccruedBonusesCurrent_07e95771-aec7-4ecf-8f76-7ef6d36a41ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_6b7da9d9-2857-459e-b034-34e4004e3bc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_6b7da9d9-2857-459e-b034-34e4004e3bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_e5ea24b7-0e65-4232-96b5-b2b695d5ed43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_e5ea24b7-0e65-4232-96b5-b2b695d5ed43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_d804ebd5-506a-46a6-a388-072a9c107643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_d804ebd5-506a-46a6-a388-072a9c107643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_dbf4b2c8-6b85-4e5d-89c3-a5da97af31e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_dbf4b2c8-6b85-4e5d-89c3-a5da97af31e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_8fd6f51d-8ee4-4c88-b371-889131f99095" xlink:href="apyx-20200930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_8fd6f51d-8ee4-4c88-b371-889131f99095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_97562dea-3627-48e8-b3cd-b2a2291aba30" xlink:href="apyx-20200930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_apyx_UncertainTaxPositionsLiability_97562dea-3627-48e8-b3cd-b2a2291aba30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_4d2cd875-a9e7-4f3e-8e23-7f05657fcfec" xlink:href="apyx-20200930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_4d2cd875-a9e7-4f3e-8e23-7f05657fcfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9ed5199a-cd48-49b4-a067-8f6565bd25e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49377fcb-e6d6-4308-aca6-09a74a1ae535" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9ed5199a-cd48-49b4-a067-8f6565bd25e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTEREST" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTEREST"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTEREST" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_e97dca33-5187-4672-96fa-7813ae2edd00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_4bd5b9f4-e226-4ce2-9565-1f373f06801c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_e97dca33-5187-4672-96fa-7813ae2edd00" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_4bd5b9f4-e226-4ce2-9565-1f373f06801c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_b61deab0-08f2-4ace-a701-1ed40df1c902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock_fa09fa80-492e-4fef-8f0f-586a63dd68c7" xlink:href="apyx-20200930.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_b61deab0-08f2-4ace-a701-1ed40df1c902" xlink:to="loc_apyx_NoncontrollingInterestTableTextBlock_fa09fa80-492e-4fef-8f0f-586a63dd68c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_ea369359-6089-4b40-9aa6-0b76da6b2f05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_bb769dbe-6a2d-4120-99a4-1ad792bff0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_ea369359-6089-4b40-9aa6-0b76da6b2f05" xlink:to="loc_us-gaap_MinorityInterestTable_bb769dbe-6a2d-4120-99a4-1ad792bff0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_523f2f7d-b92a-4a43-af8f-8efed0c3428f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_bb769dbe-6a2d-4120-99a4-1ad792bff0e8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_523f2f7d-b92a-4a43-af8f-8efed0c3428f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_21d51b91-1d80-493a-9988-9a095ca5a7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_523f2f7d-b92a-4a43-af8f-8efed0c3428f" xlink:to="loc_us-gaap_RelatedPartyDomain_21d51b91-1d80-493a-9988-9a095ca5a7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_ee309263-4ede-40f0-9651-e966166ec0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_21d51b91-1d80-493a-9988-9a095ca5a7e4" xlink:to="loc_us-gaap_CorporateJointVentureMember_ee309263-4ede-40f0-9651-e966166ec0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_6cb68df0-7ac9-4485-baa2-27a3cd0bd368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_bb769dbe-6a2d-4120-99a4-1ad792bff0e8" xlink:to="loc_us-gaap_MinorityInterestLineItems_6cb68df0-7ac9-4485-baa2-27a3cd0bd368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_2054783e-536f-47c8-a6e5-2b31ba1ffd5f" xlink:href="apyx-20200930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6cb68df0-7ac9-4485-baa2-27a3cd0bd368" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_2054783e-536f-47c8-a6e5-2b31ba1ffd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_ed8b8d81-3227-4d9c-a6f7-5a8e63d16957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_6cb68df0-7ac9-4485-baa2-27a3cd0bd368" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_ed8b8d81-3227-4d9c-a6f7-5a8e63d16957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_a1b14164-9057-4aff-a77d-af75dd6a77e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_a1b14164-9057-4aff-a77d-af75dd6a77e0" xlink:to="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e29bb9fc-9659-4717-91ae-45ce84f576ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e29bb9fc-9659-4717-91ae-45ce84f576ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f8252681-67f5-4457-905c-587f591c72a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e29bb9fc-9659-4717-91ae-45ce84f576ef" xlink:to="loc_us-gaap_RelatedPartyDomain_f8252681-67f5-4457-905c-587f591c72a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_1bde4cdc-8f92-404c-b938-4d87eb65872a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f8252681-67f5-4457-905c-587f591c72a5" xlink:to="loc_us-gaap_CorporateJointVentureMember_1bde4cdc-8f92-404c-b938-4d87eb65872a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:to="loc_srt_OwnershipAxis_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_457abebb-3ac6-4746-bbeb-eea02ac4eb72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_8f8aca0e-10bf-4fb7-8839-4cdd9f939e38" xlink:to="loc_srt_OwnershipDomain_457abebb-3ac6-4746-bbeb-eea02ac4eb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_d041fa65-90e2-4ea1-bf60-849b465397cf" xlink:href="apyx-20200930.xsd#apyx_ChineseSupplierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_457abebb-3ac6-4746-bbeb-eea02ac4eb72" xlink:to="loc_apyx_ChineseSupplierMember_d041fa65-90e2-4ea1-bf60-849b465397cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_48914031-8ef9-4507-a175-64a37bc11dff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e2f47de5-2711-4708-bd9a-b9155892a4f9" xlink:to="loc_us-gaap_MinorityInterestLineItems_48914031-8ef9-4507-a175-64a37bc11dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_9835fbe2-1609-4633-983b-27921fb9626e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_48914031-8ef9-4507-a175-64a37bc11dff" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_9835fbe2-1609-4633-983b-27921fb9626e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_48914031-8ef9-4507-a175-64a37bc11dff" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_d8740720-a3c8-4bdc-9c24-0f7c33350553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:to="loc_us-gaap_MinorityInterest_d8740720-a3c8-4bdc-9c24-0f7c33350553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_962368ad-b7a7-4b0b-b30e-3758113e4e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_962368ad-b7a7-4b0b-b30e-3758113e4e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b781b263-9e9f-4d36-b70d-d347989a8c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b781b263-9e9f-4d36-b70d-d347989a8c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_fcf93269-6f33-4afe-9244-e7a6df47549e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_d8479374-ce34-490b-a6a9-e4bcf6dbf141" xlink:to="loc_us-gaap_MinorityInterest_fcf93269-6f33-4afe-9244-e7a6df47549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8cbbacba-81e7-411d-9922-727c8b9ae5a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b29cd0ef-4c76-47a5-be31-61298fa6cb57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cbbacba-81e7-411d-9922-727c8b9ae5a8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b29cd0ef-4c76-47a5-be31-61298fa6cb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_70b54ec5-65ae-4f18-9be3-185a3db734a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0db88451-72d2-4878-9584-2b6c4db4a225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70b54ec5-65ae-4f18-9be3-185a3db734a0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0db88451-72d2-4878-9584-2b6c4db4a225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3889d90d-667d-4c49-b555-32a976abfd7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23741cf9-b9c4-463e-a5dd-79682dead46e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3889d90d-667d-4c49-b555-32a976abfd7c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23741cf9-b9c4-463e-a5dd-79682dead46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bc0e3b04-4831-4b35-8177-f275663324a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23741cf9-b9c4-463e-a5dd-79682dead46e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bc0e3b04-4831-4b35-8177-f275663324a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_087ab634-2904-482c-9ed5-cfc2ef2fec44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bc0e3b04-4831-4b35-8177-f275663324a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_087ab634-2904-482c-9ed5-cfc2ef2fec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3dd52b5e-a5b2-4eeb-a9b9-6235cf9d6a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_087ab634-2904-482c-9ed5-cfc2ef2fec44" xlink:to="loc_us-gaap_RestrictedStockMember_3dd52b5e-a5b2-4eeb-a9b9-6235cf9d6a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0e21869b-4806-4b43-b638-b8e1e041accf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_087ab634-2904-482c-9ed5-cfc2ef2fec44" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0e21869b-4806-4b43-b638-b8e1e041accf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_23741cf9-b9c4-463e-a5dd-79682dead46e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_693ba596-f62f-4883-8245-760538c78894" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_693ba596-f62f-4883-8245-760538c78894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8b770cf-257d-43fa-b82e-70f767ce2daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_693ba596-f62f-4883-8245-760538c78894" xlink:to="loc_us-gaap_NetIncomeLoss_f8b770cf-257d-43fa-b82e-70f767ce2daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_318e8412-ddd2-42af-916e-2d3910d46e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_318e8412-ddd2-42af-916e-2d3910d46e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_198f49b3-d264-4b92-b606-a12aa8b3dd65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_318e8412-ddd2-42af-916e-2d3910d46e0a" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_198f49b3-d264-4b92-b606-a12aa8b3dd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_364c9627-7489-46be-b54b-427c9790e27d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_364c9627-7489-46be-b54b-427c9790e27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_6407c371-d50c-4044-896f-3e9dd5929932" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_364c9627-7489-46be-b54b-427c9790e27d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_6407c371-d50c-4044-896f-3e9dd5929932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_0dc4257a-9749-45b8-a5cb-a92a425ea591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ee056bf4-a683-4621-87f4-32ae0eb003df" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_0dc4257a-9749-45b8-a5cb-a92a425ea591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ff5439cb-5617-4fa9-933d-96bbafea683c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_0dc4257a-9749-45b8-a5cb-a92a425ea591" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ff5439cb-5617-4fa9-933d-96bbafea683c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3817248-ca12-47f5-9204-7026a07ad212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ffbe8434-b6ba-45f1-9263-6d446c314fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e3817248-ca12-47f5-9204-7026a07ad212" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ffbe8434-b6ba-45f1-9263-6d446c314fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7832a411-2e25-4141-be07-34884e309d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b9cc2946-6426-4525-bb0a-392a1fa8945c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7832a411-2e25-4141-be07-34884e309d6b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b9cc2946-6426-4525-bb0a-392a1fa8945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_be1a034a-943b-4a8b-9b0a-c48c06d64acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7832a411-2e25-4141-be07-34884e309d6b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_be1a034a-943b-4a8b-9b0a-c48c06d64acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0eb3f33b-76a3-498c-b85c-d0aca9d88ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b88e5c-0deb-4074-8d09-4c56b5da9fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0eb3f33b-76a3-498c-b85c-d0aca9d88ca0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b88e5c-0deb-4074-8d09-4c56b5da9fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9ab5fb49-6ce7-4f14-a344-60034dccabbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b88e5c-0deb-4074-8d09-4c56b5da9fc1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9ab5fb49-6ce7-4f14-a344-60034dccabbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_202bc50a-ba05-4a82-b372-bacb46ea2e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9ab5fb49-6ce7-4f14-a344-60034dccabbb" xlink:to="loc_us-gaap_ClassOfStockDomain_202bc50a-ba05-4a82-b372-bacb46ea2e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07f7ef35-0343-427a-b332-948826435874" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_202bc50a-ba05-4a82-b372-bacb46ea2e95" xlink:to="loc_us-gaap_CommonStockMember_07f7ef35-0343-427a-b332-948826435874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28b88e5c-0deb-4074-8d09-4c56b5da9fc1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3b3fb9fb-a7f2-4633-94cb-acba21272b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3b3fb9fb-a7f2-4633-94cb-acba21272b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_274af901-3231-4d9e-ab29-73455dde07d5" xlink:href="apyx-20200930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_274af901-3231-4d9e-ab29-73455dde07d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_14dd792d-f625-43b6-bc3e-492a9bd0a8d1" xlink:href="apyx-20200930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_af077f17-5dd5-415b-816e-8f1114b68f33" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_14dd792d-f625-43b6-bc3e-492a9bd0a8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2389e059-e268-47bd-8bc1-b589f8b93f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8eeb3172-0a72-4370-b3d2-a3778c02e99b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2389e059-e268-47bd-8bc1-b589f8b93f2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8eeb3172-0a72-4370-b3d2-a3778c02e99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03a41166-d0a4-45ba-b64b-f970db7f8a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8eeb3172-0a72-4370-b3d2-a3778c02e99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_03a41166-d0a4-45ba-b64b-f970db7f8a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cb2459d6-7e2f-4dab-a678-00846056ff0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8eeb3172-0a72-4370-b3d2-a3778c02e99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cb2459d6-7e2f-4dab-a678-00846056ff0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fafa80dc-7f54-4c7e-ac7e-6c7349fcaa87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8eeb3172-0a72-4370-b3d2-a3778c02e99b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fafa80dc-7f54-4c7e-ac7e-6c7349fcaa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_215a878e-cfb6-418d-b0bd-7f916c140bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8eeb3172-0a72-4370-b3d2-a3778c02e99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_215a878e-cfb6-418d-b0bd-7f916c140bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_321c03c8-01c0-4e0c-baeb-8c541584d246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8eeb3172-0a72-4370-b3d2-a3778c02e99b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_321c03c8-01c0-4e0c-baeb-8c541584d246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9eb03cd-58c2-4568-9715-71c5ab9b2bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2389e059-e268-47bd-8bc1-b589f8b93f2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9eb03cd-58c2-4568-9715-71c5ab9b2bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50ac27a0-7383-4b48-91bb-08afb2e9be7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9eb03cd-58c2-4568-9715-71c5ab9b2bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50ac27a0-7383-4b48-91bb-08afb2e9be7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ad83599d-67ec-4b8d-8037-02b6d44a9ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9eb03cd-58c2-4568-9715-71c5ab9b2bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ad83599d-67ec-4b8d-8037-02b6d44a9ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c342d7e6-4e1c-4913-8b60-9c6ba854d1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9eb03cd-58c2-4568-9715-71c5ab9b2bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c342d7e6-4e1c-4913-8b60-9c6ba854d1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2e93cbc7-039e-484a-972c-7130c55e459a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9eb03cd-58c2-4568-9715-71c5ab9b2bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2e93cbc7-039e-484a-972c-7130c55e459a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18769a00-7d49-41ce-afb7-25db326e914f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e9eb03cd-58c2-4568-9715-71c5ab9b2bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18769a00-7d49-41ce-afb7-25db326e914f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef0a02b2-845d-4928-b481-4678a37be1b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592053df-4461-4ebf-a427-fbaa188c1597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef0a02b2-845d-4928-b481-4678a37be1b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592053df-4461-4ebf-a427-fbaa188c1597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7d0a0a0-0822-40d0-bc7d-d61394786a3a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592053df-4461-4ebf-a427-fbaa188c1597" xlink:to="loc_srt_RangeAxis_c7d0a0a0-0822-40d0-bc7d-d61394786a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f869c5d8-b504-4915-95f0-c4fff7fdfe47" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c7d0a0a0-0822-40d0-bc7d-d61394786a3a" xlink:to="loc_srt_RangeMember_f869c5d8-b504-4915-95f0-c4fff7fdfe47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e69a2913-31e2-43c7-8e7b-cb4bb8961e22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f869c5d8-b504-4915-95f0-c4fff7fdfe47" xlink:to="loc_srt_MinimumMember_e69a2913-31e2-43c7-8e7b-cb4bb8961e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40bf115f-ab07-460c-b46a-845fe70ba3a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f869c5d8-b504-4915-95f0-c4fff7fdfe47" xlink:to="loc_srt_MaximumMember_40bf115f-ab07-460c-b46a-845fe70ba3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_592053df-4461-4ebf-a427-fbaa188c1597" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a28af5d7-50a7-4ba9-bb00-679d0ddc2b08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a28af5d7-50a7-4ba9-bb00-679d0ddc2b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_281ca68f-4b5e-4e2a-bca4-b2b4a0945ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_281ca68f-4b5e-4e2a-bca4-b2b4a0945ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4fd73279-641f-4c3d-841d-6a24f81e7540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4fd73279-641f-4c3d-841d-6a24f81e7540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b57838c5-7e20-4d54-bc8f-f47bc9e248d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b57838c5-7e20-4d54-bc8f-f47bc9e248d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a6c006fb-8691-4246-8c67-3ff880c516b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbfe5c38-807b-4c65-8ac7-12ee792ec7fe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a6c006fb-8691-4246-8c67-3ff880c516b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20200930.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6fe1e026-4ea8-4ab9-b6a4-ded7f42af773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_838782d0-8097-412a-af66-951d17638d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6fe1e026-4ea8-4ab9-b6a4-ded7f42af773" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_838782d0-8097-412a-af66-951d17638d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_c6475c22-21c6-4de7-8b6d-f9e8f3a19845" xlink:href="apyx-20200930.xsd#apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_c6475c22-21c6-4de7-8b6d-f9e8f3a19845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_364c25c0-9cce-4365-92b2-d7dc48e1f62a" xlink:href="apyx-20200930.xsd#apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes_364c25c0-9cce-4365-92b2-d7dc48e1f62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_aea86596-2e8b-4d63-b82e-28b75ef08e84" xlink:href="apyx-20200930.xsd#apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses_aea86596-2e8b-4d63-b82e-28b75ef08e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9e2e0f60-8dc0-4690-8f55-d23c38973633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9e2e0f60-8dc0-4690-8f55-d23c38973633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ddebefd0-111d-44d7-9c5e-12bbf5db476c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ddebefd0-111d-44d7-9c5e-12bbf5db476c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7b6b3dd0-553e-4cd2-872a-66719622d48b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7b6b3dd0-553e-4cd2-872a-66719622d48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0e048188-b92f-4ae1-8dc8-bb2928fac510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0e048188-b92f-4ae1-8dc8-bb2928fac510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_51d3e278-6f39-46c4-82e0-8c2302ba13df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_51d3e278-6f39-46c4-82e0-8c2302ba13df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_47fc2720-4a7a-4297-86a6-9e3eaa8fe1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eedbd117-08af-44d0-b4da-61018ebb2d03" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_47fc2720-4a7a-4297-86a6-9e3eaa8fe1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20200930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9947d1a2-961e-47f5-bf33-a16281ac5fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b7acec4-257c-46d0-94e9-b9b9e8d587ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9947d1a2-961e-47f5-bf33-a16281ac5fc3" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b7acec4-257c-46d0-94e9-b9b9e8d587ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91fa906d-02ae-44ec-a157-117d0aae7e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_91123c61-9244-4abb-ba78-35826779bf30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_91fa906d-02ae-44ec-a157-117d0aae7e2a" xlink:to="loc_us-gaap_OtherCommitmentsTable_91123c61-9244-4abb-ba78-35826779bf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_53757b7f-8d30-4202-966d-6e3e7aee3bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_91123c61-9244-4abb-ba78-35826779bf30" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_53757b7f-8d30-4202-966d-6e3e7aee3bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_24b043cb-f377-43f9-9c0b-b36a71aab8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_53757b7f-8d30-4202-966d-6e3e7aee3bac" xlink:to="loc_us-gaap_RelatedPartyDomain_24b043cb-f377-43f9-9c0b-b36a71aab8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_4891a815-538b-423d-b189-40c900430d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_24b043cb-f377-43f9-9c0b-b36a71aab8d5" xlink:to="loc_us-gaap_CorporateJointVentureMember_4891a815-538b-423d-b189-40c900430d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_91123c61-9244-4abb-ba78-35826779bf30" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_fb9c6ae0-2161-4b07-84ba-670e081e7d83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:to="loc_us-gaap_PurchaseObligation_fb9c6ae0-2161-4b07-84ba-670e081e7d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_97fca3d4-12dc-4908-85af-52b52ec50f57" xlink:href="apyx-20200930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_97fca3d4-12dc-4908-85af-52b52ec50f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining_93c88da1-a365-46f4-9701-bee652d08fe9" xlink:href="apyx-20200930.xsd#apyx_PaymentsToAcquireInterestInJointVentureRemaining"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_b2fa9066-0ba7-4dbb-af34-017cec845dd5" xlink:to="loc_apyx_PaymentsToAcquireInterestInJointVentureRemaining_93c88da1-a365-46f4-9701-bee652d08fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20200930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_bb648317-fd3d-43d4-816c-40c5c687b532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9ba3d46c-a265-4a5a-9382-f2f1ded70f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_bb648317-fd3d-43d4-816c-40c5c687b532" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_9ba3d46c-a265-4a5a-9382-f2f1ded70f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_90516b6b-44ed-4104-b0b5-ae9b21596cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_90516b6b-44ed-4104-b0b5-ae9b21596cb5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f8a1b9-14e1-4984-9a20-28b55d399fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f8a1b9-14e1-4984-9a20-28b55d399fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1965b97a-aeae-4dd9-ac08-798da8137e0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_48f8a1b9-14e1-4984-9a20-28b55d399fc9" xlink:to="loc_us-gaap_RelatedPartyDomain_1965b97a-aeae-4dd9-ac08-798da8137e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_2ed5fe80-8f1d-4fc7-a1f7-37426d7ce4e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1965b97a-aeae-4dd9-ac08-798da8137e0f" xlink:to="loc_srt_DirectorMember_2ed5fe80-8f1d-4fc7-a1f7-37426d7ce4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_a439aae9-c678-44ad-b940-3ef54c4806da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1965b97a-aeae-4dd9-ac08-798da8137e0f" xlink:to="loc_us-gaap_CoVenturerMember_a439aae9-c678-44ad-b940-3ef54c4806da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_39c8b52a-2faf-4079-bcf2-fb4ebc44de09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_39c8b52a-2faf-4079-bcf2-fb4ebc44de09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e92db6d1-6592-41a8-a85e-a7cbe13d99f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_39c8b52a-2faf-4079-bcf2-fb4ebc44de09" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e92db6d1-6592-41a8-a85e-a7cbe13d99f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_BulgariaManufacturingPlantPurchaseMember_09f2621e-edf4-42ae-89ad-70078845e448" xlink:href="apyx-20200930.xsd#apyx_BulgariaManufacturingPlantPurchaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_e92db6d1-6592-41a8-a85e-a7cbe13d99f0" xlink:to="loc_apyx_BulgariaManufacturingPlantPurchaseMember_09f2621e-edf4-42ae-89ad-70078845e448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0afd8886-f318-4234-844d-a5317947018f" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_8cddfc76-96c6-4326-a547-65996343b472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_8cddfc76-96c6-4326-a547-65996343b472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_af0c610d-7488-403a-8248-aa17b150262a" xlink:href="apyx-20200930.xsd#apyx_TermOfPaymentDueNotesPayableRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_apyx_TermOfPaymentDueNotesPayableRelatedParties_af0c610d-7488-403a-8248-aa17b150262a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_b734d3c4-5a2b-4b71-8692-84e1e8168062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_b734d3c4-5a2b-4b71-8692-84e1e8168062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_98bbdfa0-5f1d-41c3-bc49-f02b11fb0b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0d5f6249-ed5e-4ce3-8113-19a29ccd0dae" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_98bbdfa0-5f1d-41c3-bc49-f02b11fb0b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4e29924b-e631-462e-8383-66ff24188dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_11dfa8a7-8af0-489c-8245-0c91b4577a4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e29924b-e631-462e-8383-66ff24188dfe" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_11dfa8a7-8af0-489c-8245-0c91b4577a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d594c59e-23dd-4792-bd4e-fcdfc5b51013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_fc0d7dcb-aae7-4cea-9314-3a87c7a93488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d594c59e-23dd-4792-bd4e-fcdfc5b51013" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_fc0d7dcb-aae7-4cea-9314-3a87c7a93488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_09561b05-5fb7-48f2-b9d8-5edbd3eafc27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d594c59e-23dd-4792-bd4e-fcdfc5b51013" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_09561b05-5fb7-48f2-b9d8-5edbd3eafc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f8703a7a-e9ac-44b9-8528-adb2f8da50c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_17c430b8-885f-4213-98b3-fe2b6a7edb93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f8703a7a-e9ac-44b9-8528-adb2f8da50c0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_17c430b8-885f-4213-98b3-fe2b6a7edb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent_907df646-9f63-4989-ac31-1fce527cf6f1" xlink:href="apyx-20200930.xsd#apyx_TotalRevenuePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f8703a7a-e9ac-44b9-8528-adb2f8da50c0" xlink:to="loc_apyx_TotalRevenuePercent_907df646-9f63-4989-ac31-1fce527cf6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c8caa40b-ebcc-4c70-a1fd-0ff39fe42660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c8caa40b-ebcc-4c70-a1fd-0ff39fe42660" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e6d0084a-70aa-4161-9e20-e2c5a341452b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:to="loc_srt_ConsolidationItemsAxis_e6d0084a-70aa-4161-9e20-e2c5a341452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_de58bd77-c642-4b74-8a54-cf9139cf343a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e6d0084a-70aa-4161-9e20-e2c5a341452b" xlink:to="loc_srt_ConsolidationItemsDomain_de58bd77-c642-4b74-8a54-cf9139cf343a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c9b238b8-d848-4094-9659-973f3263fee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_de58bd77-c642-4b74-8a54-cf9139cf343a" xlink:to="loc_us-gaap_OperatingSegmentsMember_c9b238b8-d848-4094-9659-973f3263fee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_b73f86da-e64e-42cc-b1ad-ad13f2dad168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_de58bd77-c642-4b74-8a54-cf9139cf343a" xlink:to="loc_us-gaap_CorporateNonSegmentMember_b73f86da-e64e-42cc-b1ad-ad13f2dad168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3cc6efa2-e453-4047-a256-20425c183669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3cc6efa2-e453-4047-a256-20425c183669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3dbf6e20-ced3-4daf-91ed-1ec26720df20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3cc6efa2-e453-4047-a256-20425c183669" xlink:to="loc_us-gaap_SegmentDomain_3dbf6e20-ced3-4daf-91ed-1ec26720df20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_6abe143c-6347-4d33-b616-0d26064a11a8" xlink:href="apyx-20200930.xsd#apyx_AdvancedEnergyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3dbf6e20-ced3-4daf-91ed-1ec26720df20" xlink:to="loc_apyx_AdvancedEnergyMember_6abe143c-6347-4d33-b616-0d26064a11a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_c363957c-5712-438d-8d9a-7fd9e0b929f1" xlink:href="apyx-20200930.xsd#apyx_OEMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3dbf6e20-ced3-4daf-91ed-1ec26720df20" xlink:to="loc_apyx_OEMMember_c363957c-5712-438d-8d9a-7fd9e0b929f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_435d2984-6122-4cf7-94e1-3f11e0663ff5" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dd15f12-1b89-4cb7-8d70-f1d9eae4df35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3dd15f12-1b89-4cb7-8d70-f1d9eae4df35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_953260d5-925a-4d63-bc97-75086d0d1923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_OperatingIncomeLoss_953260d5-925a-4d63-bc97-75086d0d1923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_92ec31d8-b874-4bae-948f-5c2e304c70cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_InterestIncomeOperating_92ec31d8-b874-4bae-948f-5c2e304c70cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ffdd465c-e058-43d0-ab12-25ffb3951a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_InterestExpense_ffdd465c-e058-43d0-ab12-25ffb3951a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_eaa0b1d9-2d51-442e-a496-2f12fea1cb60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_eaa0b1d9-2d51-442e-a496-2f12fea1cb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70fba991-c53a-4ef2-9919-65f17219be95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_45267487-4198-4e00-ac75-0001256228c1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70fba991-c53a-4ef2-9919-65f17219be95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20200930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a6404741-c528-494b-a8aa-3a9b38ff1654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_26d513c3-b684-4957-8d9f-50d084eb58c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a6404741-c528-494b-a8aa-3a9b38ff1654" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_26d513c3-b684-4957-8d9f-50d084eb58c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_06b862f1-332a-436d-b578-e7af15a2f9d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_26d513c3-b684-4957-8d9f-50d084eb58c7" xlink:to="loc_srt_StatementGeographicalAxis_06b862f1-332a-436d-b578-e7af15a2f9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_01819a65-e126-495e-9713-0ddbb7731289" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_06b862f1-332a-436d-b578-e7af15a2f9d6" xlink:to="loc_srt_SegmentGeographicalDomain_01819a65-e126-495e-9713-0ddbb7731289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3c9f15de-da84-46be-b30b-bb5007d27915" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_01819a65-e126-495e-9713-0ddbb7731289" xlink:to="loc_country_US_3c9f15de-da84-46be-b30b-bb5007d27915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_c161a501-e897-48d1-86f7-e89f002d1225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_01819a65-e126-495e-9713-0ddbb7731289" xlink:to="loc_us-gaap_NonUsMember_c161a501-e897-48d1-86f7-e89f002d1225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_623df63e-e60d-4e0c-8240-5eba73de9105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_26d513c3-b684-4957-8d9f-50d084eb58c7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_623df63e-e60d-4e0c-8240-5eba73de9105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_750dcb33-5302-4267-9a86-350d2869d342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_623df63e-e60d-4e0c-8240-5eba73de9105" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_750dcb33-5302-4267-9a86-350d2869d342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>apyx-20200930_g1.jpg
<TEXT>
begin 644 apyx-20200930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *0 _(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "L;Q5XNTGP5I$NI:S>)9VB< MRSMV5
M5'+'V%/\4^)K#P=X?O=8U*3RK.U3>Y')8YP% [DD@#W-?"'Q(^(^J_$OQ!)J
M.H2,D"DBVLU8F.W3T'N<#+=_R ^7SO.X93348J]26R_5^7YGU>0Y%/.*CE)\
MM..[[^2\_P CU#QW^UEK>JS20>&+=-'L^@N9T66X;WP<JOTPWUKR#5_'7B+7
MG9M1UW4;S/\ #-<N5'?@9P/PK#HK\>Q69XS&R<J]1ORV7W;'[1A,KP6!BHT*
M27GN_O>I=@US4;6020ZA=0R#H\<S C\0:[KPK^T%XX\*R)MUB35+<'FWU+,X
M/_ B=X_!J\XHKFHXO$8>7-1J.+\F=5?!X;$QY*U-27FD?;/PL_:%T+XB216%
MPO\ 8^MMPMK,^4F/_3-^,G_9.#Z9ZUZO7YHQR-%(KHQ1U.593@@CN*^O/V<O
MC2_C2R_X1[6I]^MVL>Z&>0_-=1#U]77C/J.>Q-?J.0\2/&36%Q?QO9]_)^?Y
M_G^4<0<,K!0>+P?P+==O->7XKTV]RHHHK]!/SD**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLWQ%KEMX9T
M&_U:\?;;6<+3/[@#.![GH/<U,I*$7*3LD5&,IR48J[9\S_M;>/#?:U9>%;67
M]Q9J+F[53UE8?(I_W4.?^VGM7SS6AXAURY\3:Y?ZK>-NNKR9II/0%CG ]AT'
MTK/K^=\SQLLPQ<\0]F]/3I^!_265X&.78.GAENEKYOK^(4445YAZ@4444 %:
M7AO7[OPKKUAJ]BYCNK.994.>N#R#[$9!]B:S:*J,I0DI1=FB91C.+A)73/T>
M\.ZY;>)M!L-6LWW6UY"LR>P(S@^XZ'W%:5?/'[(_CK[=HM_X6N),S6)-U:@]
M3$Q^=1_NN0?^VE?0]?T/EF,6882GB%NUKZ]?Q/YNS3 RR[&5,,]D]/1[?@%%
M%%>H>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?/'[7'CK[#HMAX6MY,37Q%U= =1$I^13_ +S@G_MG7T'/,EM#
M)-*ZQQ1J7=V. H R2:_/OXF>,I/'WCC5=:8MY,TNV!6_AA7Y4&.W !/N37Q?
M%6/^JX+V$7[U33Y=?\OF?<<)9?\ 6\=[>:]VGK\^G^?R.7HHHK\6/W ***.M
M !174^/_ (>ZE\.[W3[;45PUY917:\$;2P^9#_M*P(/X>M<M6M6E.A-TZBLU
MT,J5:G7@JE)WB^H4445D:G4?#/QE)X!\<:5K2EO)AEVSJO\ %"WRN,=^"2/<
M"OT$@F2YACFB=9(I%#HZG(8$9!%?FG7V=^S#XZ_X2KX?IIL\N^^T9A;,">3"
M<F(_D"O_  "OT?@_'\E6>"F]):KU6_WK\C\TXTR_VE*&.@M8Z/T>WW/\SV*B
MBBOU8_(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ&X
MNH;*!YKB6."%!EI)&"JH]23TKS/Q/^TEX&\-EXTU)]8N%_Y9Z;'Y@_[[.$/X
M$UR8C%X?"1YJ\U'U9V8;!XG&2Y</3<GY(]2HKY:\0?MBZA(S+HGA^WMUZ"2^
ME:4GWVKMQ^9KS_6/VC?'^K[A_;?V*,_\L[.!(\?\"QN_6OF*_%F74M(-S]%_
MG8^KP_"&9UM9J,/5_P"5S[EJ*:XBMU#2RI$I. 78#^=?GCJ'CSQ+JV?MOB#5
M+H'M->2,._8GW/YUB22/,Y=V9W/5F.2:\:IQI#_EW0OZRM^C/:I\#S?\3$)>
MD;_JC]&V\3:0K%6U6Q# X(-RF1^M'_"4:-_T%K'_ ,"4_P :_.*BN;_72I_S
MX7_@7_ .C_4>G_T$/_P'_@GZ0PZYIMUGR=0M9L<'RYE;'Y&K]?F?5JSU6]TT
MYM+RXM3ZPRLG\C6L.-/YZ'_DW_ ,Y<#_ ,F(^^/_ -L?I-17Y_Z7\8/&VC$?
M9O$^I8'19YS,H_!\BNWT/]J_QKIK*+X6&KI_$9X/+?\  QE0/R->I1XPP,]*
MD)1^YK\[_@>36X+Q]/6E.,OO3_*WXGV317@'AO\ :_T*^98]:TB[TMSP9+=A
M<1CW/W6'X UZYX6^(?AOQJ@;1=8M;Y\9,*OME ]T;##\J^FPN:8+&Z4*J;[;
M/[GJ?+8O*<=@=<12:7?=?>KHZ.BBBO5/)"BBB@ HHJ.:(3PR1DLH=2I9&*L,
MCL1R#[T@)**^#_&GBCQQX-\5ZIHMQXLU[S+.=HPQU&;YUZJWWNZE3^-8O_"S
M_&7_ $-NN?\ @RF_^*K\_J<84:<W"=&2:=GJNA^C4^"ZU6"J0KQ::NM'U/T*
MHK\]?^%G^,O^AMUS_P &4W_Q5*GQ1\91L&'BS7"0<_-J,Q'Y%JC_ %SP_P#S
MY?WHT_U(Q/\ S^C]S/T)HKXX\ ?M1>)?#MY%%KTG]O:82 ^]56XC'JK@#<?9
MNO3(KZVT'7K'Q-H]KJFF7"W5C<IOCE7N/0CL0<@@]",5]1EF<87-(OV+M);I
M[_\ #'R>:9+BLIDO;J\7LUM_P&:-%%%>X>"%%%% !1110 4444 %%%% !111
M0 4444 %%%% !17(?$KXE:7\,= .HZAF::0E+:TC(#SOCH/0#C+=L]S@'Y+\
M5?M%>-_$UU(T6J-H]J3\EOI_[O:/=_O$_C^ KYS,\^PF5R]G4O*?9?KV/ILJ
MX?QF;1]I3M&'=_IW/N.BOSU_X6?XR_Z&W7/_  93?_%4?\+/\9?]#;KG_@RF
M_P#BJ^=_USP__/E_>CZ3_4C$?\_H_<S]"J*_/7_A9_C+_H;=<_\ !E-_\57O
M7[*\_B3Q1J&K:UJ^NZIJ&GVJ"UBANKR22-I6PS'#,1E5 _[[KT,!Q-3S#$1P
MU.D[OS6AYV8<*U,NPTL34K)J/2SU/I"BBO%/VD/#_B6+1E\2>&M;U6R-FF+V
MSL[R6-&B_P">H56QE>_'3G^&OI\;B982A*O&#ERZV6]O^ ?*X'#1QF(C0E-0
MYM+O:_3[SVNBOSU_X6?XR_Z&W7/_  93?_%4?\+/\9?]#;KG_@RF_P#BJ^(_
MUSP__/E_>C[O_4C$?\_H_<S]"J*_/7_A9_C+_H;=<_\ !E-_\51_PM#QE_T-
MNN?^#&;_ .*H_P!<\/\ \^7]Z#_4C$?\_H_<S]"J*^)_!O[2OC'PQ=Q_;KS^
MWK'(WV][C?C_ &9 -P/UR/:OK?P+XXTOXA>'8-8TJ0M!(2KQR8$D+CJC#L1Q
M]001P:^ERS/,+FEXTKJ2Z/?Y=SY?-<AQ>4VE62<7U6WH^QT-%%%?0'SH4444
M %%%% !1110 4444 %%%% !117C?QL_: M_AO*VCZ5#'?Z^R!G\P_NK8$9&X
M#DL1R%XX()/0'BQF,HX&DZ]>5HK^K([L'@J^85E0P\;R?]7?D>R45\"ZQ\;/
M'.M3M+/XFU" DY"V<QMU'L!'BL__ (6?XR_Z&W7/_!E-_P#%5\5+C/#7]VE)
MKY'W4>",4U[U:*?S/T*HK\]?^%G^,O\ H;=<_P#!E-_\51_PL_QE_P!#;KG_
M (,IO_BJC_7/#_\ /E_>BO\ 4C$?\_H_<S]"J*_/W3_'WCK5KZWLK3Q-K]Q=
M7$BQ11)J,Q9V)P /F]:^V_AWX9O_  IX5M+'5-4N]8U(CS;FZN[AYCYA RJE
MCD*,8 ]L]2:]_*<[6;3DJ=)I1W;?X'SV<9$\GA%U*JE*6R2U]3IZ**^:/&WP
MI\>>#?"NI:V_Q.U>Z6RB,IA6XG4OR!C/FG'6O3QV+JX.'/"DYK5NS2M;U_3L
M>7E^#I8V?LZE90=TE=-W;]/U[GTO17R_\._AOX[^('@[3]?C^)>KV27GF8@:
MXG<KLD9.OFCKMST[UT?[3FMZUX2\'^&4T_6;ZSN?-,4UQ:W#Q--B,<L5.3SS
MS7G+.)K!RQM2@XP236JU3]/U/2>2PEC88&E74IMM/1KE:[WW^1[[17$?!WQX
MOQ$\!V&ILP-]&/L]XH[3*!D_\"&&_P"!5YS^U'\4KOPQ9V'A_1K^:QU*Y/VF
MXGM93')'$"0JAE.1N;/X+[UVXC-*&'P7UYN\6DUYWV1PX;*L1B,=]02M--I^
M5MW_ %N>^T5\T>'?%FN3>']+DDUK4))'M8F9FNG))*#))SUHKBCG=.45+D>I
MWRR&I&3CSK0^EZ***^D/EPHHHH **** "BBB@ HHHH **** /'?VGO'7_"*_
M#]]-@EV7VLL;90#R(1@RG\B%_P"!U\8UZ5^T%XX_X3?XCWS0R^9I^G_Z%;;3
MP0I.]O?+;N?0+7FM?@W$&/\ K^/G*+]V/NKY=?FS^@N'<O\ [/R^$9+WI>\_
MGLODK?,****^;/I@KTG]GWP-_P )Q\1K%9H_,T_3_P#3;G(X(4C8OOEMO'H&
MKS:OL_\ 9A\#?\(K\/TU*>+9?:RPN&)'(A'$0_(EO^!U])P_@?K^/A&2]V/O
M/Y=/F_P/F>(LP_L_+YRB_>E[J^>[^2_$/VGO W_"5?#]]2@BWWVC,;A2!R83
MQ*/R ;_@%?&%?I7/!'=020RHLL4BE'1AD,I&""/3%?GY\3/!LG@'QQJNBN#Y
M4,NZW8\[H6^9#GN=I /N#7T?&& Y*L,;!:2T?JMOO7Y'S7!>8>TI3P,WK'5>
MCW^Y_F<O1117YP?I85Z5^S[XX_X0CXCV+32^7I^H?Z%<[CP Q&QO;#;>?0M7
MFM'2NK"XB>$KPKT]XNYRXK#0QE">'J;25C],**X/X)^./^$^^'NFW\L@DOH1
M]EN_7S4 &X_[PVM_P*N\K^B\/7AB:4:U/:23^\_FG$4)X6M.A46L6T_D%%%%
M=!SA1110 4444 %%%% !1110 4444 %%%% !117FWQ9^-VC_  OMS;G&H:Y(
MN8K"-L;<]&D/\*^W4]O4<V(Q-'"4W6KRY8HZL-A:V,JJC0CS29W>L:U8>']/
MEOM2O(;&TB&7FG<*H]LGO[=Z^?/B!^UM!;M+9^$K(73#C^T;P$)]4CX)^K$?
M0UX-XY^(VN_$34C=ZS>-*%),5LGRPPCT5>WUZGN37,U^59GQ97K-T\$N2/?[
M3_R_/S/UO*^$,/ATJF.?/+M]E?Y_EY&]XJ\>>(/&USYVMZK<7_.Y8W;$:'_9
M085?P%8-%%?"5*DZLG.HVV^KU/OZ=.%&*A3BDET6B"BBBLS0**** "BBB@ H
MHHH **** "GPS/;R+)$[1R*<JZ'!!]0:910!ZUX%_:6\6^$6C@OIQX@L%/,=
MZQ,H'^S+U_[ZW?2OI;X=?&[PS\2%6&RN39ZGC)T^[PLGOMYPX^G/J!7P?3HY
M'AD61&9)%(974X((Y!!KZO+N),;@6HS?/#L_T>_YKR/DLRX9P.8)RA'V<^ZV
M^:V?X/S/TNHKY0^$?[4%YH[P:7XN>2_L.%34L%IH>WS_ -]??[W7[W2OJ?3[
M^VU2SAN[.>.ZM9E#QS0L&1U/0@CK7ZWEN:8;-*?/0>JW3W7]=S\=S/*<5E53
MDKK1[-;/^NQ8HHHKUSQCY?\ VO/!/DWFE^*;>/Y)A]BNB.FX9:-OQ&X?\!6O
MF^OT*^)'@^/QWX)U;17"^9<0DPNW195^9#_WT!GVS7Y\30R6TTD,J-'+&Q1T
M88*D'!!K\8XKP/U;&^WBO=J:_-;_ */YG[?PCC_K6!^KR?O4]/D]OU7R&444
M5\2?<A7TA^R'XX:.\U/PK<RDQR+]LM%8]&&!(H^HVG'^RWK7S?6UX+\33^#?
M%6EZU;@F2RG60J.-Z]&7\5)'XUZV58UY?C*=?HGKZ/<\C-L"LQP53#]6M/5;
M'Z+456T^^@U2QMKVVD$MM<Q+-%(.C(P!4_B"*LU_0R:DKH_F]IQ=F%%%%,04
M444 %%%% !1110 4444 %%%% !117&?%[QH/ 7P_U;54<)=^7Y-KZF9^%(]<
M<M]%-85ZT,/2E6J;13;^1O0HSQ%6-&FM9-)?,^3_ -H;QP?&GQ(OEBEWZ?II
M-E;@?=^4_.WXOGGN M>94I)8DDY)Y.:2OYSQ6(GBZ\Z]3>3N?TOA<-#!T(8>
MGM%6_P"#\PHHHKE.H4 L0 ,D\#%??OPD\&#P'\/])TID"W2Q^==>IF?YF'OC
M.WZ**^3?V>/!?_"9?$RP,J;K+3O].GXX.PC8OXN5X] :^Y*_4N#L#:-3&R6_
MNK]?T^YGY1QKC^:5/ P>WO/\E^OWH*9)&DT;QR(KQL"K*PR"#U!%/HK]+/RX
M^'OCU\*7^&OBDRV<;?V%?DR6C=1$>K1$^W;U!'4@UYA7Z&^/_!%C\0O"UYHM
M^-J2C=%,!EH9!G:X^A_,$CO7P-XF\.7WA'7KW2-2B\F\M9#&X['T8>H(P0>X
M-?B/$>4?V?7]K27[N>WD^W^7_ /W;AG.?[2P_L:K_>PW\UW_ ,_/U,NBBBOD
M#[(*](^!OQ4D^&?BI#<NQT2](BO(QSM_NR@>JY_$$CTKS>BNG#8FIA*T:])V
ME$Y<5AJ6,HRH5E>,E8_2R">.ZACFA=98I%#I(IR&4C((/IBI*^;OV6_BX;F)
M?!NJS9EC!;3I7/WE')A_#DK[9'85](U_0.6X^GF6&CB*?7==GU1_.V9Y?5RS
M$RP]7IL^ZZ/^NH4445Z9Y04444 %%%% !1110 4456U#4+;2K&XO+N9+>UMX
MVEEFD.%10,DG\*3:BKL:3D[(Y+XM?$BV^&/A&?4I-LM_+F*RMV_Y:2D<$_[*
M]3],=2*^#M2U*YU?4+F^O)FN+NXD:665SDLQ.2:Z_P",'Q+N/B=XNFOR7CTV
M',-E;L?N1Y^\1_>8\G\!V%</7X9Q!FSS/$VIO]W'1>?=_/IY'[YP[DZRO#<U
M1?O)ZOR[+Y=?/Y!1117RQ]6%%%>E_ GX5O\ $OQ4IND8:'8E9+Q^F_\ NQ#W
M;'/H ?:NG"X:IC*T:%)7E(Y<5B:6#HRQ%9VC%7/6/V6_A+]AME\9:K#_ *1,
MI73HW'W(SP9?JW0>V3W%?1M1QQI!&D<:+'&@"JBC 4#@ #M4E?T%EV!IY=AH
MX>GTW?=]6?SKF685<SQ,L15Z[+LNB_KJ%<-\</\ DDOB?_KT/\Q7<UPWQP_Y
M)+XG_P"O0_S%7C_]TK?X9?DS/+O]]H_XH_FC,_9M_P"2*^'?^WG_ -*9:X[]
MK0!M+\)@C(.HG(_X"*[']FW_ )(KX=_[>?\ TIEKC_VM/^0;X2_[")_]!%?-
MXK_DG8_X(?\ MI]1A/\ DI9?]?*G_MQC:+?0_L\?&35-,O','A+6HC=0/_#$
M1N90/H=T>.I!0FN(U32[GQYX)^(/Q*U6(AII8;;3XVY\M?M$0)'^ZFU >^7K
MZ9^)7PIT7XIV-G;ZLUS ;60R13VC*L@R,,N65A@X!Z?PBN2^-7AVR\(_L[ZI
MH^G(R6=G':Q1[B"S?Z3$2QQW)R3QU)KBQF4UJ=*O&37L(1G*"\W';TCJUZG;
M@<WHU:M"44_K%25.,W_=4EKZR5D_0\T\+_\ (M:3_P!>D/\ Z **/"__ "+6
MD_\ 7I#_ .@"BO-I?PX^B/6K?Q)>K/JNBBBOU(_) HHHH **** "BBB@ HHH
MH *X+XV>.?\ A ?AYJ-_%)LOIQ]EM.>?-<$9'^Z-S?\  :[VOC[]JSQS_;_C
M2'0K>3=9Z0F)-IX:=P"W_?(VCV.ZOG\^QW]GX&=2+]YZ+U?^2U/H^'\O_M''
MPIR7NQ]Y^B_S=D>(=:***_ C^A0HHHH ZCX9^#9/'WCC2M%0'RII=UPPXVPK
M\SG/8[00/<BOT#@@CM8(X8D6**-0B(HP%4#  'IBOGW]D;P/]AT74/%-Q'B:
M])M;4D=(E.78>Q8 ?]LZ^AZ_:>%<#]5P7MI+WJFORZ?Y_,_#^+<P^MX[V$7[
MM/3Y]?\ +Y!7SQ^USX'^W:+I_BFWCS-9$6MT0.L3'*,?8,2/^VE?0]9OB/0K
M;Q-H-_I-XNZVO(6A?U (QD>XZCW%?09G@UF&$J8=[M:>O3\3YS*\=++L93Q*
MV3U]'O\ @?G#16AX@T.Y\-:Y?Z5>+MNK.9X)/0E3C(]CU!]#6?7\\2BX2<9*
MS1_2,9*<5*+NF%%%%24>W_LI^.?[ \:3:%<2;;/5TQ'N/"SH"5_[Z&X>YVU]
M@U^:^GWT^EW]M>6LAAN;>198I%ZJRG(/YBOT*\#>*H/&WA/2];M\!+N$.R*?
MN..'7\&!'X5^M<(8_P!I0E@YO6&J]'O]S_,_'^,\O]E7AC8+2>C]5M]Z_(WJ
M***_0S\W"BBB@ HHHH **** "BBB@ HHHH ***X+XR?$Z#X7^$I+P;9-3N28
M;&!OXGQRQ']U1R?P'>N?$5Z>%I2K57:,=6=&'P]3%5HT**O*3LCFOCM\=(OA
MU:G2=(:.X\13+SGYEM$(X=AW8\84_4\8!^.+Z^N-2O)KN[GDN;F9B\DTK%F=
MCU))ZT[4M2NM8U"XOKV=[F[N',DLTARSL3DDU6K\'S;-JV:UN>>D%LNW_![G
M]!9/D]'**')#6;^)]_\ @=@HHHKPCW@HHHH ***LZ?IMYJURMO8VL][<-TAM
MXS(Y_ #--)R=D)M15V]"M17HNC_L]^/M:4/'H$MK&?XKV1(<?\!8[OTKK]/_
M &0O%=P UWJ>DV@]%DDD8?AL _6O7I9/F%;6%"7W6_.QX];.LNH:3KQ^^_Y7
M/"Z*^C8/V-;UMGG>*((^?F\NS9L?3+C-6)/V,G6,F/Q<K/V#:=@?GYIKM7#>
M:M7]C^,?\S@?$^4)V]O_ .2R_P CYJHKZ&NOV.=70?Z-XBLICC_EM \?.?8M
M7-ZI^RGXYL%)@33]2Q_#;76TG_OX%K"ID.9TU>5!_+7\KG13X@RNKI&NOGI^
M=CQVBNG\0?#'Q9X75GU/P_?VT2]9A"7C'U=<K^M<Q7C5*-2C+EJ1<7YJQ[=.
MM3K1YJ4E)>3N%%%%9&H4444 %>F_!GXVZA\,=06VG,EYX>F?,]IG)C)ZR1^A
M]1T/Y$>945U87%5<'55:A*TD<N*PM'&TI4*\;Q?]?>?I'H^KVFO:7;:CI]PE
MU9W*"2*:,\,I_P ].U7:^-OV=?C$W@?6ET/5)_\ B0W\@"LYXM93P']E/ ;T
MX/8Y^R:_>,HS2GFN'56.DEI)=G_D^A_/^<Y54RG$NE+6+UB^Z_S74*^*OVFO
M!/\ PBOQ&FO88]ECK"_:T(& ),XE'UW8;_@8K[5KR?\ :4\%?\)9\-[JYAC#
M7NDG[9&<<F,#]XO_ 'S\WU05Q\18'Z[@)\J]Z'O+Y;_@=G#6/^HYC#F?NS]U
M_/;\;?*Y\3T445^$G[\%%%% 'V+^ROXU_P"$@\!OH\\FZ[T>3RU!/)A;)0_@
M=R_0"O:Z^&/V??&W_"%_$K3WE?98ZA_H-QD\ .1M;\'"\^F:^YZ_<N&<=]<P
M$8R?O0]U_I^&GR/P;BC ?4LPE**]VI[R]>OXZ_,****^K/D HHHH **** "B
MBB@ HHHH **** "OE']KGQM_:'B#3_#-O)F'3T^T7('0S./E!_W4Y_[:&OJ#
M6M6MM T>]U*\?R[6TA:>5O15&3CWXK\[_$NO7/BCQ!J.KW9S<7L[3.,Y"Y.0
MH]@, >PKX+B['>QPL<+%ZS>OHO\ -V_$_0N#<![?%RQ<EI36GJ_\E?\  S:*
M**_'S]F"BBMOP5X8G\9^*]+T2WR)+R=8RP_@3J[?@H)_"KITY59J$%=MV7S(
MJ5(TH.I-V25WZ(^K/V5_!9\.^ 7U:9-MWK$GFC(Y$*Y$8_'YV^C"O::KV-C#
MIMC;V=L@BM[>-8HD'154  ?D*L5_1F!PL<%AJ>'C]E?CU?S9_-./Q<L=BJF)
ME]I_AT7R04445W' %>*?M)?"3_A--!_M[3(=VMZ=&=Z(,M<0#DK[LO)'XCN*
M]KHKAQN#I8^A+#U5H_P\_D=^!QM7+\1'$47K'\5U3]3\SZ*]I_:2^$O_  A>
MO?V[ID&W1-1<ED1?EMYCR5]E;DC\1V%>+5_/N-P=7 UY8>JM5^/G\S^B\#C*
M688>.)HO27X=T_0****XCN)K*\GTZ\@N[65H+F!UEBE0X9&!R"#Z@BONSX-?
M$^#XG^$X[MBL>JVV(KZ!?X7QPX']UNH_$=J^#:Z_X6_$2[^&GBVVU6#=);-^
MZN[<'B6(GD?4=0?4>F:^FR'-GE>)]]_NY:2_S^7Y'R_$&3K-L-[B_>1UC_E\
M_P S] :*I:/K%IK^EVNHV$RW%G=1B6*1>A4C]#[=JNU^ZQDI)2B[IGX#*+BW
M&2LT%%%%42%%%% !1110 5\N?M2?%HWEPW@W2IOW$)#:E(A^^XY6+Z#@GWP.
MQKUKXY?%2/X9^%&:W=3K=\&BLXSSM_O2$>BY_$D>]?#<TTEQ,\LKM)*[%G=C
MDL2<DD^M?G7%6;^RA]0HOWG\7DNWSZ^7J?I?"63>VG_:%=>['X?-]_ET\_09
M1117Y.?KH4444 :7ASP_?>*M<L])TZ(S7MW((XU[>Y)[ #))[ &OOCX>>!;'
MX=^%;31K$;O+&^:;&#-*?O.?Z>@ ':O-?V:/A+_PB.A_\)%J<.W6-2C'E1N.
M;> X('LS<$^@P..:]PK]EX9RCZG1^M5E^\G^"_S?4_$^*LY^O5_JE%_NX/7S
M?^2V7S"BBBON#X,*KWUA;:I:RVMY;Q7=M*NV2&= Z./0J>"*L44FDU9C3<7=
M%33=+L]&LXK/3[2"QM(\[+>VC6.-<DDX50 ,DD_4U#JWA_2]?6)=4TVSU)86
MWQK=P)*$;U7<#@_2M&BH]G%QY&M.W0I5)J7.GKWZA534M+L]9LY;/4+2"^M)
M,;[>YC62-L$$95@0<$ _45;HJY14E9[$QDXM-.S1DQ>$]#AC2./1=/CC0!51
M;5 % Z #'2BM:BL_94_Y5]QK[:I_,_O"BBBM3$**** "BBB@ HHHH **** ,
M'QSXJ@\$^$]4UNXP4M(2ZHQ^^YX1?Q8@?C7YZZA?3ZI?W-Y=2&:YN)&EED;J
MS,<D_F:^C/VO/'&Z33/"EM)D+_IMWM/?D1J?PW,1[J:^:Z_&>+,?]8QBP\7[
MM/\ -[_=HOO/VWA#+_JN#>)FO>J?DMOOU?W!1117Q!]V%:'A_0[GQ+KEAI5F
MNZZO)D@C] 6.,GV'4GT%9]?0?[(_@;[?KE_XHN(\PV*FVM6;_GLP^=A]$./^
MVE>GEF#EF&+IX==7KZ=?P/+S3'1R[!U,2]TM/7I^)]-^'-"MO#.@V&DV:[;:
MSA6%/4@#&3[GJ?<UI445_1$8J$5&*LD?S;*4IR<Y.[844451)\I?M<>!OL&N
M6'BBWCQ#?*+:Z9?^>RCY&/U08_[9U\^5^@OQ/\&Q^/O ^JZ,54SS1;[=F_AF
M7E#GMR,'V)K\_9H7MYGBE0QR1L596&""#@@_C7XKQ5@?JN-]M%>[4U^?7_/Y
MG[CPEF'UO ^PD_>IZ?+I_E\AE%%%?&'VX5]*?LA^.-LFI^%+F3 ;_3;3<>_
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MVX9RCZ]6^LUE^[A^+[?+=_<?#<49S]0H?5J+_>3_  7?U>R^;->BBBOV<_$
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MK\\/$WA^Y\*^(-1TB['^D64[0L<8#8/##V(P1[&OR+B_ ^RQ$<7%:3T?JO\
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MR/R+C3'^TK0P47I'5^KV^Y?F%%%%?HI^:!1110 4444 %%%% !1110 4444
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M^G*+BY Z&9Q\H/\ NH?_ !\^E?3GB;Q!;>%?#^H:O>'%M9PM,PZ%L#A1[DX
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M\[****_FD_J **** /H[]C7_ )"7BG_KC;_^A25]15\N_L:_\A+Q3_UQM_\
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M6C7I.THO^OO.7%86GC*$\/65XR5OZ]#]+E99%5E(96&00<@BG5X+^R[\5/\
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MYJZ:L_F:4ZDJ,XU(.S3NO5'YJ7=K-8W4UM<1F*XA=HY(VZJP."#]"*BKV/\
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M<![#"O%36L]O1?YO]#\8XQS#ZQBHX2#]VGO_ (G_ )*WXA1117WI^?!1110
MUF"*68@*!DD]!7XE?M6_&)OCC\<?$/B**4R:3')]@TL9.!:Q$A&&>F\[I,=C
M(:_27]OCXR_\*F^ FI6EI/Y6N>)2=)M-K89(V7]_(._$>5R.C2(:_'ZOJ\EP
M]E*O+T7ZG@9E6NU27JPHHHKZ@\,**** "OV(_80^,O\ PMWX":7'>3^;KGAX
MC2;W<V6=44>3(<\G='M!)ZLCU^.]?3?_  3Y^,P^%GQVM=*O9_*T3Q0JZ9<;
MCA4GSFW<_P# R4]A*3VKR<SP_M\.[;QU._!5O95E?9Z'Z\4445\$?6!1110
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MC"/#3?O4_P GM]SO^!^+<89?]7Q:Q4%[M3?_ !+?[U9_>7****^Z/@ HHHH
M_/7XG_\ )2O%O_87N_\ T<]<S73?$_\ Y*5XM_["]W_Z.>N9K^:\5_O%3U?Y
MG]/87_=Z?^%?D@HHHKF.HV/!VNGPQXKT?5ADBRNXIV [JK L/Q&1^-?HI#,E
MQ$DL;!XW4,K+T(/(-?FG7V9^S-\1H_%O@N/1KF4'5='00E6/,D'2-A]!\I^@
M]:_1.#\=&G6GA)OXM5ZK?\/R/S;C3 RJT:>,@O@T?H]G\G^9[)1117ZR?D 4
M444 %%%% !1110 4444 %%%% !1110 5YA^TAX@70?A+JR[]LU\4LXN?O%FR
MP_[X5Z]/KX[_ &HOB+'XJ\71:)8R^98:/N1V4_*]P<;_ /OG 7Z[J^<X@QL<
M%E]1W]Z2Y5\_\EJ?3<.X&6.S&FK>[!\S^7^;LCQ.BBBOP4_H(**** /I_P#8
MTM2ECXJN?X9);:,?\!$A_P#9Q7TC7C/[*.CG3OA;]J9<&_O99U)[JNV/^:-7
MLU?ON04W1RRA%]K_ 'MO]3^>>(:JK9K7DN]ON27Z!1117T!\Z%%%% !1110!
MYA^T5X)_X3+X:WSPQ[[[3?\ 38,#DA0=Z_BF[CU KX>K]+G4.I5@"I&"#TKX
M!^+?@L^ OB!JVDJA6U63SK7WA?YD'OC.T^ZFORSC' \LH8V*W]U_I^OW'ZSP
M7C^:%3 S>WO+\G^C^;./HHHK\U/T\*Z'P7X^UWX?:A+>:'>FTEE3RY%**Z.O
M495@1P>AZ_K7/45I3J3HS52G)IKJM&9U*<*T'3JQ4HO=/5%[7-;OO$FK76IZ
ME<-=7UR_F2S-@%C]!P!TX'3%4:**F4G-N4G=LJ,8PBHQ5D@HHHJ2B]H>CW'B
M#6+'3+1=]U>3)!&O^TQ 'X<U^A_AO0;;POX?T[2+0?Z/90+ AQ@MM&-Q]R>3
M[FOEC]DWP5_;'C"[\03IFVTJ/9$2.#-(",_@N[_OI:^NJ_7>$,#[+#2Q<EK/
M1>B_S?Y'XYQEC_;8F.$B](*[]7_DOS"BBBOT _.@HHHH **** "BBB@ HHHH
M **** "BBB@#.\0:Y9^&=$O=5U"7R;.TC,LC=\#L/4DX '<D"O@/XA>-KSXA
M>++W6KWY6F;;%#G(AB'W4'T'7U))[UZS^U'\5/[>UC_A%--FSI]@^Z\9#Q+.
M/X/HG_H6?05X'7XYQ1FWUNO]4I/W(;^<O^!M]Y^U<*91]3H?6ZR]^:T\H_\
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M*^8/J0KW#]F/XJ?\(KX@_P"$<U&;;I.IR#R6<\0W!P ?8-PI]]OO7A]'2N_
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M,_9.#<O]CAI8R:UGHO1?YO\ )!1117Y^?H@5);V\EW<100HTLTC!$11DLQ.
M!^-1U[%^R_X&_P"$H^("ZG/'NL=&47!R.#,<B(?@06_X *[<%A9XW$PP\-Y/
M_AW\EJ<..Q<,#AJF)GM%7_R7S>A]3_#;P='X#\$Z5HJ!?-@B!G=?XY6^9S_W
MT3CV KIZ**_HNE2C1IQI05E%67R/YJK59UZDJM1W<G=_,****U,@HHHH ^+/
MVQOV1?BC^TE\2+34M*UKPW9>&M,M%MK"TO[NY67<WS32,JP,H9FPO#'*QIT.
M17@W_#K+XK_]#!X-_P# V[_^1:_4RBO5I9EB*,%3A:R\C@G@J523G*]V?EG_
M ,.LOBO_ -#!X-_\#;O_ .1:/^'67Q7_ .A@\&_^!MW_ /(M?J916O\ :^*[
MK[B/[/H=F?EG_P .LOBO_P!#!X-_\#;O_P"1:/\ AUE\5_\ H8/!O_@;=_\
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M:<8'EN2=H]E;<O\ P&OO.O$?VJO W_"0>"8M;MTW7FCN6; Y:!\!_P CM;V
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MWK#[DW#!6!"0GYG<WN"M>WU7L;&#3;*WL[:,16]O&L44:]%50 !^ %6*_HK
M82.!PT,/'[*_'J_FS^:\PQDL?BJF)G]I_AT7R04445WGGA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !5>^L8-2LKBSN8Q+;W$;12QMT96
M!!'X@U8HI-)JS&FXNZ/SM\>>%)_!'B_5=$GR3:3%$<_QQGE&_%2#^-8-?3G[
M7G@?S(--\5VZ?-'_ *%=D?W228V/T.X?BM?,=?SWF^!>7XV=#INO1[?Y']'9
M/CUF6!IXCKL_5;_Y_,****\<]D<CM&ZNC%74Y#*<$&OOWX2^-E^('@/2]6+
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M/#1J_"M?=EOUZ=SY>HKZA_X8UL_^AIG_ / )?_BZ/^&-;/\ Z&F?_P  E_\
MBZ\[_5C-?^?7_DT?\ST_]:LH_P"?O_DLO\CY>KZI_93^&,^CV=QXLU& Q37D
M?DV*.,,(<Y:3'^T0,>P)Z$5T_@O]F'PCX5NH[N[$VNW2'*_;<>2I]?+ P?\
M@1(KU_IP.!7UV1<-5,'66*Q;5ULEKKW?Z?>?&Y_Q/3QE!X3!IV>[>FG9?K?T
ML+1117Z*?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/XN\-6WC#PSJ6BW?\ J+R%HBV,E#U5A[A@"/I7Y^^*O"^H>#=>
MN](U2 P7=NVUA_"P[,I[J1R#7Z-5R_CCX;>'_B)9I;ZW8K.T8(BN$.R:+/\
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MX'Z]CX1DO=C[S^7^;LCYKB+'_P!GY?.47[TO=7J_\E=GME%%%?O1_/@4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHK[H^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?GK\3_^2E>+?^PO=_\ HYZY
MFNF^)_\ R4KQ;_V%[O\ ]'/7,U_->*_WBIZO\S^GL+_N]/\ PK\D%%%%<QU'
MH7[/W_)8O#7_ %VD_P#13U]W5\(_L_?\EB\-?]=I/_13U]W5^P<&_P"XU/\
M&_R1^,\;?[_3_P "_-A1117WI^>A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\-_M)?\EJ\1?\ ;M_Z315]R5\-_M)?\EJ\1?\
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MBBOK#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[QJ7(N "Q"C)  SV%<O_ ,/3?BO_ -"_X-_\ KO_ .2:^>?VBO\ DX+XG?\
M8SZI_P"E<M>?5]_3P.&<(MP6Q\E/%5U)I2/V,_8R_:@G_:4\$ZK/K%M96'B?
M2;D1W=MIZ.D+1."89%#LQ&=KJ06/*$\9 KZ'K\7?V-/C5_PI'XZ:-J5W.T6@
MZD?[,U09^40R$;9#_N.$?/7 8=Z_:*OE<RPJPU;W5[KV/=P5=UJ7O;H****\
MH] **** "H;JZAL;:6XN)4AMX4,DDDC!510,DD]@!4U?*W_!1+XU'X9_!*3P
M_87!AUOQ6S6$>PX9+4 &X;\598_^VI]*WHTG7J1IQZF56HJ4'-]#YR\8?\%2
M?'D/BK5X_#F@^&)- 2ZD2PDOK6Y:=X Q",Y6=1N(P2 HQG%9/_#TWXK_ /0O
M^#?_  "N_P#Y)KXXHK[M9?A4K<B/E7BZ][\Q^U7[(_QHUOX]_!VV\6>(+73[
M/49+R>W,6FQND6U& !P[N<\\\U[37RQ_P38_Y-AL?^PI=_\ H0KZGKX?%14*
M\XQ6B;/I\/)RI1E+>P4445RG0?GA\>O^"A_Q'^%OQB\5^$])T7PO<:=I-XUO
M!+>6ERTS* #EBMPH)Y[ 5P7_  ]-^*__ $+_ (-_\ KO_P"2:\:_;&_Y.<^(
MO_84;_T%:\=K[VC@<-*E%N"O9'RE3%5E.24NI]C_ /#TWXK_ /0O^#?_  "N
M_P#Y)H_X>F_%?_H7_!O_ (!7?_R37QQ16WU#"_\ /M&7UNO_ #L^Q_\ AZ;\
M5_\ H7_!O_@%=_\ R31_P]-^*_\ T+_@W_P"N_\ Y)KXXHH^H87_ )]H/K=?
M^=GV/_P]-^*__0O^#?\ P"N__DFC_AZ;\5_^A?\ !O\ X!7?_P DU\<44?4,
M+_S[0?6Z_P#.S['_ .'IOQ7_ .A?\&_^ 5W_ /)-?J!I-T]_I=G<R!1)-"DC
M!> "5!./SK^?BOZ O#O_ "+^E_\ 7K%_Z *^?S;#TJ"A[.-KW_0]?+ZU2JY<
M[OL:-%%%?.'LGYX?'K_@H?\ $?X6_&+Q7X3TG1?"]QIVDWC6\$MY:7+3,H .
M6*W"@GGL!7!?\/3?BO\ ]"_X-_\  *[_ /DFO&OVQO\ DYSXB_\ 84;_ -!6
MO':^]HX'#2I1;@KV1\I4Q593DE+J?8__  ]-^*__ $+_ (-_\ KO_P"2:/\
MAZ;\5_\ H7_!O_@%=_\ R37QQ16WU#"_\^T9?6Z_\[/L?_AZ;\5_^A?\&_\
M@%=__)-3V?\ P50^)L<V;OPSX3GC_NPV]U&?S,[?RKXQHH_L_"_\^T'UNO\
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MB5%,L3'WRC(/^NAKLS/#JM0<K:QU_P SGP-9TJJ71Z'ZVT445\&?5A7YZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?A;^T5_R<%\3O\ L9]4_P#2N6O/J]!_:*_Y."^)
MW_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZA0K%&#*2K Y!'45[S\1/@BMK^RK\*OB
MAID&%NC>Z7J^Q?XQ?7)@F/U4&,D_W8QWKP:G3J1JIN/1M?<*<'!I/R?WG[4_
MLA_&@?'+X':)K5S/Y^N6:_V=JN?O&XC !<_[ZE'^KD=J]JK\G?\ @G+\;/\
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MN<8RQ4$U=K.\._\ (OZ7_P!>L7_H K1K\Y>Y]DM@HHHI#/Q._;&_Y.<^(O\
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M_>:GJSZS"_P8>@4445Q'2?B=^V-_R<Y\1?\ L*-_Z"M>.U[%^V-_R<Y\1?\
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M97/B?(_?BQM%L;&WMD8LD,:QJS=2 ,<_E5BBBORT^Z"OSU_X*T_\TJ_[BO\
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M_!AZ+\CXJM_$EZL_6S_@FQ_R;#8_]A2[_P#0A7U/7RQ_P38_Y-AL?^PI=_\
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M*7D89X!VJ0,]R.O2OT>4HTH-O1(^,BG.5ENSSNBOTZ_X=4_#[_H;O$WYV_\
M\:H_X=4_#[_H;O$WYV__ ,:KRO[6PO=_<>A_9]?M^)^8M%?IU_PZI^'W_0W>
M)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU1_:V%[O[@_L^OV_$_,6BOTZ_X=4_#[
M_H;O$WYV_P#\:KX]_;"_9M@_9K^(&G:5IM[=:GHFI6(NK:ZO OF;PQ62,[0
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MJ]!_:*_Y."^)W_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZG[&_P#!/_\ Y-&\!_\
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M,E9:16W^9]/A,*L/&[^)A1117E'>%?GK_P %:?\ FE7_ '%?_;.OT*K\]?\
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MOP-:I.LHRDVC[9HHHKXT^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6*W\[^]A[&G_ "K[CQO_ (8[^"W_ $3K1O\ OVW_ ,51_P ,=_!;_HG6C?\
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M?C-XLC\-^%=9N+[5I(7G6*2PFA&Q!ECN90.]>T5^2/\ P39_Y.>L?^P7=_\
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MUYHHHKQ3TPHHHH XWXT?\D=\=_\ 8!O_ /TG>OP>K]X?C1_R1WQW_P!@&_\
M_2=Z_!ZOK<D^"?JCY_-/BB?L;_P3_P#^31O ?_;_ /\ I?<U]#5\\_\ !/\
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MPG5]E9IGVS1117DGH!17Y'_&#]N[XHWWQ0\42>$_&5QIOAI;^6/3K>&W@91
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MW8[_ '>7]=3Y(_8Y_P"3G/AU_P!A1?\ T%J_;&OQ._8Y_P"3G/AU_P!A1?\
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MY;:?BSBI<F)Q#G5>G]61[5I_["OP.L=)-A_P@MO<(R@--<7=PTS>^_S,J?\
M=P*^-?VT/V%[7X-Z$_C?P-+<S^&(Y%2_TVY?S)+'<0JR*_5HRQ"D'YE)!R03
MM^T/^&XO@;_T4"S_ / 6Y_\ C5<O\4/VN/@5XY^&_BGP])XZL;@:IIEQ:",V
MMP,L\;*N#Y?!R00>Q&:\+#U<=2J*4E)KK=,]2M3PM2#2<4^FQ^:7[.OQFO\
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M*G_DL7BW_L G_P!*(J^8_CK\3I/C)\7/%'C)HF@35+LO!"_WD@11'"K>XC1
M<=P:^G/^"5/_ "6+Q;_V 3_Z415]MB(.GE[@]U%?H?+T9*IC.9;-L_3VO*/V
MI/A;_P +A^!/BSPY%%YNH-:F[L /O?:8CYD8'IN*[#[.:]7HKXFG-TY*<=T?
M42BIQ<7LS^>^&:6SN(Y8G:&:)@Z.IPRL#D$>A!K]6?CG^TE%>_L)Q^,[6X5-
M4\5Z=%I2>6P&VZE!CNE7'0H$N,8_NCI7P=^V5\+?^%2_M#>*-,AB$.F7TO\
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M&T"-;A&UO0;>/2M2M=PWHT:[8Y"/1T56SC&=X_A-?0%<-7-,52J2IR2T\O\
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MGZ5^.=FL+7<"W+,EN742,G4+GDCWQFNG)J,.259K6]C#,JLN94UMN>P_"?\
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MJ<.(_P!]^:_0_9^BBBOBCZ8_&_\ ;^_Y.Y\>?]N'_I!;5[M_P2=_Y&#XC_\
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M^\T_5?F<V)_@S]&?D%7]"=?SV5_0G7NYY_R[^?Z'EY7]OY?J%?C1^W)\*_\
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ML1/$=TO^#^AX$J[J48T>W](_2_\ X)?_  L/AOX6ZUXVNX=EUXBNO(MF8?\
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M:XN/ %K'(3G;:7MU;)_WS%*J_I7:_#O]GOX;_"BX%UX4\'Z9I-X 5%X(S+<
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M/4_$;G6+C<,$(X A7Z>4J-]7-?2=06=G#I]G!:VT206\"+%%%&,*B@8"@=@
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MO4KGQ#K=S=ZE>:A.YEU&Z+.9I %+#<>I 9.!T!7H,5[=^P#_ ,G<^ _^W_\
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M=P=_D>-_9M5.RDK'Y$7?PC\3Z=\+8?B#>Z=)9>&KG48],M)[@%&NI'CED+1
MCYD41$%NF2 ,X;"?!?\ Y+%X$_[#UC_Z4)7Z&_\ !4[4;6S^"'A/25VQS3>(
M(YX8U  \N*VG5L#T!E3\Z_/WX!Z?)JWQS^'EG'G=-XAT]<@9VC[0F3CV&3^%
M>CA\0\3AY59*VYQUJ*HUE33OL?NQ1117Y^?7!1110!QOQH_Y([X[_P"P#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<91P]#ZMAW=[>B_S'AL/4K5?;5EYG6T445\D?0A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>apyx-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apyx="http://apyxmedical.com/20200930"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apyx-20200930.xsd" xlink:type="simple"/>
    <context id="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib05f5eea79d74e0aaa4c9a5d10733dfd_I20201105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="i3aeb98b19ed344b38761f3312c3cef29_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i73c621036a99473780d3074110069a13_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a8c6709ab6545788f01bb876f8ad5fb_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iae41f525baaa42f39576509f7721cc15_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if0cce47726d34e2ebdd2418732677619_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iec6913c76db848e48f75b33fdd549043_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4f64a85dde3d4406b0968a6843b6650a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if1017cca871c456794046e8f6db58bad_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib55f9c780b1545c394b8709a246c5d8d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icccdbde53c634286a08502b7067c3bd4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8247c825010848fe816f263c06eb0578_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i78ecaae1891940d8b30cde984cfab290_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib934edd7927e448fa857c4334c0b224d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic57895c375be486494052fff7c84896e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5e15604132e64bd7be8c75ff25d7ad0f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i925ea0d8fa8047c0944ddd95c69a0069_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifbfeeeeb5d894c0aa6a94f455268d87a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i67fcb851c8f84550946c58cdf9f7aa5c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8bf1b493fcef4659bc8ded12611e9884_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9f5e2ba84d164ba7a5ffa6e3aeaae063_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie1b33044ef2c41908861223ecfd71ee6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64e52d7a0147408f9c71d68e6fbcaa1d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9dc2aaaf8f7f4a9b85cf16e63389f75a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i913d962436cd4db8a7740c64ad7493b5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i28f36fa133df4eaf9642016fef6664fe_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9a5510f10b3844959983d33e64e5204e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i92085eaad57f43949f28a8490b3618a3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i274049f33bc542f2b5c4a1edc98332f2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic0abc8cd3d9e4b8aacdbb3de72f2dd69_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3ef3ec014e56475892c3f14c254b885d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5a68681edbde45efadb3509ae7c13af1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia0ae8661537740f6926d686bfe24cd51_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0fbc93ccd4814ef99c90d7c8890ea00d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8bf8a9b477f84987a0b6c058bcd7e649_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i48fc99dafca2425db5c4a6fcb37ec8ea_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6b83789be6c1428f8e0e804d7baf2a2f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iedf6a9cfc3ce4884aee9545865031864_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifa6da815695f48cf8033a128044cf36f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba6dfcb91e634687989de6d0e02edef7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46a48387011840968abaf55fba3a032e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i54b5bfcc70b54a58914b26f39e6b0701_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib7aebc2db6474548be882738252f5712_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifde6c535194047a4ab3e479617f5d580_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3ca82284cce84aec9905621979eac687_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0448759fc2be4fa382f8f4658e300986_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="ib14b6c67e6dd455abc6901028ba4538a_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i852d57be8ad6467b9ab3b88460783b01_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i956b294a00a54308901dd7f15329f5a2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i35b49cbb47b64d98abab16201295d5a6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i85c0390a429a4234aa1f855c20366a70_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6dd1a24600384e0c988695d6cf2c976e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9bc6a13d050543ca9de29ba517195a6e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ied11d7234a5948deb5fe2210e04162f5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i055002fdfdea449397dfa999e230e0cb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic4e8528a777540ed922e20d4c68e0ad9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98a828c250044883817cff327ba04649_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d0ef098d3204c5c98b0e22874cdea4f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i231f501bd1f2450b9fa914b657791e11_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34a1bdc5e0da4360939ec99da52debd2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idd5dddf56d00470b8aa7a88a79e92300_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99f0487382914de3b1695fcaf943831e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if7f84ddfcfe34ee2b4fe9e0f5995eafe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibbc35ac6e31d4dd7a206d50f3668f460_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iabf0bad69e934fb18dc921efbd473e9f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:BulgariaManufacturingPlantPurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6aad088e173447ad8a7e163f390e1c17_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:BulgariaManufacturingPlantPurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i356212dfd54e49b3aaec12d12ef5c598_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i759891cb08514e4a9829b1b1f2315bfc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i573e9d9d81ad4ecb9dbd2be6bddc6fb8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i055a981a44044179a950382ce6694d05_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3ba6db9cd9234659951d70f1a84a0210_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8c4a8fb0f73460292e4e20ebc69a371_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ied82ea81f7c940e7ab5b2c914bbb80be_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9c037d9010f4687af65b47252416f9d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8d3b458e10584d0ca1129fd062442050_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i392395d0a19242688757fc5acfd48f41_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i153bf9c378f14f8cae2822d51169a108_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b43886dc0fa410d95320ffb2f4fede0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>apyx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV8xLTEtMS0xLTA_af652279-2e82-4488-95ea-d27b9f826458">0000719135</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV8yLTEtMS0xLTA_ee616794-d3da-4efb-a955-20282e77974a">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV8zLTEtMS0xLTA_9dc4e553-10ac-487a-81a4-a471212bcfdd">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV80LTEtMS0xLTA_9eec1596-c4ff-494b-8d4e-c99ab8d53c6a">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80L2ZyYWc6MTY5NzkwNzQzOWM3NDc5ZWEwYjYxYTY2ZWQ2Nzc1YmMvdGFibGU6NjBlOWUxM2IzNGI1NDBiY2FmY2RkMGM1YTBjNGRhYzkvdGFibGVyYW5nZTo2MGU5ZTEzYjM0YjU0MGJjYWZjZGQwYzVhMGM0ZGFjOV81LTEtMS0xLTA_03feaed7-3a0d-4577-87af-da50bd8761e8">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentType
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU3_07f80dc2-88c3-4dad-896c-fca7f37202dc">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZDQ4ZDhlNTA4NjA1NDdmZjhmMDMxZjNhNmEyZWU2OTkvdGFibGVyYW5nZTpkNDhkOGU1MDg2MDU0N2ZmOGYwMzFmM2E2YTJlZTY5OV8wLTItMS0xLTA_8b91956c-bb9d-4649-930f-4db442200b5e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZDQ4ZDhlNTA4NjA1NDdmZjhmMDMxZjNhNmEyZWU2OTkvdGFibGVyYW5nZTpkNDhkOGU1MDg2MDU0N2ZmOGYwMzFmM2E2YTJlZTY5OV8xLTQtMS0xLTA_12dae4d2-cbcc-481b-82aa-1109ec9b5f93">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZDQ4ZDhlNTA4NjA1NDdmZjhmMDMxZjNhNmEyZWU2OTkvdGFibGVyYW5nZTpkNDhkOGU1MDg2MDU0N2ZmOGYwMzFmM2E2YTJlZTY5OV81LTItMS0xLTA_ac1f2b28-433e-4a49-a0db-ae654c65adbf">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZDQ4ZDhlNTA4NjA1NDdmZjhmMDMxZjNhNmEyZWU2OTkvdGFibGVyYW5nZTpkNDhkOGU1MDg2MDU0N2ZmOGYwMzFmM2E2YTJlZTY5OV83LTQtMS0xLTA_fb3b9014-8440-4113-bc86-3d03edbe92d8">0-12183</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6ZGI0MDE5NjcyNTZiNDYyZjgyZDRkMDg5YWRlZWQ2NTIvdGFibGVyYW5nZTpkYjQwMTk2NzI1NmI0NjJmODJkNGQwODlhZGVlZDY1Ml8xLTAtMS0xLTA_c50abff8-d228-425f-9b36-e42aa0cdb053">APYX MEDICAL CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MTgyMTRhNmJkZTAxNDE5OTg2MzQ4M2I3NGE0ZjExMzEvdGFibGVyYW5nZToxODIxNGE2YmRlMDE0MTk5ODYzNDgzYjc0YTRmMTEzMV8wLTAtMS0xLTA_789b2201-b5f0-4c3b-9ddd-53ba07107b2e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MTgyMTRhNmJkZTAxNDE5OTg2MzQ4M2I3NGE0ZjExMzEvdGFibGVyYW5nZToxODIxNGE2YmRlMDE0MTk5ODYzNDgzYjc0YTRmMTEzMV8wLTItMS0xLTA_ae3ce53e-78da-48b3-ab87-ee577edd1876">11-2644611</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU4_6bd0b139-23aa-40c2-942f-a4a58554921a">5115 Ulmerton Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU5_ae3a1daf-9b1b-4445-93e9-3d3a3e673698">Clearwater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTYw_6098fa18-8488-4432-96c7-84d03d10f673">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTUx_2fac5774-9d8f-4c08-9637-debeec180f44">33760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTUy_4f0c428e-160f-4d11-a7ee-b07ae5208a64">727</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTUz_6b9e5951-03e5-4ed8-9acf-64b09064fe9b">384-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MjVhZmQ1NDcyMDgzNGE4ZDk3ZWUzZmU5NjlhZDM3YTEvdGFibGVyYW5nZToyNWFmZDU0NzIwODM0YThkOTdlZTNmZTk2OWFkMzdhMV8xLTAtMS0xLTA_a96232fd-eedc-44e7-b6fb-46b263e691c4">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MjVhZmQ1NDcyMDgzNGE4ZDk3ZWUzZmU5NjlhZDM3YTEvdGFibGVyYW5nZToyNWFmZDU0NzIwODM0YThkOTdlZTNmZTk2OWFkMzdhMV8xLTEtMS0xLTA_60237d9b-dcbe-4fa4-a276-f4bb6d162856">APYX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6MjVhZmQ1NDcyMDgzNGE4ZDk3ZWUzZmU5NjlhZDM3YTEvdGFibGVyYW5nZToyNWFmZDU0NzIwODM0YThkOTdlZTNmZTk2OWFkMzdhMV8xLTItMS0xLTA_8f2d85d3-20b2-4b7e-8ae8-b51a6b8b0191">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU0_44341943-f37f-4c52-856d-508f44235816">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU1_f51b1397-064c-40bd-9568-52f16f63198c">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6YmQ0MzQ3N2U0Mzg0NDQzOTkzYTlmMWJiMzE5MTcxNGYvdGFibGVyYW5nZTpiZDQzNDc3ZTQzODQ0NDM5OTNhOWYxYmIzMTkxNzE0Zl8wLTMtMS0xLTA_a501f3b3-851f-4980-80eb-a2f31a2b03b1">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6YmQ0MzQ3N2U0Mzg0NDQzOTkzYTlmMWJiMzE5MTcxNGYvdGFibGVyYW5nZTpiZDQzNDc3ZTQzODQ0NDM5OTNhOWYxYmIzMTkxNzE0Zl8xLTQtMS0xLTA_51a31a13-ab03-4f34-b7df-4131790edd31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGFibGU6YmQ0MzQ3N2U0Mzg0NDQzOTkzYTlmMWJiMzE5MTcxNGYvdGFibGVyYW5nZTpiZDQzNDc3ZTQzODQ0NDM5OTNhOWYxYmIzMTkxNzE0Zl8yLTQtMS0xLTA_a975a459-997a-4df8-98ce-2447e9cf55b9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8xNTU2_01314eaa-845f-405f-9ff0-4a8e8dbb2484">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib05f5eea79d74e0aaa4c9a5d10733dfd_I20201105"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xL2ZyYWc6MDNhNjVlZDE4NWFiNGEyZmFjMDFmYTMwMDU1M2MyYzIvdGV4dHJlZ2lvbjowM2E2NWVkMTg1YWI0YTJmYWMwMWZhMzAwNTUzYzJjMl8yMTk5MDIzMjU3MjE5_0c25b83e-332a-4048-9ada-70da2fbbe26e"
      unitRef="shares">34274771</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMy0xLTEtMS0w_96a0d977-ce76-4a6d-89d4-0db3c9fadc2a"
      unitRef="usd">43539000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMy0zLTEtMS0w_408dc61b-c386-4a40-b930-426913ef3200"
      unitRef="usd">58812000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNS0wLTEtMS0wL3RleHRyZWdpb246MTQ5YzMxNTE2ODAxNDBiNGJmM2Y1NjI5ZTU0NDJlNjBfNTQ5NzU1ODEzODk0OA_b9ae97de-bd04-4c55-97f4-daec57be37ec"
      unitRef="usd">760000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNS0wLTEtMS0wL3RleHRyZWdpb246MTQ5YzMxNTE2ODAxNDBiNGJmM2Y1NjI5ZTU0NDJlNjBfNTQ5NzU1ODEzODk1Nw_274bdb23-8674-4be2-a434-f1a3fb174038"
      unitRef="usd">273000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNS0xLTEtMS0w_671294a5-868d-4716-966e-c466d7643c6e"
      unitRef="usd">6154000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNS0zLTEtMS0w_58e49a51-0d77-479b-ba5a-0190fa6e302a"
      unitRef="usd">7987000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNi0xLTEtMS0w_bb4ca73f-2887-45f9-820b-557134471c2f"
      unitRef="usd">7238000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNi0zLTEtMS0w_2ddfecd4-41c0-4a6f-bc5b-f3054d34e219"
      unitRef="usd">426000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNy0xLTEtMS0w_5bf01d9f-d91f-4e10-824e-e53e96339479"
      unitRef="usd">1158000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNy0zLTEtMS0w_2749cab9-d1ff-4231-947d-31dfc487f096"
      unitRef="usd">1233000</us-gaap:OtherReceivablesNetCurrent>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOC0wLTEtMS0wL3RleHRyZWdpb246ZDcyYzcyYThlNWY0NDRiMDk2NTM2YjYyNjUzM2UyYmVfNTQ5NzU1ODEzODk1MQ_9a0e7801-df0b-4f6e-a077-13fc1001967f"
      unitRef="usd">537000</apyx:ProvisionForObsolescenceInventory>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOC0wLTEtMS0wL3RleHRyZWdpb246ZDcyYzcyYThlNWY0NDRiMDk2NTM2YjYyNjUzM2UyYmVfNTQ5NzU1ODEzODk1OQ_13216140-4954-42e2-91e2-5631394175f1"
      unitRef="usd">392000</apyx:ProvisionForObsolescenceInventory>
    <us-gaap:InventoryNet
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOC0xLTEtMS0w_8edf29a6-c991-4f65-9e17-b39a64e0fd4b"
      unitRef="usd">5416000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOC0zLTEtMS0w_868fe0b8-cfd2-4a4f-bf5d-2cfb5b697df9"
      unitRef="usd">5068000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOS0xLTEtMS0w_a72a1813-fbb8-406e-b19c-65d18ae0dd3f"
      unitRef="usd">4159000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfOS0zLTEtMS0w_a4d438e5-f1dc-41ba-8af5-311f19b4a901"
      unitRef="usd">3207000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTAtMS0xLTEtMA_d488215a-d4ad-4e51-bf25-230db68475c8"
      unitRef="usd">67664000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTAtMy0xLTEtMA_e780cf80-acee-417b-b775-e23261762343"
      unitRef="usd">76733000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjJiNmNhZWVlMGRmNTRkZjRhOTQ5MTA1N2YwMjVmN2Y5XzU0OTc1NTgxMzg5ODM_2982d2ea-3bf8-4c58-bbbb-55cd44e45575"
      unitRef="usd">4677000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTEtMC0xLTEtMC90ZXh0cmVnaW9uOjJiNmNhZWVlMGRmNTRkZjRhOTQ5MTA1N2YwMjVmN2Y5XzU0OTc1NTgxMzg5OTM_873742bf-5028-42f5-a80a-6b08bd2da24b"
      unitRef="usd">4403000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTEtMS0xLTEtMA_8ae000f6-f361-472b-8eeb-ca60a3da6630"
      unitRef="usd">6348000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTEtMy0xLTEtMA_e5792dcb-887b-4d9e-b18c-5b7f3ada8314"
      unitRef="usd">6618000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTItMS0xLTEtMA_a9164c69-99a9-454c-a74d-8b14af9e9ef3"
      unitRef="usd">266000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTItMy0xLTEtMA_163d010f-b7dc-47da-bf03-6cb726d3b598"
      unitRef="usd">350000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTMtMS0xLTEtMA_e5a932dd-850f-4336-859b-eb9afa155a5c"
      unitRef="usd">629000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTMtMy0xLTEtMA_feb82611-dbb8-4ba9-ba87-6da9ac302a59"
      unitRef="usd">653000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTUtMS0xLTEtMA_a343f81d-319f-4733-9dce-7a122934b206"
      unitRef="usd">508000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTUtMy0xLTEtMA_38124c8d-ce42-4721-af63-675088ae5995"
      unitRef="usd">391000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTYtMS0xLTEtMA_de80e3f0-a44d-47d1-9ae8-41805833bc56"
      unitRef="usd">75415000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMTYtMy0xLTEtMA_23b3660b-4249-4592-9e4b-8dbada68db77"
      unitRef="usd">84745000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjItMS0xLTEtMA_b1eef9fe-0806-4a1b-b163-4a569f298371"
      unitRef="usd">2479000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjItMy0xLTEtMA_8b6e0d71-8c6a-4220-8a58-dc2095862eee"
      unitRef="usd">2438000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjMtMS0xLTEtMA_db2f397f-878c-469e-80d9-5f100b3f7a79"
      unitRef="usd">6588000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjMtMy0xLTEtMA_da83ff65-293b-4c77-997f-453f908d9a18"
      unitRef="usd">9396000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjQtMS0xLTEtMA_87585322-7807-4b91-8a2f-91e4b70faefc"
      unitRef="usd">118000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjQtMy0xLTEtMA_ba7135ac-5d21-4d40-83c3-065cc785391d"
      unitRef="usd">108000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjUtMS0xLTEtMA_c49929fc-8d4e-441b-afb7-403fbccf1fa5"
      unitRef="usd">269000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjUtMy0xLTEtMA_7f733c34-7159-4e70-9135-5ef568666d0d"
      unitRef="usd">229000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjYtMS0xLTEtMA_78faecd7-6490-4f09-9441-71a912c1c559"
      unitRef="usd">140000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjYtMy0xLTEtMA_991486c4-93d8-44e1-8c04-b0614ef05936"
      unitRef="usd">140000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjctMS0xLTEtMA_029d8500-29cc-415c-8076-9249ee8edfe1"
      unitRef="usd">9594000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjctMy0xLTEtMA_d7714246-49f2-4a58-b2e9-e53161abdbe0"
      unitRef="usd">12311000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjgtMS0xLTEtMA_0fc8d352-3be4-403b-81db-7e9bb70bf6ad"
      unitRef="usd">153000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjgtMy0xLTEtMA_9cf80f19-4d7e-47d5-80a6-56da9e9ad16c"
      unitRef="usd">235000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjktMS0xLTEtMA_1ba4c154-f526-453f-92e8-017bb50fbdfe"
      unitRef="usd">347000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMjktMy0xLTEtMA_de449070-6b0e-4c5a-8ea5-1ce91f3330ec"
      unitRef="usd">421000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzAtMS0xLTEtMA_6212cca3-0c0a-4e41-8be3-7bc5a4eed31e"
      unitRef="usd">583000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzAtMy0xLTEtMA_025ddebb-0df2-4801-a03f-b17ce2260128"
      unitRef="usd">405000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzItMS0xLTEtMA_b818760f-7995-4570-8466-fd12db09695b"
      unitRef="usd">400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzItMy0xLTEtMA_a34f5458-91aa-4753-8b29-6d3341f45bda"
      unitRef="usd">114000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzMtMS0xLTEtMA_cc086f6c-9e80-4916-8839-a6f4d41ec794"
      unitRef="usd">11077000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzMtMy0xLTEtMA_f250d12d-2a43-4f31-aa8f-7c627fc52d4f"
      unitRef="usd">13486000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkwODQ_14fd3191-fbbb-49b2-a54d-e33234ab8caa"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkwODQ_acd45b57-7add-4e2f-ae21-f531ed6b456b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkwOTg_17e2e957-b123-40c8-a2fe-4b3ff035bdda"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkwOTg_673121d8-38c2-460d-985f-9a67a1a8b58e"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkxMTE_7cfd729b-74d2-4994-8f5b-5f3d1909ddb7"
      unitRef="shares">34222505</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkxMTE_89f122c1-a090-4371-83d6-3f2f2dbff0b2"
      unitRef="shares">34222505</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkxMjQ_6caa97e9-4d32-438e-94b3-3ac9c714da30"
      unitRef="shares">34312527</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjE5MWZhNzYwM2JjMTRkNjg4ZGUxODZlMTI5NWFkNDM2XzU0OTc1NTgxMzkxMzc_0fdcf7b1-39c0-4174-8c45-b082662cb02c"
      unitRef="shares">34169952</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMS0xLTEtMA_19da23fd-146e-46c5-af4a-eb2c3657759e"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzUtMy0xLTEtMA_a7a1116f-66ec-465f-befc-d829edd95c63"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzYtMS0xLTEtMA_59a759a3-5b52-4cf4-bd92-b39fb6fef8ce"
      unitRef="usd">60014000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzYtMy0xLTEtMA_274363e6-ef3e-498e-b701-e4fca36800e3"
      unitRef="usd">56708000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzctMS0xLTEtMA_4cb30e6f-27a6-4cbb-a7ec-0c474169f7e3"
      unitRef="usd">4148000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzctMy0xLTEtMA_1d67d88c-183e-43af-ab71-d07fada80621"
      unitRef="usd">14517000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzgtMS0xLTEtMTQzNw_a3671aa7-e642-411f-91a5-ff6dff1e39e1"
      unitRef="usd">64196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzgtMy0xLTEtMTQzNw_a293f5ad-b024-421e-9564-8f9b428695c4"
      unitRef="usd">71259000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzktMS0xLTEtNDkz_3ea45035-dda9-460c-95a3-0e333e9a391f"
      unitRef="usd">142000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfMzktMy0xLTEtNDk2_c6f94b7e-553e-457e-9612-a8e2a3598ca9"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNDAtMS0xLTEtMA_2982e694-877a-4f37-b7e4-afb4e29ea221"
      unitRef="usd">64338000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNDAtMy0xLTEtMA_cce51627-f07e-4720-950d-4fed9e5a06b0"
      unitRef="usd">71259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNDEtMS0xLTEtMA_67de530d-db2f-4338-8d16-d11e312f8d30"
      unitRef="usd">75415000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xNi9mcmFnOmY2Mzk4OTZiNDYzYjRjZWQ5ODQ5ZDE1YmI5MDFjOTdhL3RhYmxlOjk4ZDU2YzY1NDQ0OTQ0NDRhZGU4MzQ0MzM3Zjk3MWZmL3RhYmxlcmFuZ2U6OThkNTZjNjU0NDQ5NDQ0NGFkZTgzNDQzMzdmOTcxZmZfNDEtMy0xLTEtMA_cda531d9-5098-4fc4-aacf-bf0499a54a4a"
      unitRef="usd">84745000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMi0xLTEtMS0w_1d7132a7-79d1-4c35-a3da-fc37666b1d3b"
      unitRef="usd">6954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMi0zLTEtMS0w_569d1879-66ff-4fca-9f51-a99717693fc7"
      unitRef="usd">7575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMi01LTEtMS0w_8685870b-9f1f-4e17-8996-315085bba581"
      unitRef="usd">16247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMi03LTEtMS0w_99a063de-902c-4111-a2aa-07ffe9ed1f54"
      unitRef="usd">19853000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMy0xLTEtMS0w_481e46a4-030a-4426-b207-9e8700e826c2"
      unitRef="usd">2229000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMy0zLTEtMS0w_7f4a6da8-130a-4b3d-a664-e5151bce1d5e"
      unitRef="usd">2281000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMy01LTEtMS0w_9a27a49d-c5af-4675-8fd5-d264b178afc4"
      unitRef="usd">6444000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMy03LTEtMS0w_6148dc10-d06a-4805-bb4b-0f7d50d44074"
      unitRef="usd">6322000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNC0xLTEtMS0w_53caf8d4-6f09-4020-8d11-2c18fcbc2ddd"
      unitRef="usd">4725000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNC0zLTEtMS0w_e73bc6bd-947d-412c-8a54-1aaee076f211"
      unitRef="usd">5294000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNC01LTEtMS0w_c3865745-0dd4-4736-a9e0-a7e30f195757"
      unitRef="usd">9803000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNC03LTEtMS0w_4ffc588f-704b-43c6-a120-6e9ab6bd60f1"
      unitRef="usd">13531000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNi0xLTEtMS0w_f85d2e71-fb2a-4c3b-b02f-7e5af47fd1d6"
      unitRef="usd">1047000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNi0zLTEtMS0w_28ce74cc-c524-4e33-b6f9-4adf0f4a4922"
      unitRef="usd">1016000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNi01LTEtMS0w_374242a6-2d90-4158-a3e3-9053b183990e"
      unitRef="usd">3002000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNi03LTEtMS0w_540d33fc-f0f2-4d33-a613-debfb5d7e9a5"
      unitRef="usd">2634000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNy0xLTEtMS0w_ad970967-5f42-4de3-b5bd-6456779e97d5"
      unitRef="usd">1835000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNy0zLTEtMS0w_02546a50-5f6f-427c-bec0-15eb99eb1b76"
      unitRef="usd">2039000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNy01LTEtMS0w_f122b3fa-8b58-40c1-9c03-7ba4642946e8"
      unitRef="usd">5882000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfNy03LTEtMS0w_d24dd312-fc51-49e4-a1bb-7c4c5d894ec0"
      unitRef="usd">5818000</us-gaap:ProfessionalFees>
    <us-gaap:SalariesAndWages
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOC0xLTEtMS0w_15bbcfe1-6b50-4f7a-95ab-a3ae321a82d5"
      unitRef="usd">3508000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOC0zLTEtMS0w_ee2be44c-516a-43e5-9199-cc7b58e99188"
      unitRef="usd">3159000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOC01LTEtMS0w_cde976ed-3d31-46ce-9635-3d9aad688cbc"
      unitRef="usd">10258000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOC03LTEtMS0w_d2959f8b-0d0d-478f-a100-afc0e792cad5"
      unitRef="usd">10157000</us-gaap:SalariesAndWages>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOS0xLTEtMS0w_1caea3f8-b289-4827-b6ff-3c024ed1dbff"
      unitRef="usd">2706000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOS0zLTEtMS0w_65e02f9a-4033-431a-9d0a-6b6181751dd8"
      unitRef="usd">3836000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOS01LTEtMS0w_af7a5522-554c-4d7d-8efc-74c7417baf96"
      unitRef="usd">8691000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfOS03LTEtMS0w_fa58f4ec-c0f7-408d-b1ae-528da2195d2e"
      unitRef="usd">9830000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTItMS0xLTEtMA_235c0f32-a8f5-476e-928d-5ce37aa56b36"
      unitRef="usd">9096000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTItMy0xLTEtMA_0c8b67cb-705a-4e69-8583-83774708aa12"
      unitRef="usd">10050000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTItNS0xLTEtMA_2ccf7be9-4795-4d1f-87ea-3780b4aa68fd"
      unitRef="usd">27833000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTItNy0xLTEtMA_ccc189e5-9afa-4126-9d9b-81eb74f36d15"
      unitRef="usd">28439000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTMtMS0xLTEtMA_5f807800-2f17-472e-95dd-33208bf619ae"
      unitRef="usd">-4371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTMtMy0xLTEtMA_458d1df2-78eb-4d90-b820-be03b8de1152"
      unitRef="usd">-4756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTMtNS0xLTEtMA_0b6c050c-c562-4c4d-9e59-5f74c290e67a"
      unitRef="usd">-18030000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTMtNy0xLTEtMA_7cbe3912-7980-4080-bc8a-a27afd5676af"
      unitRef="usd">-14908000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTQtMS0xLTEtMA_5b83d3a7-1f23-4111-92f3-d69eba21bfde"
      unitRef="usd">10000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTQtMy0xLTEtMA_81b6ffc0-6e17-47d9-b05d-1d1ef1b990ad"
      unitRef="usd">327000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTQtNS0xLTEtMA_186065c9-1492-4be4-901d-1f59cab85717"
      unitRef="usd">233000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTQtNy0xLTEtMA_f86fbfee-eb72-4ab7-a8e0-beb4bf383a1d"
      unitRef="usd">1153000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTctMS0xLTEtMA_a5acbf41-ad74-4693-86be-3284fa221e62"
      unitRef="usd">25000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTctMy0xLTEtMA_899c10b3-0287-42d2-8256-b6e0fa94de86"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTctNS0xLTEtMA_efff4e42-2fa8-446f-a508-f47152101da9"
      unitRef="usd">39000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTctNy0xLTEtMA_790b6431-f48a-41ad-86c1-9f17da936825"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTgtMS0xLTEtMA_97b0acbe-52df-42e6-818e-68ecece5744e"
      unitRef="usd">-63000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTgtMy0xLTEtMA_89b4180a-b9f2-4c64-b17d-02cbc8d0b41e"
      unitRef="usd">230000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTgtNS0xLTEtMA_3b374796-dcab-43ae-ab95-115fd6a5ac6d"
      unitRef="usd">349000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMTgtNy0xLTEtMA_3fb8d264-5c23-453a-a8a7-946503abc176"
      unitRef="usd">-265000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjEtMS0xLTEtMA_1b6abb39-3683-4ec3-83f6-b52116aba682"
      unitRef="usd">-78000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjEtMy0xLTEtMA_b9af75bd-d7fc-48f0-b961-5e32eafdec2d"
      unitRef="usd">557000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjEtNS0xLTEtMA_35e977c0-916a-4e72-8540-109b13fa177a"
      unitRef="usd">543000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjEtNy0xLTEtMA_c90114f9-809c-4cde-af22-95eb027a9000"
      unitRef="usd">888000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjItMS0xLTEtMA_6bd2c926-26f0-4a5b-be60-1791b1b8d78a"
      unitRef="usd">-4449000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjItMy0xLTEtMA_41af75b5-d75a-415f-9ce1-a0c92609283a"
      unitRef="usd">-4199000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjItNS0xLTEtMA_16d3cd2d-92f1-45c3-97e5-f275f93d28c9"
      unitRef="usd">-17487000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjItNy0xLTEtMA_2647c2e9-8c8d-4b34-8912-4d3898d8d013"
      unitRef="usd">-14020000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjMtMS0xLTEtMA_51f1211c-e470-445a-aa0d-1ee1271c2040"
      unitRef="usd">-715000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjMtMy0xLTEtMA_65384acf-bfd5-43fc-a799-a6512792429e"
      unitRef="usd">171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjMtNS0xLTEtMA_5e38b147-4c9e-42c0-aeea-1af758ce3386"
      unitRef="usd">-7112000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjMtNy0xLTEtMA_3cfb4585-8b23-4214-8e8b-a263cbf1df6d"
      unitRef="usd">253000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtMS0xLTEtMA_01215ac8-c5ff-4ac3-a44c-40d2d83510ee"
      unitRef="usd">-3734000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtMy0xLTEtMA_361f459f-b83f-4389-9c92-511b6b9b9529"
      unitRef="usd">-4370000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtNS0xLTEtMA_7f21f655-2bff-41a2-8634-58c47414f93d"
      unitRef="usd">-10375000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtNy0xLTEtMA_624a91ae-8064-4455-a7f8-006dd315caea"
      unitRef="usd">-14273000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjctMS0xLTEtNTA5_26da5411-bcbf-4aff-bf65-734d345bbf3f"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjctMy0xLTEtMTQ1Nw_9e3e6c5a-baea-4246-83a9-53e6faedd68d"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjctNS0xLTEtNTE5_9eff1044-5c77-42be-ba5c-9261d9fea0d5"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjctNy0xLTEtMTQ1Nw_e71ba39d-dabb-4471-b603-242cb04186cd"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtMS0xLTEtMTQ1Nw_e6db3069-dbbd-4a1e-a296-4fa96c4b790a"
      unitRef="usd">-3728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtMy0xLTEtMTQ1Nw_1f1b4c01-8665-42de-a6f7-79fcb23e8fa3"
      unitRef="usd">-4370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtNS0xLTEtNTIw_5129959b-be5e-4c90-8d1a-561b9babe1b3"
      unitRef="usd">-10369000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMjgtNy0xLTEtMTQ1Nw_eab218ca-0e01-4446-8279-a694e0aeab20"
      unitRef="usd">-14273000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMzItMS0xLTEtMA_fa8c7be1-2f88-46fc-ae9b-994c9bca9204"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMzItMy0xLTEtMA_cf8be5e0-3a85-494a-bb7e-3f8bfd7a5607"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMzItNS0xLTEtMA_7359c49f-1698-4a9a-b543-45dc76399701"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yMi9mcmFnOjQ0MDhmZTZlN2U3NjQ4MTJiMmM0OTA0ODIzNDJkM2VmL3RhYmxlOmQ0ZmMzNzcwZmI3ODQ1OTFiZGJiNGE1NWI2YTNjNzIxL3RhYmxlcmFuZ2U6ZDRmYzM3NzBmYjc4NDU5MWJkYmI0YTU1YjZhM2M3MjFfMzItNy0xLTEtMA_a7d05f28-6e9f-44b4-80bf-100aceacf6ea"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="i4a8c6709ab6545788f01bb876f8ad5fb_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy01LTEtMS0w_eeb7e0e9-19b9-4f40-8ba5-2a45f1dfeffd"
      unitRef="shares">33921000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a8c6709ab6545788f01bb876f8ad5fb_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy03LTEtMS0w_1ce9dc70-48fb-4465-b89e-8242fdfb2409"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae41f525baaa42f39576509f7721cc15_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy05LTEtMS0w_c433c52e-1479-4b2e-a120-593c7125673f"
      unitRef="usd">55086000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0cce47726d34e2ebdd2418732677619_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy0xMS0xLTEtMA_529a0a3e-8a9e-47ef-a60c-4547f3d0e7fe"
      unitRef="usd">24320000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec6913c76db848e48f75b33fdd549043_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy0xMy0xLTEtMTQ2Ng_d41fba2c-183c-4e4e-8783-c7d70bdc6a82"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f64a85dde3d4406b0968a6843b6650a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMy0xNS0xLTEtMA_bcc5bc9f-04d9-4bac-9d2e-f47a2f0aa1bd"
      unitRef="usd">79440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if1017cca871c456794046e8f6db58bad_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNC01LTEtMS0w_248adac3-192b-46aa-b9ad-5a53bb6a7237"
      unitRef="shares">21000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib55f9c780b1545c394b8709a246c5d8d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNC05LTEtMS0w_1e23685b-62de-426d-9235-b616edd4043a"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNC0xNS0xLTEtMA_39437f67-8682-4253-a3dc-84f65fd362c3"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib55f9c780b1545c394b8709a246c5d8d_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNS05LTEtMS0w_5dad065f-bf3c-48a9-8ca1-e7e6e2827209"
      unitRef="usd">543000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNS0xNS0xLTEtMA_e97e8cac-e43c-4067-b212-972aaa0ce1bf"
      unitRef="usd">543000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="if1017cca871c456794046e8f6db58bad_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNi01LTEtMS0w_5a36d28e-cb3f-4457-ac4f-2fa838deb34f"
      unitRef="shares">35000</apyx:StockSwapToAcquireOptionsShares>
    <apyx:StockSwapToAcquireOptionsAmount
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNi0xNS0xLTEtMA_58aef9fd-7042-458c-80b5-d64ef0f53e97"
      unitRef="usd">0</apyx:StockSwapToAcquireOptionsAmount>
    <us-gaap:ProfitLoss
      contextRef="icccdbde53c634286a08502b7067c3bd4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNy0xMS0xLTEtMA_a6439ef8-b9ab-43f5-a7e1-1c669639cdbb"
      unitRef="usd">-4370000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNy0xNS0xLTEtMA_24a44a10-c2ca-4eeb-94a4-a42b777fe3eb"
      unitRef="usd">-4370000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i8247c825010848fe816f263c06eb0578_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC01LTEtMS0w_974538f6-28dc-4adf-93ab-3a455b1a3ac3"
      unitRef="shares">33977000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8247c825010848fe816f263c06eb0578_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC03LTEtMS0w_a24dd748-4d07-47de-859b-f9a388e27202"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78ecaae1891940d8b30cde984cfab290_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC05LTEtMS0w_8f485885-8cd6-4d61-9004-3709a540fa50"
      unitRef="usd">55668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib934edd7927e448fa857c4334c0b224d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC0xMS0xLTEtMA_b8e2a388-1af6-458d-bfcd-57f701234866"
      unitRef="usd">19950000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic57895c375be486494052fff7c84896e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC0xMy0xLTEtMTQ3Mg_ac1deba1-5520-4921-af28-b733c6cbe300"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e15604132e64bd7be8c75ff25d7ad0f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfOC0xNS0xLTEtMA_4cb33de8-44ee-483a-b073-d0ef322cf21d"
      unitRef="usd">75652000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i925ea0d8fa8047c0944ddd95c69a0069_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtNS0xLTEtMA_395d3459-4339-42db-8466-a6714f804adf"
      unitRef="shares">34202000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i925ea0d8fa8047c0944ddd95c69a0069_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtNy0xLTEtMA_ee05791f-f577-4614-88b5-f56e4ffcad76"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifbfeeeeb5d894c0aa6a94f455268d87a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtOS0xLTEtMA_6fe0b3d1-d3d6-459a-b164-1dcfa520da7a"
      unitRef="usd">58926000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67fcb851c8f84550946c58cdf9f7aa5c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtMTEtMS0xLTA_db673d33-152e-4b21-903e-7d2cf7cb9417"
      unitRef="usd">7876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8bf1b493fcef4659bc8ded12611e9884_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtMTMtMS0xLTA_184a6430-1a66-4ef2-82d7-753ba0947bb5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f5e2ba84d164ba7a5ffa6e3aeaae063_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTAtMTUtMS0xLTA_ff5d1c31-d895-48c9-938c-fcb5abfb58be"
      unitRef="usd">66836000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ie1b33044ef2c41908861223ecfd71ee6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtMTMtMS0xLTUzMw_bb423cef-5e6e-41e0-91aa-4ac1c8cd6b33"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtMTUtMS0xLTU1MA_551f69b1-7416-40da-8f61-ec69ad94fc43"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i64e52d7a0147408f9c71d68e6fbcaa1d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtNS0xLTEtMA_e61211ea-5cf3-4724-a2ba-fce665135d34"
      unitRef="shares">10000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9dc2aaaf8f7f4a9b85cf16e63389f75a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtOS0xLTEtMA_dea6a744-bcc0-4eaf-ad0a-303b4d6ce29f"
      unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTEtMTUtMS0xLTA_e0c3dd8b-4e47-4bcb-aee0-fd15db40bf32"
      unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9dc2aaaf8f7f4a9b85cf16e63389f75a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTItOS0xLTEtMA_f4d6b906-6542-4c41-a3c6-09bbc7b0d5e4"
      unitRef="usd">1063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTItMTUtMS0xLTA_6a436622-d3b1-4986-8875-86029f0aced0"
      unitRef="usd">1063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="i64e52d7a0147408f9c71d68e6fbcaa1d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTMtNS0xLTEtMA_8a449585-a1ea-4609-8d9f-aeed897af1aa"
      unitRef="shares">11000</apyx:StockSwapToAcquireOptionsShares>
    <apyx:StockSwapToAcquireOptionsAmount
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTMtMTUtMS0xLTA_b6910021-5770-452f-8ed5-28086c532683"
      unitRef="usd">0</apyx:StockSwapToAcquireOptionsAmount>
    <us-gaap:ProfitLoss
      contextRef="i913d962436cd4db8a7740c64ad7493b5_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTQtMTEtMS0xLTA_66b55dfb-12e3-4717-acb5-967cd97ccd68"
      unitRef="usd">-3728000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie1b33044ef2c41908861223ecfd71ee6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTQtMTMtMS0xLTA_c357d017-ec33-439d-b62a-18e19824a585"
      unitRef="usd">-6000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTQtMTUtMS0xLTA_ac2819eb-b0fa-49d9-8ed8-513675327517"
      unitRef="usd">-3734000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i28f36fa133df4eaf9642016fef6664fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtNS0xLTEtMA_e350e604-8d37-4e76-95c7-dc8ccae8db6d"
      unitRef="shares">34223000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28f36fa133df4eaf9642016fef6664fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtNy0xLTEtMA_256f9f63-fe3c-4884-82e1-7e4443eef9f9"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a5510f10b3844959983d33e64e5204e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtOS0xLTEtMA_49a1c308-5ecf-49a5-98f6-269b8bb114e2"
      unitRef="usd">60014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i92085eaad57f43949f28a8490b3618a3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtMTEtMS0xLTA_efb91159-01ee-4542-b2d2-38672e68b532"
      unitRef="usd">4148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i274049f33bc542f2b5c4a1edc98332f2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtMTMtMS0xLTA_c03485fd-1fc2-4ecd-8233-e9cbaa4be807"
      unitRef="usd">142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMTUtMTUtMS0xLTA_571c3d64-78d1-4066-90dc-c9801163b968"
      unitRef="usd">64338000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ic0abc8cd3d9e4b8aacdbb3de72f2dd69_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtNS0xLTEtMA_073f9eb9-9265-414e-a11e-5be884728e0e"
      unitRef="shares">33705000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0abc8cd3d9e4b8aacdbb3de72f2dd69_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtNy0xLTEtMA_1d7a3985-a3e2-49d8-85ee-abba56609e0d"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ef3ec014e56475892c3f14c254b885d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtOS0xLTEtMA_2a2ec329-6e98-47a7-9f8f-2766a7db18e3"
      unitRef="usd">52920000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a68681edbde45efadb3509ae7c13af1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtMTEtMS0xLTA_70d06fba-b585-4281-9f82-7816c2c9ffcf"
      unitRef="usd">34223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0ae8661537740f6926d686bfe24cd51_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjEtMTMtMS0xLTE0NzY_af5853dc-d42f-402e-8ab0-a678f74165d7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fbc93ccd4814ef99c90d7c8890ea00d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjAtMTUtMS0xLTA_681d2745-7ab8-4ebb-8cc1-f48d8d9b93e9"
      unitRef="usd">87177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8bf8a9b477f84987a0b6c058bcd7e649_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjEtNS0xLTEtMA_b54be022-c7b0-4a9d-bbe1-e91ba96763c9"
      unitRef="shares">51000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i48fc99dafca2425db5c4a6fcb37ec8ea_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjEtOS0xLTEtMA_f8708d0d-4b0c-42c3-a8ec-d15d2f00b8df"
      unitRef="usd">154000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjEtMTUtMS0xLTA_556c1480-3a5f-4a27-b175-b4dba9c79643"
      unitRef="usd">154000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i48fc99dafca2425db5c4a6fcb37ec8ea_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjYtOS0xLTEtMA_e654d63c-22a3-497d-9ff7-e9ab115c3eb9"
      unitRef="usd">2594000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjYtMTUtMS0xLTA_e2bfbbde-1e57-4480-b23a-acb912286d93"
      unitRef="usd">2594000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="i8bf8a9b477f84987a0b6c058bcd7e649_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjgtNS0xLTEtMA_69286109-2d79-4b5c-9aa7-32a09d9f18c4"
      unitRef="shares">221000</apyx:StockSwapToAcquireOptionsShares>
    <apyx:StockSwapToAcquireOptionsAmount
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjgtMTUtMS0xLTA_f66a6636-4412-4df7-a4cf-4694d52ac4d5"
      unitRef="usd">0</apyx:StockSwapToAcquireOptionsAmount>
    <us-gaap:ProfitLoss
      contextRef="i6b83789be6c1428f8e0e804d7baf2a2f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjktMTEtMS0xLTA_b41f5c06-b310-49f3-a506-ff02a7922a3c"
      unitRef="usd">-14273000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMjktMTUtMS0xLTA_bb7026e2-47db-4709-aa78-188313e90ab2"
      unitRef="usd">-14273000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i8247c825010848fe816f263c06eb0578_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtNS0xLTEtMA_45daa9fe-e963-4609-85e4-18253ac70e43"
      unitRef="shares">33977000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8247c825010848fe816f263c06eb0578_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtNy0xLTEtMA_3a47f623-0c11-4482-90ab-6477fd12ca08"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78ecaae1891940d8b30cde984cfab290_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtOS0xLTEtMA_f1a13bd7-3b0b-4ffd-bc4d-8fb9911317b4"
      unitRef="usd">55668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib934edd7927e448fa857c4334c0b224d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtMTEtMS0xLTA_7d1f1900-bfab-4bf2-90d3-9ab9e026019c"
      unitRef="usd">19950000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic57895c375be486494052fff7c84896e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzEtMTMtMS0xLTE0Nzk_13900279-6c78-436b-984f-da0468677c7e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e15604132e64bd7be8c75ff25d7ad0f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzAtMTUtMS0xLTA_de0e67e6-a548-4c42-b787-5880d29023a3"
      unitRef="usd">75652000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iedf6a9cfc3ce4884aee9545865031864_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtNS0xLTEtMA_067e7f0d-a014-4ece-baef-5f8db25bc09f"
      unitRef="shares">34170000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iedf6a9cfc3ce4884aee9545865031864_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtNy0xLTEtMA_6b9f712f-493c-4dcf-a239-1f6278fcc52a"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa6da815695f48cf8033a128044cf36f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtOS0xLTEtMA_d6da7268-a88f-4c17-a02b-4ca9199a8cf8"
      unitRef="usd">56708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba6dfcb91e634687989de6d0e02edef7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtMTEtMS0xLTA_4413e221-6de4-4181-9cac-23e6cf9d1118"
      unitRef="usd">14517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46a48387011840968abaf55fba3a032e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzQtMTMtMS0xLTE0ODE_6ae8f061-87be-4ce8-b572-59d1d1104645"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzMtMTUtMS0xLTA_2b48e2aa-856a-4123-9da8-1a38d4e88e06"
      unitRef="usd">71259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i54b5bfcc70b54a58914b26f39e6b0701_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzUtMTMtMS0xLTU1NA_3983aceb-f8da-4eb3-b787-5987d3fe95f4"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzUtMTUtMS0xLTU1NA_063f54b0-9446-4e11-9741-fba418379bf2"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib7aebc2db6474548be882738252f5712_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzQtNS0xLTEtMA_a57cefaa-e9b5-42bc-9dc7-c867e5321788"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifde6c535194047a4ab3e479617f5d580_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzQtOS0xLTEtMA_38c95318-1edf-4efe-84cd-01afc58ca0cb"
      unitRef="usd">97000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzQtMTUtMS0xLTA_9085cbf9-3396-4891-a576-24eacc9b2b39"
      unitRef="usd">97000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifde6c535194047a4ab3e479617f5d580_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzktOS0xLTEtMA_a9b09057-a0c9-4e07-a55c-cd36eaf4d35b"
      unitRef="usd">3209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfMzktMTUtMS0xLTA_0972cb04-2079-4fc9-9740-c5d226218835"
      unitRef="usd">3209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="ib7aebc2db6474548be882738252f5712_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDAtNS0xLTEtMA_f7975d0f-e673-4e18-9fae-e6f438f45c7c"
      unitRef="shares">33000</apyx:StockSwapToAcquireOptionsShares>
    <apyx:StockSwapToAcquireOptionsAmount
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDAtMTUtMS0xLTA_2610e748-568c-4b3a-a09b-5069f21f861c"
      unitRef="usd">0</apyx:StockSwapToAcquireOptionsAmount>
    <us-gaap:ProfitLoss
      contextRef="i3ca82284cce84aec9905621979eac687_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDItMTEtMS0xLTA_02a21a28-1e67-4b5a-87a8-1e26347b8065"
      unitRef="usd">-10369000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i54b5bfcc70b54a58914b26f39e6b0701_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDItMTMtMS0xLTA_58a0f039-bcbb-4783-9d50-c91ceb936320"
      unitRef="usd">-6000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDItMTUtMS0xLTA_607e386e-da2e-4b5e-bdd2-4480d076c419"
      unitRef="usd">-10375000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i28f36fa133df4eaf9642016fef6664fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtNS0xLTEtMA_c97b60e4-16dc-47db-bdc3-1ecbda7b17df"
      unitRef="shares">34223000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28f36fa133df4eaf9642016fef6664fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtNy0xLTEtMA_c71c5ce7-73cd-4e62-8748-28eb5d3f5bf7"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a5510f10b3844959983d33e64e5204e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtOS0xLTEtMA_6759407e-0e05-43a6-a6a1-5fef21b1bb8d"
      unitRef="usd">60014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i92085eaad57f43949f28a8490b3618a3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtMTEtMS0xLTA_d0e6238d-697d-451e-8ba3-530aa9ad1bc1"
      unitRef="usd">4148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i274049f33bc542f2b5c4a1edc98332f2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtMTMtMS0xLTA_534657b9-ebd3-4add-9a1a-1c9d037ad3e0"
      unitRef="usd">142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yNS9mcmFnOjhkMDZlYzBhMzgwMzRkYTdiMmRlNjg2OWQxMGQ3YjgxL3RhYmxlOmZkYWRmNGI1Y2VjZDQ1Mzg5NmVkM2ZmZjllYzY0OGI5L3RhYmxlcmFuZ2U6ZmRhZGY0YjVjZWNkNDUzODk2ZWQzZmZmOWVjNjQ4YjlfNDMtMTUtMS0xLTA_de0a1f0f-b561-44ac-b39d-ede22530c0ac"
      unitRef="usd">64338000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMy0xLTEtMS0w_b9dbd6fa-ab2b-43cf-87b2-e4fa3cabfce2"
      unitRef="usd">-10375000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMy0zLTEtMS0w_0e11c0e6-d9ea-4f7c-807d-67543206b920"
      unitRef="usd">-14273000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNy0xLTEtMS0w_86e9913f-9b91-4071-ba9a-c81592d82813"
      unitRef="usd">662000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNy0zLTEtMS0w_7af58124-d41b-4acd-a717-e6a918fb6811"
      unitRef="usd">510000</us-gaap:DepreciationDepletionAndAmortization>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfOC0xLTEtMS0w_e6b24278-b0c9-4d6e-81ac-6b1439016756"
      unitRef="usd">427000</apyx:ProvisionForInventoryObsolescence>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfOC0zLTEtMS0w_6461d10f-0fc0-49b9-9257-d1ac68833f4e"
      unitRef="usd">36000</apyx:ProvisionForInventoryObsolescence>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTAtMS0xLTEtMA_3b5e0519-d2c4-45e9-877e-433471d0e261"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTAtMy0xLTEtMTUwMg_85c77a7e-fe29-45fb-aa8c-cbed2e57efca"
      unitRef="usd">-19000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTEtMS0xLTEtMA_c3e7bd4c-b1b5-4d33-88a7-b9a438320da9"
      unitRef="usd">3209000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTEtMy0xLTEtMA_85f88fd6-74e2-49dd-a77b-4fd08c5527f1"
      unitRef="usd">2594000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseExpense
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTMtMS0xLTEtMA_ec4f5421-dbcd-4081-beeb-c16d9a6a4958"
      unitRef="usd">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTMtMy0xLTEtMA_899dd88c-5db1-4109-acfb-9ea1effb9db5"
      unitRef="usd">2000</us-gaap:OperatingLeaseExpense>
    <us-gaap:GainLossOnInvestments
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTQtMS0xLTEtMA_65f8eaac-b38e-4d73-9b7c-b10bea1f4b67"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTQtMy0xLTEtMA_2c2162d7-6a0d-4bc3-bf69-efc06e265e24"
      unitRef="usd">164000</us-gaap:GainLossOnInvestments>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTUtMS0xLTEtMA_10e8441d-a90d-4ecf-8bd2-60aba00cf3f3"
      unitRef="usd">486000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTUtMy0xLTEtMA_11245e67-ebcd-44cb-897a-9a074b933d92"
      unitRef="usd">-238000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTgtMS0xLTEtMA_b890597b-aa1f-41e6-ae2c-5930cad42d50"
      unitRef="usd">-1389000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTgtMy0xLTEtMA_91f94ba6-d234-42ce-bea6-da2636098096"
      unitRef="usd">2397000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <apyx:IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTktMS0xLTEtMA_e7aad6bf-c732-444e-aa8b-4c629b46772f"
      unitRef="usd">7793000</apyx:IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets>
    <apyx:IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMTktMy0xLTEtMA_885bd428-c34e-4d4e-9674-39a383cca5f8"
      unitRef="usd">1202000</apyx:IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjAtMS0xLTEtMA_93c590ba-23b8-4e4c-817f-a5270773beea"
      unitRef="usd">717000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjAtMy0xLTEtMA_f470bcae-3c0e-4f62-b60e-c9ca56fb474b"
      unitRef="usd">1772000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjItMS0xLTEtMA_2db857ab-72a8-470a-bdc0-1092d7d1d50f"
      unitRef="usd">15000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjItMy0xLTEtMA_48544e0f-3d9f-442a-8c5a-accc16ee0dcd"
      unitRef="usd">50000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjUtMS0xLTEtMA_af14903b-1b70-41f9-85fa-1ff08f41945b"
      unitRef="usd">-2352000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjUtMy0xLTEtMA_61a79522-8824-4590-b693-8d289e7387b7"
      unitRef="usd">1611000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjctMS0xLTEtMA_bbb28e81-9488-4778-85e0-0e60f17f2263"
      unitRef="usd">-15049000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjctMy0xLTEtMA_099efc67-f24a-42c3-a82a-bbf63a99afb9"
      unitRef="usd">-15224000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjktMS0xLTEtMA_7d52f463-47d6-4a3c-8572-0837cb52496b"
      unitRef="usd">193000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMjktMy0xLTEtMA_90d317d3-697b-4573-b6f0-20c7a2c3491f"
      unitRef="usd">1076000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzAtMS0xLTEtMA_0b3989f1-3b43-420c-a17a-1e78227177fc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzAtMy0xLTEtMA_bc0a5b77-dfea-48f5-aa40-4fb45ee8c51b"
      unitRef="usd">18884000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzEtMS0xLTEtMA_93f56c52-8b24-428a-9aa9-66afadd64b60"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzEtMy0xLTEtMA_52c9e7d0-7dc2-4a01-afac-6bcac3569fba"
      unitRef="usd">80726000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzUtMS0xLTEtMA_3b3907a2-2849-47f0-976b-eb77b84dfdd8"
      unitRef="usd">-193000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzUtMy0xLTEtMA_f226818a-f83b-4ce5-95c0-7e4f75c1d28d"
      unitRef="usd">60766000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzctMS0xLTEtMA_daad03ad-aad0-447c-a93e-a500ff87c445"
      unitRef="usd">97000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzctMy0xLTEtMA_19526f9c-484b-440d-a103-9160024924f2"
      unitRef="usd">154000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzktMS0xLTEtMA_c83f1188-bd5e-4695-9142-bda310648f6a"
      unitRef="usd">184000</apyx:RepaymentofFinanceLeaseLiabilities>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfMzktMy0xLTEtMA_efc405e0-a560-490b-8c60-df17400404be"
      unitRef="usd">2000</apyx:RepaymentofFinanceLeaseLiabilities>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDAtMS0xLTEtMA_7604de05-3891-4c7a-b93b-fe4642818dbf"
      unitRef="usd">148000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDAtMy0xLTEtMTUwMA_04574bb7-cc52-435f-b843-0dd9b143cac0"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDQtMS0xLTEtMA_5962a179-ea8d-48be-8842-f25f65200644"
      unitRef="usd">61000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDQtMy0xLTEtMA_a15bfdc4-d0f6-4fd8-8280-c3cba4e167ce"
      unitRef="usd">152000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDUtMS0xLTEtMA_7a568cd7-246e-4846-b755-fc42f158fed0"
      unitRef="usd">-92000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDUtMy0xLTEtMA_1bc28229-d3c7-49f7-9081-cca0eb57aec4"
      unitRef="usd">-18000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDYtMS0xLTEtMA_4ecc01a2-c43b-4ac4-9dd1-11982398a502"
      unitRef="usd">-15273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDYtMy0xLTEtMA_f8e551bb-774b-475a-8e29-c8a508e22550"
      unitRef="usd">45676000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDctMS0xLTEtMA_cbe133c9-2764-455b-9d08-70794e50e9f2"
      unitRef="usd">58812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0fbc93ccd4814ef99c90d7c8890ea00d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDctMy0xLTEtMA_dbba8824-97e2-45db-b0ff-306080240224"
      unitRef="usd">16596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDgtMS0xLTEtMA_05d497dc-b214-4d5f-84eb-65adc7551a6b"
      unitRef="usd">43539000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5e15604132e64bd7be8c75ff25d7ad0f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNDgtMy0xLTEtMA_5d8e0874-c376-49ce-bb18-2648dedfc412"
      unitRef="usd">62272000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTEtMS0xLTEtMA_09cdc57d-2226-492e-8fe1-ded43e5253dc"
      unitRef="usd">39000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTEtMy0xLTEtMA_9c8849ec-aaa6-4a53-bc2a-f5066f8854d2"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTItMS0xLTEtMA_ea408cf8-14ec-41ee-8bf8-ba30968df8c5"
      unitRef="usd">54000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTItMy0xLTEtMA_60f69a26-d423-47f4-a7e2-51adbc13519b"
      unitRef="usd">248000</us-gaap:IncomeTaxesPaid>
    <apyx:LeaseAdoption
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTYtMS0xLTEtMA_dca68aa6-972b-4b35-8ace-49c10bfb0c2b"
      unitRef="usd">0</apyx:LeaseAdoption>
    <apyx:LeaseAdoption
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTYtMy0xLTEtMA_a91e767f-05fb-4717-b0e2-f5b8ed73280f"
      unitRef="usd">212000</apyx:LeaseAdoption>
    <apyx:CapitalizationOfLeaseNonCash
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTctMS0xLTEtMA_cd747b43-435f-41c3-bdbd-86911282fd6b"
      unitRef="usd">0</apyx:CapitalizationOfLeaseNonCash>
    <apyx:CapitalizationOfLeaseNonCash
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTctMy0xLTEtMA_a8fe0365-1999-42de-a01c-83e4bc4f4156"
      unitRef="usd">207000</apyx:CapitalizationOfLeaseNonCash>
    <apyx:CapitalizationOfLeaseExecution
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTgtMS0xLTEtMA_ae182425-1c5f-45f2-915e-85d27aac8929"
      unitRef="usd">150000</apyx:CapitalizationOfLeaseExecution>
    <apyx:CapitalizationOfLeaseExecution
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTgtMy0xLTEtMA_81e0c51a-2833-4e4b-973b-5e905fa5457e"
      unitRef="usd">662000</apyx:CapitalizationOfLeaseExecution>
    <apyx:NonCashTransferOfOtherAssetsToFixedAssets
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTktMS0xLTEtMA_3b84e84a-7a6e-49a6-8238-33643b86ea0d"
      unitRef="usd">0</apyx:NonCashTransferOfOtherAssetsToFixedAssets>
    <apyx:NonCashTransferOfOtherAssetsToFixedAssets
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNTktMy0xLTEtMA_7ce16032-d9f6-4228-9614-a2fdef0609ee"
      unitRef="usd">42000</apyx:NonCashTransferOfOtherAssetsToFixedAssets>
    <apyx:NonCashTransfersOfInventoryToFromFixedAssets
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNjAtMS0xLTEtMA_3129ecca-380e-45e7-8df1-517ad4b9739a"
      unitRef="usd">10000</apyx:NonCashTransfersOfInventoryToFromFixedAssets>
    <apyx:NonCashTransfersOfInventoryToFromFixedAssets
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8yOC9mcmFnOjNhZjcwYjNkNzY5MjQ2ODBhNmY0ZGQ2NGExMTkwM2ZhL3RhYmxlOjM5MDRlNTNiODE0YTQ0NTQ4ZjJlNzNhZDM1MGU3YTJhL3RhYmxlcmFuZ2U6MzkwNGU1M2I4MTRhNDQ1NDhmMmU3M2FkMzUwZTdhMmFfNjAtMy0xLTEtMA_2f881a36-6103-4712-b8ab-59c893e4ba7b"
      unitRef="usd">264000</apyx:NonCashTransfersOfInventoryToFromFixedAssets>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8zNC9mcmFnOjQzOGZkNzY4ZTA3ZTQyNTJiN2JmYzgyZjRhMmI3YmUwL3RleHRyZWdpb246NDM4ZmQ3NjhlMDdlNDI1MmI3YmZjODJmNGEyYjdiZTBfNDM4NA_043e0974-fd70-4d01-aee7-6f760a24489a">BASIS OF PRESENTATION&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless the context otherwise indicates, the terms  &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; &#x201c;Apyx,&#x201d; and similar terms refer to Apyx Medical Corporation and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are an advanced energy technology company with a passion for elevating people&#x2019;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#xae; in the cosmetic surgery market and J-Plasma&#xae; in the hospital surgical market. Renuvion&#xae; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#xae; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization recognized the novel strain of coronavirus ("COVID-19"), as a pandemic. This pandemic has severely restricted the level of economic activity around the world. In response, the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. The long-term impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict as the environment created by the pandemic is rapidly changing. In late February, we began to experience the effects of the pandemic which have been material and adverse on our business. However, starting late in the second quarter and continuing through the third quarter, we started to see positive indications in our business. We believe the severity of the impact of the COVID-19 pandemic on our business will continue to depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers and suppliers, all of which are uncertain and cannot be predicted. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most of the procedures performed using our Helium Plasma Technology are elective, and as a result many of our customers have been affected by the actions taken by various governmental authorities requiring non-essential businesses to shut down temporarily.   As these shut-downs have begun to be reversed, we have started to see an increase in demand for elective cosmetic and plastic surgery procedures, resulting in higher than expected revenues in our Advanced Energy segment.  In international markets, a greater portion of these procedures are performed in a hospital, and it is less certain when elective procedures will fully return to normal.. While we experienced a significant decline in sales towards the end of our first fiscal quarter, we began to see an increase in sales towards the end of our second fiscal quarter, which continued through the third quarter, as local jurisdictions started to re-open. As cases have started to increase again, it is unknown whether these trends will continue. The full extent to which the COVID-19 pandemic may materially and adversely impact the Company's future financial position, liquidity, or results of operations remains uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019. These condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:AccountingChangesTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8zNy9mcmFnOmFmMjJmMTFiM2UzNzRlYzY5M2E2ZjQyZjIzNWFhOWYzL3RleHRyZWdpb246YWYyMmYxMWIzZTM3NGVjNjkzYTZmNDJmMjM1YWE5ZjNfMTAyNQ_00641d00-31c6-48e6-88ce-4f811018ca44">CHANGE IN ACCOUNTING POLICY&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.&lt;/span&gt;</us-gaap:AccountingChangesTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8zNy9mcmFnOmFmMjJmMTFiM2UzNzRlYzY5M2E2ZjQyZjIzNWFhOWYzL3RleHRyZWdpb246YWYyMmYxMWIzZTM3NGVjNjkzYTZmNDJmMjM1YWE5ZjNfMTAyNw_6a88681b-bede-431e-862d-e29ec9ab0392">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation-Stock Compensation,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80MC9mcmFnOmQ2ZjU1Y2YwZGRiMjQ0ZTBhZjZhZGViNDA2ZGU3YmJjL3RleHRyZWdpb246ZDZmNTVjZjBkZGIyNDRlMGFmNmFkZWI0MDZkZTdiYmNfMjU4OQ_3943c0be-4168-4174-9d83-c315e2af417f">RECENT ACCOUNTING PRONOUNCEMENTS &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements, we do not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU 2017-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#x2019;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80MC9mcmFnOmQ2ZjU1Y2YwZGRiMjQ0ZTBhZjZhZGViNDA2ZGU3YmJjL3RleHRyZWdpb246ZDZmNTVjZjBkZGIyNDRlMGFmNmFkZWI0MDZkZTdiYmNfMjU4NQ_6d474095-923e-4704-8a36-14df4723a31d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements, we do not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU 2017-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#x2019;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTAx_b610bbdb-bca9-42bc-8552-56ed7be075c7">DISPOSAL OF BUSINESS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2018, we closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly-owned subsidiary of Symmetry Surgical Inc. (&#x201c;Symmetry&#x201d;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie&#xae; brand and trademarks, to Symmetry for gross proceeds of $97&#160;million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Asset Purchase Agreement, we entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, whereby we will manufacture certain Core products and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in our Condensed Consolidated Statements of Operations as other income or (loss). Core activity for the three months ended September 30, 2020 amounted to&#160;$1.8&#160;million&#160;with cost of sales equivalents of&#160;$1.6&#160;million&#160;and related other expenses of&#160;$0.3&#160;million for net other (loss) of $0.1&#160;million. Core activity for the three months ended September 30, 2019 amounted to&#160;$2.5&#160;million&#160;with cost of sales equivalents of&#160;$2.2&#160;million&#160;and related other expenses of&#160;$0.1&#160;million for net other income of $0.2&#160;million. Core activity for the nine months ended September 30, 2020 amounted to&#160;$6.9&#160;million&#160;with cost of sales equivalents of&#160;$6.1&#160;million&#160;and related other expenses of&#160;$0.5&#160;million for net other income of $0.3&#160;million. Core activity for the nine months ended September 30, 2019 amounted to&#160;$6.9&#160;million&#160;with cost of sales equivalents of&#160;$6.6&#160;million&#160;and related other expenses of&#160;$0.2&#160;million for net other income of $0.1&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i0448759fc2be4fa382f8f4658e300986_D20180830-20180830"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTAz_7004f703-d5fc-4f4f-99bf-46f85e2993cf"
      unitRef="usd">97000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <apyx:AssetPurchaseAgreementTerm
      contextRef="ib14b6c67e6dd455abc6901028ba4538a_D20180830-20180830"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMzU0_76742043-6a49-4398-b70e-60cc22753618">P4Y</apyx:AssetPurchaseAgreementTerm>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTE2_622f1aba-4f2d-4e2a-9eda-194f50e66c77"
      unitRef="usd">1800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTMw_60202f12-1f0c-4ca5-b94c-505ee523c99b"
      unitRef="usd">1600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTQ0_66eeefa8-2272-4237-91b3-171eb651ec85"
      unitRef="usd">300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i145166856d6b42b2af10197e0e5e688d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjAw_a6aaee67-6b3d-4177-af11-a00ff3988484"
      unitRef="usd">-100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i852d57be8ad6467b9ab3b88460783b01_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTU4_54d3b701-e25d-4db7-b70f-32e2aa5ff7ea"
      unitRef="usd">2500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i852d57be8ad6467b9ab3b88460783b01_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMzI4_3b2824a8-90bd-4c16-a54e-e973d0fb7672"
      unitRef="usd">2200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMzkz_d9b98bd5-338e-48cf-953b-2a2967532ba4"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i852d57be8ad6467b9ab3b88460783b01_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTcy_5a3ae48b-8345-4b55-af89-00a2a833785a"
      unitRef="usd">200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i956b294a00a54308901dd7f15329f5a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjI4_6fae21ff-12ae-436a-8669-991e101bfa33"
      unitRef="usd">6900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i956b294a00a54308901dd7f15329f5a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMTg2_48d8b465-6f53-4097-9bed-938a2bd6e63d"
      unitRef="usd">6100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i956b294a00a54308901dd7f15329f5a2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMzEy_9eba25fd-9b3d-4d3e-a09c-0372ab108335"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxNDA3_311bba90-62c8-4433-be37-c1c5521ffacb"
      unitRef="usd">300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjk4_270631e3-f6e9-448e-a8be-5a925a7e5dd5"
      unitRef="usd">6900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjU2_a8dd5db3-ad85-41cb-86d6-4b8474fcf907"
      unitRef="usd">6600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjcw_829b6d61-71ae-43f9-ba95-b9406e8286ab"
      unitRef="usd">200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i2d4d9fe249654c7d82af9ee7288817ac_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMTEyL2ZyYWc6ODNkMGQ1ZWEzY2U1NDU3NWE4ZjRhYzgyYjM0N2ZjM2EvdGV4dHJlZ2lvbjo4M2QwZDVlYTNjZTU0NTc1YThmNGFjODJiMzQ3ZmMzYV8yMTk5MDIzMjYxMjg0_30c2881f-97a5-4c82-89cc-1a19c1a803d6"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RleHRyZWdpb246YzZiYTUxNGEzY2NkNDY3NThhYmEyMjRjMWU5ZjhjMTFfMTAwNg_4e3d108a-11f4-4658-a829-aa2007c52698">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2020, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs, and earlier than expected completion of product registrations in some of our foreign markets.&#160; As a result, certain products were reduced to a lower carrying value, and some components were also written down as we determined to cease further production on these older models. The total impairment was approximately $400,000 and is included in cost of sales in the accompanying consolidated statement of operations for the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RleHRyZWdpb246YzZiYTUxNGEzY2NkNDY3NThhYmEyMjRjMWU5ZjhjMTFfMTAwMg_032b7afc-bf8c-474f-9b83-af93f0877077">Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RleHRyZWdpb246YzZiYTUxNGEzY2NkNDY3NThhYmEyMjRjMWU5ZjhjMTFfMTAwOQ_81fdf870-a4e9-45dc-a28c-fcf013b80da0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMS0xLTEtMS0w_9053d8a6-5134-49ec-8c6a-a3945a669dfc"
      unitRef="usd">2487000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMS0zLTEtMS0w_c40c097b-e8c5-47ee-9280-7aee5241f977"
      unitRef="usd">2935000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMi0xLTEtMS0w_210d7977-2a3c-4a89-90bd-bb99a5fd1b20"
      unitRef="usd">1522000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMi0zLTEtMS0w_e2f20e62-d71f-4ecd-bdc3-ea3f1b273ac9"
      unitRef="usd">1209000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMy0xLTEtMS0w_85f4bb09-b995-46df-ad26-2234e2c6537b"
      unitRef="usd">1944000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfMy0zLTEtMS0w_99bb7b09-150c-4d1d-b8d7-98cda7a8bc64"
      unitRef="usd">1316000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNC0xLTEtMS0w_54b24571-3664-405c-b305-f057e0e05a3e"
      unitRef="usd">5953000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNC0zLTEtMS0w_5d8bee3f-6e04-45ff-9262-ce64d8e04d43"
      unitRef="usd">5460000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNS0xLTEtMS0w_0a0dc6f4-84bf-4845-8bf0-cf1ab2648cc1"
      unitRef="usd">537000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNS0zLTEtMS0w_7001e2b3-b0e5-4284-831c-44e0f2be0957"
      unitRef="usd">392000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNi0xLTEtMS0w_3eed6657-1d1e-416e-a71a-a7b98cd64468"
      unitRef="usd">5416000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RhYmxlOjhmZjNmZmMxNzRjMDQ4NDE5NmQyYzQ1MTFhZDJhZTU5L3RhYmxlcmFuZ2U6OGZmM2ZmYzE3NGMwNDg0MTk2ZDJjNDUxMWFkMmFlNTlfNi0zLTEtMS0w_29d79677-e620-49f6-b541-522db7fa5b86"
      unitRef="usd">5068000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80My9mcmFnOmM2YmE1MTRhM2NjZDQ2NzU4YWJhMjI0YzFlOWY4YzExL3RleHRyZWdpb246YzZiYTUxNGEzY2NkNDY3NThhYmEyMjRjMWU5ZjhjMTFfODYw_0afdb9f6-d285-4547-bd86-e1692d911eb1"
      unitRef="usd">400000</us-gaap:InventoryWriteDown>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RleHRyZWdpb246ZTU5ZGI5NzAwMGZjNDhmODhjOWY2OTQ0NmQ1NTk5YWJfMTQ3_affead6e-bbdc-4e61-ad56-9fb2789a3cbf">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RleHRyZWdpb246ZTU5ZGI5NzAwMGZjNDhmODhjOWY2OTQ0NmQ1NTk5YWJfMTQ5_d274714d-82dd-46d7-ace9-c3384338ecce">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.573%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMS0xLTEtMS0w_28f1995d-3828-4929-95f9-c8443a3e790c"
      unitRef="usd">497000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMS0zLTEtMS0w_8c7dae9e-7f9a-4aed-b96c-dab8ea3eafe3"
      unitRef="usd">694000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMi0xLTEtMS0w_102678c9-1b5e-47b4-b62e-fc2c7247cdeb"
      unitRef="usd">0</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMi0zLTEtMS0w_60fda279-f8bf-401b-9b3c-2d662f552d5f"
      unitRef="usd">1306000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMy0xLTEtMS0w_5e1e541d-89ba-4265-8434-e5a6dc61ff02"
      unitRef="usd">620000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMy0zLTEtMS0w_66e7a68d-cfd7-4abe-b38a-0795612ebb31"
      unitRef="usd">877000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNC0xLTEtMS0w_02dbef7b-8ad2-4eb3-80e8-ee47658b8288"
      unitRef="usd">471000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNC0zLTEtMS0w_81b2fee2-7da7-456a-89f9-e1bb0f3de63c"
      unitRef="usd">452000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNS0xLTEtMS0w_06f9bac1-da5a-4880-b340-bbd16ed65adb"
      unitRef="usd">632000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNS0zLTEtMS0w_6b36cf5c-166c-4a38-ba16-078678a7ccee"
      unitRef="usd">1170000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNi0xLTEtMS0w_1a64c1de-a549-459a-8d66-15b0a1e52572"
      unitRef="usd">744000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNi0zLTEtMS0w_34dce3bf-8f65-4e3a-952e-ca5d6deabb02"
      unitRef="usd">1383000</us-gaap:AccruedProfessionalFeesCurrent>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNy0xLTEtMS0w_6614f9de-fadd-4cb3-8ab4-a27803fba97c"
      unitRef="usd">1045000</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfNy0zLTEtMS0w_7c76c515-d0dd-4382-8c27-a0739622072c"
      unitRef="usd">1045000</apyx:JointAndSeveralPayrollLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfOC0xLTEtMS0w_266386ee-50ad-40ae-b812-02861766388b"
      unitRef="usd">1616000</apyx:UncertainTaxPositionsLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfOC0zLTEtMS0w_c3f5d1fd-1f43-4756-9063-32bfdd4a386b"
      unitRef="usd">1491000</apyx:UncertainTaxPositionsLiability>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfOS0xLTEtMS0w_dc55aa39-46ad-4d80-bdc4-461c39e5a1ad"
      unitRef="usd">963000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfOS0zLTEtMS0w_458a93f8-1394-48bb-a26f-69b8d32d0685"
      unitRef="usd">978000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMTAtMS0xLTEtMA_db2f397f-878c-469e-80d9-5f100b3f7a79"
      unitRef="usd">6588000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV80OS9mcmFnOmU1OWRiOTcwMDBmYzQ4Zjg4YzlmNjk0NDZkNTU5OWFiL3RhYmxlOjI1NzJlZjA5MzY1YjRhYjE5ZTk0MDc2MDg0ZmE3MDczL3RhYmxlcmFuZ2U6MjU3MmVmMDkzNjViNGFiMTllOTQwNzYwODRmYTcwNzNfMTAtMy0xLTEtMA_54e68571-abfc-4067-bb70-95cb49def25c"
      unitRef="usd">9396000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3NzMz_8d396a0a-3b7b-4903-801f-9cf3cbd7b1a5">NON-CONTROLLING INTEREST&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In late 2019, we executed a joint venture agreement with our Chinese supplier ("China JV"). The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;$360,000, of which approximately $154,000 was contributed during the three months ended September 30, 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our ownership interest in our 51% owned China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <apyx:NoncontrollingInterestRequiredCapitalContribution
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3NzEz_1bb28c0a-cfa4-4f7a-a0c7-8d1db6907aed"
      unitRef="usd">360000</apyx:NoncontrollingInterestRequiredCapitalContribution>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3NzIz_88387c44-3df6-4916-be3e-ae877d23b5a0"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <apyx:NoncontrollingInterestTableTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3NzMy_81483306-b679-4a06-a59e-5e2d9ea40507">Changes in our ownership interest in our 51% owned China JV were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</apyx:NoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i35b49cbb47b64d98abab16201295d5a6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGV4dHJlZ2lvbjpiYjg0ZGQ0NmYxZTQ0Nzg2OTQ0MDQxOWJmNDg4MTczYV8yMTk5MDIzMjU3Njk5_b4f329d2-787a-48d0-bb24-8554ba22058e"
      unitRef="number">0.51</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterest
      contextRef="i85c0390a429a4234aa1f855c20366a70_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF8yLTEtMS0xLTE2NDU_a5a409e5-1fd3-48a9-be05-897892d3699c"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i6dd1a24600384e0c988695d6cf2c976e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF8yLTUtMS0xLTE2NDg_f5130467-2c77-4977-a86f-b4921c69dbdf"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i9bc6a13d050543ca9de29ba517195a6e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF8zLTEtMS0xLTE2NDU_35a0063b-90cf-4447-89e4-dca05c166fca"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF8zLTUtMS0xLTE2NDg_1016869b-299e-4ceb-a31a-c8610fb5fdf2"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9bc6a13d050543ca9de29ba517195a6e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF80LTEtMS0xLTE2NDU_94e45d00-c219-4eb3-9d37-a3edfbadca12"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF80LTUtMS0xLTE2NDg_473d8861-728a-4988-b5de-5f2c3f253600"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="ied11d7234a5948deb5fe2210e04162f5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF81LTEtMS0xLTE2NDU_d23b2d71-d90a-4cd9-b3d2-dc2e734c603c"
      unitRef="usd">148000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ied11d7234a5948deb5fe2210e04162f5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV8xMDU4L2ZyYWc6YmI4NGRkNDZmMWU0NDc4Njk0NDA0MTliZjQ4ODE3M2EvdGFibGU6NjM4MzI3YmFiYWFiNDI3ZGI1YTdkZjVkMDkyMTk5ZDAvdGFibGVyYW5nZTo2MzgzMjdiYWJhYWI0MjdkYjVhN2RmNWQwOTIxOTlkMF81LTUtMS0xLTE2NDg_503ddd45-e0f1-4f12-9641-61a203b68ddb"
      unitRef="usd">148000</us-gaap:MinorityInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RleHRyZWdpb246OGMwY2YxNDJmNTIxNGM4ODlhYjI0ODNlNWYzODg2NGRfNTc0_ab24df65-1b8d-4315-a566-658af8463244">EARNINGS (LOSS) PER SHARE &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We compute basic earnings per share (&#x201c;basic EPS&#x201d;) by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period adjusted for other units required to be included in basic EPS. Diluted earnings per share (&#x201c;diluted EPS&#x201d;) gives effect to all dilutive potential shares outstanding. As we are in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RleHRyZWdpb246OGMwY2YxNDJmNTIxNGM4ODlhYjI0ODNlNWYzODg2NGRfNTgx_82b6a82d-d1b9-4dc1-987b-c5c34f129e61">The following table provides the computation of basic and diluted earnings per share.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMy0yLTEtMS0w_e39c8c1c-e682-4234-b4c3-b95245c38a08"
      unitRef="usd">-3728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMy00LTEtMS0w_739023bf-9e5c-4b1e-9677-9f61b3d7ec69"
      unitRef="usd">-4370000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMy02LTEtMS0w_aec9a028-c3ae-4275-b866-917087251c66"
      unitRef="usd">-10369000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMy04LTEtMS0w_3ac992ef-7d71-4c96-a2af-6f346f1f9f82"
      unitRef="usd">-14273000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfNi0yLTEtMS0w_cd6f184b-5f52-45c8-bfdd-d10f9708b561"
      unitRef="shares">34216000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfNi00LTEtMS0w_8c62d7e3-fb3f-4106-86c6-c33b3639b7da"
      unitRef="shares">34078000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfNi02LTEtMS0w_57ba4d33-a3c7-432f-bb81-770957fcece2"
      unitRef="shares">34193000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfNi04LTEtMS0w_0e282e37-c916-4d99-9b50-2389b6b6cab3"
      unitRef="shares">34039000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfOS0yLTEtMS0w_e2509928-95e1-44f8-8d90-65d81366c98c"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfOS00LTEtMS0w_49b7d2a0-30d3-43fc-9f06-6d82c16ed3af"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfOS02LTEtMS0w_a268c015-6391-4375-af64-4610f543ad80"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfOS04LTEtMS0w_b5f8f978-6f25-49f6-bf67-09ed71f17501"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i055002fdfdea449397dfa999e230e0cb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItMi0xLTEtMTY2Mw_81d73e37-b3db-404f-8695-ae7e2f29740c"
      unitRef="shares">45000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic4e8528a777540ed922e20d4c68e0ad9_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItNC0xLTEtMTY2Mw_a5fef082-50b6-4800-90ee-9c42aef0583a"
      unitRef="shares">90000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i98a828c250044883817cff327ba04649_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItNi0xLTEtMTY2Mw_d6b53ac8-83c1-4f67-807d-97a805888d54"
      unitRef="shares">45000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9d0ef098d3204c5c98b0e22874cdea4f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItOC0xLTEtMTY2Mw_f597854d-4682-4a4a-aa09-9bd437b7d991"
      unitRef="shares">90000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i231f501bd1f2450b9fa914b657791e11_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItMi0xLTEtMA_db2ea22b-d442-4de8-8126-ceb663f30f49"
      unitRef="shares">5028000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i34a1bdc5e0da4360939ec99da52debd2_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItNC0xLTEtMA_ab953c9f-a82b-4bfd-a822-181c0f26ebcd"
      unitRef="shares">4060000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idd5dddf56d00470b8aa7a88a79e92300_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItNi0xLTEtMA_030665ca-169f-4944-acfa-cf6dfd2f5599"
      unitRef="shares">5028000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i99f0487382914de3b1695fcaf943831e_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81Mi9mcmFnOjhjMGNmMTQyZjUyMTRjODg5YWIyNDgzZTVmMzg4NjRkL3RhYmxlOjJmNjAyZTBhYmQyNzQ3ZGNiODIwZDRlOWQ4YjM4NTI1L3RhYmxlcmFuZ2U6MmY2MDJlMGFiZDI3NDdkY2I4MjBkNGU5ZDhiMzg1MjVfMTItOC0xLTEtMA_c0bd6a66-e958-43bf-bc03-4b3743d3d1f1"
      unitRef="shares">4060000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMTc3MQ_28e5e43a-3833-402b-850a-0bfef3ae1379">STOCK-BASED COMPENSATION &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our stock option plans, our board of directors may grant restricted stock and options to purchase common shares to our employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing a trinomial lattice model through 2018 and the Black Scholes model for grants in 2019 and 2020, both of which include a number of estimates that affect the grant date fair value and the amount of expense to recognize.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized approximately $1,063,000 and $3,209,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2020, as compared with $543,000 and $2,594,000, respectively, for the three and nine months ended September 30, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,966,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allow stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2020 and 2019, respectively, we received 16,140 and 26,572 options as payment in the exercise of 10,610 and 34,928 options. For the nine months ended September 30, 2020 and 2019, respectively, we received  29,149 and 118,170 options as payment in the exercise of 32,637 and 220,879 options. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common shares required to be issued upon the exercise of stock options would be issued from our authorized and unissued shares. We calculated the grant date fair value of options granted in 2020 ("2020 Grants") utilizing a Black Scholes model with an expected life calculated via the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.432%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfNjQ5_e1b9def6-6c53-404c-a197-452707948a4d"
      unitRef="usd">1063000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfNjU2_97deb726-8153-4771-9e82-bc35edb27cef"
      unitRef="usd">3209000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfNzUy_f917ee42-7833-46a7-aca0-bd0951c213a5"
      unitRef="usd">543000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfNzU5_f2380eb9-6d89-42d7-a69f-5a793076c205"
      unitRef="usd">2594000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMTc3OQ_6ad3aa2f-12f5-43bb-9d3d-b93a190e0ed6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,966,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81,131)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNS0xLTEtMS0w_be475cf6-e1e5-4941-9ece-a94ef43cec84"
      unitRef="shares">3966858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i73c621036a99473780d3074110069a13_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNS0zLTEtMS0w_874d4b8d-0255-473c-9f71-d2904e6ef9ea"
      unitRef="usdPerShare">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNi0xLTEtMS0w_8bc844f3-3655-43d6-ac71-ebc5d47ecd84"
      unitRef="shares">1376900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNi0zLTEtMS0w_d368f0f8-5c57-4f3b-9155-1098da86ef11"
      unitRef="usdPerShare">7.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNy0xLTEtMS0w_3a7970b1-caa3-47af-a728-63f5d72897fc"
      unitRef="shares">81131</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfNy0zLTEtMS0w_09d3f170-6c7c-4a73-b862-61d3cd7f32eb"
      unitRef="usdPerShare">3.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfOC0xLTEtMS0w_9d3f88e9-496f-4a35-a887-6ba8ba20f535"
      unitRef="shares">234600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfOC0zLTEtMS0w_42763469-4745-480f-9bac-400b3050676b"
      unitRef="usdPerShare">7.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfOS0xLTEtMS0w_a7340e71-b7e6-4d8a-bc7f-8656f2d6c4df"
      unitRef="shares">5028027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjVhZTRkY2NiZGQ4ZjQ0YzdhNjc2Yjk1N2FlNDIzMWEyL3RhYmxlcmFuZ2U6NWFlNGRjY2JkZDhmNDRjN2E2NzZiOTU3YWU0MjMxYTJfOS0zLTEtMS0w_6dd5aee9-64c5-4ed9-9c38-bc17d5b8cd7d"
      unitRef="usdPerShare">5.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzYyNw_5bcf114f-5413-4662-a82a-c4479e37af57"
      unitRef="shares">16140</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzYzNQ_056c9885-5667-4f00-994d-13f6750207fd"
      unitRef="shares">26572</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzY2MA_75b06028-c93b-4f1a-be94-c84772df1d5d"
      unitRef="shares">10610</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzY2OA_4d262493-157f-4ddc-84d1-90a0b417edf3"
      unitRef="shares">34928</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzY0Mw_0f543cdd-27ff-49d1-bf0e-367bea08b390"
      unitRef="shares">29149</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzY1MQ_9a7432fc-6979-47aa-aeeb-7a1bec4e09b0"
      unitRef="shares">118170</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzYxMA_3675169f-1cdb-4c2a-8d07-cfcd18834ae2"
      unitRef="shares">32637</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMjE5OTAyMzI1NzYxOA_c4761703-7b05-44eb-98e0-c6ef3a3a5adc"
      unitRef="shares">220879</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RleHRyZWdpb246M2RiYzlhZTE5ZTAzNGRmOWIxYTBjODc2YzA4MTRlOTdfMTc4MA_9db98e97-597b-49ca-af78-c1df8b22a3eb">We calculated the grant date fair value of options granted in 2020 ("2020 Grants") utilizing a Black Scholes model with an expected life calculated via the simplified method.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.432%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if7f84ddfcfe34ee2b4fe9e0f5995eafe_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMS0xLTEtMS0w_9843f360-c0a9-47f9-8423-9c334eca0612"
      unitRef="usdPerShare">4.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibbc35ac6e31d4dd7a206d50f3668f460_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMS0zLTEtMS0xNjcx_5e090d07-bd98-4b9c-892f-0ff3750139c8"
      unitRef="usdPerShare">8.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if7f84ddfcfe34ee2b4fe9e0f5995eafe_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMi0xLTEtMS0w_994e527e-f086-4874-a949-e32e1ca87a53"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibbc35ac6e31d4dd7a206d50f3668f460_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMi0zLTEtMS0xNjcz_4e3a428a-7983-4205-b8ea-36b037f15e18"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfMy0xLTEtMS0w_4472740b-b302-48dc-967f-7613ce3931ec"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if7f84ddfcfe34ee2b4fe9e0f5995eafe_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfNC0xLTEtMS0w_ef6745bf-ea0c-43df-9640-e1d7bab2365f"
      unitRef="number">0.659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibbc35ac6e31d4dd7a206d50f3668f460_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfNC0zLTEtMS0xNjc1_5ca38fd4-fabb-4630-8bb2-6c799394aa09"
      unitRef="number">0.701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81NS9mcmFnOjNkYmM5YWUxOWUwMzRkZjliMWEwYzg3NmMwODE0ZTk3L3RhYmxlOjQ3Nzg2ODY5NDg4ZTQ1MDliZjUzZTAxZjNiMDg4NGE1L3RhYmxlcmFuZ2U6NDc3ODY4Njk0ODhlNDUwOWJmNTNlMDFmM2IwODg0YTVfNS0xLTEtMS0w_b2969c12-501a-4158-9928-32d583f95f4c">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjczNg_7a545046-55d4-41a2-8399-f98d884e5572">INCOME TAXES On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#x2019;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, we generated a significant amount of taxable income in 2018. Subsequent to this, we generated net losses in 2019 and through the first three quarters of 2020. For the net losses generated in 2019, we previously recorded a full valuation allowance on the deferred tax assets associated with our NOL carryforwards due to realization of the NOL not being probable under then existing tax law. The CARES Act makes these assets realizable, and as of the date of the CARES Act, we have recognized an income tax benefit of approximately $3.7 million associated with the release of the valuation allowance on our Federal NOL carryforward related to 2019. We also recognized income tax benefits of approximately $0.8&#160;million and $3.3&#160;million, related to our loss before income taxes for the three and &lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2020, respectively. There are approximately $2.4&#160;million of 2018 Federal income tax payments available to offset against any other 2020 losses that may be incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax (benefit) expense was approximately  $(715,000) and $171,000 with an effective tax rate of 16.1% and (4.1)% for the three months ended September 30, 2020 and 2019, respectively. Our income tax (benefit) expense was approximately $(7,112,000) and $253,000 with an effective tax rate of 40.7% and (1.8)% for the nine months ended September 30, 2020 and 2019, respectively. For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our NOL carryforward from 2019. For the three months ended September 30, 2020, and the three and nine months ended September 30, 2019, the effective rate differs from the statutory rate primarily due to interest and penalties on our uncertain tax positions. &lt;/span&gt;&lt;/div&gt;We have gross unrecognized tax benefits of approximately $1,313,000 at September 30, 2020. We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in our condensed consolidated financial statements. As of September 30, 2020, we had approximately $300,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax benefit for the three and nine months ended September 30, 2020, respectively are approximately $43,000 and $125,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $1,616,000 of income tax benefits in the consolidated statement of operations. It is expected that all of the uncertain tax positions should be resolved by October 2022.</us-gaap:IncomeTaxDisclosureTextBlock>
    <apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfODc3_ff06d704-0751-42c2-966e-bfc15dae4c53"
      unitRef="usd">-3700000</apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards>
    <apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQxMQ_f1d6b1d9-7fe2-44a1-a8a9-aa488e115e95"
      unitRef="usd">-800000</apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes>
    <apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQyNQ_5c7d6e18-f32f-4b5a-bd72-8bfae2c1200d"
      unitRef="usd">-3300000</apyx:CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes>
    <apyx:CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQzOQ_a8cd8c0c-b391-4cf5-a149-db8de1605688"
      unitRef="usd">2400000</apyx:CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMzI5ODUzNDg4ODk0Mw_baaf2027-0bb5-4db0-a539-b91bb42839d6"
      unitRef="usd">-715000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMzI5ODUzNDg4ODk1Nw_396354f5-5d20-4495-8963-d2a7c4fc1882"
      unitRef="usd">171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ2OA_9e9bf7e0-9b68-4359-91f5-19f8c8a1e162"
      unitRef="number">0.161</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ3NQ_cb165b18-27f7-447e-9bdb-759bf2f3e232"
      unitRef="number">-0.041</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMzI5ODUzNDg4ODk4OA_e3daf71e-0860-4e0a-b4bf-c2f344bf28ff"
      unitRef="usd">-7112000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODUwNg_52b02d98-81f0-4b67-a5a0-3da439832c54"
      unitRef="usd">253000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ1Mw_67455f25-3cd1-4d04-8f14-cde4fc1e5157"
      unitRef="number">0.407</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ2MA_479a03ef-50d6-4b74-a959-049c2d4bb12b"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2OTQ0OQ_6ab8bdbc-19ad-4e9b-b77f-66e95f837c06"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ4Mw_70502b1b-a6d8-4949-8957-42297d322ccc"
      unitRef="usd">300000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjM2Ng_0565a096-1fef-46df-8d60-49d57839e708"
      unitRef="usd">43000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjE5OTAyMzI2ODQ5Mw_cf9004ac-f0e4-4daa-9327-e9fe404c9d5a"
      unitRef="usd">125000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV81OC9mcmFnOjRlMzY1ZTU5ZTFiMDQ4Yzg4Zjg2NzI2MWRlYjBmMTdiL3RleHRyZWdpb246NGUzNjVlNTllMWIwNDhjODhmODY3MjYxZGViMGYxN2JfMjU4OQ_2160b17a-7a5f-470c-ba97-65ed35a73ba9"
      unitRef="usd">1616000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82MS9mcmFnOjNmZGNlNTZmNWNiZDQzZTdiZjUwYTk5YTY1ZTUyODdiL3RleHRyZWdpb246M2ZkY2U1NmY1Y2JkNDNlN2JmNTBhOTlhNjVlNTI4N2JfNDQ4Nw_e15994f4-353f-42b3-ad58-cb0b31e94c7d">COMMITMENTS AND CONTINGENCIES&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. We believe that such claims are adequately covered by insurance; however, in the case of one of our carriers, we are in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policies or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated results of operations, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2019, a complaint (the &#x201c;Complaint&#x201d;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#x2019;s President and Chief Executive Officer and a member of the Company&#x2019;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.&#160; On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#x2019;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#x201c;Amended Complaint&#x201d;) with the Court.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#x2019;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#x2019;s J-Plasma&#xae; technology for use in dermal resurfacing procedures. &#160;On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.&#160; On July 10, 2020, the parties executed a settlement agreement, which was subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020.&#160;The settlement agreement provides for the dismissal of the action with prejudice.&#160;On November 6, 2020, the Court issued its final order approving the settlement and dismissing the action and all claims contained in the Amended Complaint with prejudice. At September 30, 2020,&#160;we have settled and fully paid all obligations related to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, we had purchase commitments totaling approximately $1,800,000, substantially all of which is expected to be purchased within the next six months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;China Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our agreement in the China joint venture requires the Company to make a capital contribution into the newly formed entity of $357,000. As of the date of these consolidated financial statements, approximately $203,000 of our capital commitment remains to be funded.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82MS9mcmFnOjNmZGNlNTZmNWNiZDQzZTdiZjUwYTk5YTY1ZTUyODdiL3RleHRyZWdpb246M2ZkY2U1NmY1Y2JkNDNlN2JmNTBhOTlhNjVlNTI4N2JfMjE5OTAyMzI3MDQyNQ_e0b4ae14-75f0-4b5b-8a62-04f2088d1939"
      unitRef="usd">1800000</us-gaap:PurchaseObligation>
    <apyx:NoncontrollingInterestRequiredCapitalContribution
      contextRef="i3aeb98b19ed344b38761f3312c3cef29_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82MS9mcmFnOjNmZGNlNTZmNWNiZDQzZTdiZjUwYTk5YTY1ZTUyODdiL3RleHRyZWdpb246M2ZkY2U1NmY1Y2JkNDNlN2JmNTBhOTlhNjVlNTI4N2JfMjE5OTAyMzI3MDUyMQ_48838517-cd01-45a1-b142-ee5c37528e56"
      unitRef="usd">357000</apyx:NoncontrollingInterestRequiredCapitalContribution>
    <apyx:PaymentsToAcquireInterestInJointVentureRemaining
      contextRef="iee2461b09ba34e4682afe3756bc08656_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82MS9mcmFnOjNmZGNlNTZmNWNiZDQzZTdiZjUwYTk5YTY1ZTUyODdiL3RleHRyZWdpb246M2ZkY2U1NmY1Y2JkNDNlN2JmNTBhOTlhNjVlNTI4N2JfMjE5OTAyMzI3MDUzMQ_ef7801c2-f3b0-485b-a25b-485d63499b57"
      unitRef="usd">203000</apyx:PaymentsToAcquireInterestInJointVentureRemaining>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfODg2_34217bbe-e248-4526-8a6b-ee4f0193d40d">RELATED PARTY TRANSACTIONS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several relatives of Nikolay Shilev, Apyx Bulgaria&#x2019;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#x2019;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#x2019;s sister, is the Manager of Production and Human Resources. Svetoslav Shilev, Mr. Shilev&#x2019;s son, is an engineer in the quality assurance department.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as part of the purchase of the Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for $140,000 to be paid 5 years after the original purchase date, which came due in October 2020. The note was paid in full on October 20, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The partner in our China joint venture is also a supplier of the Company. During the three and nine months ended September 30, 2020, we made purchases from this supplier of approximately $410,000 and $1,250,000, respectively. At September 30, 2020, we owed this supplier approximately $123,000.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="iabf0bad69e934fb18dc921efbd473e9f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfNTcx_4c8335eb-6157-4f28-aaa2-417b2d53df01"
      unitRef="usd">140000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <apyx:TermOfPaymentDueNotesPayableRelatedParties
      contextRef="i6aad088e173447ad8a7e163f390e1c17_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfNTg1_8b650386-8021-4d71-89c9-dbf576432a0f">P5Y</apyx:TermOfPaymentDueNotesPayableRelatedParties>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i356212dfd54e49b3aaec12d12ef5c598_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfMjE5OTAyMzI1NjY0MQ_a64fe967-9d10-4e17-af36-73338d636c2e"
      unitRef="usd">410000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i759891cb08514e4a9829b1b1f2315bfc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfMjE5OTAyMzI1NjU3NA_bbcd4a9f-2637-450a-b487-36ebe1f2903c"
      unitRef="usd">1250000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i573e9d9d81ad4ecb9dbd2be6bddc6fb8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82NC9mcmFnOjQ2ODM3N2NjMjNjMzRiMmY5Y2Q5NGRiODUxNmY1YTYzL3RleHRyZWdpb246NDY4Mzc3Y2MyM2MzNGIyZjljZDk0ZGI4NTE2ZjVhNjNfMjE5OTAyMzI1NjU4Ng_cb985e04-a80f-47d9-a838-a53aa4cbcb65"
      unitRef="usd">123000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTcyOA_755921b1-19ef-40a9-ac11-f77e2d6b9340">GEOGRAPHIC AND SEGMENT INFORMATION &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, we have not presented a measure of assets by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our reportable segments are principally organized and managed as&#160;two&#160;operating segments: Advanced Energy and OEM. "Corporate &amp;amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International sales represented approximately 25.0% and 24.8% of total revenues for the three and nine months ended September 30, 2020, respectively, as compared with 26.7% and 29.5% of total revenues for the same prior year period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all of our sales are denominated in U.S. dollars. Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfODM0_294f2127-fdf5-40df-bce1-19e3bb5dd738"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTcyOQ_04c384b3-a9bf-4fa7-93ce-af5ed86a0de8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMi0zLTEtMS0w_88b4af7c-8f63-40ef-aaf6-70e69cd0a90a"
      unitRef="usd">5479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMi01LTEtMS0w_25c40129-4940-4a72-9ee4-5ced87df96f9"
      unitRef="usd">1475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMi03LTEtMS0w_70eb2b05-e976-4235-95a0-3b74034a0dff"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMi05LTEtMS0w_33a4ad91-4a35-4f93-a65d-75bd9c470309"
      unitRef="usd">6954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTQtMy0xLTEtMA_af9401d1-e9e4-455a-ae7e-d53faf513d61"
      unitRef="usd">-1095000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTQtNS0xLTEtMA_0c4e6465-bdc5-4126-8af0-e985f138eb7b"
      unitRef="usd">556000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTQtNy0xLTEtMA_992a9553-9fbb-4a7e-8aa3-82fa8fa8c743"
      unitRef="usd">-3832000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTQtOS0xLTEtMA_3f475eba-ef69-4187-afab-42d9afa82c06"
      unitRef="usd">-4371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTYtMy0xLTEtMA_90189d3e-6447-4cb3-ba35-a2e8f9ef14a5"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTYtNS0xLTEtMA_2ffbfe8e-50f4-4fef-ae00-b92ab8ef6c7c"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTYtNy0xLTEtMA_c06a0cd0-74db-4d89-9489-f297d734797e"
      unitRef="usd">10000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTYtOS0xLTEtMA_5a84e989-41a9-4868-ae4a-bd3237f8185d"
      unitRef="usd">10000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTctMy0xLTEtMA_941b1436-1b52-4159-b715-efa32a98ebae"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTctNS0xLTEtMA_f6c17853-ebc9-472e-a175-60d1ae721c4a"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTctNy0xLTEtMA_134a06f7-640b-4cce-abdc-0aa792062006"
      unitRef="usd">25000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTctOS0xLTEtMA_f8ae160c-1807-4345-be84-76b9a8cec825"
      unitRef="usd">25000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTgtMy0xLTEtMA_a1682239-f69d-48fe-ab85-7b8387be090b"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTgtNS0xLTEtMA_4629dec1-c989-466c-858b-f8899607e115"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTgtNy0xLTEtMA_a9903ffb-2071-4bc3-985b-a0e3a660a64c"
      unitRef="usd">-63000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMTgtOS0xLTEtMA_f6bcd764-bda9-4a47-b528-51659d18be49"
      unitRef="usd">-63000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMjItMy0xLTEtMA_080801c3-99cb-447b-9ebd-22cd323180e6"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia9148b3c3b3242a5b5403149bc5a7fde_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMjItNS0xLTEtMA_84b10e5e-3400-4ee8-bbfe-c4a71fb200fd"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i24a62b5504d74dc19431a861ea649e39_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMjItNy0xLTEtMA_5ef53591-4114-4342-9c6d-57462ba61548"
      unitRef="usd">-715000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmM4ZmVlN2M3ZGExYzQyZGQ4YjIyOWQ4MWM4ZGVmZjE5L3RhYmxlcmFuZ2U6YzhmZWU3YzdkYTFjNDJkZDhiMjI5ZDgxYzhkZWZmMTlfMjItOS0xLTEtMA_eb0f93ab-f94a-4ffa-a8b9-632ad0225eab"
      unitRef="usd">-715000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMi0zLTEtMS0w_5518842a-ab43-4029-96e5-1bcfd435913e"
      unitRef="usd">6094000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMi01LTEtMS0w_fbe6f11c-41b4-438c-8a23-0c7859543148"
      unitRef="usd">1481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMi03LTEtMS0w_5fcb2647-a393-4c26-8b83-816071430e87"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMi05LTEtMS0w_7d3f2b23-4ef8-4c19-8a5a-5e9978bd4c8d"
      unitRef="usd">7575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTQtMy0xLTEtMA_aafc8eb9-f3f5-41af-8534-53ac76c43a79"
      unitRef="usd">-1357000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTQtNS0xLTEtMA_c69f3d4e-8d06-4e07-a902-6ef0e9a780d7"
      unitRef="usd">268000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTQtNy0xLTEtMA_e8954f8e-e492-4d40-b11b-954a3089d1db"
      unitRef="usd">-3667000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTQtOS0xLTEtMA_2b25bd71-917e-43e7-b868-dec7824241be"
      unitRef="usd">-4756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTYtMy0xLTEtMA_fd6f24c7-2530-430f-bb2e-6493061ce142"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTYtNS0xLTEtMA_7ccc6aac-8780-493a-a45b-044adb161bf9"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTYtNy0xLTEtMA_b7d5f0a3-b649-46ac-8080-d0ac142259bd"
      unitRef="usd">327000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTYtOS0xLTEtMA_697fa0c5-ce33-4396-b0e1-7c7da604279a"
      unitRef="usd">327000</us-gaap:InterestIncomeOperating>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTgtMy0xLTEtMA_562eeb4b-9ba3-411e-899a-eb41a57b964e"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTgtNS0xLTEtMA_17301445-2d07-4c65-9cd7-d0dd8f1718e5"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTgtNy0xLTEtMA_c83bfc6d-b875-4e6c-8efc-df8a763a7794"
      unitRef="usd">230000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMTgtOS0xLTEtMA_3dd9b3e9-8189-4418-af8a-539f29fbb582"
      unitRef="usd">230000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i40f27ee273c546bdb217d795e3c850d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMjItMy0xLTEtMA_0e6b80fa-af45-439b-bb5f-a22650f76941"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaf29c69e0afb4891af31f2f7a31fe2e6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMjItNS0xLTEtMA_d9cfadaf-c121-4f7d-9eb7-acc07d4ca7a1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i736c68764afa40a7a5a9c84fd9dfa247_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMjItNy0xLTEtMA_d52df477-61aa-4e41-ad8d-3e0162c1cae5"
      unitRef="usd">171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmNjYTU2MzJmNjE5ZDRlY2NhOTk5MDE5NzRkMmI0ZWI1L3RhYmxlcmFuZ2U6Y2NhNTYzMmY2MTlkNGVjY2E5OTkwMTk3NGQyYjRlYjVfMjItOS0xLTEtMA_cbb3525e-b033-4e84-9b85-9bd2dd792e29"
      unitRef="usd">171000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMi0zLTEtMS0w_ab76031b-26e2-4111-828a-a2aebbf547f6"
      unitRef="usd">12332000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMi01LTEtMS0w_c86c6a4f-716d-4827-af47-28b4087ca8a2"
      unitRef="usd">3915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMi03LTEtMS0w_d42659bd-6221-4700-ac99-d1408b932411"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMi05LTEtMS0w_8685870b-9f1f-4e17-8996-315085bba581"
      unitRef="usd">16247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTQtMy0xLTEtMA_738aa4d8-3c45-4317-a520-1b5e16f0bda3"
      unitRef="usd">-8371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTQtNS0xLTEtMA_d9653ccd-220e-442f-b78d-445b8c4b2449"
      unitRef="usd">1387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTQtNy0xLTEtMA_5cd5dfa4-cdca-4a6b-992d-d7e71c32e59c"
      unitRef="usd">-11046000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTQtOS0xLTEtMA_0b6c050c-c562-4c4d-9e59-5f74c290e67a"
      unitRef="usd">-18030000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTYtMy0xLTEtMA_b8408eca-ff70-4e90-a71b-5d4c0f9cd531"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTYtNS0xLTEtMA_2a2bdedf-f549-4390-8306-89852a78ae36"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTYtNy0xLTEtMA_186065c9-1492-4be4-901d-1f59cab85717"
      unitRef="usd">233000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTYtOS0xLTEtMA_6f9d1eb7-1b7b-4812-a12e-1230e2480b46"
      unitRef="usd">233000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTctMy0xLTEtMA_6f097119-f090-40fb-a131-0c2fbfd8bcc0"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTctNS0xLTEtMA_b3eae4c7-c7ca-408a-b4a2-7b0b497bb93f"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTctNy0xLTEtMA_efff4e42-2fa8-446f-a508-f47152101da9"
      unitRef="usd">39000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTctOS0xLTEtMA_e19b6d4d-6ed7-492c-a112-73b37f4d2eb6"
      unitRef="usd">39000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTgtMy0xLTEtMA_118f9897-a374-4c91-8985-b04d9fc4c252"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTgtNS0xLTEtMA_12ca2ef3-8724-4001-904d-38797025651a"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTgtNy0xLTEtMA_86cf3d9b-b22c-41a4-80c6-f9b47dc0ce95"
      unitRef="usd">349000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMTgtOS0xLTEtMA_f490ecae-b0c8-426a-88a8-5d392859a4cf"
      unitRef="usd">349000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibd53f637456647a7b79bd39b49fe55dc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMjItMy0xLTEtMA_4570c61f-6c39-4b96-b1eb-ac952ec02466"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic3817b8cf2fd4431ab23a8f2962c57e0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMjItNS0xLTEtMA_f4133c3b-c2ff-4729-a0dd-5bdb35813fbf"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i23afe08a6c6a4c029a11ace4128fe2f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMjItNy0xLTEtMA_5e38b147-4c9e-42c0-aeea-1af758ce3386"
      unitRef="usd">-7112000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmE1ZmQyOTMwZjcxMDRjY2I5M2UxYjc5M2QxY2U2YzRjL3RhYmxlcmFuZ2U6YTVmZDI5MzBmNzEwNGNjYjkzZTFiNzkzZDFjZTZjNGNfMjItOS0xLTEtMA_0157032d-91b8-41b6-aeac-60dd9f6f29c2"
      unitRef="usd">-7112000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfMi0zLTEtMS0w_3068db34-d643-432d-b457-732101b536f1"
      unitRef="usd">15815000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfMi01LTEtMS0w_b36d4968-5549-4966-bb73-ce20c58e7265"
      unitRef="usd">4038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfMi03LTEtMS0w_7a2e1cfd-2f8c-4035-b8fb-0a126c9dddfc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfMi05LTEtMS0w_a38ced24-f5a7-412f-ac1f-74ff92ff686a"
      unitRef="usd">19853000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNC0zLTEtMS0w_5b727d20-b389-4b8e-93e6-0efcc59fc9f0"
      unitRef="usd">-5653000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNC01LTEtMS0w_7fbe75a5-57fa-40b9-bb42-6b0c4cc00b78"
      unitRef="usd">995000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNC03LTEtMS0w_c7f18409-0045-44a4-a750-ed5c5d1a3edd"
      unitRef="usd">-10250000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNC05LTEtMS0w_f62b2ac0-ed4b-479b-b7c5-dcf7b8c039c6"
      unitRef="usd">-14908000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNi0zLTEtMS0w_a2fbc1bb-8e00-4be5-8892-35ac63904d52"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNi01LTEtMS0w_89c16e63-2e21-4e17-bbd7-7cd5f299ebb3"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNi03LTEtMS0w_bf6625df-6940-4c2e-97c3-2859094ed531"
      unitRef="usd">1153000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNi05LTEtMS0w_4b19e11d-0e9e-4bf2-a01e-06f3f73ae1c9"
      unitRef="usd">1153000</us-gaap:InterestIncomeOperating>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNy0zLTEtMS0w_1ff99a0a-e1b7-4633-b19a-13f2195d0c56"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNy01LTEtMS0w_4fef79ae-c58e-4438-98f2-04a4d97a8705"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNy03LTEtMS0w_7d561bd4-981e-453a-8876-479d70760310"
      unitRef="usd">-265000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfNy05LTEtMS0w_66349e5b-373f-45e9-b223-d6b908948e5c"
      unitRef="usd">-265000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i055a981a44044179a950382ce6694d05_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfOC0zLTEtMS0w_eb35feb3-2659-4be9-ad44-0c1e37b923f3"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7fa57cbc3a0b4f7fb8e43231d324eae6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfOC01LTEtMS0w_3bb7edc6-78f8-4965-979c-48b0e90674d6"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i404e1a8fffa341bd81715048d419e91d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfOC03LTEtMS0w_01486099-b97d-4612-9d25-89f9335e2fca"
      unitRef="usd">253000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmI5YmIwN2NiODUwMTQwODVhMmJkMzZmM2QxZTJlNzU2L3RhYmxlcmFuZ2U6YjliYjA3Y2I4NTAxNDA4NWEyYmQzNmYzZDFlMmU3NTZfOC05LTEtMS0w_f5f2078d-81f9-492e-8d23-5d6d6aef8df3"
      unitRef="usd">253000</us-gaap:IncomeTaxExpenseBenefit>
    <apyx:TotalRevenuePercent
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTM4NA_c0beed91-13f3-4d9e-b502-766089bfa1fa"
      unitRef="number">0.250</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTM5MQ_4b3cfe50-2124-4e64-aed9-844398eb7739"
      unitRef="number">0.248</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTQ5Mw_a2550040-e9d9-4961-8192-b16d307b6584"
      unitRef="number">0.267</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTUwMA_212ddd8b-8ccb-45df-9218-d948ceec61df"
      unitRef="number">0.295</apyx:TotalRevenuePercent>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RleHRyZWdpb246MWQzNTQ4MDIwZDY2NDM2MzlmMzA5MGIzZDZkZWU4MDRfMTczNw_6e9dede3-6ed6-486d-ac30-557c603b5670">Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ba6db9cd9234659951d70f1a84a0210_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfMy0xLTEtMS0w_b9278000-1df6-4632-aa80-cfab5b91340f"
      unitRef="usd">5214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8c4a8fb0f73460292e4e20ebc69a371_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfMy0zLTEtMS0w_665d18f2-7132-4c6a-a07d-320e8b4b5541"
      unitRef="usd">5552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied82ea81f7c940e7ab5b2c914bbb80be_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfMy01LTEtMS0w_60d083d2-d2ff-4873-9b73-5b7cd8f9e63b"
      unitRef="usd">12225000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9c037d9010f4687af65b47252416f9d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfMy03LTEtMS0w_a2ceca53-6fe7-42fb-b10e-d228f854d919"
      unitRef="usd">14002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d3b458e10584d0ca1129fd062442050_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNC0xLTEtMS0w_c2f3b107-ef85-4f4b-8a97-6bb03f59e9b3"
      unitRef="usd">1740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i392395d0a19242688757fc5acfd48f41_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNC0zLTEtMS0w_6b9f6a43-4259-4e89-b1f9-062bd055eb39"
      unitRef="usd">2023000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i153bf9c378f14f8cae2822d51169a108_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNC01LTEtMS0w_cc70cf07-af94-440b-90f4-bc0246068091"
      unitRef="usd">4022000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b43886dc0fa410d95320ffb2f4fede0_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNC03LTEtMS0w_d9c8d7ff-cbde-417d-94a6-00c5c0112df8"
      unitRef="usd">5851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNS0xLTEtMS0w_1d7132a7-79d1-4c35-a3da-fc37666b1d3b"
      unitRef="usd">6954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9738f65974048f18179578e6b8e23eb_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNS0zLTEtMS0w_832fe136-60fa-4452-952d-eeb54b6081dd"
      unitRef="usd">7575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNS01LTEtMS0w_8685870b-9f1f-4e17-8996-315085bba581"
      unitRef="usd">16247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3149fee6b8f042e6b552a068e8a29fc1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg1ZDI4NzBmMmM1OTQ1MzlhNGQ3MzM5YjdiMWY3ZmQxL3NlYzo4NWQyODcwZjJjNTk0NTM5YTRkNzMzOWI3YjFmN2ZkMV82Ny9mcmFnOjFkMzU0ODAyMGQ2NjQzNjM5ZjMwOTBiM2Q2ZGVlODA0L3RhYmxlOmUzYjJjNGUzMDYwMTQ5NTBiNjRhYjFhODBjNzcxMjhmL3RhYmxlcmFuZ2U6ZTNiMmM0ZTMwNjAxNDk1MGI2NGFiMWE4MGM3NzEyOGZfNS03LTEtMS0w_81430b14-a2e4-4b76-86c6-04dfb0d15102"
      unitRef="usd">19853000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920166638920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APYX MEDICAL CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2644611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5115 Ulmerton Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Clearwater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APYX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,274,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000719135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920159503544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 43,539<span></span>
</td>
<td class="nump">$ 58,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net of allowance of $760 and $273</a></td>
<td class="nump">6,154<span></span>
</td>
<td class="nump">7,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">7,238<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of provision for obsolescence of $537 and $392</a></td>
<td class="nump">5,416<span></span>
</td>
<td class="nump">5,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,159<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">67,664<span></span>
</td>
<td class="nump">76,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $4,677 and $4,403</a></td>
<td class="nump">6,348<span></span>
</td>
<td class="nump">6,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">75,415<span></span>
</td>
<td class="nump">84,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">2,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">6,588<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party note payable</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,594<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,077<span></span>
</td>
<td class="nump">13,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,222,505 issued and outstanding as of September 30, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">60,014<span></span>
</td>
<td class="nump">56,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">4,148<span></span>
</td>
<td class="nump">14,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">64,196<span></span>
</td>
<td class="nump">71,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">64,338<span></span>
</td>
<td class="nump">71,259<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 75,415<span></span>
</td>
<td class="nump">$ 84,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920172739800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProvisionForObsolescenceInventory', window );">Inventories, provision for obsolescence</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">$ 4,677<span></span>
</td>
<td class="nump">$ 4,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,222,505<span></span>
</td>
<td class="nump">34,312,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,222,505<span></span>
</td>
<td class="nump">34,169,952<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForObsolescenceInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Obsolescence, Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForObsolescenceInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920159558616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 6,954<span></span>
</td>
<td class="nump">$ 7,575<span></span>
</td>
<td class="nump">$ 16,247<span></span>
</td>
<td class="nump">$ 19,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">2,281<span></span>
</td>
<td class="nump">6,444<span></span>
</td>
<td class="nump">6,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">5,294<span></span>
</td>
<td class="nump">9,803<span></span>
</td>
<td class="nump">13,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Other costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
<td class="nump">3,002<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">2,039<span></span>
</td>
<td class="nump">5,882<span></span>
</td>
<td class="nump">5,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related costs</a></td>
<td class="nump">3,508<span></span>
</td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">10,258<span></span>
</td>
<td class="nump">10,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">8,691<span></span>
</td>
<td class="nump">9,830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total other costs and expenses</a></td>
<td class="nump">9,096<span></span>
</td>
<td class="nump">10,050<span></span>
</td>
<td class="nump">27,833<span></span>
</td>
<td class="nump">28,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,371)<span></span>
</td>
<td class="num">(4,756)<span></span>
</td>
<td class="num">(18,030)<span></span>
</td>
<td class="num">(14,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (loss) income, net</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (loss) income, net</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(4,449)<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
<td class="num">(17,487)<span></span>
</td>
<td class="num">(14,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(715)<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="num">(7,112)<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(3,734)<span></span>
</td>
<td class="num">(4,370)<span></span>
</td>
<td class="num">(10,375)<span></span>
</td>
<td class="num">(14,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Apyx</a></td>
<td class="num">$ (3,728)<span></span>
</td>
<td class="num">$ (4,370)<span></span>
</td>
<td class="num">$ (10,369)<span></span>
</td>
<td class="num">$ (14,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per Share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920163037144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 87,177<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 52,920<span></span>
</td>
<td class="nump">$ 34,223<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(14,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised for cash</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">2,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsAmount', window );">Shares issued on net settlement of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">75,652<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">55,668<span></span>
</td>
<td class="nump">19,950<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="nump">79,440<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">55,086<span></span>
</td>
<td class="nump">24,320<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(4,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised for cash</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsAmount', window );">Shares issued on net settlement of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">75,652<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">55,668<span></span>
</td>
<td class="nump">19,950<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">71,259<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">56,708<span></span>
</td>
<td class="nump">14,517<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(10,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,369)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised for cash</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">3,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsAmount', window );">Shares issued on net settlement of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">64,338<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">60,014<span></span>
</td>
<td class="nump">4,148<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="nump">66,836<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">58,926<span></span>
</td>
<td class="nump">7,876<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(3,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,728)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised for cash</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">1,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsAmount', window );">Shares issued on net settlement of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 64,338<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 60,014<span></span>
</td>
<td class="nump">$ 4,148<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920166275576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (10,375)<span></span>
</td>
<td class="num">$ (14,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProvisionForInventoryObsolescence', window );">Provision for inventory obsolescence</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Net, non cash lease expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Unrealized gain on short term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision (benefit) for allowance for doubtful accounts</a></td>
<td class="nump">486<span></span>
</td>
<td class="num">(238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">1,389<span></span>
</td>
<td class="num">(2,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets', window );">Income tax receivables, prepaid expenses and other assets</a></td>
<td class="num">(7,793)<span></span>
</td>
<td class="num">(1,202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(717)<span></span>
</td>
<td class="num">(1,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(2,352)<span></span>
</td>
<td class="nump">1,611<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,049)<span></span>
</td>
<td class="num">(15,224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(1,076)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">80,726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(193)<span></span>
</td>
<td class="nump">60,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_RepaymentofFinanceLeaseLiabilities', window );">Repayment of finance lease liabilities</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Contributions from non-controlling interests</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(15,273)<span></span>
</td>
<td class="nump">45,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">58,812<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">43,539<span></span>
</td>
<td class="nump">62,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_LeaseAdoption', window );">Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseNonCash', window );">Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CapitalizationOfLeaseExecution', window );">Right-of-use assets capitalized and lease liabilities recognized upon execution of lease</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NonCashTransferOfOtherAssetsToFixedAssets', window );">Transfer of other assets to property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NonCashTransfersOfInventoryToFromFixedAssets', window );">Transfer of inventory from property and equipment</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseExecution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Execution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseExecution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CapitalizationOfLeaseNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalization Of Lease, Non Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CapitalizationOfLeaseNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Income Tax Receivables, Prepaid Expenses And Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_LeaseAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease Adoption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_LeaseAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NonCashTransferOfOtherAssetsToFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash, Transfer Of Other Assets To Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NonCashTransferOfOtherAssetsToFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NonCashTransfersOfInventoryToFromFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash, Transfers Of Inventory To (From) Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NonCashTransfersOfInventoryToFromFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForInventoryObsolescence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Inventory Obsolescence</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForInventoryObsolescence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_RepaymentofFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Finance Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_RepaymentofFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156849112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise indicates, the terms  &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Apyx,&#8221; and similar terms refer to Apyx Medical Corporation and its consolidated subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization recognized the novel strain of coronavirus ("COVID-19"), as a pandemic. This pandemic has severely restricted the level of economic activity around the world. In response, the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. The long-term impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict as the environment created by the pandemic is rapidly changing. In late February, we began to experience the effects of the pandemic which have been material and adverse on our business. However, starting late in the second quarter and continuing through the third quarter, we started to see positive indications in our business. We believe the severity of the impact of the COVID-19 pandemic on our business will continue to depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on our customers and suppliers, all of which are uncertain and cannot be predicted. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the procedures performed using our Helium Plasma Technology are elective, and as a result many of our customers have been affected by the actions taken by various governmental authorities requiring non-essential businesses to shut down temporarily.   As these shut-downs have begun to be reversed, we have started to see an increase in demand for elective cosmetic and plastic surgery procedures, resulting in higher than expected revenues in our Advanced Energy segment.  In international markets, a greater portion of these procedures are performed in a hospital, and it is less certain when elective procedures will fully return to normal.. While we experienced a significant decline in sales towards the end of our first fiscal quarter, we began to see an increase in sales towards the end of our second fiscal quarter, which continued through the third quarter, as local jurisdictions started to re-open. As cases have started to increase again, it is unknown whether these trends will continue. The full extent to which the COVID-19 pandemic may materially and adversely impact the Company's future financial position, liquidity, or results of operations remains uncertain. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019. These condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158917512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHANGE IN ACCOUNTING POLICY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesTextBlock', window );">Change in Accounting Policy</a></td>
<td class="text">CHANGE IN ACCOUNTING POLICY<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes, excludes error corrections information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156865928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements, we do not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU 2017-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#8217;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158942728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSAL OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSAL OF BUSINESS</a></td>
<td class="text">DISPOSAL OF BUSINESS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, we closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly-owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie&#174; brand and trademarks, to Symmetry for gross proceeds of $97&#160;million in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, we entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, whereby we will manufacture certain Core products and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in our Condensed Consolidated Statements of Operations as other income or (loss). Core activity for the three months ended September 30, 2020 amounted to&#160;$1.8&#160;million&#160;with cost of sales equivalents of&#160;$1.6&#160;million&#160;and related other expenses of&#160;$0.3&#160;million for net other (loss) of $0.1&#160;million. Core activity for the three months ended September 30, 2019 amounted to&#160;$2.5&#160;million&#160;with cost of sales equivalents of&#160;$2.2&#160;million&#160;and related other expenses of&#160;$0.1&#160;million for net other income of $0.2&#160;million. Core activity for the nine months ended September 30, 2020 amounted to&#160;$6.9&#160;million&#160;with cost of sales equivalents of&#160;$6.1&#160;million&#160;and related other expenses of&#160;$0.5&#160;million for net other income of $0.3&#160;million. Core activity for the nine months ended September 30, 2019 amounted to&#160;$6.9&#160;million&#160;with cost of sales equivalents of&#160;$6.6&#160;million&#160;and related other expenses of&#160;$0.2&#160;million for net other income of $0.1&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156852120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,416&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs, and earlier than expected completion of product registrations in some of our foreign markets.&#160; As a result, certain products were reduced to a lower carrying value, and some components were also written down as we determined to cease further production on these older models. The total impairment was approximately $400,000 and is included in cost of sales in the accompanying consolidated statement of operations for the nine months ended September 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158454904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"/><td style="width:62.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, <br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,396&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156845928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">NON-CONTROLLING INTEREST</a></td>
<td class="text">NON-CONTROLLING INTEREST<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2019, we executed a joint venture agreement with our Chinese supplier ("China JV"). The agreement requires the Company to make a capital contribution into the newly formed entity of approximately&#160;$360,000, of which approximately $154,000 was contributed during the three months ended September 30, 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our ownership interest in our 51% owned China JV were as follows:</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.072%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158295400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings per share (&#8220;basic EPS&#8221;) by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period adjusted for other units required to be included in basic EPS. Diluted earnings per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As we are in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted earnings per share.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.193%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,369)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,273)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156822968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our stock option plans, our board of directors may grant restricted stock and options to purchase common shares to our employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing a trinomial lattice model through 2018 and the Black Scholes model for grants in 2019 and 2020, both of which include a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $1,063,000 and $3,209,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2020, as compared with $543,000 and $2,594,000, respectively, for the three and nine months ended September 30, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,600)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allow stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2020 and 2019, respectively, we received 16,140 and 26,572 options as payment in the exercise of 10,610 and 34,928 options. For the nine months ended September 30, 2020 and 2019, respectively, we received  29,149 and 118,170 options as payment in the exercise of 32,637 and 220,879 options. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from our authorized and unissued shares. We calculated the grant date fair value of options granted in 2020 ("2020 Grants") utilizing a Black Scholes model with an expected life calculated via the simplified method.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.432%"><tr><td style="width:1.0%"/><td style="width:68.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.373%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.98</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158295400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#8217;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, we generated a significant amount of taxable income in 2018. Subsequent to this, we generated net losses in 2019 and through the first three quarters of 2020. For the net losses generated in 2019, we previously recorded a full valuation allowance on the deferred tax assets associated with our NOL carryforwards due to realization of the NOL not being probable under then existing tax law. The CARES Act makes these assets realizable, and as of the date of the CARES Act, we have recognized an income tax benefit of approximately $3.7 million associated with the release of the valuation allowance on our Federal NOL carryforward related to 2019. We also recognized income tax benefits of approximately $0.8&#160;million and $3.3&#160;million, related to our loss before income taxes for the three and <div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2020, respectively. There are approximately $2.4&#160;million of 2018 Federal income tax payments available to offset against any other 2020 losses that may be incurred. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax (benefit) expense was approximately  $(715,000) and $171,000 with an effective tax rate of 16.1% and (4.1)% for the three months ended September 30, 2020 and 2019, respectively. Our income tax (benefit) expense was approximately $(7,112,000) and $253,000 with an effective tax rate of 40.7% and (1.8)% for the nine months ended September 30, 2020 and 2019, respectively. For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our NOL carryforward from 2019. For the three months ended September 30, 2020, and the three and nine months ended September 30, 2019, the effective rate differs from the statutory rate primarily due to interest and penalties on our uncertain tax positions. </span></div>We have gross unrecognized tax benefits of approximately $1,313,000 at September 30, 2020. We recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in our condensed consolidated financial statements. As of September 30, 2020, we had approximately $300,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax benefit for the three and nine months ended September 30, 2020, respectively are approximately $43,000 and $125,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $1,616,000 of income tax benefits in the consolidated statement of operations. It is expected that all of the uncertain tax positions should be resolved by October 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156852120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and we are and may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within our complete control and may not be known for prolonged periods of time. We believe that such claims are adequately covered by insurance; however, in the case of one of our carriers, we are in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on our financial condition. However, in the event that damages exceed the aggregate coverage limits of our policies or if our insurance carriers disclaim coverage, we believe it is possible that costs associated with these claims could have a material adverse impact on our consolidated results of operations, financial position or cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2019, a complaint (the &#8220;Complaint&#8221;) was filed in the United States District Court for the Middle District of Florida, against the Company and Charles D. Goodwin, the Company&#8217;s President and Chief Executive Officer and a member of the Company&#8217;s Board of Directors, alleging certain violations of the Securities Exchange Act of 1934, as amended.&#160; On July 16, 2019, the Court appointed lead plaintiff for the putative class and approved the lead plaintiff&#8217;s selection of counsel. On September 3, 2019, lead plaintiff filed an amended complaint (the &#8220;Amended Complaint&#8221;) with the Court.&#160; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Amended Complaint seeks class action status on behalf of all persons and entities that acquired the Company&#8217;s securities between December 21, 2018 and April 1, 2019, and alleges violations by the Company and Goodwin of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended and Rule 10b-5 thereunder, primarily related to certain public statements concerning the Premarket Notification 510(k) submission made to the US Food and Drug Administration for a new indication for the Company&#8217;s J-Plasma&#174; technology for use in dermal resurfacing procedures. &#160;On October 3, 2019, defendants filed a motion to dismiss the Amended Complaint, and on March 11, 2020, the Court denied that motion.&#160; On July 10, 2020, the parties executed a settlement agreement, which was subject to Court approval. The Court preliminarily approved the settlement on July 21, 2020.&#160;The settlement agreement provides for the dismissal of the action with prejudice.&#160;On November 6, 2020, the Court issued its final order approving the settlement and dismissing the action and all claims contained in the Amended Complaint with prejudice. At September 30, 2020,&#160;we have settled and fully paid all obligations related to this matter.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, we had purchase commitments totaling approximately $1,800,000, substantially all of which is expected to be purchased within the next six months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">China Joint Venture</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreement in the China joint venture requires the Company to make a capital contribution into the newly formed entity of $357,000. As of the date of these consolidated financial statements, approximately $203,000 of our capital commitment remains to be funded.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158295400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is the Manager of Production and Human Resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is an engineer in the quality assurance department.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of the purchase of the Bulgaria manufacturing facility, Mr. Shilev was issued a note payable for $140,000 to be paid 5 years after the original purchase date, which came due in October 2020. The note was paid in full on October 20, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in our China joint venture is also a supplier of the Company. During the three and nine months ended September 30, 2020, we made purchases from this supplier of approximately $410,000 and $1,250,000, respectively. At September 30, 2020, we owed this supplier approximately $123,000.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158457992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC AND SEGMENT INFORMATION</a></td>
<td class="text">GEOGRAPHIC AND SEGMENT INFORMATION <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, we have not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are principally organized and managed as&#160;two&#160;operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 25.0% and 24.8% of total revenues for the three and nine months ended September 30, 2020, respectively, as compared with 26.7% and 29.5% of total revenues for the same prior year period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our sales are denominated in U.S. dollars. Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,002&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,853&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158293928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share based compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, we began granting stock option awards deeper within the organization. We do not have sufficient experience with grants to these employees and we have experienced challenges in developing reliable forfeiture estimates at the grant date. Accounting for revising the forfeiture estimates has been burdensome. Accounting Standards Codification 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prescribes two methods for accounting for forfeitures on stock option awards, either the estimation method utilized by the Company previously, or by accounting for forfeitures as they occur. On January 1, 2020, we made an accounting policy election change and began accounting for forfeitures on stock option awards using actual forfeitures. This accounting policy election change was made on a retrospective basis. However, the changes to the current and prior periods were determined to be immaterial and there have been no changes to previously reported results as a result of the change.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements, we do not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU 2017-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit&#8217;s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories are stated at the lower of cost or net realizable values. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156662264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,416&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,068&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156855128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.444%"><tr><td style="width:1.0%"/><td style="width:62.522%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, <br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,396&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158525016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NoncontrollingInterestTableTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text">Changes in our ownership interest in our 51% owned China JV were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.072%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158570648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings (loss) per share</a></td>
<td class="text">The following table provides the computation of basic and diluted earnings per share.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.193%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,369)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,273)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158500408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options and stock awards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234,600)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of option fair value assumptions</a></td>
<td class="text">We calculated the grant date fair value of options granted in 2020 ("2020 Grants") utilizing a Black Scholes model with an expected life calculated via the simplified method.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:56.432%"><tr><td style="width:1.0%"/><td style="width:68.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.267%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.373%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.98</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920156888264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of reporting information by segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,815&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of revenue by geographic area</a></td>
<td class="text">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,002&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,575&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,853&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920166283848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSAL OF BUSINESS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from the disposition of Core business</a></td>
<td class="nump">$ 97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Net other income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member', window );">Symmetry Surgical Inc. | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_AssetPurchaseAgreementTerm', window );">Asset purchase agreement, term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Net other income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AssetPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AssetPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920162978120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,487<span></span>
</td>
<td class="nump">$ 2,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross inventories</a></td>
<td class="nump">5,953<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: provision for obsolescence</a></td>
<td class="num">(537)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 5,416<span></span>
</td>
<td class="nump">$ 5,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920158241240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Impairment of inventory</a></td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920163043000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued commissions</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Accrued product warranties</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Accrued insurance</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_UncertainTaxPositionsLiability', window );">Uncertain tax positions</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accrued expenses and current liabilities</a></td>
<td class="nump">963<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 6,588<span></span>
</td>
<td class="nump">$ 9,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accrued Expenses And Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_UncertainTaxPositionsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Positions Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_UncertainTaxPositionsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68070138&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920166268472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NoncontrollingInterestRequiredCapitalContribution', window );">Required capital contribution</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestRequiredCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Required Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestRequiredCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920162858376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST - Rollforward of Joint Venture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=apyx_ChineseSupplierMember', window );">Chinese Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apyx_ChineseSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apyx_ChineseSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920159563656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Apyx</a></td>
<td class="num">$ (3,728)<span></span>
</td>
<td class="num">$ (4,370)<span></span>
</td>
<td class="num">$ (10,369)<span></span>
</td>
<td class="num">$ (14,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">34,216<span></span>
</td>
<td class="nump">34,078<span></span>
</td>
<td class="nump">34,193<span></span>
</td>
<td class="nump">34,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments (in shares)</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments (in shares)</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920166232040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">$ 1,063<span></span>
</td>
<td class="nump">$ 3,209<span></span>
</td>
<td class="nump">$ 543<span></span>
</td>
<td class="nump">$ 2,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived', window );">Stock swaps equity instruments received (in shares)</a></td>
<td class="nump">16,140<span></span>
</td>
<td class="nump">26,572<span></span>
</td>
<td class="nump">29,149<span></span>
</td>
<td class="nump">118,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps (in shares)</a></td>
<td class="nump">10,610<span></span>
</td>
<td class="nump">34,928<span></span>
</td>
<td class="nump">32,637<span></span>
</td>
<td class="nump">220,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920166244712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Summary of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares) | shares</a></td>
<td class="nump">3,966,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,376,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(81,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(234,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares) | shares</a></td>
<td class="nump">5,028,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">7.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">3.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in dollars per shares) | $ / shares</a></td>
<td class="nump">7.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920171196584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 7.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 4.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 8.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920159812760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards', window );">Release of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes', window );">Income tax benefits, related to current period net loss before income taxes</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses', window );">Federal income tax payments available to offset current period losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (715)<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="num">$ (7,112)<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate, percent</a></td>
<td class="nump">16.10%<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
<td class="nump">40.70%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties included in income tax expense</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Uncertain tax positions that would impact effective tax rate</a></td>
<td class="nump">$ 1,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920154692024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NoncontrollingInterestRequiredCapitalContribution', window );">Required capital contribution</a></td>
<td class="nump">357<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_PaymentsToAcquireInterestInJointVentureRemaining', window );">Remaining payments to acquire interest in joint venture</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestRequiredCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Required Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestRequiredCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_PaymentsToAcquireInterestInJointVentureRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Interest In Joint Venture, Remaining</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_PaymentsToAcquireInterestInJointVentureRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920162866184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director | Bulgaria Manufacturing Plant Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_TermOfPaymentDueNotesPayableRelatedParties', window );">Term of payment due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CoVenturerMember', window );">Co-venturer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases from related party</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_TermOfPaymentDueNotesPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Payment Due, Notes Payable, Related Parties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_TermOfPaymentDueNotesPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=apyx_BulgariaManufacturingPlantPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=apyx_BulgariaManufacturingPlantPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CoVenturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CoVenturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920155326424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_TotalRevenuePercent', window );">International sales, percent of total revenue</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">26.70%<span></span>
</td>
<td class="nump">24.80%<span></span>
</td>
<td class="nump">29.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_TotalRevenuePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Revenue, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_TotalRevenuePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920171269272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 6,954<span></span>
</td>
<td class="nump">$ 7,575<span></span>
</td>
<td class="nump">$ 16,247<span></span>
</td>
<td class="nump">$ 19,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(4,371)<span></span>
</td>
<td class="num">(4,756)<span></span>
</td>
<td class="num">(18,030)<span></span>
</td>
<td class="num">(14,908)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(715)<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="num">(7,112)<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Advanced Energy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">5,479<span></span>
</td>
<td class="nump">6,094<span></span>
</td>
<td class="nump">12,332<span></span>
</td>
<td class="nump">15,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(1,095)<span></span>
</td>
<td class="num">(1,357)<span></span>
</td>
<td class="num">(8,371)<span></span>
</td>
<td class="num">(5,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | OEM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">3,915<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate &amp; Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(3,832)<span></span>
</td>
<td class="num">(3,667)<span></span>
</td>
<td class="num">(11,046)<span></span>
</td>
<td class="num">(10,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">$ (715)<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="num">$ (7,112)<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139920162956520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 6,954<span></span>
</td>
<td class="nump">$ 7,575<span></span>
</td>
<td class="nump">$ 16,247<span></span>
</td>
<td class="nump">$ 19,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">5,214<span></span>
</td>
<td class="nump">5,552<span></span>
</td>
<td class="nump">12,225<span></span>
</td>
<td class="nump">14,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 1,740<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
<td class="nump">$ 4,022<span></span>
</td>
<td class="nump">$ 5,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ3X#  #_"   &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)667V_B.!#
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M RNZCG8)OV-/[VA]0WX9;\F2HOH+GFI;KP>6NX*SM'86"M(XVW]&7^M$'#E
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M7'%6<&4$X/\+*?7^Q2QPN&N^^!]02P,$%     @ 07AI41 O(RI*"0  R14
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MCA&IOKN]?O>]TE6@GBO%-^$<U?2%7=+:0,]T$'D]5&^=>J=#40O39T;ZZ /
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M;Z?F<.<&JMDOTSTK_=C:V%U&V]GM57[1W6 _/^_^!WQ4?JG!R? "H?G!T71
MOKM;NT%T3;K/YB[B=DRO<M"PEP^POG N;@:28/L'Y_P?4$L#!!0    ( $%X
M:5&C:N/I$P,  +\&   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;+55
M;8_B-A#^*Z.TJEH);5X("6P!"5BJH[K;0[#;5JKZP203L"ZQ4]M9=O]]QT[(
M<=+N2O>A7VR/9YYGWN+)]"S5%WU"-/!<E4+/O),Q]:WOZ^R$%=,WLD9!FD*J
MBAD2U='7M4*6.U!5^E$0)'[%N/#F4W>W5?.I;$S)!6X5Z*:JF'I98BG/,R_T
M+A<[?CP9>^'/IS4[XA[-8[U5)/D]2\XK%)I+ 0J+F;<(;Y>QM7<&?W \ZZLS
MV$P.4GZQPB:?>8$-"$O,C&5@M#WA"LO2$E$8_W:<7N_2 J_/%_;?7.Z4RX%I
M7,GR3YZ;T\P;>Y!CP9K2[.3Y W;YC"Q?)DOM5CBWMG'J0=9H(ZL.3!%47+0[
M>^[J< 48!V\ H@X0N;A;1R[*.V;8?*KD&92U)C9[<*DZ- 7'A6W*WBC2<L*9
M^6*UVCVN[V#]UW9]OU_O87%_!Y\?/JQWL'K<[=;W#_!QLUAN/FX>-NO]U#?D
MTR+]K.-?MOS1&_P3^"2%.6E8BQSS;_$^Q=H''%T"7D;O$NZQOH%A,( HB()W
M^(9] 8:.;_@&WY:]L$.)&IC(89%EJF&EAK\7!VT4?3+_O.,B[EW$SD7\O]7X
M77[[;F]US3*<>?0P-:HG]+[3:9LYYH#/]-QU5PYI3JCH*U0*A8&2LP,ON>&D
MS20]2VT(( L@*RAD2>^;B^,M_,P%7<E&$X7^!:AA!JL#$=FNW6'6">&@=UJS
M%T5X^!'B24IK,HE[W4&*QL;STP_C*(Q^A7 P#))>F\FJXMI." U)%, X3;^R
M*IDWF8$S4XH)%W:<AA"/HMZ$"]V0+D-(AA%1AVEP#2_04;,2"B1T&L?6_7@(
MOTM.!;$ETOB$B@PN*5R*]$*603SJUD=RH0RSA6'/4$O-C0LY'"1A0FL\">&S
M*S9[K0^O=6"2#&&2CN%!&G+_*NSM]E&)!Z/QF/;)8#A)X+6/W+\:*A6JHQN=
MMO.-,.U\Z6_[Z;QHA])7\W:T?V+J2*6&$@N"!C?IR /5CLM6,+)V(^H@#0T\
M=SS1'P:5-2!](:6Y"-9!_\^:_P=02P,$%     @ 07AI47NRD4%S P  4 <
M !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULK57?;]LV$/Y7#EH[)$!F
MR;*3IIEMP/:R+4/K!$G:/0Q[H*6SQ84B5?(4V?]]CY2M.D/CISY8)GGW??>3
MQU%C[),K$ DVI=)N'!5$U54<NZS 4KB>J5"S9&5L*8BW=AV[RJ+( ZA4<9HD
M%W$II(XFHW!V9R<C4Y.2&N\LN+HLA=W.4)EF'/6C_<&]7!?D#^+)J!)K?$#Z
M5-U9WL4=2RY+U$X:#197XVC:OYH-O7Y0^"RQ<0=K\)$LC7GRFYM\'"7>(528
MD6<0_/>,<U3*$[$;7W:<46?2 P_7>_;?0^P<RU(XG!OUM\RI&$>7$>2X$K6B
M>]/\B;MXSCU?9I0+7VA:W<%Y!%GMR)0[,'M02MW^B\TN#P> R^050+H#I,'O
MUE#P\C=!8C*RI@'KM9G-+T*H <W.2>V+\D"6I9)Q-%G<+GZ9WRX>[V\_?+A9
M_ $WB\?K^^N'QU%,S.YUXFS'-&N9TE>8WL-'HZEP<*USS%_B8_:J<RW=NS9+
MCQ(^8-6#07(&:9(F1_@&7:B#P#=X+52C,_;0&L62-=QH0HN.X)_ITI'E]OCW
MB)%A9V08C Q_0#Z/,OG;>.4JD>$XXNOFT#YC]"H]1P-*$'*N^N_/H$' #68U
M80X"_C-2$SRCIMHBB+5%Y&M%W&E4@*DMS NV[9!O9E4IB19.(G\DX*_/T6D/
M'HM#E,4OM62'@/AX;LI*Z"V0X:9\8C7(1"5)* BIELLZW#VV;X*^QD9MP<\2
M]HS9)&W!K$!4E34;R9<,6?QF<)&<)0E7GD5-(;/B_PK]\Z%7@$:X;X:8,:^M
M+ZVW1 4[#&7;DNA;$KBA",LEQ[?OJAY,G3?B ;E/7[OF5#!KSJ.'4;QR1DDO
MSF'%6=&9Y/@<\8%/B#L+\)=)+M@Q;8C!)>MDC*S8LTQ6C.2!:H5/B^MQYH5>
M<RZE#H4PC4;K"EGYC+7=N9.<]]\&:0[[RG"1?34=9U/Q:'57<,)-0(6IG="Y
M.^6R^0P<7DI8<)U?GLQP+;7V23NTV-EX S__=)GVTU\/5O.#RCK@4H3?@A\0
M99P#0:U4+!7ZOIA6VPV<7)R&'QL]8JL_O-Q]OW<3XX,I5Z)=AUGNZU]K:@=>
M=]H]%]-V2GY3;]^:C\)RV X4KAB:]-[Q=+;M_&XW9*HP,Y>&> *'9<%/'EJO
MP/*5,;3?> /=(SKY"E!+ P04    " !!>&E10+RU!]@#  "4"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6RM5M^3XC8,_E<TZ4T'9C@2$G;Y<< ,
MW&Y[-]/C&&B[#YT^F$0A[B9VSG:6W?^^LA-R['7AJ2]$MJ5/^F198G:4ZE%G
MB :>BUSHN9<94TY]7\<9%DSW98F"3E*I"F9HJ0Z^+A6RQ!D5N1\&P:U?,"Z\
MQ<SM;=1B)BN3<X$;!;HJ"J9>5IC+X]P;>*>-+3]DQF[XBUG)#KA#\T>Y4;3R
M6Y2$%R@TEP(4IG-O.9BNAE;?*?S)\:C/9+!,]E(^VL7G9.X%-B#,,386@='G
M"3]BGEL@"N-;@^FU+JWAN7Q"_\5Q)RY[IO&CS!]X8K*Y-_8@P915N=G*XR=L
M^-Q8O%CFVOW"L=:- @_B2AM9-,840<%%_67/31[.#,:7#,+&('1QUXY<E'?,
ML,5,R2,HJTUH5G!4G34%QX6]E)U1=,K)SBSNE]OUY_6O.^C\]G6WZ\+F?@N[
M3\OM_<PW!&^5_+B!6M50X06H"7R1PF0:[D6"R6M[G\)J8PM/L:W"JX [+/L0
M!3T(@S"X@A>U7".'%UWBRI3@XJ!A@PIV&5,(?RWWVB@JC;^OX ];_*'#'_X?
MN;P*99_B5)<LQKE';TVC>D+O,CX\(,2R*"N#MD1Y#'BB6A)5[:AV?OYI'(;!
MAUKA?K-SZ\&'+NQ?(.%//"$#,!F"H%[ !0$B2 6YU-JJV).C*W),@#VAHC<+
MHBKVY$&FUG]!K\SYTD#/7QLF'"1U#F>LL)3*V!T*BDL"2?ZA B<TJR%)14$E
MN-&D^:WBB@Z,A#W:6/**2HH$:*/OPQW/*VM]A6O2J)RS/5 7T(!I2GW!.F!Y
M#DZ/]J&4!H7A+'^#2!^6FC( U@%%PER>7'9*J;GK,9:(Q:L)TH&].T$1].KM
M*^@.EM'I^U,P??B=LI;*G!JGNQJVSRE")>FJR-:FM+YTYGS3'=3)(3Q(+N;&
MHBK$5V\5UE1^KW<ZQ-!DLM*$IGN SS&6YBS#"36;KGN8]#.8G$GKJJ#:,%)-
M87U*$#-&\7U5,Z"<+\N79W@'G:@W"L==*PU[T2APTB#H1;>36ASVPE'4A3L4
MDGI?#?KP8PV^D<OW;Z0B(K#!K?T$H[']#":16T43:#M#QX;;_<YS"JO_ %%@
M07\PZ#9"U A1T C#L O+\XND:J$F0VD15-N4R;J84R6+%K,N(_)Z_HRFL$4R
MY+'5H$D0/\+P!B9!\_NUM/>NX:87A&,@(K?!*_FMCN:?30JZIH.;AYJ\5L+4
M0Z/=;4?NLIXTW]7K>?V%J0,1@QQ3,@WZHQL/5#T#ZX61I9L[>VEHBCDQH[\-
MJ*P"G:>2GD.SL [:/R*+?P%02P,$%     @ 07AI44;2OQK;!0  ; T  !D
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M.Z>W#<(CIATDLC1MT^!H.-@S*_*&T\%S9EG*_ZV^<.IW^==5G9LNPFQ(Z&[
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M/)UEPVU%/Q[0\@+Z7AKCUP_L8/-SY/!?4$L#!!0    ( $%X:5%>72?<10D
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M0BF'BFKFB:WJ218%136EW@EZ_W>XJI&ZH;,:=-S@_('Z6ICP"\8WB$9<99U
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M7[WO$_%.AA+"*4Q6\%I)8*$\5: _E,NAQ TH;NA[A-.XJ'B6>O5%>(4]2*.
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M/E!7J[KOZXV1A>NUC334N6Z9TJA$90/(OY72[#>6H!V^D[]02P,$%     @
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M-(7,?#BR!.0&?]G7QY>^/QG#!05][$=C>.3ZY2)7B*"L(Z&??*7+R!_!5ZJ
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M WR_YEP=!_IF5W]<C/\!4$L#!!0    ( $%X:5%2S^UDN0(  '8'   9
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;(V5VV[B,!"&7\6*>M%*;1-R(E2
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MM=M:ME3CO>0_66:*2? U@ QS6G.SELUW[.JY=GRIY-H_H6ESQ[<!I+4VLNS
MUD')1/NF;UT?C@#1\ 0@Z@"1]]T*>9=S:F@2*]F <MF6S2U\J1YMS3'A/LK&
M*'O*+,XD#\N7Q?+IQ_IAL8'/L*1*4=<FN)RCH8SK*[@ )N"ID+6F(M,Q,5;5
M84G:*<Q:A>B$PBT\2F$*#0N18?8OGEBWO>7H8'D6G27<8#6 4?@)HC *GS=S
MN+RX.D,[ZCLQ\K2C4YT0>Q1&JG>8,YURJ6N%\&NZU4;9T?E]1F'<*XR]POB4
M0EE1INQ$&Y"Y[6JG][^6MD0WGLC=JWTR#L.8[(_5R=%7+U'M_&QK2&4M3#L
M_6Y_?:;MU/Q-;^_>(U4[)C1PS"TT''RY#D"U\]P&1E9^AK;2V(GTR\+^ E"Y
M!'N>2VD.@1/H?RK)!U!+ P04    " !!>&E10\E!;%X#  !T"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6R-EMN.VC 0AE_%BGK12NWF2 X5(+%
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M]RUD0446:++@$AE<ARD3 F$I>;+>2[Q."9(,S?)?;Z:=4]#U-9VZ"%^GM_[
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MX1C[7"H@\;?%4QS'4DBD\59I:G5(26R.]^J?5>VBEA5B>$KB'U' PZ'6UT"
MURB/^1,ION"J'D?J^21FZA<4);;G:<#/&2=)1189)%%:_J/WRH<&0>AT$V!%
M@&V"?81@503KW AV1;#/C>!4!%6Z7M:NC)LACD8#2@I )5JHR8%R7[&%7U$J
M]\F24_$T$CP^6CX_3K]>3\;+^0Q,'^\7\X?E^/GN\0%<@P=$*9*O$5S.,$=1
MS*[$ZLMR!BXOKL %B%+P')*<H31@ YV+9*2D[E>!)V5@>"2P!>Y)RD,&YFF
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M<R]S:&5E=#,U+GAM;*66;6_:,!#'OXH5[44KM>0YA J0@'9;-;6@TJVO37*
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MFQO$#1-SR:.T >9]+,R'6$ZL0/6W8? +4$L#!!0    ( $%X:5&//33_J@(
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M" J(A5+ \K&#"12%$I)A_&PUC<ZE H_7!_4[G;O,98,Y3&CQ+4]$-C2N#93
M%M>%6-'] [3YZ !C6G#]B_;-V<LK \4U%[1L81E!F9/FB5_:.AP!4J<?<%K
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MP  W!OC0"%9C8!T:P6X,*NI&S;UJN"!BT7R6TV>0EVCNK;RH6K^RYNT59^5
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M&MV^+LIUII Y]/MRTTNS<-X>RC+6;6F]DL7F^('L^''OPT]02P,$%     @
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MHP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M
M(:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"
M0M8$A:S)?Y+U7>O57_]+:->X5F5S]&?=#YOY)U!+ 0(4 Q0    ( $!X:5$'
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @ 0'AI4=-9R _N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 0'AI49E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " ! >&E1B#R;<"8%  ! %0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 0'AI46%_3_Q:!@  <AD
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M965T-BYX;6Q02P$"% ,4    " !!>&E1$"\C*DH)  #)%0  &
M    @($&+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M07AI4:Q&^(V] P  7 @  !@              ("!AC4  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $%X:5%/[>O$1 8  *P.   8
M          " @7DY  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " !!>&E1 BD3'($$  !N"P  &0              @('S/P  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $%X:5'<\;9Q7P0  .P(
M   9              " @:M$  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ 07AI4:-JX^D3 P  OP8  !D              ("!04D
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !!>&E1>[*1
M07,#  !0!P  &0              @(&+3   >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( $%X:5% O+4'V ,  )0(   9
M  " @350  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M07AI44;2OQK;!0  ; T  !D              ("!1%0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " !!>&E1Z!M%3RL%  ":#   &0
M            @(%66@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( $%X:5%>72?<10D  +D5   9              " @;A?  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 07AI48\+F+S: P
M3P@  !D              ("!-&D  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " !!>&E1\UOT(\L&  "$$0  &0              @(%%
M;0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $%X:5&N
M1MH^;P@  +@4   9              " @4=T  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ 07AI49@K2J6J @  <04  !D
M     ("![7P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $%X:5'8:D>JA@0  &4,   9              "
M@1Z-  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 07AI
M41XPDX;! P  : P  !D              ("!VY$  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " !!>&E14L_M9+D"  !V!P  &0
M        @('3E0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( $%X:5%;K?,@'0(  & $   9              " @<.8  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 07AI44/)06Q> P  = H
M !D              ("!%YL  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " !!>&E1B(8D L0"   0"   &0              @(&LG@
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $%X:5&Q+.>.
MKP,  *4-   9              " @:>A  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ 07AI4:!].*7% P  - T  !D
M ("!C:4  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !!
M>&E1%H,*U X#  #1"   &0              @(&)J0  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $%X:5'-HQ.%* ,  %L*   9
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M970S.2YX;6Q02P$"% ,4    " !!>&E1CSTT_ZH"  ![!P  &0
M    @('#O0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M $%X:5$^PBQ;M@4  %D=   9              " @:3   !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ 07AI4;CIBI4& P  W D  !D
M             ("!D<8  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " !!>&E1THV.8$\"  !<#   #0              @ '.R0  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $%X:5&7BKL<P    !,"   +
M      "  4C,  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $%X:5$+$J#7\P,
M & <   /              "  3'-  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !!>&E1OLLS09D!  !U&0  &@              @ %1T0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !!>&E1(]5N#:@!  "X
M&0  $P              @ $BTP  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    ,@ R )4-  #[U      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>96</ContextCount>
  <ElementCount>269</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>21</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - CHANGE IN ACCOUNTING POLICY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY</Role>
      <ShortName>CHANGE IN ACCOUNTING POLICY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105104 - Disclosure - DISPOSAL OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSALOFBUSINESS</Role>
      <ShortName>DISPOSAL OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107105 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/NONCONTROLLINGINTEREST</Role>
      <ShortName>NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2118108 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2121109 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126110 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128111 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2130112 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2132113 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - NON-CONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables</Role>
      <ShortName>NON-CONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/NONCONTROLLINGINTEREST</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - DISPOSAL OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails</Role>
      <ShortName>DISPOSAL OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/DISPOSALOFBUSINESS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - INVENTORIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESNarrativeDetails</Role>
      <ShortName>INVENTORIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - NON-CONTROLLING INTEREST - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails</Role>
      <ShortName>NON-CONTROLLING INTEREST - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2417406 - Disclosure - NON-CONTROLLING INTEREST - Rollforward of Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails</Role>
      <ShortName>NON-CONTROLLING INTEREST - Rollforward of Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2420407 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2423408 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424409 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2425410 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2429412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2431413 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434414 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2435415 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="apyx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2436416 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="apyx-20200930.htm">apyx-20200930.htm</File>
    <File>a2020q310-qexhibit311.htm</File>
    <File>a2020q310-qexhibit312.htm</File>
    <File>a2020q310-qexhibit321.htm</File>
    <File>a2020q310-qexhibit322.htm</File>
    <File>apyx-20200930.xsd</File>
    <File>apyx-20200930_cal.xml</File>
    <File>apyx-20200930_def.xml</File>
    <File>apyx-20200930_lab.xml</File>
    <File>apyx-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>apyx-20200930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "apyx-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 96,
   "dts": {
    "calculationLink": {
     "local": [
      "apyx-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apyx-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "apyx-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "apyx-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apyx-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "apyx-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 299,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 26,
   "keyStandard": 243,
   "memberCustom": 6,
   "memberStandard": 15,
   "nsprefix": "apyx",
   "nsuri": "http://apyxmedical.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://apyxmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105104 - Disclosure - DISPOSAL OF BUSINESS",
     "role": "http://apyxmedical.com/role/DISPOSALOFBUSINESS",
     "shortName": "DISPOSAL OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107105 - Disclosure - INVENTORIES",
     "role": "http://apyxmedical.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - NON-CONTROLLING INTEREST",
     "role": "http://apyxmedical.com/role/NONCONTROLLINGINTEREST",
     "shortName": "NON-CONTROLLING INTEREST",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118108 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121109 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126110 - Disclosure - INCOME TAXES",
     "role": "http://apyxmedical.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128111 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130112 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132113 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - BASIS OF PRESENTATION (Policies)",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies",
     "shortName": "BASIS OF PRESENTATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - INVENTORIES (Tables)",
     "role": "http://apyxmedical.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - NON-CONTROLLING INTEREST (Tables)",
     "role": "http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables",
     "shortName": "NON-CONTROLLING INTEREST (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i0448759fc2be4fa382f8f4658e300986_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - DISPOSAL OF BUSINESS (Details)",
     "role": "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
     "shortName": "DISPOSAL OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i0448759fc2be4fa382f8f4658e300986_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - INVENTORIES (Details)",
     "role": "http://apyxmedical.com/role/INVENTORIESDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - INVENTORIES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/INVENTORIESNarrativeDetails",
     "shortName": "INVENTORIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413404 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416405 - Disclosure - NON-CONTROLLING INTEREST - Narrative (Details)",
     "role": "http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails",
     "shortName": "NON-CONTROLLING INTEREST - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i73c621036a99473780d3074110069a13_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417406 - Disclosure - NON-CONTROLLING INTEREST - Rollforward of Joint Venture (Details)",
     "role": "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails",
     "shortName": "NON-CONTROLLING INTEREST - Rollforward of Joint Venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i85c0390a429a4234aa1f855c20366a70_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420407 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423408 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i73c621036a99473780d3074110069a13_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424409 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Summary of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i73c621036a99473780d3074110069a13_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425410 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3aeb98b19ed344b38761f3312c3cef29_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "iabf0bad69e934fb18dc921efbd473e9f_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431413 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i6aad088e173447ad8a7e163f390e1c17_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "apyx:TermOfPaymentDueNotesPayableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434414 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435415 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i5a25b388cfd6436ebce3fa07885d8980_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ice82f677edf044c0951a37cc6e0bd98d_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436416 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i3ba6db9cd9234659951d70f1a84a0210_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ic0abc8cd3d9e4b8aacdbb3de72f2dd69_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "ic0abc8cd3d9e4b8aacdbb3de72f2dd69_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountingChangesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - CHANGE IN ACCOUNTING POLICY",
     "role": "http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY",
     "shortName": "CHANGE IN ACCOUNTING POLICY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountingChangesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20200930.htm",
      "contextRef": "i852c8d150ac045f98ecd1ec558b3d14e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 21,
   "tag": {
    "apyx_AdvancedEnergyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Advanced Energy [Member]",
        "label": "Advanced Energy [Member]",
        "terseLabel": "Advanced Energy"
       }
      }
     },
     "localname": "AdvancedEnergyMember",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AssetPurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Purchase Agreement, Term",
        "label": "Asset Purchase Agreement, Term",
        "terseLabel": "Asset purchase agreement, term"
       }
      }
     },
     "localname": "AssetPurchaseAgreementTerm",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_BulgariaManufacturingPlantPurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bulgaria Manufacturing Plant Purchase [Member]",
        "label": "Bulgaria Manufacturing Plant Purchase [Member]",
        "terseLabel": "Bulgaria Manufacturing Plant Purchase"
       }
      }
     },
     "localname": "BulgariaManufacturingPlantPurchaseMember",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses",
        "label": "CARES Act, Federal Income Tax Payments Available To Offset Current Period Losses",
        "terseLabel": "Federal income tax payments available to offset current period losses"
       }
      }
     },
     "localname": "CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes",
        "label": "CARES Act, Income Tax Expense (Benefit), Related To Current Period Net Income (Loss) Before Income Taxes",
        "negatedTerseLabel": "Income tax benefits, related to current period net loss before income taxes"
       }
      }
     },
     "localname": "CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards",
        "label": "CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards",
        "negatedTerseLabel": "Release of valuation allowance"
       }
      }
     },
     "localname": "CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CapitalizationOfLeaseExecution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capitalization Of Lease, Execution",
        "label": "Capitalization Of Lease, Execution",
        "terseLabel": "Right-of-use assets capitalized and lease liabilities recognized upon execution of lease"
       }
      }
     },
     "localname": "CapitalizationOfLeaseExecution",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_CapitalizationOfLeaseNonCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capitalization Of Lease, Non Cash",
        "label": "Capitalization Of Lease, Non Cash",
        "terseLabel": "Right-of-use assets capitalized and lease liabilities recognized upon lease remeasurement"
       }
      }
     },
     "localname": "CapitalizationOfLeaseNonCash",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ChineseSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chinese Supplier",
        "label": "Chinese Supplier [Member]",
        "terseLabel": "Chinese Supplier"
       }
      }
     },
     "localname": "ChineseSupplierMember",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "label": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "terseLabel": "Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement"
       }
      }
     },
     "localname": "ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Income Tax Receivables, Prepaid Expenses And Other Assets",
        "label": "Increase (Decrease) In Income Tax Receivables, Prepaid Expenses And Other Assets",
        "negatedTerseLabel": "Income tax receivables, prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_JointAndSeveralPayrollLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Joint And Several Payroll Liability",
        "label": "Joint And Several Payroll Liability",
        "terseLabel": "Joint and several payroll liability"
       }
      }
     },
     "localname": "JointAndSeveralPayrollLiability",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_LeaseAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Adoption",
        "label": "Lease Adoption",
        "terseLabel": "Right-of-use assets capitalized and lease liabilities recognized upon adoption of Topic 842"
       }
      }
     },
     "localname": "LeaseAdoption",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NonCashTransferOfOtherAssetsToFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Cash, Transfer Of Other Assets To Fixed Assets",
        "label": "Non Cash, Transfer Of Other Assets To Fixed Assets",
        "terseLabel": "Transfer of other assets to property and equipment"
       }
      }
     },
     "localname": "NonCashTransferOfOtherAssetsToFixedAssets",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NonCashTransfersOfInventoryToFromFixedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Cash, Transfers Of Inventory To (From) Fixed Assets",
        "label": "Non Cash, Transfers Of Inventory To (From) Fixed Assets",
        "terseLabel": "Transfer of inventory from property and equipment"
       }
      }
     },
     "localname": "NonCashTransfersOfInventoryToFromFixedAssets",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestRequiredCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling Interest, Required Capital Contribution",
        "label": "Noncontrolling Interest, Required Capital Contribution",
        "terseLabel": "Required capital contribution"
       }
      }
     },
     "localname": "NoncontrollingInterestRequiredCapitalContribution",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestTableTextBlock",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_OEMMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "OEM [Member]",
        "terseLabel": "OEM"
       }
      }
     },
     "localname": "OEMMember",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Accrued Expenses And Liabilities, Current",
        "label": "Other Accrued Expenses And Liabilities, Current",
        "terseLabel": "Other accrued expenses and current liabilities"
       }
      }
     },
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_PaymentsToAcquireInterestInJointVentureRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments To Acquire Interest In Joint Venture, Remaining",
        "label": "Payments To Acquire Interest In Joint Venture, Remaining",
        "terseLabel": "Remaining payments to acquire interest in joint venture"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInJointVentureRemaining",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "label": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForInventoryObsolescence": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provision For Inventory Obsolescence",
        "label": "Provision For Inventory Obsolescence",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "ProvisionForInventoryObsolescence",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForObsolescenceInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provision For Obsolescence, Inventory",
        "label": "Provision For Obsolescence, Inventory",
        "terseLabel": "Inventories, provision for obsolescence"
       }
      }
     },
     "localname": "ProvisionForObsolescenceInventory",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_RepaymentofFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayment of Finance Lease Liabilities",
        "label": "Repayment of Finance Lease Liabilities",
        "negatedTerseLabel": "Repayment of finance lease liabilities"
       }
      }
     },
     "localname": "RepaymentofFinanceLeaseLiabilities",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "terseLabel": "Stock swaps equity instruments received (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockSwapToAcquireOptionsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock swap to acquire options amount.",
        "label": "Stock swap to acquire options, Amount",
        "terseLabel": "Shares issued on net settlement of stock options"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsAmount",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_StockSwapToAcquireOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock swap to acquire options shares.",
        "label": "Stock swap to acquire options, Shares",
        "terseLabel": "Shares issued on net settlement of stock options (in shares)"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsShares",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_SymmetrySurgicalInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Symmetry Surgical Inc. [Member]",
        "label": "Symmetry Surgical Inc. [Member]",
        "terseLabel": "Symmetry Surgical Inc."
       }
      }
     },
     "localname": "SymmetrySurgicalInc.Member",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TermOfPaymentDueNotesPayableRelatedParties": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Of Payment Due, Notes Payable, Related Parties",
        "label": "Term Of Payment Due, Notes Payable, Related Parties",
        "terseLabel": "Term of payment due"
       }
      }
     },
     "localname": "TermOfPaymentDueNotesPayableRelatedParties",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_TotalRevenuePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Revenue, Percent",
        "label": "Total Revenue, Percent",
        "terseLabel": "International sales, percent of total revenue"
       }
      }
     },
     "localname": "TotalRevenuePercent",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_UncertainTaxPositionsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Uncertain Tax Positions Liability",
        "label": "Uncertain Tax Positions Liability",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositionsLiability",
     "nsuri": "http://apyxmedical.com/20200930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r128",
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r148",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r128",
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r148",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r205",
      "r206",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r333",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r205",
      "r206",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r333",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r333",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r203",
      "r205",
      "r206",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r333",
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r156",
      "r157",
      "r200",
      "r202",
      "r334",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r200",
      "r202",
      "r334",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]",
        "terseLabel": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting accounting changes, excludes error corrections information.",
        "label": "Accounting Changes [Text Block]",
        "terseLabel": "Change in Accounting Policy"
       }
      }
     },
     "localname": "AccountingChangesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHANGEINACCOUNTINGPOLICY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r17",
      "r28",
      "r162",
      "r163"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, net of allowance of $760 and $273"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued insurance"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "verboseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "verboseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r20",
      "r21",
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r29",
      "r229"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r207",
      "r208",
      "r232",
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r208",
      "r224",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r164",
      "r170",
      "r171",
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive instruments (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r136",
      "r143",
      "r150",
      "r168",
      "r258",
      "r265",
      "r271",
      "r313",
      "r322"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r56",
      "r89",
      "r168",
      "r258",
      "r265",
      "r271"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r15",
      "r39",
      "r84"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r84",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r272"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r88",
      "r89",
      "r107",
      "r108",
      "r109",
      "r111",
      "r113",
      "r120",
      "r121",
      "r122",
      "r168",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CoVenturerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.",
        "label": "Co-venturer [Member]",
        "terseLabel": "Co-venturer"
       }
      }
     },
     "localname": "CoVenturerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,222,505 issued and outstanding as of September 30, 2020, and 34,312,527 issued and 34,169,952 outstanding as of December 31, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r197",
      "r198",
      "r201"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate &amp; Other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r68",
      "r299"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Other costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r131"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.",
        "label": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r8",
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "terseLabel": "Net other income (loss)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r8",
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r13",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DISPOSAL OF BUSINESS"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r42",
      "r92",
      "r287"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party note payable"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r92",
      "r287",
      "r317",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per Share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r119",
      "r169",
      "r194",
      "r195",
      "r226",
      "r227",
      "r228",
      "r245",
      "r246",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r70",
      "r82",
      "r167"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized gain on short term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r66",
      "r89",
      "r136",
      "r142",
      "r146",
      "r149",
      "r152",
      "r168",
      "r271"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r136",
      "r142",
      "r146",
      "r149",
      "r152",
      "r312",
      "r318",
      "r321",
      "r330"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r9",
      "r10",
      "r11",
      "r12",
      "r183",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r243",
      "r244",
      "r247",
      "r249",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r104",
      "r105",
      "r134",
      "r237",
      "r248",
      "r250",
      "r331"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "netLabel": "Income tax (benefit) expense",
        "terseLabel": "Income tax (benefit) expense",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r79",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r49",
      "r316",
      "r328"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r130",
      "r279",
      "r280",
      "r320"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r75",
      "r78",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r16",
      "r54"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventories, net",
        "verboseLabel": "Inventories, net of provision for obsolescence of $537 and $392"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r22",
      "r55",
      "r87",
      "r118",
      "r174",
      "r176",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r54",
      "r93",
      "r177"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: provision for obsolescence"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Impairment of inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r89",
      "r144",
      "r168",
      "r259",
      "r265",
      "r266",
      "r271"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r89",
      "r168",
      "r271",
      "r315",
      "r325"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r89",
      "r168",
      "r259",
      "r265",
      "r266",
      "r271"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r89",
      "r168",
      "r271",
      "r314",
      "r324"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending interest in China JV",
        "periodStartLabel": "Beginning interest in China JV",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "NON-CONTROLLING INTEREST"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTEREST"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r50",
      "r67",
      "r255",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r57",
      "r58",
      "r61",
      "r83",
      "r89",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r104",
      "r105",
      "r110",
      "r136",
      "r142",
      "r146",
      "r149",
      "r152",
      "r168",
      "r271",
      "r319",
      "r329"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Apyx",
        "totalLabel": "Net loss attributable to Apyx"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r58",
      "r104",
      "r105",
      "r261",
      "r268"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to Apyx"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r196",
      "r257",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Contributions from non-controlling interest",
        "verboseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r195",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r92",
      "r287",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total other costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r142",
      "r146",
      "r149",
      "r152"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r283"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Net, non cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r14",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other (loss) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other (loss) income, net",
        "verboseLabel": "Other income (loss), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r18",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from the disposition of Core business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Contributions from non-controlling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r45",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Accrued product warranties"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r57",
      "r58",
      "r76",
      "r89",
      "r97",
      "r104",
      "r105",
      "r136",
      "r142",
      "r146",
      "r149",
      "r152",
      "r168",
      "r256",
      "r260",
      "r262",
      "r268",
      "r269",
      "r271",
      "r321"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r23",
      "r24",
      "r181",
      "r326"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $4,677 and $4,403"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r63",
      "r172"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision (benefit) for allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r204",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r204",
      "r286",
      "r287",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchases from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r204",
      "r286",
      "r289",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTNarrativeDetails",
      "http://apyxmedical.com/role/NONCONTROLLINGINTERESTRollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r284",
      "r285",
      "r287",
      "r290",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r235",
      "r353"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r195",
      "r229",
      "r323",
      "r339",
      "r340"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r169",
      "r226",
      "r227",
      "r228",
      "r245",
      "r246",
      "r336",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r141",
      "r147",
      "r148",
      "r155",
      "r156",
      "r159",
      "r199",
      "r200",
      "r299"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Salaries and related costs"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and diluted earnings (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r22",
      "r34",
      "r35",
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r91",
      "r288",
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r65",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of revenue by geographic area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r136",
      "r139",
      "r145",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r136",
      "r139",
      "r145",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of reporting information by segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r209",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r211",
      "r216",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock options and stock awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of option fair value assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r123",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r152",
      "r159",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r125",
      "r126",
      "r136",
      "r140",
      "r146",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r158",
      "r159",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r213",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Strike price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r87",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r219",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r123",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r152",
      "r159",
      "r179",
      "r182",
      "r186",
      "r187",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r88",
      "r89",
      "r107",
      "r108",
      "r109",
      "r111",
      "r113",
      "r120",
      "r121",
      "r122",
      "r168",
      "r194",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r48",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r105",
      "r119",
      "r169",
      "r194",
      "r195",
      "r226",
      "r227",
      "r228",
      "r245",
      "r246",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r119",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r194",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r194",
      "r195",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r194",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Options exercised for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r31",
      "r32",
      "r89",
      "r165",
      "r168",
      "r271"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r94",
      "r95",
      "r96",
      "r98",
      "r103",
      "r168",
      "r169",
      "r195",
      "r226",
      "r227",
      "r228",
      "r245",
      "r246",
      "r254",
      "r255",
      "r267",
      "r271",
      "r273",
      "r274",
      "r278",
      "r337",
      "r338"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r236",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties included in income tax expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Uncertain tax positions that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r354": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r355": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r356": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r357": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r358": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r359": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0000719135-20-000076-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000719135-20-000076-xbrl.zip
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M2 (G.6ZI?484MP+G'%[DR]8=A6L=A>B(QGD7Y+ @=?!E*?<UX!ZT=QNX?'>
MVZ\W#V@>SJ7%3"&&/B-^'6!52M8!S^SV52AKCB7 4O24YV&=&30 (ILIZ^D1
M5C+Q[9"FOR7656XV,N(>?44BOD50M>!M*E0@6?AB=:2$/Q2QV=@JH;A1- "5
MRP6?+!)J*;.4POUBM3[?>S+55L(A!_*F2BEDJ@JRB%,.P+"\$[=2 #5R8;&:
M,?!M+,D0-(WZ4CR-EG<=W>/=07=!R^O@WIK;[F%\>U;<&NI8'C,E",'<ZH03
M_7,+])-4)5AS(TJ( ?2*CU6DW(+DP4/=TH+S:/1 R]?*FNF*_O%9YJ884)IA
M0V41!9(S0:"-\ YXT3N1"51*!+RC1*:TD,@$@C['-!:<2D'T+QO5P>Z@NN3L
MBQF/,D]L%',9AG1D-T.T[ /Z<2E&MB#J_/%A2>E1C(H@69L+U['.W&8/MDDE
M?&DM292'7]]<L7&I]OW"E/E,E,<!U,&+!:+8'2"6])J'^#Y4:-]?R$%?\B >
M'T&JI =T$&2& +&2?!]H-=;6X3V=Y:(M2X=&Q1$3>[->Y351869 ='?L"I>Q
M*9/^L(+.,9)LZ=';W)\IMTN-0A3IUP!!TS _$06M+UBDKF54'%S<,7_RU#P=
M];N^U^OM'.K_M[V>/_H4Y8*IWO(8T>HJ:&\IC<#W",UR3Q(O7>.0Q4X;NY0)
M_@6:C&/EG)1?2!IC#2%"Y4+!/]_(&R <'&TI!^ OB?-R/<H_,@7W_=K+$O\[
MDGW[UY;N.\N#TPAZ#W/E?]V#3[1+#Y0$8(H4O]Q:S26_IIR=ZS^?M;UR]0>R
MY1'5HV!8[(+RDXT'*) +5+3RJPQ8ZEU4 >X@2ZNY<+!0#3:+@1K,DA],>3KW
MT%G>RQ<%N[?G.D7N#PT8I@HL2$^*0),_5"]@5\T3J$IF.II)RJ()GQ2_#9B"
M1V6<1GHA43J?ZIP\^1JH <+'B N[$;'U+;%!MQ:*-TZG@_P>@O,;M\)^#)A*
M4\/D1SRU<E!^.0+MIQ%?#%3BI]!7.II1IH#L*("%-HM+$?U^_:!Y0/<BG,%_
M439?7)FH^RL3#2?NEW7WZ_U^9V-QL][:6/:E9COU7K_][5OMU)O[W6_>;*M5
M[_<V5UUMMN'G-Y]CQ,JF/'E7Z53*"@6Z!^WTAK7668  ?S> .4R^/PWX*S3G
M6%H^S[*/P'D\!M3[57_99XGN8C8>-]"2[G9IK.\7ZXKB.0W,MSA0#KT%6PSU
MU5X79.8_;R],U%=N3#QB$IHT!8^$_EJ=)YL6_$CL"5OFCV=9.:V[%ZLO1N;Y
M1^.93?@G V5*<LN+O@W7@IX4@(;/RP_H@#M7%U.=W]T<Y#]&S.3&RXR%<FC>
M5N%CH#YSFZMLNHZV\69A\9G?T_0W1D_^"U!+ P04    " !!>&E1<R,'7D\(
M  !\*@  &0   &$R,#(P<3,Q,"UQ97AH:6)I=#,Q,BYH=&WM6FMOVS@6_;Z_
M@N-@^P#\DNTDM9,&2)T$8V"FZ:0>=/?3@A(IFQM*U)"4'>VOWWM)R8_$3IW-
M3M<)MD =2[R7O"0/SSVD>?K3Q?5P_/<OEV1J$TF^_/[IE]&0U!JMUK?NL-6Z
M&%^0G\>__D)ZS79 QIJF1EBA4BI;K<O/-5*;6IL-6JWY?-Z<=YM*3UKCFQ96
MU6M)I0QO,LMJ9Z?X!CXY96=_.?VIT2 7*LH3GEH2:4XM9R0W(IV0;XR;6])H
ME%9#E15:3*:6=-J=-OFF]*V845]NA97\K*KGM.6?3UNND=-0L>+LE(D9$>QC
M3?#V$>T=!U'_D,:]@-(PB&BWR^"Y'1RW.^P? 039 G/O8VPA^<=:(M+&E&/[
M@UZG>7R8V9.Y8'8Z"-KMO];63"V_LPTJQ20=N(!/W N1,HBM<@:/6$&72Y=(
M2:4'!VWW[P1+&C%-A"P&;\<BX89\YG-RHQ*:OJT;&/B&X5K$WM"(?W&( @)R
MCW,?Y#'4(T7*JZ"##H9Y^;>?1Y]&8](-FIW3%MJO=-6'!..ES];+'@S&2@\C
MZ!37_Z/N#+FV(A81H(9\R;7)*<1@%?G*(T3FFX/@J'W2;3_LZKYU1,7D*]4A
M3:'*-P<?.D%P0J[O)"_(>60)E';:+Z 7P\N;\>AJ-#P?CZX_D^LK,KRZWB7H
M?^8&IK&H;07@ IQ_7H]Z&WLTJI,QU10 E81U8J><W/"),!;(S[XU9#@5/"97
M(J5I)*@DUS& D>LZB1PP"_"@]LW!X8>3W1?;*N=0/0':"96U*O$A9Y0Q(,>&
MY+$==(^RDES6QG&-;QIH]*?C8?/H!<VJ:S^^]?61ZGQH.M(=D2F=<:+Y3/ Y
M9!H[%8;\D5,-BT86\#Y3&M9;2JZ43DC0;OR&B^\\*^[(KYP!T4C(0QJ,J.>7
MP_[#F7TML]?9N]G[1 W,&<Q.4I#;5,TE9Q->]Y-83AU3$$*J0$M "U2DA*8%
MR5.K<PX]@#SAA ;,*24)/&E<M3%%CM5$)<)E#V?WP"#E$3>&Z@)-$GK+'1TL
MZC3PCD$PT*1T*@7:0(-(:% E8):".T3"N";SJ8BFQ.3XL?2?<\W+2K #B3 2
MY LJH;FP4^B@R2"M8>M8;P:A*0;=G($;(V&Q.@RO&YC=EP-,3N)%<EB9:IJ"
M-93JE6*1QL YCE?@>R1S!E4"FE;1'5.!-)4!%A#&"&\IES@M(6+N-0Q+@3FE
M7D>+7((!@%,!@EQK/IR(FBF)I9J;"KEZD>D(Q9=U9P=!UE< :*I@'@3[NC'8
MVSL,CM>FS(G(XQ-3PJS4(T@FRFL4-YDC0C5WL $8B%!RG%[" :FA%&:*YFB6
M )$BF>(S$R:2RN3@AQ2KE?3XR;2*.(/7AKP#N# .^/.8N+R+IC2=<"=E;W()
M%D&7-H+#=_R]<PT.F7_RCP(5;.IQB_43I+@5.'MX82P[-Q2O-11#0]C/^R '
M"U0'F_7:KL ][NPW<.G^ +??;!_C.%QP R,%<^@RXO<!5L=D'='<[.Z"63/D
M ):R)9^'5:ZA B"RF3".'L&*IZX>%.Y+8EWE9LTE=>@K$_$20?62M[%0 ,E"
M+$9)P=R9ALE#(YB@6F 'A)<++EFD6%-N,(6[Q6I<OG=DJ@R'@"R0-SIE(%-%
ME$N*.0"ZY8)82@'P\,)B-6/ MY"C(= T^'/V/%K>=W2'^X/NDI;7P;TSMSW
M^.ZLN#/487G,!$,$4Z-2BO1/#: ?I2K"FFI600Q +V@HI+ %RH--S>*"<VAT
M0/-K9<UT1?^X+'-7=BC+84-E8!90SD21TLP%X$3OA*>@4B3@'4IXA@L)34#0
M>TS#@A,9$/WK1G6T/ZBN./MR1F7NB WGG,<QGKC-8+;,!OVX$",[$+5_W"PI
M'8K!$4C6>.$:JMQNCV"75$(7UAQ%>?S]S14)*[7O%B;W(U$=!V #KQ:(;'^
M6-&KG^*'4,%]?RD'7<E&/#Z!5%$/J"C*-0)B)?ENJ#51QL)[/(J%N@P>&I5'
M3.3=NLM;I,)< ]'=LRM#ADT9=X<5>(Z1YHN(WOMXIM0L- I2I%L#"$U-W$"4
MM%X0*6ZY+ \N[ID_>VB>C_I]W^L=[AWJ_[.]GCOZ9-6"J2]Y#&EU%;1+2D/P
M/4&S/)#$B] HR&*KM%G(!/<"JDP282WGCR2-4($0P7(F(#Y7R3M .'"TP1P
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MN8Y@(BGA&$LA"&XP9PM#'U!4^<5[W58+R+,!4P#6^C,HK6>A$D\25)$((;+
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M_[%8_D>Q%;_H/%PZ(/?34N2J V(]2=11C3AC$7$+#HC%P2$;<U<M*6QP:>2
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M2N:OY>+,.3 '2\Z='<X]^/A5@A]K5,P;W!@@(M,1&0 QQ*PW7A$>+.!6YEP
MM&5!;RY57&74.6"_4BO/& ^>^:\X!9^4(X@9#^A)%&AESP5R6%,IJ7>8^H('
MB33+1M";/'@3(:O1CP"29( DYB+*&YK?R@27Y]P#<"%Q12RJ7%=ZJ)1=V05H
M@J4L!42X!.]<>H%LXA9%!U210BEABEV ,Y354B:>S<PJ<"F7XY7+*^EFRA)"
M9$)2QMPJ323D8O(H: KP&8SPDLV87/YB+7!.JQVOP:CSQ-I6Y<@V VIV*MX>
M-0>V=8_\LL7&C4FT8;R8_0\P^1N=-\.I+Y'E0<ARK=BQ,!:4NF5(. 'NF$\<
MN6 H<LPD)U-,VH/&EW@9/S27]?F4^P-T^&*+W"1:)Y8B-QZ1NU3F5'$F690H
M)@9&MM$1.84)BCQYRZ3&.((R%W)9/;0+T@RE8<V+0M^* PL_ADJTO0Z,O]PT
M-DT%?TZ-]1$QUKP_;A\7Q=.K,35]L]RT\C#@N5:3F'O'< 0O@BHK0=<[AZP"
M?P)[#DI#FJ0R\/!EPLN&RPLLQQ.P&DHY'K\<7QH0)$@5M/:(Z&Q ,)N0=8J@
M@%6RP6H,Y,W=#Y8%F:5R72]P_UF1!+S?;878Z_]O)?[GN#DXO4_V]UVY]C_+
ME)YK3)J ;;%]A1;K!25*#'H0!EVI*-SX>%;__A6<%46L52A*3A$HD-QMV0J4
MD@PID<A,[G$@P:"XI07\/<3@(?L47IS$3$"+EQ+S=(DYO2XQU+ D;$ .4XXX
M)1$9(7-.F'&<:FF$YTNKBBQ3<;.EX36)>6%N>KW;09G]>]U6*Z^Y-T$2>K$_
MJ)3N^G.OK]>:G6X/9']C-.4E!CP( RZK[-:KAV=?6;1<8"90"-;D;&4/")"K
MZT7&6#26&9)W;O*;.2>E![XPHCD>W7T6>]U@^_NEP(Y;8$\O!)9^]3(9[E1$
M0F1G6\ G(PE%5D=JF3#:6[,$PJDIH7_,D-"^0&_[%_YU6?QAYCSPC8YO'>=)
M_=#MY0&N#0:]ICL>Y/;1C6XN575I\Y5P]@@XJU>O%?.E1M,H\R84I6RN&Z$0
M0!M'-CD>J8F6TJ''SMB3EP#*&C&+"!-3"3N4,#$)F#B]4DHJ"B*I0@D738@H
M!B<%!P",&$P4%DN'[PQ3S"A,O,#VRU>JWQ6[96ZWC^[99'+X/J\93$'H'H/@
M75#G?K'76Z%PYN),_SVMV5D8!3'9@H%KG5!&J9\(_>O7VCVH$ 4#K ^.)L3!
M#D0Z$(D"(1&(F'3(V_.46.;DR17DQRM"4XYNE3!:PNA\V=DEC(X;1J]8T,$*
M1H)! AL-=K,'']OZA%S"W!@KN.5V:57S9<47!$87K25&.>#Q#/A5X:6?;X.^
M4K'Q"GOYF)WV$2BO_NEZKU:O[YZ^QV43Q'):N%C[L6*][[;AV:=Y2;K3'60_
MJP<_=XKUZ;U>L4NL-\C;PP=P.@!\B)U^S!/8*<0O)T2.&LHVBW0Q^*$-;]5?
MN?/]1X/@><7^J-LO-F>\[L66'32_Q3^^-\-@_US;7+EJA KX\A+K8 3'@[LO
MF96)IC]LI+_RWSS:0C-I$:A6.%$O#!?,6!X48\8I1Y)*@7RE=.G\HOW>97[1
M7D2N%^TAL@E>\+5M?;>G_:57U^:AW>R<#TAP&/&/\W7GK*3T;+,RQ&;0Z]W<
MB1NH">H@]O)9,"8[,V.I[/>R,?./7]-'@4!EG,BBDIN$91GX\Y6=)1BX$6DI
MN'/MP\Z_*[7UZL:;M?>5-YM;'S:WUAH;F_4[!]ZVO3W@J$LU_<>LO,J;33!B
MZMOK57B/^O;F^XWJ6@.^;#?@3VV]WMBN;+ZM;'Y8'[[@]FUB.8/P\=M&!\"W
M>PSW"/WE2CSQ$2R<H]@;5GFK  ;;Y<JGCCT.34#CW^])N R_HU^R034L-URH
MNA]2$N$]6_:H'U^??_CC7%4V.\5HBXM^M*W@GB.@,7I%,)VQ9J3Z1[<?P=!*
M 4,_V(C#8]RL$"/O/(Q7R)W'?G9;@E>4-(^Z[<^/"?ZX*\O!3FNPBM_WMI,V
MAG^YRF?NJD1P$XYG*[(/*C56:G#>?K^R#IHV%.;RM?ILXTBMGM?YJ<,O#YF>
MIRX+/:6&_D/6O&9\VG-,_REM#>XU%>5<C^;Z2G&Q*;5_6*CI+%EWQEAW(J;!
MG.V V+:MFTWL?K7[:<%6C^[]F@NS#.2CIDDJ%4/"G'ML!+%,>2\C=L'H\+5:
MK*;G\B%C*+[P+7:.X]M>MWU;G_;UDU$2UEJ_'^'_0\.>S,H2T6GM?(GHX".N
M5??;NXW=5IU^8O6#C[S6^+L)S\2;C36\6=TXJU?_/JS1SQ?+/9OMCWBW73NK
MG\&SVAMLL_H1QO>VN?ON[V;]W3JI?]F@.XWZ0?ULX^3'):+=ZE9[YZS&\GOM
M''A>KWX2M2]_'^ZT-_!.XQ/9.=C=K]$:JQV\3;7F:'EH&W__2H(BC%J%E D$
M<<\$LBQ8E#Q34DI' G-+JW+9B(<6=9M.ON6OEL5+A%I4A#**Z22%41QSG8@F
MR@BEHW0Z4A9=1BAB1@B52]Z7"#7+"'5V@5!" C)I99"4*>4E;(M,$@198Q11
MTK#DU=*J6A;JH2O8)4*5"#5!A-*">AV(P-9C+I+1T0<2O1#:L4!X'-E0I+2A
MY@*AR 5"::F%5M@!+A% J$@4TL9(Q(#66CAGA<YU<.0RY0^M@U-"5 E1DTR:
M)MRDF&TF</,H_!6"6BQUU)::Y,G(B"*E$347$,4N(,H8(",+$1E,?2Z1 _83
MM19AE5(T,9 D<E-VLZP%FPN(>M;0W*)5+7G3[1?)7_W;8G=E.81I!+DR23;3
MNVXW%$G/L?<-'M_?[K9""7(/ ;G3*[$LKDGDTG*$&;:(<RJ1HU@A$\$ZPT!<
MZ>G2*EVF],F[!<NJ)C,LQA.,!)5B/"XQO@SXJ,2M#%8C4H@Q.,?(2LE1%$00
MYR,)(A9BK&_VC"[%>&'$>)+ADE*,QR7&EU$18ZFRW #3"IL0ETH@G8) @4KN
MB-(VY1J#<IGS66H75(KQ'(<42C$>EQA?1@XDX3IX@E' $K2QQ@(YQQW"206!
M ^=8%6+,Z.R7"IQD/L^,! 1NSW]ZU^OV^Y6C7C<U!_>)![S<.D.3C D45/E0
M$*7$JP?@5?W-E2" 8-XF'3B2"1O$@2:Y< 10QQ.=O/,TA)";BR@ZW\O%I9A.
MR^<OQ?318GKIY$?%G)<N(,-50)Q0C[05'!%K8\1*)DK(TJI8IF:^\\Y*,9V6
M3U^*Z:/%]-*)]TQ+H;A .(!*Y8I)9$W$N5\7PXD Q@JUM&J6-9Z/9<-23&?-
M9R_%]-%B>NFD\Y2\T#HAA<$UY\R#F!*P?&4TUH&6E2"K2ZN$+0OVT)AYN;P_
M\\O[FX/]V(,7[0]&]35/CG)YE_[K:>_.*^\QU7N4V]=NZ[/;C[;G]PM!"?%;
M;'6/<J6C>T3!%EOG3W:'UY (:YU0O23!^A"V2BO@(5; U;U<*9<WBHJ@Y*C-
M>[E<[N\%1D$4-O%<WRA(L *6\4/3D&?"'E]P\9OH]J52_,8F?I<A+:I]5-Q[
MY$5NJA<90TXF@[@%2$W<<I.KOX'XD9M=*$OQ>SF!J5+\QBA^EZ$JICCEU$I$
M@\&($Z&199$A@P5S1#-C,-BV;!GC!RY4E^*W4 &G4OS&*'Z7(2C!<6 L>02Z
MCB(.GY&5A*$077(BJ&BLR%F;DCUP0:<,,LV$-.<0;>SW@5RY0/ HM:K<2S(+
M[O15TKR-L5^"V$- [.H.$AN,PD8J)%+N)!_ ?'#"!22Y %J::%00V837;%S5
M\LN<U5D4W@DZXZ7P/DUX+_UO3 675F 07ID0I\HC%SU&1$1G3'3$*9DM$,S*
M[5\+++R3=.5+X7V:\%YZ[XE0ZEBR2#MPW#GV!!F/&5+.<LFIX3+JG ^F]>RG
MF9?".Q>!@%)XGR:\E[Y_H#P$1BA*7A#$3>[D3)Q#RG,O@C8<U' AO.3)W9P7
M:H_(O/C^V[9E>^?=6XL>/T7OH/[@/@& Q0:L2?KYYV18ZX0O=J\$K <!UN;5
M32)$..=3) @4#$8\*8N,L Y99B.CQ&J:_7RV+/ # :M<*U@HY[R4N*=)W)7]
M'I&Z" ")!,G;2%D4R!!CD/<*#/YH#-$Z2QQY:"?W4N(6RJ,N)>YI$G=EZT:(
M1LD8$ /3'''I(S*2"?AJK U2:^_\TBK!RU242F[61&Z2?G I<D\3N:M^L!$F
M:8=PP %QI1/XP1@CFSR.RE!OB^4C#%IN9C(PRT7PASC"L04_[BU7]F(GYK:Z
MV2&VH=WL-/N#7M'ZMEP2GPE7>4BH=T,R ;*M72-2F>WS"*3;ONI >QLM2QHY
MJ@WBFJJ<ZYH0\YCR&$AP*>6U-H4?F.M:ANOG2J0GZ8N7(OT,(GWIH4L1,4T&
MG'/,&'CHQ"(3L$72R4Q704(H/'3-2I%>8)&>J+-?BO0SB/1E", F9<%QI$@(
M[A$/*B =DT>*>\6)<C89N;2JEZ4I*ZDNL$A/-)A0BO0SB/1EB"%9H1./'GF<
M%*AJ'9 C-B)!=;"4F+P#M"C(PO#,B_2SAAZ>=O/RS))8+_;,!2ITVN@.;*O2
MO:- 2EGZ=%;B=9M',1L(G;V1@5 N0CRH8'-C(UL'P_#<VE?*!%@'C"*KDT!<
MR8@,F =(^,B4M4(Z)K.-@,U#/?FR:-L,B^L$8W&EN#Y97$\OQ!5[[:3R#BDL
M+.)1&J2%9D@SI;C"VEI"BU5#+!YJTY?R.KOR.LE 6RFO3Y77^A7UZGU2+AK0
MK ;4:R ):14M8DICQZV5.H6E5:K !R^+HBZ.O$XRBE;*ZY/E]5*_>N^)-CGA
MU":;2XU+9()Q2)/H%$], @B#O.IE_N"-H2^X..I,N_WO<WN3U.NV*]VA)'4[
M3ZI5L6BP]]MDPP!]>&'X]!@ W.CX;CMF>I80^" (K%V-"(BD,5@G&-%$%-@M
M-"(C0D",4:Q=DL38F)NB,'5S(?#WARX83 D5GW6!\$4#P-,#"R4 3 4 +FT@
M+L#5#(DBH)L#G\5@Y#2%_T3,G Z1$$&+KDCB9DBP!( 7#@!CB%24 # - +@2
MM,!.>BQP+DXK*>*>!P0ND4$B*>ZIP5$JN[1*]#*^)7&@1( 7C@!CB'V4"# 5
M!+@T 91WD1D")H#1.&<.@?;WVJ+<ICD%(96T"1" +YM;-KW/"P*4U3MN"OH&
M"'(O]@>59B%'9<F.IP<TK@/5^00/<>H"MDJP>A!8?;P6L'":!685(HDRQ DA
MR-#$4) F.DN)2R'F-=%9V459;EP>7["@%*YG$:Y+2T"3O%?/Y_9P130P&.2P
M"(B 5Y>(,P;;L+3*Z,SL42ZE:R1=E-D4L;;22PN:BQI+B/61$ZI3I G?PQ,O
MI>LYI.N*ITVTQ%)X@\!G D_;18[ ,P+I2L)XZ[101"VMTH?F!I32M5 K_*7@
MC4GP+M5:TC(YH!^*3H'@6:>0U3''N!UWB6EF2<C%VXF8&=&;B97\N?-C1^G[
M+ZS2QH37[&^'JW+_WF-@RE]U;:VPWB5.D V*(RX-0UJZB!C5/%E*2904[(.;
M#28>'(.;TT#[',KF]-+TSV*O&VQ_OQ38,0OL%7?9&$^P8PA3#>XR#11I*B1R
M@*;)&AZBEDM@06A*Z!\SO^FV%-W'J]5G<[]+*7V<E%YQNX']$H^<(IJL1IS+
MA*S &B6NB*! DF#-TNHM&;ZE6IU9V9R>[UZJU6<2V"OKT08[R1D!"=4Y+=\&
ML(-SVY=$%,@JDZ!DYT>ME@O/-\5WL]AV_UNKV^__/EI\7JYTXF Q5Z"GE5/_
M0]),GO,?,F=&8%6/@Q*O'H17>U?]=J,<!L\]E]H)N;U<E$@3'1'H& __)Q3G
M(,_R9FSQ+@.CC.C/@[-=BM=SBM=5+]MQHK%%SN3^T5YRY, 0^'_LO7E3&TG6
M+_Q5*GCN&V]W!.G)?>F>(((&W,/<!MP&3S_V/QVY&ME"8K08XT]_3U9)2&"P
M$68IB>R(QEI255EY\OS.FN> T>V=UP'#MS&'S4K*1]N8[![2PPN3/2"3S1G)
MS#'%E9$H>.L09S8BZXQ A(@49/9,RYSYP4L/EM:IC/>9@EW8[2'9;2;36'(Z
M4)!DPN<L1L$LLMHJ9+@4F%GG2=V16-X^UK.D!FS[:MP]YY&%6$LT\CF4:YBO
MTG@G=U$YM/7X3J;]?J]_K=)0-(9%-(8/._-.)N*D=8X9Q*0&C2'Z7 8N2>0$
M)02^LE+3M0VUO >TRA'-9?)T%1Z_-QZ?607.V*2$"RBHY!$0"R-G)$$B,AIM
M J)0,,+%HBWB"J<_#TY_&'=;X?3[XO1Y=YN(1BF/D:F;'D=%D18<(X*-(RQ9
MHG+1!<$7+1-9./U9</H]N/P*IS\DI\_5F 0R$)X,TMB 3/<A(ILH149$AZFR
M!C;5VH;6"W9:;ANGE[X2\P4F74S]09RX*JJ1_?PL.TJTOI;DK'S,RT'_9 OF
MT^F-89$/+DJ#_E83LAEWE,FX\WDTL$"G3L\.SG='\60(J)F?9-"OVUM-TP +
M9"X$F9>Z5$@7J#=4(BK! N)6..2B!.5(&>*(TT%IFTO2\6NBD3=Z.TH![39S
M_U,4DBS<WR+NGRM(26HGB$!!Y:871"1D?"3(XHP)V%#-:NXGIG#_:G#_DU21
M+-S?'NZ?KY$A _.!AES4B2 N/$-&18$25; S6*#:F[4-HM:Y_MH+6MA_&=G_
M24I(%O9O$?O/A#^57'D:#=(@$1!WC".=*U/RP#18@3I@PNI2E" 'VL[^K<CN
M:-^)H.O=)KL7KI+J)Q=[,75&/T_+>52EGL<3I')<(-_$"?Q;0Y6";@NAV^5F
M&R012HA'D2N,. ?[QEH<$(F14$4\Q1RO;2A2*GPL$;<^;0G,PJ/WPJ,S#40*
MIKGU";D4!.(L>625,<A* 3QJ**<FUY>]IAU.VPX>%T9]TGH>=[5)"C?_*#?/
MN1-$9-H1KA#W)B)./48V1HMJ'Z/VD;%<H4>M$T*+S%T>5G[*5(G"I??$I7.G
MH7QR7&B!M,NGH2@!JS]JARR5S+M$0LJ'#^FBU3E7K=A'^XZ@/.>1A5A+-+(0
M:XE&%F(MT<@52MW;CZ,JGS$LJ7KM2]5[->B#DETZO2VL:%^J5(4))<)ZC;Q(
M"7'K&;) 0L1QH$$S07 $QF;KBO&V1]=*<+V]F76%6>_.K'-6L22)"Y.0TPR8
ME6F#C#<4"4*<=,8904W3FKWUH?#"K.U-A"O,>F=FG7,TJT0)P*Q U&7)2BQ%
M6C*.A/9<\7P B.46,QBX=8'H;N'6%G/KD^2M%6Z].[?.!7DIMX;8B#26/"=B
M"&15T@AC&0(CPMMHZS0SJFY?M?4YIYFUQ*Z_GJF;(,'\WZFE7]G1:-!QXY%U
MW5B-^A4L#9I+Z:PZDYS.&UT"/[94RPV #Y=[!O29)>ANSM'HJ%]R;N\!#&=M
MI_:/-L7?5 8K."'(>9?= BEGOTB!%..!<>%<8FEM0WX?"4OHNF7I8K?I7%&8
M[<&9;:IYP//OG_UM(HO2"XL<J!F(4RZ19M8@ 1\G&T.0.BQ/?XO"X.TP^ M3
M/RY3[U](T!T!+)T2 24(":]R)S@7@;F%1X9*$L!*M#B(6TG0PL=MX>/VM9@J
M//W@/'U94$=%G&4FH&"=0YPKT) E9HARZAWF1$N_1(*ZQ/FOQ/F_LOXW3\\_
M+^K<^3ZTM<X?\G]^[!G;#=NMSV2XA.(%H>^:S#!!:!D<P]*@X%Q W)*(0.1*
MQ),UTG.G#+9U0@-=H##RK=C@<4(N!7U6&'V>(C6CH,^]9&<TZ$,2<2 V"-)2
MBMS_&]!')H44*/T.2*B39?>6H5'0IZ!/2UU/!7T>-=UD_VCW[&]!J#'"Y-*(
M(N;CC1@!.2T2DCCCK(O$L2;A1-Y#G;0"/@5\ECUUIH#/O63/3 POZRC1WB(<
M@4B<YQ@65;E,@N$1V_PUOK\,FK9[Q:9#I@PA:B2[;S_[+:XQMX(,EBGTQ]FU
M=34)Z;G?83EFN41W**[EB1#<L8,>S'4X;59W&@?5X;$=Q%]ND2JSP(*7H>6(
MZ;,9N;*E$*]7I'^SPXZO;"]4H=,=CV+XD1#BDAM&MWK$);:+7L5!+1[N-S!%
M;TP+FLJGZ7WKO;;9"]O-3KNPBG"QBKYO%7VYU+4B6>V5BT"1I#7B,A>.B\8A
M8[@WSEM#,5_;P"_(UY7CECD+J(#1RH/1C\6I"A@]&AC-=1U+.ON%,6)6"\0-
MM\@Y%1&#SU-05DBL:C!:P#E3P*B T9.#T0^&K0H8/188S9^-9L)X;A(BTH!F
M9 V D> ,<1&\DLP8$!T9C-@"4?("1@6,GAR,?C",5<#HT<!HIAE9%;!(5",9
M 9$X=QQI[ ";,(B4:'V2^>@W?L%;71"X>#^?S<A"K"4:68BU1",+L99H9"'6
M$HTLQ%JBD8582S2R$&N)1A9B+='(0JPE&EF(M40C"[&6:&0AUA*-+,1:HI&%
M6$LTLA!KB4868BW1R$*L)1I9B+5$(PNQEFAD(=82C2S$6J*1A5A+-+(0:XE&
M%F(MT<A"K"4:68BU1"-K8OVCKAH-_X;.IXU_UG_R;S?^Z0;_V+A(%)]^.;W<
M7.ZWC[E*^]JCGW:@^;3#T7&LK/?]$[CW>6YTU>N/X.IV !_WZJY7[P>V6YW:
MP:CJIVH$PWV_%V)O&/,R]>K23'8$;U*G9WN^ X.'(_C@!)YJ^.+&YY],@N<:
M#*?]82?GU?\RB%T[ZGR*OYYUPNAX6GY_[E=-1OPO>/83ZV &X]'-/VG+0K/+
M2S'_-\^V/KVA1:!:X42],%PP8WE0C!FG'$DJ!?(W%6O3'QU?U)HZM>\C<H-H
M/R*;X %_L=TS>SY<^\>E=3CI]*83$AQF?'6];ER5E!YL59H3$"'Z_L#6U!S#
MSAKD43 GVYJY5,>#?,KG?[Y/'P4,5=>0!U;9R@>$@ ?^^0_;)ACXJEQ1O3LW
M7[W]WVIO9WMW:_./:NO@]:N#UYM'NP?[-T[\Q [>PXZ:,"2[?%[M21]EZV!_
M>V?_<&<;GF/_\."/W>W-(WAS> 3_[.WL'QU6!R^KK7]M[O^^<UCM[E<[?[[9
M/7I['7>V$$5^VNT!!O?'<(TP7*_>].PX= !]?[XEH3+<3C[)Q;[$#71K&B%<
M@&Y=' P>L6M/A_&7Z8M?IR*QTZLG6O_HZADFN,L,:E[@!FXF^LWD^I.O7]1?
M327PI>^8>L$QO?%K_(+\?^U0"!8:>>O'5R^$-K=]^@6^XU+?Z9??GBNCMZ;4
MD\]5"[4D<S4OC)%+,E>"7RASM\L^Q2:X[<(N0W5"<ZOBA$>@T,3J!,8=#ZL(
M>DZH#N,IZ.PN#BJ&UZM\2+DN/)9+)]RB8&$K\?4;-+I-K<Q&ZDWDYLU]G!_W
M4F7HCPZ]H5 O?^!"O>WF$//]9UVDJ?G7.F6;T&^K?P+05QV.^O[C@_8MAFL,
M^F?-ZUNT1ER=%=Z$N68;VG:K5[83$!@M6_:T,[+=LMX/L=ZOX\C"AZ&ZJ#I<
MUODAUGF_WT-SW36K:7O-LMH/HJ7V 3"JG?^..Z/S2RN\0B+\&9"QKELT_!$6
MN=5:W%/Y^R5?[%=V4/W'=L?QH2%IJ:^QC);\327"N[;G8QUK_/>X%R^L]Z4W
MVN=$W6VY<]G[B0]KI+Q26HY;[:7"QCHIN%!:)TR<TTHF;8-([N_=NJ*<_'8G
M\6_V0VH0>G<X',]5E&-/7%%N_W!:4>[XX][V._C];\=[7]Z?[7UY_?'M$5S[
MY'5W_\-[>O#7GY_WX)YO/[S_/*LH]^[CV[]>G^S_ODO>TO]\>+>=Y_9>[)_\
MY^,>?7?R[D,7KO<6'_R^*[ZJ*'?R^OC=[V_QVP_PN[_V/^YOO_ERL/V1OOOK
MSR_PRY.#O_[S(5>U>_NAF_;.,:FKR1WBL[]C="KB:! QSB">.$;:68&HY2*1
MD "-PMH&8^N&?EWX^]LMPA<03RWHQW8KMER>DI:W?LPE19VOF[+='7*NX$KV
ML!SWN[!^PT:-W^WY[CBOV*O^(,]B<Z[O^E$?S*LYZVIJ7!5$6@R1V 4B$1]-
M\ HCKI-#G$N!G#81:<II"LE1C@T@$B]H5-"HO6AD(R=)4.&LM;!OF1%*"FR2
M4I1X3\1]*$ %J)X J,0%4'G.F!<T(L(5J$X.7EE",1*&>46HD(JEM0TAUK&6
M!:P*6+47K!+V/G* )AD8CS2Z$"@G6C$JE9+$%+!:4K#Z/-?@25!CL66@2%G0
MIKB*"5F)/>*"J\0"CBK%M0W*UQG]NI%!@:NG9N<"5Q=P%;TT!&2L#$YS'<%.
M4,(QED(0W&#.;@=77^*@'^SPN"!5.Y!JUJ";[K__.X#Z["SUB&@&&!4YX);2
M#'D5%';!2ZOI&L"2IH3^6N"JP%5[X8HGR:T6(406.,?282.UE9HS)\$FM$6[
M6E;,FFL2Y;P7SIN$, _9&+0>F0 68>+*TH2M)2ZL;2BS#CN@97!U3_V)VQQP
M/#C-ZSRLXN<X\)U\"!!8J_(@_5<IXGCG3EU+!*_71AL3P41Y;[4BG@NI#,=<
M1IU 013:V?"=%I\WQ ":T.+V>)!1%!ZC'YJ0X[2E50Q;_9/3V!O6)^\*>"X
MGOM;<R%(RK4-UC-$#'6(2VN1,S8@805S3EI%F0+#=-'PXQ*TV%MQ)IYHYX5,
M[2;3 JJL$R(9KS1V1'#AF>%.YY KY=*+H.\-:.MDL/J[B>3>F0KN K.+P>PL
M7$$B95(+AR0-$7$J S*4">0DD3$$$)G,KFTP4V!VR?BWP&PA4R'3$TA#;Q0#
M(T,8!>"I$]%$&:%T;J@+6!M=D89MDX;S'AM07IA*4B$M-05Y*!BR+'BD.9 T
M!2:I9RV3AZN3 5[OYLK9IA[3S(I>(7?,$F+?;434XP=(RMJ6M6VO!;L9/HR'
MH[INW%%_=H0XGR#>[4W.#]<>0W?58_@Z_G?<&79&\3 ./G5\;(3]Z^C[[WOU
M56JY7T3\(B+^<,[@%<$&#*(<N91#R-H:I+TE**HH(]54T9Q(+#A;3,(7)BT
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ML:WLAEST?'#AYR7B9RVHUX$(;#WF(AD=?2#1"Z$="X3'PL]MYN<W\_R,)4L
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MI[%_VHUUIHGZ=5AU00W/FV/0'[\_ANW0ZW^J5?,<W0QC#\O=Z4WVSO DC@"
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MYF6K1YWE&;^H=O,,AZ>PL6/S).]A@H->LP?@&B<9=3W\:I3%T'KC&(%_?7-
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MMY2QO+J@I]: M]ZP34;W1OMH,#8?*;A$K1F_V9HO9RP_0<P)M,*'G\!&Z(,
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M?,H(=<X*P3.$+7:(8>&0RK""?W0()PO&1!Z]NH?'DA^=75XXQ%,+SEIPONJ
M6"TX[RPX9V8ND3:3(LN0$R1%3'J!-&<8<4*LSKSB.A=!<*;BNIYDKT]PWF K
M3^IF8:KNU[+VN:ZL!UP/N!YP/>!;#/A?L<Q_'B!OOMG[+_N[+R*80F,\F'0'
M'SJP,&SRG[$:C$J(E.![Q7;& Q<ZM ]CZ_;Q()@0SJ@(NU#UF$V.BI^)';N
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MW&)O$?:,(I8%Z*-44$2)]M:&V+V(/,?D"R3#_ Z^?T0^"JALES%SKD#+J<,
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MM5MHK=WJ;+;_^6>C]2G9:'76-]>W.H^-H7_SN,[/P^<F5;DAC'/#")AAGLD
M-B<R XJ(9$N+V?YGHY=TU<@E017&3C_NIS/C ,VNDL.8HQ9:MHQ#1YO]@2M[
MA9P4HX/86F?M )XW=,EP?'P<F_7\L12^4LG?7Y?^++O5S.X:N/^,"V">"/B^
M5C8D"3UPCM1WN"R!/0[@V7%5!X4>ESO1@PMB(Q)WTCV->CEXQ;#N91>A<VUO
M2DEPE]XW3WV"U>KWXG3Z75CX_8GPV"P7PJZ5,UZ;F_"BM,-9 '&R?K:'M2:!
MJY#QBB$&S@U2J<D0"'.KA4PSY>S2>RJN;H^S' CDY* P!P_HCN0<80+K5&I%
MF6,B)P$B,N-"FS077#QF=Z2KJ66C:J'U<= _VAKK86$+-3A=!Q("=30<CD/Y
M4DTV4[+9 "V4TSPSC"%JO0 MA 72CCJD7)YEEE#-5;KT'G-V=5>ET$YK*H1
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ML'JY2<'F]3T_Q*CNB(5A[%&PECFPHQ&B=38!.[XX*BVXTZXKV .Q70/Y=;2
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MC[%^N_ >(ORB%+Y% %]/6 8(QLMWEVC9;34/$C,N*BZZF)>??./A!$T>[7>
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MHQA\$/$'V^U46,E!?H7CO&9(U,^U+IO_"1RS#[SB6APMJM_H,(03$OIXH7G
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MR0HK S<A@D2ERB\R$3 >5D2U%@LJ]U0CD)GY (0H@J,=QEP,41YG*5(U:$3
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M#4_E6JF1*M=*C=RE7*N"]5$T*D=I+F+O7XO+X^2&%S'<DB_6GRKBRO7I(RP
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MX<\MK:NU.K]L55);)ROQ290VFZ,H+P<6TMU=(PGO"73G/(5JZ \3*WV0JD)
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MCB93GL"WG?*I$MOEQO/9&0 G!EB.;FIV(6;5]HUQGR6K+RK!/:)NR+J0$MI
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M)=!VIR?0MMMQ=PS_-\B&X6__#U!+ P04    " !!>&E1<D>^D!@,  "+<
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MAD9M9(YUTYRHAGFC&&I)/G>*BN>T<[EU_IRM% 9\9D"_  H%.%;-6:@TI0D
MQ!-:KY,O!PL9J>.,MLNRU?*>"$&8W-JM;KX$%)!3P_1E6GK_7U<*?P?NEBU>
MJKQN4" L3&$TB;5ZSSGA0!)' EFHVA-1*8<)(819K-WNY(N\(E+JF,1VF_;
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M[/>\YWP\9\&\N+BRULH<<XXY_K\QUERL<=8,X.1M77U=P($#!P /V3\ UF_
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MAS7]:%9N@46#UV<CO ?6J3S) XXU'L&G"QB7L-;;QV$==A)C7U*-QWQ$>UB
M8V/R]_UFG#GP15<AA'5SY\CVKI\-NO0JF&_'AM =U.%7X5'<^@&;S+U\W^,O
MC"L_ZI_XYG,L-+-#Z2#TI%LM'K5Q&!?#W9GJ\T'%X'E ]7"Y.A0OX1?35/A+
MML15O5Y7W';851USSL>B:;;T\GRQH7Y 5D@YOISTMA\MH0]ZV\P".*RY-T_V
M4/1C&$IP1<2$NG;RFAT*EG*Y<^!62:3Q\(+572[)&A0*ZJP0I8 S4"#K5>;O
MK?F6;H8% 'M]3A*)/CCMS/36L=4K0#[-QZ."@H0&)$)FB<)$?/+D/%;$+Z[
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M9_V<A8*SR3;2D4K23KTP2W=R![O<'7CG1_73QOV+L4$T]Q&2&,=KEYC'<EB
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M>I1K]H. ;.:]]^&70-<: 8&/T"&,V'H@24SP'L&PU3]E-]7&1._6IX7Q( $
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M&9&;B/FGU3+,D,?&,=15X"XJ![* '1]CWK [SP*4J+( 5/X$(@B^TB)77Y#
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M%6[\QKDZ]RY!HLE7\#^!8>)\T9T;\?=K6L>&4 3]:'[P9MX,7*;!KY*6!%R
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M+GRAECY%$(FH'9T O9,/X$6!YJ%H/]3,#@,X#IOGGF861/KX@KRRY\H9D-$
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ME%:1*9R-I MLTYS@<9(](2W(T3\I+:Y?0S)WH>I27.ZXI<85X:3JX2X_5>/
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MNF(_4NATRS;0D9*&S.A<T=->\QC$2<CQ@[FOFX>A;[( 9I2/'S3$[WOZ/%Q
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M>;ZYZHUZZ0\%[1GI%_&3#Y -JJ![==O;J_#L1E_P>3C&U&D+F0W9'/*%?J.
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M"#/IEQ 4H&PWR0+PFB]0 ^#669F/E+%FF@; Y\_!WPK8 G;BX?[>L#?\,=U
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MB">V2Z;@,4LY':;_[UW]@O#/L@'VR[F>Z<V?KZZ*>U#^2EC?SB-(A^M\[ (
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MS&62?D&/+C!4FIX+)-M:@:C"[,6J%V<!II8W$QHIN5XD!$4)T<60=3>[U\]
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M$B:MNRN _&C,K9-NK-(UKTDYS_O@=[>9MQFWE"ZVON=_;YK0SGQ:8.:Y=*M
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MLGB2_K:O/7%OSV:YZ]@U7MK+&::,7IF_;%:*,"S?:^"KGHOK\=6;:=="7[X
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M+U:G7(ML%Q7:F&40G9Q#PTRPT7E@9M\3[L-/COU0XE,[*[/9E.#]> G^M?F
MZF _%+6 (QD:1)H'GG29T)6^>/)=2;E)X9YE6AUR36HF2VK^[ N\L>E=F I2
MKB%.LJ(TD8Y*]QBE2@0W*O$>=.$F+NQ3''1/)[[LQJQ,FF]B]P(:9P+7ME,V
MI.)KRI]A7-X)3VK%+F>8K P*?;==C@7K4(U"Q5_@]<QJX$7T("$3G^5K""+]
M)",+<1KN%W*.-%)TII>R$G#*:"]'?:/XX6BA8],<>X9"-Q>8\*>K>5<'?\HL
MB\?U+;"=T%"6,9Q\X,9_W^V0R"NIC42*!*/\"WEZ.?Z%ZKEA#(7^(4RW;^C
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M1T=./K)Y"QF14"),6@7HZP53LULZ$9C CZ;$Z$T;@+WV"G/M $YH/P :8FP
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MYNX('Q0H+<CZ0H%X2>2QC8TV=+##/4GA EM!Q0>^AP>=NN9V7$9:5$1,T;A
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M\8UG8ANG$>JEZ^/+$6^9B[9OC(?UU5:DYD?9=Q?<5UV<\PH[B'$ C 47CV5
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M"MVMX)%B:P: _,-(:@)DW(J*909% )X,M%L(UA'Y[3FZE;G)5&?^JO."N;-
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MC6S$+<#_T;#K&;4 'J'8E/V=2J(;B'L)/WK O4VD,X*O*J.%3ZL9\5U,/ %
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M8%(5>UF>V4EBJ3V_DW,EI9P_BGP>TXPNNSSL#B^'-!L*V%.M+^V%&)OIGWK
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M'7H!MQM@44N)YEJ\Z?W@8#ZRXUCQ<(84>$L[L\ZY?/PN'>8U0MH'/]W6E1_
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MF(/RO$.<=Q<#EUUU6S'NQ:RT99)\\?JH6B\(*WMZ][KY+Y??I\4D$1+2."7
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M:$F]3'H%49C;VNV.XFEJH^L#)>?VN J@4LR2*1I!/2UIGY:W4VCT:V4[VMO
M%K536N];STZ^T8T?/DWG63Y=O-[,U<03Q>)1\] D\2.!<< !3"+-#P$!!+,8
MT"@)H10I02&WH8:#O8R-%6[5X&7SA>IO5EV*5;)Z?Y326FXG#N-J1A%GH^68
M';H"9<T.K4#T20R'.QJ4$UIUW:6#]H<[VLP7ZLQ2VEZ6Q70NBN)!/%7F>GWZ
M1I GT(\#H X5(8!QQ "%ZJ^<XBA$*"4TB*VLWVV]C8T9&MDZF3C:<36T1O>%
MEFN[LB%0]C9@$P!ZM>:V=CBL7=9$]ST+J]%+9S+%]=^7BH2T"3>;K[[H!(51
M2"D&B L?0 DAH!0RP'V4H)CY*8Y))Z8XU-O8F**2T5L+>1YE' 38DC+.A<TQ
M95@CUIT[VI!PPAT'.WP;[FC3_2AWM+[4]9ZE6.13MA#\89&QOWT2SU3D$\%%
M0G"" 5,G#  I20!*T@A(QCCU42023NVN5 [T,C:N6 OI%5I*VYN30T":7I*<
M"8_S^Y 5,J6 WA^5B+U>BK1 T._]QZ&.!K[J:-%U_U:C[>%NDW[MX',G-R]\
MZWL2;=PHROM>NG'?NS:_0^%S'@D$.$0!@,1/ 4DY!<A/>)Q&*!18VK##>>*,
MC48.^FALN'%TO1 Y<]#,F&BXH7!]\CE_%*PYK!_P^B2[,R4:E!7[06^7/GMJ
MU8YGBWRA34+3Y^5SO0]@40(%10PP0@2 *4H!#2@#O@^IGR*?I;Z1C\I>RV-C
MOUHX,VK;QZF=I<[2WC'AU'+UN#4ZJFT+0ZAW-MA!_6V7&?8;'622']6EF:_'
M'^BVQ;F9?U43.<M??\^G"_$^^S:?T)"R-.4() FA $81 RB- N G B*?(\QB
M9+-MV>]B;)/QYOF%3/-RO<ND-VWDM=MW'$#2;"]Q'CZ.I^M*.*^4#G E7G\[
M@>.J][FZ'^AET!7[N):[JW#+DQU=L/*,"<&+#TJH!S(3EW/^B2R6^@[F3GXB
M^=_$0E_!/ BF?S<5Q20()$J0B(%/&%&'%A@#%$,,$BZ(GR0T3:11E'1G"<9&
M#HT"59J4YTIV'=ZCJ.)Y);]7K!2P]-^R'B$S5G&*NV/2V89<2U_Z<C3R:^37
M&G@/IY&W]P'KBEZOGF'60@SK+]85HSTOLLX-=0Q0;P)4/PIUF/DX)70ZT_;B
M99XK]IT$%$)." $<TP! &C"@FE$#% OATU2()$EL&+"]N['172V6]Y+E962-
MFFOK@.N9UL";U2I8<]T)X,V(K3\X';/82E"OE/3"6\EZX=72]ABP;H1*KP'K
M[3T.&[!NI/U>P+K96W8D0UY>OT_*+ _W0FWFEN*S4-^3^KK#D&",20Q2& D
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M?2&X2\B]M=LQRP8IOGR89=]TA)7Z49M("IVOYW+.JQA-_3-3:\1.SJY5/>>
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M^D:NM7OBC-7']AAN9SC;'FVR*YO.EHOI5_$@V#(O:VRMM@AI($D81QR@"(8
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MOUGZ>\A&]+XK;K4-BQG#N07;,=V=J,"U4F*C I>3"^?N( Y0E*M-BC$4YS)
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ML0JSZH[B  N/,Q3-]MB=L7&\Q&A8ZMS?=3H(UY6I#R+1L_O?1@=#>_;MZW;
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MS[H4\79?8OA!K=AR5R5LG!8H2RA7B&,.8F+Y3ZD$4$8T2+(XX3PA,?3K03)
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MPB-P[LI5<5.GK-RR^T*FRLU;>B:H?']<KI^5:AUYU&&\4"HBD,* EYY(DDO
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M+H$39P YV'Z>_N-RDQ^';#>[Q<>_5N93_%8\WO\LM@N2Q!D5$@&1HAR@6":
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M+TCA%$^!DYR+F *8,>-UV9XEE&<4Q&8E+9(XS:6D?2(\!J Y9:1'4"S=F#4
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M*&(7$1C:+CX2$&C[] F,18R5H,)I)1%&G;EQZ6]J5Q]55K5@HE=+HZ5G/O+
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MK<G:_-?I]]SY_$F^;1<+F^_<Z5K_;_X?[&?Q_>E[O6J%)%<R(QA(I:'MP8X
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M[G:JW1NV_?:P6=N01?GZ^?>M;217K7J,H'NK1=G);)'C#-/<K%8TYPB@F G
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MRJE3M/@-.7,CQ$;3J%'5ON1_\^F7?AW2[H\_(%!CK^XO8M2GFEH'6#YMXX.
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MQ()W)'%.(3$F-:_BA*TFJ=];U#H06(VS7>31 +)N+_,^^>L22[\-4S 6K-:
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M8&5%V_CE8BA+*NC,2<BEL;=VL8S/P;4E)EG@6C%7)2+T(E7]EA5TCZ'N1-
MGAYWBU^NPM((J'DM'NMXP$MO!;%26>)\4$%*)B*O<G@]3TZ_Q0;=(Z@#IC<
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M-DB3>:T!(JNI:JV2=4]J<5NYM(RU6U7_R5_?Z'G&>:2*$A9@,0(8]3PNE>2
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MKZ*HWPO8JE#J1@H-P&E'S?_Q+E4'@"H=LB1>6X$&#&?$&OP2S7Z@$)#T5&?
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M-B[1E"(/U#9Y<=?QE7I[N2Y;PK?/*_(-L+3U-L,7ATG?9\MSP;6SX>P?'Z8
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MU_5)[!=Y'>!ALA?A- :[]Y-+/QP/N Q4BAA(%L80*;(C+E+DEM#>,.^#?3Q
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M]VZY64W)$1_1<38./1[+A %:12V^X>N<C83^^G7.)A+HN;/V>W26(_YX>8/
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MCC_4CQ1W]/W++U!+ 0(4 Q0    ( $%X:5']._/"4@@  (PJ   9
M      "  0    !A,C R,'$S,3 M<65X:&EB:70S,3$N:'1M4$L! A0#%
M  @ 07AI47,C!UY/"   ?"H  !D              ( !B0@  &$R,#(P<3,Q
M,"UQ97AH:6)I=#,Q,BYH=&U02P$"% ,4    " !!>&E1";I]B/X$  #T%@
M&0              @ $/$0  83(P,C!Q,S$P+7%E>&AI8FET,S(Q+FAT;5!+
M 0(4 Q0    ( $%X:5'FA_WL\00  '\6   9              "  406  !A
M,C R,'$S,3 M<65X:&EB:70S,C(N:'1M4$L! A0#%     @ 07AI41@N&@H1
M: $ 2<81 !$              ( !;!L  &%P>7@M,C R,# Y,S N:'1M4$L!
M A0#%     @ 07AI47)'OI 8#   BW   !$              ( !K(,! &%P
M>7@M,C R,# Y,S N>'-D4$L! A0#%     @ 07AI459+/,]&&0  4/0  !4
M             ( !\X\! &%P>7@M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( $%X:5&K*=^B?B8  $=Y 0 5              "  6RI 0!A<'EX+3(P
M,C P.3,P7V1E9BYX;6Q02P$"% ,4    " !!>&E1;+9((&81 0!,/ $ %
M            @ $=T $ 87!Y>"TR,#(P,#DS,%]G,2YJ<&=02P$"% ,4
M" !!>&E1#'NTO5F*  !SJ04 %0              @ &UX0( 87!Y>"TR,#(P
M,#DS,%]L86(N>&UL4$L! A0#%     @ 07AI47BYR]_D4   !84# !4
M         ( !06P# &%P>7@M,C R,# Y,S!?<')E+GAM;%!+!08     "P +
+ .@"  !8O0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
